{"00d4ff0cfe5582b3f2746b2a33d67f6bd4307e98": [["INTRODUCTIONSpatial and temporal organization of cellular signaling pathways heavily relies on compartmentalization.", [["cellular", "ANATOMY", 49, 57], ["cellular", "CELL", 49, 57], ["INTRODUCTIONSpatial", "TREATMENT", 0, 19], ["temporal", "OBSERVATION_MODIFIER", 24, 32], ["cellular signaling", "OBSERVATION", 49, 67]]], ["Structural surfaces for signal transduction can be formed by membranes, components of the cytoskeleton, membrane-surrounded organelles, or membrane-less organelles (MLOs).", [["membranes", "ANATOMY", 61, 70], ["cytoskeleton", "ANATOMY", 90, 102], ["membrane", "ANATOMY", 104, 112], ["organelles", "ANATOMY", 124, 134], ["membrane", "ANATOMY", 139, 147], ["organelles", "ANATOMY", 153, 163], ["MLOs", "ANATOMY", 165, 169], ["membranes", "CELLULAR_COMPONENT", 61, 70], ["cytoskeleton", "CELLULAR_COMPONENT", 90, 102], ["membrane", "CELLULAR_COMPONENT", 104, 112], ["organelles", "CELLULAR_COMPONENT", 124, 134], ["membrane", "CELLULAR_COMPONENT", 139, 147], ["less organelles", "CELLULAR_COMPONENT", 148, 163], ["MLOs", "CELLULAR_COMPONENT", 165, 169], ["signal transduction", "TREATMENT", 24, 43]]], ["These MLOs occur in the cytoplasm and nucleoplasm of eukaryotic cells and have recently also been discovered in bacteria (Uversky, 2017; Brangwynne, 2013; Al-Husini et al., 2018) .", [["cytoplasm", "ANATOMY", 24, 33], ["nucleoplasm", "ANATOMY", 38, 49], ["cells", "ANATOMY", 64, 69], ["MLOs", "GENE_OR_GENE_PRODUCT", 6, 10], ["cytoplasm", "ORGANISM_SUBSTANCE", 24, 33], ["nucleoplasm", "CELLULAR_COMPONENT", 38, 49], ["cells", "CELL", 64, 69], ["MLOs", "PROTEIN", 6, 10], ["eukaryotic cells", "CELL_TYPE", 53, 69], ["eukaryotic cells", "PROBLEM", 53, 69], ["cytoplasm", "OBSERVATION_MODIFIER", 24, 33], ["nucleoplasm", "OBSERVATION_MODIFIER", 38, 49], ["eukaryotic cells", "OBSERVATION", 53, 69], ["bacteria", "OBSERVATION_MODIFIER", 112, 120]]], ["These liquid-like subcellular compartments are believed to be formed by phase separation (Boeynaems et al., 2018) , a process that involves the spontaneous separation of a supersaturated solution into a dense and a dilute phase.", [["subcellular compartments", "ANATOMY", 18, 42], ["a supersaturated solution", "TREATMENT", 170, 195], ["liquid", "OBSERVATION", 6, 12], ["believed to be", "UNCERTAINTY", 47, 61], ["dense", "OBSERVATION_MODIFIER", 203, 208], ["dilute phase", "OBSERVATION_MODIFIER", 215, 227]]], ["The liquid-like nature of MLOs allows fusion and fission events and a dynamic exchange of components.", [["MLOs", "CHEMICAL", 26, 30], ["MLOs", "SIMPLE_CHEMICAL", 26, 30], ["MLOs", "PROTEIN", 26, 30], ["fusion", "TREATMENT", 38, 44], ["fission events", "PROBLEM", 49, 63], ["a dynamic exchange of components", "TREATMENT", 68, 100], ["liquid", "OBSERVATION_MODIFIER", 4, 10]]], ["MLOs comprise a variety of subcompartments including nucleoli, promyelocytic leukemia (PML) nuclear bodies, P bodies, and stress granules (SGs) (Boeynaems et al., 2018; Darling et al., 2018; Wheeler and Hyman, 2018) .", [["subcompartments", "ANATOMY", 27, 42], ["nucleoli", "ANATOMY", 53, 61], ["promyelocytic leukemia", "ANATOMY", 63, 85], ["PML", "ANATOMY", 87, 90], ["nuclear bodies", "ANATOMY", 92, 106], ["P bodies", "ANATOMY", 108, 116], ["stress granules", "ANATOMY", 122, 137], ["SGs", "ANATOMY", 139, 142], ["MLOs", "DISEASE", 0, 4], ["promyelocytic leukemia", "DISEASE", 63, 85], ["MLOs", "GENE_OR_GENE_PRODUCT", 0, 4], ["subcompartments", "CANCER", 27, 42], ["nucleoli", "CELLULAR_COMPONENT", 53, 61], ["promyelocytic leukemia", "CANCER", 63, 85], ["PML", "CANCER", 87, 90], ["stress granules", "CELLULAR_COMPONENT", 122, 137], ["SGs", "CELLULAR_COMPONENT", 139, 142], ["MLOs", "PROTEIN", 0, 4], ["nucleoli, promyelocytic leukemia (PML) nuclear bodies", "PROBLEM", 53, 106], ["stress granules", "PROBLEM", 122, 137], ["variety", "OBSERVATION_MODIFIER", 16, 23], ["nucleoli", "ANATOMY", 53, 61], ["promyelocytic leukemia", "OBSERVATION", 63, 85], ["bodies", "OBSERVATION_MODIFIER", 100, 106], ["stress granules", "OBSERVATION", 122, 137]]], ["The dense phase inside MLOs contains a high concentration of proteins, which may facilitate biochemical reactions and control signaling thresholds from these very crowded environments (Boeynaems et al., 2018; Gomes and Shorter, 2018; Woodruff et al., 2017) .", [["MLOs", "SIMPLE_CHEMICAL", 23, 27], ["a high concentration of proteins", "PROBLEM", 37, 69], ["biochemical reactions", "PROBLEM", 92, 113], ["control signaling thresholds", "PROBLEM", 118, 146], ["dense", "OBSERVATION_MODIFIER", 4, 9], ["phase", "OBSERVATION_MODIFIER", 10, 15], ["high concentration", "OBSERVATION_MODIFIER", 39, 57]]], ["In addition, MLOs can act as dynamic buffers for RNAs and proteins.", [["MLOs", "SIMPLE_CHEMICAL", 13, 17], ["MLOs", "PROTEIN", 13, 17], ["RNAs", "RNA", 49, 53], ["RNAs and proteins", "PROBLEM", 49, 66]]], ["This buffering function also serves as a passive noise filter and thus reduces the inherent randomness of chemical reactions (Saunders et al., 2012) .", [["a passive noise filter", "TREATMENT", 39, 61], ["chemical reactions", "PROBLEM", 106, 124], ["filter", "OBSERVATION", 55, 61], ["chemical reactions", "OBSERVATION", 106, 124]]], ["Different MLOs have a variety of functions ranging from the expression of rRNAs and pre-assembly of ribosomes (nucleoli) to the organization of the spindle apparatus (centrosomes) and mRNA splicing (splicing speckles) (Bernardi and Pandolfi, 2007; Boulon et al., 2010; Brangwynne, 2013; Hyman et al., 2014) .", [["ribosomes", "ANATOMY", 100, 109], ["nucleoli", "ANATOMY", 111, 119], ["spindle apparatus", "ANATOMY", 148, 165], ["centrosomes", "ANATOMY", 167, 178], ["MLOs", "GENE_OR_GENE_PRODUCT", 10, 14], ["rRNAs", "CELLULAR_COMPONENT", 74, 79], ["ribosomes", "CELLULAR_COMPONENT", 100, 109], ["nucleoli", "CELLULAR_COMPONENT", 111, 119], ["spindle apparatus", "CELLULAR_COMPONENT", 148, 165], ["centrosomes", "CELLULAR_COMPONENT", 167, 178], ["speckles", "CELLULAR_COMPONENT", 208, 216], ["MLOs", "PROTEIN", 10, 14], ["rRNAs", "RNA", 74, 79], ["ribosomes (nucleoli)", "PROBLEM", 100, 120], ["mRNA splicing", "PROBLEM", 184, 197], ["variety", "OBSERVATION_MODIFIER", 22, 29], ["spindle apparatus", "OBSERVATION", 148, 165]]], ["Aberrant forms of MLOs occur upon failure of the protein quality control system or by mutation of MLO-resident proteins, often causing age-related diseases such as amyotrophic lateral sclerosis, inclusion body myopathy, and frontotemporal dementia (Hock and Polymenidou, 2016; Malinovska et al., 2013; Ramaswami et al., 2013; Taylor et al., 2016) .", [["body", "ANATOMY", 205, 209], ["amyotrophic lateral sclerosis", "DISEASE", 164, 193], ["inclusion body myopathy", "DISEASE", 195, 218], ["frontotemporal dementia", "DISEASE", 224, 247], ["MLOs", "GENE_OR_GENE_PRODUCT", 18, 22], ["MLO-resident proteins", "GENE_OR_GENE_PRODUCT", 98, 119], ["MLOs", "PROTEIN", 18, 22], ["MLO", "PROTEIN", 98, 101], ["resident proteins", "PROTEIN", 102, 119], ["Aberrant forms of MLOs", "PROBLEM", 0, 22], ["failure of the protein quality control system", "PROBLEM", 34, 79], ["related diseases", "PROBLEM", 139, 155], ["amyotrophic lateral sclerosis", "PROBLEM", 164, 193], ["inclusion body myopathy", "PROBLEM", 195, 218], ["frontotemporal dementia", "PROBLEM", 224, 247], ["amyotrophic", "OBSERVATION_MODIFIER", 164, 175], ["lateral", "OBSERVATION_MODIFIER", 176, 183], ["sclerosis", "OBSERVATION", 184, 193], ["body myopathy", "OBSERVATION", 205, 218], ["frontotemporal", "OBSERVATION_MODIFIER", 224, 238], ["dementia", "OBSERVATION", 239, 247]]], ["Furthermore, various viruses hijack MLO proteins to aid in their replication (Dhillon and Rao, 2018; M\u00f6 ller and Schmitz, 2003; Nakagawa et al., 2018; Reineke and Lloyd, 2013) .", [["MLO", "GENE_OR_GENE_PRODUCT", 36, 39], ["MLO proteins", "PROTEIN", 36, 48]]], ["MLOs are dynamically formed by an interplay between RNA and intrinsically disordered proteins (IDPs) that typically harbor low-sequence-complexity domains enriched in polar side chains (Arg, Gln, Glu, Ser, Lys) or structure-breaking amino acids (Gly, Pro) (Uversky and Dunker, 2010) .", [["Arg, Gln, Glu, Ser, Lys", "CHEMICAL", 186, 209], ["amino acids", "CHEMICAL", 233, 244], ["Arg", "CHEMICAL", 186, 189], ["Gln", "CHEMICAL", 191, 194], ["Glu", "CHEMICAL", 196, 199], ["Ser", "CHEMICAL", 201, 204], ["Lys", "CHEMICAL", 206, 209], ["amino acids", "CHEMICAL", 233, 244], ["Gly", "CHEMICAL", 246, 249], ["Pro", "CHEMICAL", 251, 254], ["MLOs", "GENE_OR_GENE_PRODUCT", 0, 4], ["IDPs", "GENE_OR_GENE_PRODUCT", 95, 99], ["Arg", "AMINO_ACID", 186, 189], ["Gln", "AMINO_ACID", 191, 194], ["Glu", "AMINO_ACID", 196, 199], ["Ser, Lys", "AMINO_ACID", 201, 209], ["amino acids", "AMINO_ACID", 233, 244], ["Gly", "AMINO_ACID", 246, 249], ["MLOs", "PROTEIN", 0, 4], ["intrinsically disordered proteins", "PROTEIN", 60, 93], ["IDPs", "PROTEIN", 95, 99], ["low-sequence-complexity domains", "PROTEIN", 123, 154], ["polar side chains", "PROTEIN", 167, 184], ["intrinsically disordered proteins (IDPs", "PROBLEM", 60, 99], ["complexity domains", "PROBLEM", 136, 154], ["Arg", "TEST", 186, 189], ["Gln", "TEST", 191, 194], ["Glu", "TEST", 196, 199], ["breaking amino acids", "TREATMENT", 224, 244], ["polar", "ANATOMY_MODIFIER", 167, 172]]], ["The dynamic formation of MLOs can be regulated by post-translational modifications such as acetylation, SUMOylation, or phosphorylation (Bernardi and Pandolfi, 2007; de la Vega et al., 2011; Saito et al., 2019; Wippich et al., 2013) or by environmental cues such as changes in temperature, pH, or osmolarity (Uversky, 2017) .", [["MLOs", "GENE_OR_GENE_PRODUCT", 25, 29], ["MLOs", "PROTEIN", 25, 29], ["post-translational modifications", "TREATMENT", 50, 82], ["acetylation, SUMOylation", "TREATMENT", 91, 115], ["phosphorylation (Bernardi and Pandolfi", "TREATMENT", 120, 158]]], ["Interestingly, a small interfering RNA (siRNA) screen identified several kinases as regulators of MLO formation, including the Ser/Thr kinase TBK1 as a regulator of splicing speckles (Berchtold et al., 2018) .INTRODUCTIONTBK1 has been initially identified as a component of the antiviral response based on its ability to phosphorylate and thus activate IRF3 or IRF7 transcription factors, which in turn leads to inducible expression of type I interferons (IFN) (Fitzgerald et al., 2003; Sharma et al., 2003) .", [["INTRODUCTIONTBK1", "CHEMICAL", 209, 225], ["Ser", "CHEMICAL", 127, 130], ["Thr", "CHEMICAL", 131, 134], ["MLO", "GENE_OR_GENE_PRODUCT", 98, 101], ["TBK1", "GENE_OR_GENE_PRODUCT", 142, 146], ["IRF3", "GENE_OR_GENE_PRODUCT", 353, 357], ["IRF7", "GENE_OR_GENE_PRODUCT", 361, 365], ["type I interferons", "GENE_OR_GENE_PRODUCT", 436, 454], ["IFN", "GENE_OR_GENE_PRODUCT", 456, 459], ["kinases", "PROTEIN", 73, 80], ["MLO", "PROTEIN", 98, 101], ["Ser/Thr kinase", "PROTEIN", 127, 141], ["TBK1", "PROTEIN", 142, 146], ["INTRODUCTIONTBK1", "PROTEIN", 209, 225], ["IRF3", "PROTEIN", 353, 357], ["IRF7", "PROTEIN", 361, 365], ["transcription factors", "PROTEIN", 366, 387], ["type I interferons", "PROTEIN", 436, 454], ["IFN", "PROTEIN", 456, 459], ["a small interfering RNA (siRNA) screen", "PROBLEM", 15, 53], ["MLO formation", "PROBLEM", 98, 111], ["the Ser/Thr kinase TBK1", "TREATMENT", 123, 146], ["the antiviral response", "PROBLEM", 274, 296], ["phosphorylate", "TREATMENT", 321, 334], ["IRF7 transcription factors", "PROBLEM", 361, 387], ["type I interferons (IFN)", "PROBLEM", 436, 460], ["small", "OBSERVATION_MODIFIER", 17, 22], ["interfering RNA", "OBSERVATION", 23, 38], ["antiviral response", "OBSERVATION", 278, 296]]], ["TBK1, IRF3, and further components for induced type I IFN signaling are known to translocate to perinuclear punctate structures (Saitoh et al., 2009; Seo et al., 2016) .", [["perinuclear punctate structures", "ANATOMY", 96, 127], ["TBK1", "GENE_OR_GENE_PRODUCT", 0, 4], ["IRF3", "GENE_OR_GENE_PRODUCT", 6, 10], ["type I IFN", "GENE_OR_GENE_PRODUCT", 47, 57], ["perinuclear", "CELLULAR_COMPONENT", 96, 107], ["punctate structures", "CELLULAR_COMPONENT", 108, 127], ["TBK1", "PROTEIN", 0, 4], ["IRF3", "PROTEIN", 6, 10], ["IFN", "PROTEIN", 54, 57], ["TBK1", "PROBLEM", 0, 4], ["IRF3", "PROBLEM", 6, 10], ["induced type I IFN signaling", "PROBLEM", 39, 67], ["IRF3", "OBSERVATION", 6, 10], ["punctate", "OBSERVATION_MODIFIER", 108, 116]]], ["Recent years have witnessed the identification of many additional TBK1 functions, which range from regulation of mitotic microtubule dynamics to the regulation of tumor necrosis factorinduced cell death (Lafont et al., 2018; Pillai et al., 2015; Xu et al., 2018) .", [["microtubule", "ANATOMY", 121, 132], ["tumor", "ANATOMY", 163, 168], ["cell", "ANATOMY", 192, 196], ["tumor", "DISEASE", 163, 168], ["necrosis", "DISEASE", 169, 177], ["death", "DISEASE", 197, 202], ["TBK1", "GENE_OR_GENE_PRODUCT", 66, 70], ["tumor", "CANCER", 163, 168], ["TBK1", "PROTEIN", 66, 70], ["microtubule", "PROTEIN", 121, 132], ["many additional TBK1 functions", "PROBLEM", 50, 80], ["mitotic microtubule dynamics", "PROBLEM", 113, 141], ["tumor necrosis", "PROBLEM", 163, 177], ["cell death", "PROBLEM", 192, 202], ["mitotic microtubule", "OBSERVATION", 113, 132], ["tumor", "OBSERVATION", 163, 168], ["necrosis", "OBSERVATION_MODIFIER", 169, 177], ["cell death", "OBSERVATION", 192, 202]]], ["Furthermore, stress-regulated TBK1 functions comprise its role in autophagy, mitophagy, and xenophagy (Heo et al., 2015; Pilli et al., 2012; Wild et al., 2011) .", [["TBK1", "GENE_OR_GENE_PRODUCT", 30, 34], ["TBK1", "PROTEIN", 30, 34], ["mitophagy", "PROBLEM", 77, 86]]], ["More recent evidence shows that TBK1 directly inhibits the AMP-activated protein kinase to increase energy storage and to repress respiration in adipose tissue, thus mediating a cross talk between immune signaling and metabolism .", [["adipose tissue", "ANATOMY", 145, 159], ["AMP", "CHEMICAL", 59, 62], ["AMP", "CHEMICAL", 59, 62], ["TBK1", "GENE_OR_GENE_PRODUCT", 32, 36], ["AMP-activated protein kinase", "GENE_OR_GENE_PRODUCT", 59, 87], ["adipose tissue", "TISSUE", 145, 159], ["TBK1", "PROTEIN", 32, 36], ["AMP-activated protein kinase", "PROTEIN", 59, 87], ["TBK1", "PROBLEM", 32, 36], ["the AMP", "TEST", 55, 62], ["activated protein kinase", "TREATMENT", 63, 87], ["energy storage", "TREATMENT", 100, 114], ["respiration in adipose tissue", "PROBLEM", 130, 159], ["adipose tissue", "ANATOMY", 145, 159]]], ["Basal TBK1 signaling is also required for the development of KRAS-driven cancers (Barbie et al., 2009) .", [["cancers", "ANATOMY", 73, 80], ["cancers", "DISEASE", 73, 80], ["TBK1", "GENE_OR_GENE_PRODUCT", 6, 10], ["KRAS", "GENE_OR_GENE_PRODUCT", 61, 65], ["cancers", "CANCER", 73, 80], ["TBK1", "PROTEIN", 6, 10], ["KRAS", "DNA", 61, 65], ["Basal TBK1 signaling", "PROBLEM", 0, 20], ["KRAS", "PROBLEM", 61, 65], ["driven cancers", "PROBLEM", 66, 80], ["TBK1 signaling", "OBSERVATION", 6, 20], ["KRAS", "OBSERVATION", 61, 65]]], ["Given the involvement of TBK1 in so many stress signaling pathways, TBK1 is a frequent target of viral proteins affecting its localization or protein-protein interactions (Liu et al., 2018; Onorati et al., 2016) .INTRODUCTIONHow can one single kinase such as TBK1 contribute to so many different signaling pathways?", [["TBK1", "GENE_OR_GENE_PRODUCT", 25, 29], ["TBK1", "GENE_OR_GENE_PRODUCT", 68, 72], ["TBK1", "GENE_OR_GENE_PRODUCT", 259, 263], ["TBK1", "PROTEIN", 25, 29], ["TBK1", "PROTEIN", 68, 72], ["viral proteins", "PROTEIN", 97, 111], ["TBK1", "PROTEIN", 259, 263], ["TBK1", "PROBLEM", 25, 29], ["many stress signaling pathways", "PROBLEM", 36, 66], ["TBK1", "PROBLEM", 68, 72], ["viral proteins", "PROBLEM", 97, 111], ["TBK1", "OBSERVATION", 25, 29]]], ["One possible answer to this conundrum might rely on the differential association of TBK1 to various adapter proteins, which co-determine its function (Goncalves et al., 2011) .", [["TBK1", "GENE_OR_GENE_PRODUCT", 84, 88], ["TBK1", "PROTEIN", 84, 88], ["adapter proteins", "PROTEIN", 100, 116], ["TBK1 to various adapter proteins", "PROBLEM", 84, 116]]], ["These adapter proteins include SINTBAD (TBKBP1), TANK (I-TRAF), and AZI2 (NAP1) and serve to assist in substrate binding and also affect the subcellular localization of TBK1 (Helgason et al., 2013) .", [["subcellular", "ANATOMY", 141, 152], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 31, 38], ["TBKBP1", "GENE_OR_GENE_PRODUCT", 40, 46], ["TANK (I-TRAF", "GENE_OR_GENE_PRODUCT", 49, 61], ["AZI2", "GENE_OR_GENE_PRODUCT", 68, 72], ["NAP1", "GENE_OR_GENE_PRODUCT", 74, 78], ["TBK1", "GENE_OR_GENE_PRODUCT", 169, 173], ["adapter proteins", "PROTEIN", 6, 22], ["SINTBAD", "PROTEIN", 31, 38], ["TBKBP1", "PROTEIN", 40, 46], ["TANK", "PROTEIN", 49, 53], ["I", "PROTEIN", 55, 56], ["TRAF", "PROTEIN", 57, 61], ["AZI2", "PROTEIN", 68, 72], ["NAP1", "PROTEIN", 74, 78], ["TBK1", "PROTEIN", 169, 173], ["SINTBAD (TBKBP1)", "TREATMENT", 31, 47], ["TANK (I-TRAF)", "TREATMENT", 49, 62], ["AZI2 (NAP1)", "TREATMENT", 68, 79]]], ["Although the adapter proteins lack any intrinsic enzymatic activity, they can affect biological functions, as exemplified by AZI2-and SINTBAD-regulated intracellular xenophagy of Salmonella (Thurston et al., 2009) .", [["intracellular", "ANATOMY", 152, 165], ["AZI2", "GENE_OR_GENE_PRODUCT", 125, 129], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 134, 141], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 152, 165], ["adapter proteins", "PROTEIN", 13, 29], ["AZI2", "PROTEIN", 125, 129], ["SINTBAD", "PROTEIN", 134, 141], ["AZI2", "TEST", 125, 129]]], ["SINTBAD also facilitates activation of the autophagy-initiating kinase ULK1 to control interleukin (IL)-15-induced autophagy in natural killer T cells .INTRODUCTIONHere we have studied the intracellular distribution of SINTBAD and found its stress-regulated incorporation into cytosolic speckles not corresponding to the known MLO members that were tested.", [["natural killer T cells", "ANATOMY", 128, 150], ["intracellular", "ANATOMY", 189, 202], ["cytosolic speckles", "ANATOMY", 277, 295], ["ULK1", "GENE_OR_GENE_PRODUCT", 71, 75], ["interleukin (IL)-15", "GENE_OR_GENE_PRODUCT", 87, 106], ["natural killer T cells", "CELL", 128, 150], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 189, 202], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 219, 226], ["MLO", "GENE_OR_GENE_PRODUCT", 327, 330], ["autophagy-initiating kinase", "PROTEIN", 43, 70], ["ULK1", "PROTEIN", 71, 75], ["interleukin (IL)-15", "PROTEIN", 87, 106], ["natural killer T cells", "CELL_TYPE", 128, 150], ["SINTBAD", "PROTEIN", 219, 226], ["MLO members", "PROTEIN", 327, 338], ["the autophagy", "TEST", 39, 52], ["kinase ULK1", "TREATMENT", 64, 75], ["interleukin (IL)", "TREATMENT", 87, 103], ["its stress", "PROBLEM", 237, 247], ["cytosolic speckles", "PROBLEM", 277, 295], ["natural killer", "OBSERVATION", 128, 142]]], ["Determination of the SINTBAD interactome allowed the identification of proteins contained in constitutive and inducible SINT-speckles or as regulators of this dynamic process.", [["SINTBAD", "GENE_OR_GENE_PRODUCT", 21, 28], ["SINT", "GENE_OR_GENE_PRODUCT", 120, 124], ["SINTBAD", "PROTEIN", 21, 28], ["SINT", "PROTEIN", 120, 124], ["the SINTBAD interactome", "PROBLEM", 17, 40], ["proteins", "PROBLEM", 71, 79], ["constitutive and inducible SINT-speckles", "PROBLEM", 93, 133]]], ["The formation of inducible SINT-speckles is inhibited by the constitutive chaperone activity of heat shock proteins (HSPs) and ULK1 signaling, whereas KAT2A (also referred to as GCN5) promotes SINT-speckle formation.", [["SINT", "GENE_OR_GENE_PRODUCT", 27, 31], ["heat shock proteins", "GENE_OR_GENE_PRODUCT", 96, 115], ["HSPs", "GENE_OR_GENE_PRODUCT", 117, 121], ["ULK1", "GENE_OR_GENE_PRODUCT", 127, 131], ["KAT2A", "GENE_OR_GENE_PRODUCT", 151, 156], ["GCN5", "GENE_OR_GENE_PRODUCT", 178, 182], ["SINT", "GENE_OR_GENE_PRODUCT", 193, 197], ["SINT", "PROTEIN", 27, 31], ["heat shock proteins", "PROTEIN", 96, 115], ["HSPs", "PROTEIN", 117, 121], ["ULK1", "PROTEIN", 127, 131], ["KAT2A", "PROTEIN", 151, 156], ["GCN5", "PROTEIN", 178, 182], ["SINT", "PROTEIN", 193, 197], ["inducible SINT-speckles", "PROBLEM", 17, 40], ["heat shock proteins", "PROBLEM", 96, 115], ["HSPs", "TEST", 117, 121], ["ULK1 signaling", "TEST", 127, 141], ["KAT2A", "TEST", 151, 156], ["inducible SINT", "OBSERVATION", 17, 31]]], ["The SINT-speckle components AZI2 and SINTBAD determine the threshold of TBK1 activation, which partially occurs within SINT-speckles.", [["TBK1", "GENE_OR_GENE_PRODUCT", 72, 76], ["SINT-speckle components", "PROTEIN", 4, 27], ["AZI2", "PROTEIN", 28, 32], ["SINTBAD", "PROTEIN", 37, 44], ["TBK1", "PROTEIN", 72, 76], ["SINT", "PROTEIN", 119, 123], ["SINTBAD", "TREATMENT", 37, 44], ["TBK1 activation", "PROBLEM", 72, 87], ["TBK1 activation", "OBSERVATION", 72, 87]]], ["Knockdown of ULK1/2 was sufficient to trigger SINT-speckle formation, but interfered with focal TBK1 activation in a pathway-specific fashion.Cell Stress Triggers the Formation of SINTBAD-Containing SpecklesMany proteins participating in the induction of innate immune response signaling have a propensity to form inducible polymers or filaments, which show a reduced solubility in standard lysis buffers (David et al., 2018; Pellegrini et al., 2018; Vajjhala et al., 2017) .", [["Cell", "ANATOMY", 142, 146], ["filaments", "ANATOMY", 336, 345], ["ULK1/2", "GENE_OR_GENE_PRODUCT", 13, 19], ["SINT", "GENE_OR_GENE_PRODUCT", 46, 50], ["TBK1", "GENE_OR_GENE_PRODUCT", 96, 100], ["Cell", "CELL", 142, 146], ["filaments", "CELLULAR_COMPONENT", 336, 345], ["ULK1/2", "PROTEIN", 13, 19], ["SINT", "PROTEIN", 46, 50], ["TBK1", "PROTEIN", 96, 100], ["SINTBAD", "PROTEIN", 180, 187], ["Knockdown of ULK1/2", "TEST", 0, 19], ["focal TBK1 activation", "PROBLEM", 90, 111], ["SINTBAD", "TEST", 180, 187], ["Many proteins", "PROBLEM", 207, 220], ["a reduced solubility", "PROBLEM", 358, 378], ["standard lysis buffers", "TREATMENT", 382, 404], ["ULK1", "OBSERVATION", 13, 17], ["focal", "OBSERVATION_MODIFIER", 90, 95], ["TBK1 activation", "OBSERVATION", 96, 111], ["reduced", "OBSERVATION_MODIFIER", 360, 367], ["solubility", "OBSERVATION_MODIFIER", 368, 378]]], ["To test the possible impact of cellular stress on the solubility of SINTBAD, HeLa cells were exposed to heat shock for different periods, followed by fractionation into a cytosolic and a nuclear/insoluble fraction representing not only chromatin proteins but also poorly soluble or aggregated proteins.", [["cellular", "ANATOMY", 31, 39], ["HeLa cells", "ANATOMY", 77, 87], ["cytosolic", "ANATOMY", 171, 180], ["nuclear", "ANATOMY", 187, 194], ["chromatin", "ANATOMY", 236, 245], ["shock", "DISEASE", 109, 114], ["cellular", "CELL", 31, 39], ["SINTBAD", "SIMPLE_CHEMICAL", 68, 75], ["HeLa cells", "CELL", 77, 87], ["nuclear", "CELLULAR_COMPONENT", 187, 194], ["chromatin", "CELLULAR_COMPONENT", 236, 245], ["SINTBAD", "PROTEIN", 68, 75], ["HeLa cells", "CELL_LINE", 77, 87], ["chromatin proteins", "PROTEIN", 236, 254], ["aggregated proteins", "PROTEIN", 282, 301], ["cellular stress", "PROBLEM", 31, 46], ["HeLa cells", "TREATMENT", 77, 87], ["heat shock", "TREATMENT", 104, 114], ["a nuclear/insoluble fraction", "PROBLEM", 185, 213], ["chromatin proteins", "PROBLEM", 236, 254], ["poorly soluble or aggregated proteins", "PROBLEM", 264, 301], ["cellular stress", "OBSERVATION", 31, 46], ["chromatin proteins", "OBSERVATION", 236, 254]]], ["A western blot analysis revealed that treatment with heat shock triggered the time-dependent transition of SINTBAD from the soluble to the nuclear/insoluble fraction, whereas this dynamic redistribution between the fractions did not occur for the SINTBAD-related proteins AZI2 or TANK ( Figure 1A) .", [["nuclear", "ANATOMY", 139, 146], ["shock", "DISEASE", 58, 63], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 107, 114], ["nuclear", "CELLULAR_COMPONENT", 139, 146], ["AZI2", "GENE_OR_GENE_PRODUCT", 272, 276], ["TANK ( Figure 1A", "GENE_OR_GENE_PRODUCT", 280, 296], ["SINTBAD", "PROTEIN", 107, 114], ["SINTBAD", "PROTEIN", 247, 254], ["AZI2", "PROTEIN", 272, 276], ["TANK", "PROTEIN", 280, 284], ["Figure 1A", "PROTEIN", 287, 296], ["A western blot analysis", "TEST", 0, 23], ["heat shock", "TREATMENT", 53, 63], ["this dynamic redistribution between the fractions", "PROBLEM", 175, 224], ["the SINTBAD", "TEST", 243, 254], ["redistribution", "OBSERVATION", 188, 202]]], ["A similar inducible redistribution of SINTBAD also occurred in arsenite-treated 293T cells ( Figure 1B) , showing that various stressors can trigger the relocation of SINTBAD in different cell types.", [["293T cells", "ANATOMY", 80, 90], ["cell", "ANATOMY", 188, 192], ["arsenite", "CHEMICAL", 63, 71], ["arsenite", "CHEMICAL", 63, 71], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 38, 45], ["arsenite", "SIMPLE_CHEMICAL", 63, 71], ["293T cells", "CELL", 80, 90], ["Figure 1B", "CELL", 93, 102], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 167, 174], ["cell", "CELL", 188, 192], ["SINTBAD", "PROTEIN", 38, 45], ["arsenite-treated 293T cells", "CELL_LINE", 63, 90], ["SINTBAD", "PROTEIN", 167, 174], ["A similar inducible redistribution of SINTBAD", "PROBLEM", 0, 45], ["various stressors", "PROBLEM", 119, 136], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["inducible", "OBSERVATION_MODIFIER", 10, 19], ["redistribution", "OBSERVATION", 20, 34], ["different cell types", "OBSERVATION", 178, 198]]], ["It was also interesting to test whether SINTBAD translocation to the insoluble fraction is also seen in response to further different stimuli representing inflammatory conditions or osmotic or proteotoxic stress.", [["SINTBAD", "GENE_OR_GENE_PRODUCT", 40, 47], ["SINTBAD", "PROTEIN", 40, 47], ["SINTBAD translocation to the insoluble fraction", "PROBLEM", 40, 87], ["further different stimuli", "TEST", 116, 141], ["inflammatory conditions", "PROBLEM", 155, 178], ["osmotic or proteotoxic stress", "PROBLEM", 182, 211], ["inflammatory", "OBSERVATION", 155, 167], ["proteotoxic stress", "OBSERVATION", 193, 211]]], ["These results show that most adverse agents, with the exception of inflammatory stimuli, triggered translocation of SINTBAD to the nuclear/insoluble fraction ( Figure 1C ).", [["nuclear", "ANATOMY", 131, 138], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 116, 123], ["nuclear", "CELLULAR_COMPONENT", 131, 138], ["SINTBAD", "PROTEIN", 116, 123], ["inflammatory stimuli", "PROBLEM", 67, 87], ["inflammatory stimuli", "OBSERVATION", 67, 87]]], ["This behavior was seen for the endogenous proteins and also for the adapter proteins when expressed at moderate levels (Figures S1A and S1B).Cell Stress Triggers the Formation of SINTBAD-Containing SpecklesTo test whether the regulated solubility change of SINTBAD is associated with alterations of its intracellular distribution, immunofluorescence studies were performed in U2OS cells that are ideally suited and widely used for the characterization of subcellular compartmentation.", [["Cell", "ANATOMY", 141, 145], ["intracellular", "ANATOMY", 303, 316], ["U2OS cells", "ANATOMY", 376, 386], ["subcellular", "ANATOMY", 455, 466], ["SINTBAD", "CHEMICAL", 257, 264], ["Cell", "CELL", 141, 145], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 257, 264], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 303, 316], ["U2OS cells", "CELL", 376, 386], ["endogenous proteins", "PROTEIN", 31, 50], ["adapter proteins", "PROTEIN", 68, 84], ["S1B", "PROTEIN", 136, 139], ["SINTBAD", "PROTEIN", 179, 186], ["SINTBAD", "PROTEIN", 257, 264], ["U2OS cells", "CELL_LINE", 376, 386], ["the endogenous proteins", "PROBLEM", 27, 50], ["the adapter proteins", "PROBLEM", 64, 84], ["SINTBAD", "TEST", 179, 186], ["immunofluorescence studies", "TEST", 331, 357], ["U2OS cells", "TEST", 376, 386], ["intracellular distribution", "OBSERVATION", 303, 329], ["subcellular compartmentation", "OBSERVATION", 455, 483]]], ["In the absence of a commercial antibody faithfully detecting the endogenous SINTBAD protein in immunofluorescence studies, we generated SINT-BAD-deficient U2OS cells by CRISPR/Cas9-mediated genome editing ( Figures S2A and S2B ) that were A B C D Figure 1 .", [["U2OS cells", "ANATOMY", 155, 165], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 76, 83], ["SINT", "GENE_OR_GENE_PRODUCT", 136, 140], ["BAD", "GENE_OR_GENE_PRODUCT", 141, 144], ["U2OS cells", "CELL", 155, 165], ["CRISPR/Cas9", "GENE_OR_GENE_PRODUCT", 169, 180], ["SINTBAD protein", "PROTEIN", 76, 91], ["SINT", "PROTEIN", 136, 140], ["BAD", "PROTEIN", 141, 144], ["U2OS cells", "CELL_LINE", 155, 165], ["Cas9", "DNA", 176, 180], ["a commercial antibody", "TEST", 18, 39], ["immunofluorescence studies", "TEST", 95, 121], ["SINT", "TEST", 136, 140], ["deficient U2OS cells", "PROBLEM", 145, 165], ["CRISPR/Cas9", "PROBLEM", 169, 180], ["mediated genome editing", "PROBLEM", 181, 204], ["U2OS cells", "OBSERVATION", 155, 165]]], ["Stress-Inducible Formation of SINTBAD-Containing Speckles (A) HeLa cells were exposed for the indicated periods to heat shock, and cells were harvested and fractionated into cytosolic (cyto.) and nuclear/insoluble (nucl./insol.) extracts.", [["HeLa cells", "ANATOMY", 62, 72], ["cells", "ANATOMY", 131, 136], ["cytosolic", "ANATOMY", 174, 183], ["nuclear", "ANATOMY", 196, 203], ["extracts", "ANATOMY", 229, 237], ["shock", "DISEASE", 120, 125], ["HeLa cells", "CELL", 62, 72], ["cells", "CELL", 131, 136], ["cytosolic", "ORGANISM_SUBSTANCE", 174, 183], ["nuclear", "CELLULAR_COMPONENT", 196, 203], ["extracts", "ORGANISM_SUBSTANCE", 229, 237], ["SINTBAD", "PROTEIN", 30, 37], ["Containing Speckles (A) HeLa cells", "CELL_LINE", 38, 72], ["Stress-Inducible Formation of SINTBAD", "PROBLEM", 0, 37], ["Speckles (A) HeLa cells", "TREATMENT", 49, 72], ["heat shock", "PROBLEM", 115, 125], ["nuclear/insoluble (nucl", "TREATMENT", 196, 219], ["Inducible Formation", "OBSERVATION", 7, 26], ["shock", "OBSERVATION", 120, 125]]], ["Western blot was performed to detect the dynamic relocalization of the endogenous adapter proteins SINTBAD, AZI2, and TANK.", [["SINTBAD", "GENE_OR_GENE_PRODUCT", 99, 106], ["AZI2", "GENE_OR_GENE_PRODUCT", 108, 112], ["TANK", "GENE_OR_GENE_PRODUCT", 118, 122], ["endogenous adapter proteins", "PROTEIN", 71, 98], ["SINTBAD", "PROTEIN", 99, 106], ["AZI2", "PROTEIN", 108, 112], ["TANK", "PROTEIN", 118, 122], ["Western blot", "TEST", 0, 12]]], ["The detection of phosphorylated ERK1/2 (T202/Y204), tubulin, and histone H3 serves as a control for the treatment, cytosolic, and nuclear/insoluble fraction, respectively.", [["cytosolic", "ANATOMY", 115, 124], ["nuclear", "ANATOMY", 130, 137], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 32, 38], ["T202", "GENE_OR_GENE_PRODUCT", 40, 44], ["Y204", "GENE_OR_GENE_PRODUCT", 45, 49], ["tubulin", "GENE_OR_GENE_PRODUCT", 52, 59], ["histone H3", "GENE_OR_GENE_PRODUCT", 65, 75], ["cytosolic", "CELLULAR_COMPONENT", 115, 124], ["nuclear", "CELLULAR_COMPONENT", 130, 137], ["phosphorylated ERK1/2", "PROTEIN", 17, 38], ["T202", "PROTEIN", 40, 44], ["Y204", "PROTEIN", 45, 49], ["tubulin", "PROTEIN", 52, 59], ["histone H3", "PROTEIN", 65, 75], ["The detection", "TEST", 0, 13], ["phosphorylated ERK1", "TEST", 17, 36], ["T202", "TEST", 40, 44], ["tubulin", "TREATMENT", 52, 59], ["histone H3 serves", "TREATMENT", 65, 82], ["the treatment", "TREATMENT", 100, 113], ["nuclear/insoluble fraction", "TEST", 130, 156]]], ["The positions of molecular weight markers are indicated.", [["molecular weight markers", "TEST", 17, 41]]], ["(B) 293T cells were treated with 0.5 mM arsenite for the indicated times and further analyzed as in (A).Cell Stress Triggers the Formation of SINTBAD-Containing Speckles(C) Different cell lines were treated with various stressors; the exact conditions are indicated in the Transparent Methods section.", [["293T cells", "ANATOMY", 4, 14], ["Cell", "ANATOMY", 104, 108], ["cell lines", "ANATOMY", 183, 193], ["arsenite", "CHEMICAL", 40, 48], ["arsenite", "CHEMICAL", 40, 48], ["B) 293T cells", "CELL", 1, 14], ["arsenite", "SIMPLE_CHEMICAL", 40, 48], ["Cell", "CELL", 104, 108], ["cell lines", "CELL", 183, 193], ["293T cells", "CELL_LINE", 4, 14], ["SINTBAD", "DNA", 142, 149], ["Containing Speckles(C) Different cell lines", "CELL_LINE", 150, 193], ["0.5 mM arsenite", "TREATMENT", 33, 48], ["Cell Stress", "PROBLEM", 104, 115], ["SINTBAD-Containing Speckles(C) Different cell lines", "TREATMENT", 142, 193], ["various stressors", "TREATMENT", 212, 229], ["cell lines", "OBSERVATION", 183, 193]]], ["Following these stimulations, cells were fractionated into cytosolic and nuclear/insoluble extracts, followed by the analysis of SINTBAD translocation as described in (A and B).", [["cells", "ANATOMY", 30, 35], ["cytosolic", "ANATOMY", 59, 68], ["nuclear", "ANATOMY", 73, 80], ["extracts", "ANATOMY", 91, 99], ["cells", "CELL", 30, 35], ["cytosolic", "CELLULAR_COMPONENT", 59, 68], ["nuclear", "CELLULAR_COMPONENT", 73, 80], ["extracts", "ORGANISM_SUBSTANCE", 91, 99], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 129, 136], ["SINTBAD", "PROTEIN", 129, 136], ["these stimulations", "TEST", 10, 28], ["nuclear/insoluble extracts", "TREATMENT", 73, 99], ["the analysis", "TEST", 113, 125], ["SINTBAD translocation", "PROBLEM", 129, 150]]], ["The occurrence of SINTBAD translocation to the nuclear/ insoluble fraction is indicated by a +.Cell Stress Triggers the Formation of SINTBAD-Containing Speckles(D) Double-deficient (sgAZI2/sgSINTBAD) U2OS cells stably expressing FLAG-SINTBAD or transfected to express moderate amounts of FLAG-AZI2 or FLAG-TANK were treated with arsenite (0.5 mM, 1 h) or heat shock (43 C, 1 h) and analyzed by indirect immunofluorescence using anti-FLAG antibodies.", [["nuclear", "ANATOMY", 47, 54], ["Cell", "ANATOMY", 95, 99], ["U2OS cells", "ANATOMY", 200, 210], ["arsenite", "CHEMICAL", 329, 337], ["shock", "DISEASE", 360, 365], ["arsenite", "CHEMICAL", 329, 337], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 18, 25], ["nuclear", "CELLULAR_COMPONENT", 47, 54], ["Cell", "CELL", 95, 99], ["FLAG-SINTBAD", "GENE_OR_GENE_PRODUCT", 229, 241], ["FLAG-AZI2", "GENE_OR_GENE_PRODUCT", 288, 297], ["FLAG-TANK", "GENE_OR_GENE_PRODUCT", 301, 310], ["arsenite", "SIMPLE_CHEMICAL", 329, 337], ["SINTBAD", "PROTEIN", 18, 25], ["SINTBAD", "PROTEIN", 133, 140], ["Containing Speckles(D) Double-deficient (sgAZI2/sgSINTBAD) U2OS cells", "CELL_LINE", 141, 210], ["FLAG", "PROTEIN", 229, 233], ["SINTBAD", "PROTEIN", 234, 241], ["FLAG", "PROTEIN", 288, 292], ["AZI2", "PROTEIN", 293, 297], ["FLAG", "PROTEIN", 301, 305], ["TANK", "PROTEIN", 306, 310], ["anti-FLAG antibodies", "PROTEIN", 428, 448], ["SINTBAD translocation", "PROBLEM", 18, 39], ["Cell Stress", "TEST", 95, 106], ["SINTBAD", "TEST", 133, 140], ["Double-deficient (sgAZI2/sgSINTBAD)", "TREATMENT", 164, 199], ["U2OS cells", "TEST", 200, 210], ["FLAG", "TEST", 229, 233], ["FLAG-AZI2", "TREATMENT", 288, 297], ["FLAG-TANK", "TREATMENT", 301, 310], ["arsenite", "TREATMENT", 329, 337], ["heat shock", "PROBLEM", 355, 365], ["anti-FLAG antibodies", "TREATMENT", 428, 448], ["moderate", "OBSERVATION_MODIFIER", 268, 276]]], ["Nuclear DNA was stained with Hoechst; scale bars, 10 mm.", [["Nuclear", "ANATOMY", 0, 7], ["Nuclear", "CELLULAR_COMPONENT", 0, 7], ["DNA", "CELLULAR_COMPONENT", 8, 11], ["Hoechst", "SIMPLE_CHEMICAL", 29, 36], ["Nuclear DNA", "TEST", 0, 11], ["10 mm", "OBSERVATION_MODIFIER", 50, 55]]], ["The percentage of cells showing a localization as displayed in the figure is indicated.", [["cells", "ANATOMY", 18, 23], ["cells", "CELL", 18, 23], ["a localization", "TEST", 32, 46]]], ["Figures S3A and S3B ).", [["S3A", "GENE_OR_GENE_PRODUCT", 8, 11], ["S3A", "PROTEIN", 8, 11], ["S3B", "PROTEIN", 16, 19]]], ["These cells were used to investigate its distribution in cells exposed to arsenite, heat shock, sorbitol, or Earle's balanced salt solution (EBSS) starvation medium.", [["cells", "ANATOMY", 6, 11], ["cells", "ANATOMY", 57, 62], ["arsenite", "CHEMICAL", 74, 82], ["shock", "DISEASE", 89, 94], ["sorbitol", "CHEMICAL", 96, 104], ["EBSS", "CHEMICAL", 141, 145], ["arsenite", "CHEMICAL", 74, 82], ["sorbitol", "CHEMICAL", 96, 104], ["cells", "CELL", 6, 11], ["cells", "CELL", 57, 62], ["arsenite", "SIMPLE_CHEMICAL", 74, 82], ["sorbitol", "SIMPLE_CHEMICAL", 96, 104], ["These cells", "PROBLEM", 0, 11], ["heat shock", "TREATMENT", 84, 94], ["sorbitol", "TREATMENT", 96, 104], ["Earle's balanced salt solution (EBSS) starvation medium", "TREATMENT", 109, 164]]], ["Untreated control cells showed SINTBAD as a largely cytosolic protein, whereas the various cell stressors triggered the formation of speckles occurring mainly in the cytosol and to a minor extent in the nucleus ( Figures 1D and S4 ), reflecting the transition of SINTBAD from the cytosolic to the nuclear/insoluble fraction.", [["cells", "ANATOMY", 18, 23], ["cytosolic", "ANATOMY", 52, 61], ["cell", "ANATOMY", 91, 95], ["speckles", "ANATOMY", 133, 141], ["cytosol", "ANATOMY", 166, 173], ["nucleus", "ANATOMY", 203, 210], ["cytosolic", "ANATOMY", 280, 289], ["nuclear", "ANATOMY", 297, 304], ["cells", "CELL", 18, 23], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 31, 38], ["cell", "CELL", 91, 95], ["speckles", "CELLULAR_COMPONENT", 133, 141], ["cytosol", "CELLULAR_COMPONENT", 166, 173], ["nucleus", "CELLULAR_COMPONENT", 203, 210], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 263, 270], ["cytosolic", "CELLULAR_COMPONENT", 280, 289], ["nuclear", "CELLULAR_COMPONENT", 297, 304], ["SINTBAD", "PROTEIN", 31, 38], ["cytosolic protein", "PROTEIN", 52, 69], ["SINTBAD", "PROTEIN", 263, 270], ["Untreated control cells", "PROBLEM", 0, 23], ["SINTBAD", "PROBLEM", 31, 38], ["a largely cytosolic protein", "PROBLEM", 42, 69], ["the various cell stressors", "PROBLEM", 79, 105], ["speckles", "PROBLEM", 133, 141], ["the transition of SINTBAD", "PROBLEM", 245, 270], ["cytosolic protein", "OBSERVATION", 52, 69], ["various cell stressors", "OBSERVATION", 83, 105], ["speckles", "OBSERVATION_MODIFIER", 133, 141], ["cytosol", "ANATOMY", 166, 173], ["minor", "OBSERVATION_MODIFIER", 183, 188], ["extent", "OBSERVATION_MODIFIER", 189, 195], ["nucleus", "ANATOMY_MODIFIER", 203, 210]]], ["Staining of FLAG-tagged TANK did not reveal any arsenite or heat shockinduced changes of its cytosolic localization, whereas AZI2 already showed a speckled distribution in unstressed cells that was not further influenced by the indicated stressors ( Figure 1D ).Cell Stress Triggers the Formation of SINTBAD-Containing SpecklesIt was then interesting to directly compare the intracellular colocalization of the three TBK1-binding adapter proteins in unstressed and stressed cells.", [["cytosolic", "ANATOMY", 93, 102], ["cells", "ANATOMY", 183, 188], ["Cell", "ANATOMY", 262, 266], ["intracellular", "ANATOMY", 375, 388], ["cells", "ANATOMY", 474, 479], ["arsenite", "CHEMICAL", 48, 56], ["arsenite", "CHEMICAL", 48, 56], ["FLAG", "GENE_OR_GENE_PRODUCT", 12, 16], ["TANK", "GENE_OR_GENE_PRODUCT", 24, 28], ["arsenite", "SIMPLE_CHEMICAL", 48, 56], ["AZI2", "GENE_OR_GENE_PRODUCT", 125, 129], ["cells", "CELL", 183, 188], ["Cell", "CELL", 262, 266], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 375, 388], ["TBK1", "GENE_OR_GENE_PRODUCT", 417, 421], ["cells", "CELL", 474, 479], ["FLAG", "PROTEIN", 12, 16], ["TANK", "PROTEIN", 24, 28], ["AZI2", "PROTEIN", 125, 129], ["unstressed cells", "CELL_TYPE", 172, 188], ["SINTBAD", "PROTEIN", 300, 307], ["TBK1", "PROTEIN", 417, 421], ["binding adapter proteins", "PROTEIN", 422, 446], ["unstressed and stressed cells", "CELL_TYPE", 450, 479], ["FLAG-tagged TANK", "TEST", 12, 28], ["heat shockinduced changes", "PROBLEM", 60, 85], ["its cytosolic localization", "TEST", 89, 115], ["a speckled distribution in unstressed cells", "PROBLEM", 145, 188], ["SINTBAD", "TEST", 300, 307], ["unstressed and stressed cells", "PROBLEM", 450, 479], ["speckled", "OBSERVATION_MODIFIER", 147, 155], ["distribution", "OBSERVATION_MODIFIER", 156, 168], ["unstressed cells", "OBSERVATION", 172, 188], ["stressed cells", "OBSERVATION", 465, 479]]], ["Cell treatment with arsenite or thermal stress triggered the formation of speckles, whereas TANK remained largely cytosolic and showed only minor colocalization with focal SINTBAD (Figure 2A ).", [["Cell", "ANATOMY", 0, 4], ["speckles", "ANATOMY", 74, 82], ["cytosolic", "ANATOMY", 114, 123], ["arsenite", "CHEMICAL", 20, 28], ["arsenite", "CHEMICAL", 20, 28], ["Cell", "CELL", 0, 4], ["arsenite", "SIMPLE_CHEMICAL", 20, 28], ["speckles", "CELLULAR_COMPONENT", 74, 82], ["TANK", "GENE_OR_GENE_PRODUCT", 92, 96], ["TANK", "PROTEIN", 92, 96], ["focal SINTBAD", "PROTEIN", 166, 179], ["Figure 2A", "PROTEIN", 181, 190], ["Cell treatment", "TREATMENT", 0, 14], ["arsenite", "TREATMENT", 20, 28], ["thermal stress", "PROBLEM", 32, 46], ["focal", "OBSERVATION_MODIFIER", 166, 171]]], ["The speckled localization of AZI2 in control and stress-exposed cells showed no significant overlap with TANK ( Figure 2B ).", [["cells", "ANATOMY", 64, 69], ["AZI2", "CHEMICAL", 29, 33], ["AZI2", "GENE_OR_GENE_PRODUCT", 29, 33], ["cells", "CELL", 64, 69], ["AZI2", "PROTEIN", 29, 33], ["stress-exposed cells", "CELL_LINE", 49, 69], ["TANK", "PROTEIN", 105, 109], ["AZI2 in control", "TREATMENT", 29, 44], ["stress-exposed cells", "PROBLEM", 49, 69], ["no", "UNCERTAINTY", 77, 79], ["significant", "OBSERVATION_MODIFIER", 80, 91]]], ["Interestingly, the coexpression of AZI2 and SINTBAD triggered the formation of speckles even in unstressed cells and displayed a very high degree of colocalization within these MLOs ( Figure 2C ).Speckle Formation of SINTBAD Is Antagonized by the Chaperone Activity of Heat Shock ProteinsTo test the reversibility of inducible speckle formation, cells were exposed to heat shock and then further grown at 37 C to follow the fate of speckles over time.", [["speckles", "ANATOMY", 79, 87], ["cells", "ANATOMY", 107, 112], ["cells", "ANATOMY", 346, 351], ["speckles", "ANATOMY", 432, 440], ["shock", "DISEASE", 373, 378], ["AZI2", "GENE_OR_GENE_PRODUCT", 35, 39], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 44, 51], ["speckles", "CELLULAR_COMPONENT", 79, 87], ["cells", "CELL", 107, 112], ["Heat Shock Proteins", "GENE_OR_GENE_PRODUCT", 269, 288], ["cells", "CELL", 346, 351], ["AZI2", "PROTEIN", 35, 39], ["SINTBAD", "PROTEIN", 44, 51], ["unstressed cells", "CELL_TYPE", 96, 112], ["MLOs", "PROTEIN", 177, 181], ["Heat Shock Proteins", "PROTEIN", 269, 288], ["speckles", "PROBLEM", 79, 87], ["unstressed cells", "PROBLEM", 96, 112], ["a very high degree of colocalization", "PROBLEM", 127, 163], ["Heat Shock Proteins", "TREATMENT", 269, 288], ["inducible speckle formation", "PROBLEM", 317, 344], ["cells", "PROBLEM", 346, 351], ["heat shock", "PROBLEM", 368, 378], ["unstressed cells", "OBSERVATION", 96, 112], ["very", "OBSERVATION_MODIFIER", 129, 133], ["high degree", "OBSERVATION_MODIFIER", 134, 145], ["colocalization", "OBSERVATION", 149, 163], ["inducible", "OBSERVATION", 317, 326], ["speckle formation", "OBSERVATION", 327, 344]]], ["The size and number of speckles decreased in a timedependent manner, and speckles were not detectable after 3 h of cell recovery, as revealed by fluorescence microscopy ( Figure 3A ) and its quantitative analysis ( Figure 3B ).", [["speckles", "ANATOMY", 23, 31], ["speckles", "ANATOMY", 73, 81], ["cell", "ANATOMY", 115, 119], ["speckles", "CELLULAR_COMPONENT", 23, 31], ["speckles", "CELLULAR_COMPONENT", 73, 81], ["cell", "CELL", 115, 119], ["cell recovery", "TEST", 115, 128], ["fluorescence microscopy", "TEST", 145, 168], ["its quantitative analysis", "TEST", 187, 212], ["size", "OBSERVATION_MODIFIER", 4, 8], ["number", "OBSERVATION_MODIFIER", 13, 19], ["speckles", "OBSERVATION_MODIFIER", 23, 31], ["decreased", "OBSERVATION_MODIFIER", 32, 41]]], ["The resolution of speckles occurred also in the absence of de novo protein synthesis ( Figure S5A ) and in the presence of different lysosome inhibitors ( Figure S5B ), suggesting that lysosomal degradation and autophagic processes do not significantly contribute to this process.", [["speckles", "ANATOMY", 18, 26], ["lysosome", "ANATOMY", 133, 141], ["lysosomal", "ANATOMY", 185, 194], ["lysosomal", "CELLULAR_COMPONENT", 185, 194], ["speckles", "PROBLEM", 18, 26], ["de novo protein synthesis", "PROBLEM", 59, 84], ["different lysosome inhibitors", "TREATMENT", 123, 152], ["lysosomal degradation", "PROBLEM", 185, 206], ["autophagic processes", "PROBLEM", 211, 231], ["resolution", "OBSERVATION_MODIFIER", 4, 14], ["speckles", "OBSERVATION", 18, 26], ["lysosome inhibitors", "OBSERVATION", 133, 152], ["lysosomal degradation", "OBSERVATION", 185, 206], ["autophagic processes", "OBSERVATION", 211, 231]]], ["As chaperone function prevents aberrant phase transition of SGs (Mateju et al., 2017) it was interesting to test whether well-characterized inhibitors of HSP70 (VER155008, Pifithrin-m) or HSP90 (geldanamycin, radicicol) affect SINTBAD localization (Massey et al., 2010; Roe et al., 1999) .", [["VER155008", "CHEMICAL", 161, 170], ["geldanamycin", "CHEMICAL", 195, 207], ["radicicol", "CHEMICAL", 209, 218], ["VER155008", "CHEMICAL", 161, 170], ["geldanamycin", "CHEMICAL", 195, 207], ["radicicol", "CHEMICAL", 209, 218], ["SGs", "CELLULAR_COMPONENT", 60, 63], ["HSP70", "GENE_OR_GENE_PRODUCT", 154, 159], ["VER155008", "GENE_OR_GENE_PRODUCT", 161, 170], ["Pifithrin-m", "GENE_OR_GENE_PRODUCT", 172, 183], ["HSP90", "GENE_OR_GENE_PRODUCT", 188, 193], ["geldanamycin", "SIMPLE_CHEMICAL", 195, 207], ["radicicol", "SIMPLE_CHEMICAL", 209, 218], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 227, 234], ["HSP70", "PROTEIN", 154, 159], ["HSP90", "PROTEIN", 188, 193], ["SINTBAD", "PROTEIN", 227, 234], ["aberrant phase transition of SGs", "PROBLEM", 31, 63], ["HSP70", "TEST", 154, 159], ["VER", "TEST", 161, 164], ["Pifithrin", "TEST", 172, 181], ["HSP90 (geldanamycin", "TREATMENT", 188, 207], ["aberrant", "OBSERVATION_MODIFIER", 31, 39], ["phase", "OBSERVATION_MODIFIER", 40, 45]]], ["Inhibition of HSP70 or HSP90 function resulted in the formation of speckles even in the absence of stress signals ( Figure 3C ), revealing the importance of continuous chaperone function for the cytosolic localization of SINTBAD.", [["speckles", "ANATOMY", 67, 75], ["cytosolic", "ANATOMY", 195, 204], ["HSP70", "GENE_OR_GENE_PRODUCT", 14, 19], ["HSP90", "GENE_OR_GENE_PRODUCT", 23, 28], ["speckles", "CELLULAR_COMPONENT", 67, 75], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 221, 228], ["HSP70", "PROTEIN", 14, 19], ["HSP90", "PROTEIN", 23, 28], ["SINTBAD", "PROTEIN", 221, 228], ["HSP70", "TEST", 14, 19], ["HSP90 function", "TEST", 23, 37], ["speckles", "PROBLEM", 67, 75], ["stress signals", "PROBLEM", 99, 113], ["continuous chaperone function", "TREATMENT", 157, 186]]], ["Coimmunoprecipitation experiments showed the interaction between SINTBAD and HSP70, which was impaired under thermal stress conditions ( Figure 3D ).", [["SINTBAD", "GENE_OR_GENE_PRODUCT", 65, 72], ["HSP70", "GENE_OR_GENE_PRODUCT", 77, 82], ["SINTBAD", "PROTEIN", 65, 72], ["HSP70", "PROTEIN", 77, 82], ["Coimmunoprecipitation experiments", "TEST", 0, 33], ["HSP70", "TEST", 77, 82]]], ["The interaction between SINT-BAD and HSP90 was only detectable after coexpression of TBK1 ( Figure 3E ), suggesting a rather indirect interaction that can be controlled by the relative abundance of the known HSP90 interactor TBK1 (Yang et al., 2006) or that the interaction is phosphorylation dependent.SINTBAD-Containing Speckles Show No Colocalization with Cellular Organelles or Known MLOsTBK1 and several of its interactors including optineurin and mitochondrial antiviral-signaling protein are known to be recruited to membrane-surrounded organelles such as mitochondria (Fang et al., 2017; Moore and Holzbaur, 2016) or upon RNA virus infection to the Golgi apparatus (Pourcelot et al., 2016) .", [["mitochondrial", "ANATOMY", 453, 466], ["membrane", "ANATOMY", 524, 532], ["organelles", "ANATOMY", 544, 554], ["mitochondria", "ANATOMY", 563, 575], ["Golgi apparatus", "ANATOMY", 657, 672], ["SINT-BAD", "GENE_OR_GENE_PRODUCT", 24, 32], ["HSP90", "GENE_OR_GENE_PRODUCT", 37, 42], ["TBK1", "GENE_OR_GENE_PRODUCT", 85, 89], ["Figure 3E", "GENE_OR_GENE_PRODUCT", 92, 101], ["HSP90", "GENE_OR_GENE_PRODUCT", 208, 213], ["TBK1", "GENE_OR_GENE_PRODUCT", 225, 229], ["MLOsTBK1", "GENE_OR_GENE_PRODUCT", 388, 396], ["optineurin", "GENE_OR_GENE_PRODUCT", 438, 448], ["mitochondrial", "CELLULAR_COMPONENT", 453, 466], ["membrane", "CELLULAR_COMPONENT", 524, 532], ["organelles", "CELLULAR_COMPONENT", 544, 554], ["mitochondria", "CELLULAR_COMPONENT", 563, 575], ["Golgi", "CELLULAR_COMPONENT", 657, 662], ["SINT", "PROTEIN", 24, 28], ["BAD", "PROTEIN", 29, 32], ["HSP90", "PROTEIN", 37, 42], ["TBK1", "PROTEIN", 85, 89], ["Figure 3E", "PROTEIN", 92, 101], ["HSP90 interactor", "PROTEIN", 208, 224], ["TBK1", "PROTEIN", 225, 229], ["Cellular Organelles", "PROTEIN", 359, 378], ["MLOsTBK1", "PROTEIN", 388, 396], ["optineurin", "PROTEIN", 438, 448], ["mitochondrial antiviral-signaling protein", "PROTEIN", 453, 494], ["HSP90", "TEST", 37, 42], ["TBK1", "PROBLEM", 85, 89], ["phosphorylation dependent", "PROBLEM", 277, 302], ["Cellular Organelles", "PROBLEM", 359, 378], ["Known MLOsTBK1", "PROBLEM", 382, 396], ["optineurin and mitochondrial antiviral", "TREATMENT", 438, 476], ["signaling protein", "PROBLEM", 477, 494], ["RNA virus infection", "PROBLEM", 630, 649], ["interactor TBK1", "OBSERVATION", 214, 229], ["No", "UNCERTAINTY", 336, 338], ["Colocalization", "OBSERVATION", 339, 353], ["Cellular Organelles", "OBSERVATION", 359, 378], ["mitochondrial antiviral", "OBSERVATION", 453, 476]]], ["Thus, we asked whether SINTBAD would be found in association with these organelles.", [["organelles", "ANATOMY", 72, 82], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 23, 30], ["organelles", "CELLULAR_COMPONENT", 72, 82], ["SINTBAD", "PROTEIN", 23, 30]]], ["Costaining experiments with untreated and arsenite-or heat shock-treated cells showed significant colocalization neither with mitochondria ( Figure 4A ) nor with Golgi, lysosomes, peroxisomes, endosomes, or endoplasmic reticulum (Figure S6) .", [["cells", "ANATOMY", 73, 78], ["mitochondria", "ANATOMY", 126, 138], ["Golgi", "ANATOMY", 162, 167], ["lysosomes", "ANATOMY", 169, 178], ["peroxisomes", "ANATOMY", 180, 191], ["endosomes", "ANATOMY", 193, 202], ["endoplasmic reticulum", "ANATOMY", 207, 228], ["arsenite", "CHEMICAL", 42, 50], ["shock", "DISEASE", 59, 64], ["arsenite", "CHEMICAL", 42, 50], ["arsenite", "SIMPLE_CHEMICAL", 42, 50], ["cells", "CELL", 73, 78], ["mitochondria", "CELLULAR_COMPONENT", 126, 138], ["Figure 4A", "GENE_OR_GENE_PRODUCT", 141, 150], ["Golgi", "CELLULAR_COMPONENT", 162, 167], ["lysosomes", "CELLULAR_COMPONENT", 169, 178], ["peroxisomes", "CELLULAR_COMPONENT", 180, 191], ["endosomes", "CELLULAR_COMPONENT", 193, 202], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 207, 228], ["heat shock-treated cells", "CELL_LINE", 54, 78], ["S6", "PROTEIN", 237, 239], ["heat shock", "PROBLEM", 54, 64], ["significant colocalization", "PROBLEM", 86, 112], ["endoplasmic reticulum", "PROBLEM", 207, 228], ["endoplasmic reticulum", "OBSERVATION", 207, 228]]], ["In addition, we costained speckles with marker proteins of several known MLOs.", [["speckles", "ANATOMY", 26, 34], ["MLOs", "GENE_OR_GENE_PRODUCT", 73, 77], ["marker proteins", "PROTEIN", 40, 55], ["MLOs", "PROTEIN", 73, 77], ["marker proteins", "TEST", 40, 55]]], ["These experiments showed colocalization of speckles neither with the SG marker proteins eIF4G ( Figure 4B ) or Ras GTPaseactivating protein-binding protein 1 (G3BP1) nor with the P body marker DCP1a ( Figures S7A and S7B) .Identification of SINT-SpecklesAs none of these experiments related the SINTBAD-containing speckles to known subcellular structures, we aimed to identify the SINTBAD interactome by mass spectrometry.", [["speckles", "ANATOMY", 43, 51], ["subcellular structures", "ANATOMY", 332, 354], ["speckles", "CELLULAR_COMPONENT", 43, 51], ["eIF4G ( Figure 4B", "GENE_OR_GENE_PRODUCT", 88, 105], ["Ras GTPaseactivating protein-binding protein 1", "GENE_OR_GENE_PRODUCT", 111, 157], ["G3BP1", "GENE_OR_GENE_PRODUCT", 159, 164], ["DCP1a", "GENE_OR_GENE_PRODUCT", 193, 198], ["SINT-Speckles", "GENE_OR_GENE_PRODUCT", 241, 254], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 295, 302], ["speckles", "CELLULAR_COMPONENT", 314, 322], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 381, 388], ["SG marker proteins", "PROTEIN", 69, 87], ["eIF4G", "PROTEIN", 88, 93], ["Figure 4B", "PROTEIN", 96, 105], ["Ras GTPaseactivating protein-binding protein 1", "PROTEIN", 111, 157], ["G3BP1", "PROTEIN", 159, 164], ["P body marker", "PROTEIN", 179, 192], ["DCP1a", "PROTEIN", 193, 198], ["S7A", "PROTEIN", 209, 212], ["S7B", "PROTEIN", 217, 220], ["SINT", "PROTEIN", 241, 245], ["SINTBAD", "PROTEIN", 295, 302], ["SINTBAD", "PROTEIN", 381, 388], ["These experiments", "TEST", 0, 17], ["colocalization of speckles", "PROBLEM", 25, 51], ["Ras GTPaseactivating protein", "TEST", 111, 139], ["binding protein", "TEST", 140, 155], ["the P body marker DCP1a", "TREATMENT", 175, 198], ["SINT", "TEST", 241, 245], ["mass spectrometry", "OBSERVATION", 404, 421]]], ["Cytosolic and nuclear/insoluble fractions were prepared from 293T cells, transfected with moderate levels of FLAG-tagged SINTBAD, followed by immunoprecipitation and identification of coprecipitating proteins by mass spectrometry as schematically shown in Figure 5A .", [["Cytosolic", "ANATOMY", 0, 9], ["nuclear", "ANATOMY", 14, 21], ["fractions", "ANATOMY", 32, 41], ["293T cells", "ANATOMY", 61, 71], ["Cytosolic", "ORGANISM_SUBSTANCE", 0, 9], ["nuclear", "CELLULAR_COMPONENT", 14, 21], ["293T cells", "CELL", 61, 71], ["FLAG", "GENE_OR_GENE_PRODUCT", 109, 113], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 121, 128], ["293T cells", "CELL_LINE", 61, 71], ["FLAG", "PROTEIN", 109, 113], ["SINTBAD", "PROTEIN", 121, 128], ["coprecipitating proteins", "PROTEIN", 184, 208], ["Cytosolic and nuclear/insoluble fractions", "TEST", 0, 41], ["FLAG", "TEST", 109, 113], ["immunoprecipitation", "TEST", 142, 161], ["coprecipitating proteins", "PROBLEM", 184, 208], ["mass spectrometry", "PROBLEM", 212, 229], ["moderate", "OBSERVATION_MODIFIER", 90, 98]]], ["For further bioinformatic analysis we considered proteins identified in two independent biological and technical replicates and defined high-confidence interactors by three different criteria as specified in detail in Figure S8A .", [["further bioinformatic analysis", "TEST", 4, 34], ["proteins", "PROBLEM", 49, 57]]], ["This analysis revealed 150 high-confidence SINT-BAD interactors of which 27% were found in the cytosol, 58% in the nuclear/insoluble fraction, and 15% in both fractions.", [["cytosol", "ANATOMY", 95, 102], ["nuclear", "ANATOMY", 115, 122], ["BAD", "GENE_OR_GENE_PRODUCT", 48, 51], ["cytosol", "ORGANISM_SUBSTANCE", 95, 102], ["nuclear", "CELLULAR_COMPONENT", 115, 122], ["SINT", "PROTEIN", 43, 47], ["BAD", "PROTEIN", 48, 51], ["This analysis", "TEST", 0, 13], ["BAD interactors", "PROBLEM", 48, 63], ["the cytosol", "TEST", 91, 102], ["the nuclear/insoluble fraction", "TEST", 111, 141], ["cytosol", "ANATOMY", 95, 102]]], ["A list of the high-confidence interactors and the complete mass spectrometry dataset is given in Table S1 .", [["the high-confidence interactors", "PROBLEM", 10, 41], ["the complete mass spectrometry dataset", "PROBLEM", 46, 84]]], ["To validate the interaction between SINTBAD and some of the interactors by (D) 293T cells were transfected to express FLAG-SINTBAD together with HA-HSP70.", [["293T cells", "ANATOMY", 79, 89], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 36, 43], ["293T cells", "CELL", 79, 89], ["FLAG", "GENE_OR_GENE_PRODUCT", 118, 122], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 123, 130], ["HA-HSP70", "GENE_OR_GENE_PRODUCT", 145, 153], ["SINTBAD", "PROTEIN", 36, 43], ["293T cells", "CELL_LINE", 79, 89], ["FLAG", "PROTEIN", 118, 122], ["SINTBAD", "PROTEIN", 123, 130], ["HA", "PROTEIN", 145, 147], ["HSP70", "PROTEIN", 148, 153]]], ["One day later, one cell dish was treated with heat shock as shown and cells were lysed.", [["cell dish", "ANATOMY", 19, 28], ["cells", "ANATOMY", 70, 75], ["shock", "DISEASE", 51, 56], ["cell dish", "CELL", 19, 28], ["cells", "CELL", 70, 75], ["one cell dish", "PROBLEM", 15, 28], ["heat shock", "TREATMENT", 46, 56], ["cell dish", "OBSERVATION", 19, 28]]], ["Lysates were split into two aliquots, one being used for immunoprecipitation (IP) using an anti-HA antibody.", [["Lysates", "ANATOMY", 0, 7], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["anti-HA antibody", "PROTEIN", 91, 107], ["Lysates", "TREATMENT", 0, 7], ["immunoprecipitation (IP", "TREATMENT", 57, 80], ["an anti-HA antibody", "TEST", 88, 107]]], ["The other aliquot was used as an input control sample to ensure correct and comparable protein expression.", [["The other aliquot", "TREATMENT", 0, 17], ["an input control sample", "TREATMENT", 30, 53], ["protein expression", "OBSERVATION", 87, 105]]], ["The samples were further analyzed by western blot using appropriate antibodies as indicated.Identification of SINT-Speckles(E) 293T cells were transfected to express FLAG-HSP90 together with HA-SINTBAD or Myc-TBK1 as shown.", [["samples", "ANATOMY", 4, 11], ["SINT-Speckles(E) 293T cells", "ANATOMY", 110, 137], ["SINT-Speckles", "GENE_OR_GENE_PRODUCT", 110, 123], ["E) 293T cells", "CELL", 124, 137], ["FLAG", "GENE_OR_GENE_PRODUCT", 166, 170], ["HSP90", "GENE_OR_GENE_PRODUCT", 171, 176], ["HA-SINTBAD", "GENE_OR_GENE_PRODUCT", 191, 201], ["Myc-TBK1", "GENE_OR_GENE_PRODUCT", 205, 213], ["antibodies", "PROTEIN", 68, 78], ["SINT-Speckles(E) 293T cells", "CELL_LINE", 110, 137], ["FLAG", "PROTEIN", 166, 170], ["HSP90", "PROTEIN", 171, 176], ["HA", "PROTEIN", 191, 193], ["SINTBAD", "PROTEIN", 194, 201], ["TBK1", "PROTEIN", 209, 213], ["The samples", "TEST", 0, 11], ["appropriate antibodies", "TREATMENT", 56, 78], ["SINT", "TEST", 110, 114], ["FLAG", "TEST", 166, 170], ["HA", "PROBLEM", 191, 193], ["SINTBAD", "PROBLEM", 194, 201], ["Myc-TBK1", "PROBLEM", 205, 213]]], ["IP was performed using anti-FLAG antibodies, followed by western blot analysis of the IP and input samples.Identification of SINT-Specklesan independent experimental approach we performed coimmunoprecipitation experiments.", [["samples", "ANATOMY", 99, 106], ["SINT", "GENE_OR_GENE_PRODUCT", 125, 129], ["anti-FLAG antibodies", "PROTEIN", 23, 43], ["SINT", "PROTEIN", 125, 129], ["anti-FLAG antibodies", "TREATMENT", 23, 43], ["input samples", "TEST", 93, 106], ["coimmunoprecipitation experiments", "TREATMENT", 188, 221]]], ["These experiments confirmed the results of the mass spectrometry analysis and are exemplified for the interaction of SINTBAD and the tyrosine phosphatase PTPN23 or the autophagy regulator AMBRA1 ( Figure 5B ).", [["tyrosine", "CHEMICAL", 133, 141], ["tyrosine", "CHEMICAL", 133, 141], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 117, 124], ["PTPN23", "GENE_OR_GENE_PRODUCT", 154, 160], ["SINTBAD", "PROTEIN", 117, 124], ["tyrosine phosphatase", "PROTEIN", 133, 153], ["PTPN23", "PROTEIN", 154, 160], ["autophagy regulator", "PROTEIN", 168, 187], ["AMBRA1", "PROTEIN", 188, 194], ["Figure 5B", "PROTEIN", 197, 206], ["the mass spectrometry analysis", "TEST", 43, 73], ["SINTBAD", "TREATMENT", 117, 124], ["the tyrosine phosphatase PTPN23", "TEST", 129, 160]]], ["Also, binding of ABIN2 (A20-binding inhibitor of nuclear factor-kB activation 2, also referred to as TNIP2) to SINTBAD was confirmed, and mapping experiments revealed the importance of the N-terminal region of SINTBAD for this interaction ( Figure 5C ).", [["N", "CHEMICAL", 189, 190], ["ABIN2", "GENE_OR_GENE_PRODUCT", 17, 22], ["A20", "GENE_OR_GENE_PRODUCT", 24, 27], ["nuclear factor-kB activation 2", "GENE_OR_GENE_PRODUCT", 49, 79], ["TNIP2", "GENE_OR_GENE_PRODUCT", 101, 106], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 111, 118], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 210, 217], ["ABIN2", "PROTEIN", 17, 22], ["A20", "PROTEIN", 24, 27], ["nuclear factor-kB activation 2", "PROTEIN", 49, 79], ["TNIP2", "PROTEIN", 101, 106], ["SINTBAD", "PROTEIN", 111, 118], ["N-terminal region", "PROTEIN", 189, 206], ["SINTBAD", "PROTEIN", 210, 217], ["ABIN2 (A20-binding inhibitor", "TREATMENT", 17, 45], ["nuclear factor", "TEST", 49, 63], ["mapping experiments", "TEST", 138, 157]]], ["Interestingly, expression of SINTBAD and all of its mutants led to an increase in ABIN2 protein levels by an unknown mechanism.", [["SINTBAD", "GENE_OR_GENE_PRODUCT", 29, 36], ["ABIN2", "GENE_OR_GENE_PRODUCT", 82, 87], ["SINTBAD", "PROTEIN", 29, 36], ["ABIN2", "PROTEIN", 82, 87], ["SINTBAD", "PROBLEM", 29, 36], ["an increase in ABIN2 protein levels", "PROBLEM", 67, 102], ["increase", "OBSERVATION_MODIFIER", 70, 78]]], ["The identified interacting proteins are known to serve various biological functions, as displayed in Figure 5D .", [["interacting proteins", "PROTEIN", 15, 35], ["interacting proteins", "PROBLEM", 15, 35], ["interacting proteins", "OBSERVATION", 15, 35]]], ["While the biggest group is represented by enzymes and regulators of metabolic processes, two very prominent groups represent proteins with relevance in membrane trafficking or autophagy and also mitosis and cytoskeleton dynamics.", [["membrane", "ANATOMY", 152, 160], ["cytoskeleton", "ANATOMY", 207, 219], ["membrane", "CELLULAR_COMPONENT", 152, 160], ["mitosis", "CELLULAR_COMPONENT", 195, 202], ["cytoskeleton", "CELLULAR_COMPONENT", 207, 219], ["enzymes", "PROTEIN", 42, 49], ["enzymes", "TEST", 42, 49], ["metabolic processes", "PROBLEM", 68, 87], ["membrane trafficking", "PROBLEM", 152, 172], ["autophagy", "PROBLEM", 176, 185], ["mitosis and cytoskeleton dynamics", "PROBLEM", 195, 228], ["metabolic processes", "OBSERVATION", 68, 87], ["very", "OBSERVATION_MODIFIER", 93, 97], ["prominent", "OBSERVATION_MODIFIER", 98, 107], ["proteins", "OBSERVATION", 125, 133], ["membrane trafficking", "OBSERVATION", 152, 172]]], ["The two smallest groups are represented by regulators of innate immunity and proteins mediating transcription, probably assisting in expression of inflammatory gene expression.", [["proteins mediating transcription", "TREATMENT", 77, 109], ["inflammatory gene expression", "PROBLEM", 147, 175], ["two", "OBSERVATION_MODIFIER", 4, 7], ["smallest", "OBSERVATION_MODIFIER", 8, 16], ["inflammatory", "OBSERVATION_MODIFIER", 147, 159]]], ["To test whether mutual interactions have already been described for some of the SINTBAD-interacting proteins, we analyzed the interactors in the STRING database.", [["SINTBAD", "GENE_OR_GENE_PRODUCT", 80, 87], ["SINTBAD", "PROTEIN", 80, 87], ["interacting proteins", "PROTEIN", 88, 108]]], ["This analysis revealed the existence of known protein interaction networks between the 150 proteins, as visualized in Figure 5E .", [["protein interaction networks", "PROTEIN", 46, 74], ["150 proteins", "PROTEIN", 87, 99], ["This analysis", "TEST", 0, 13], ["known protein interaction networks", "PROBLEM", 40, 74], ["protein interaction", "OBSERVATION", 46, 65]]], ["We then compared the intracellular localization of SINTBAD with that of some of its interacting proteins.", [["intracellular", "ANATOMY", 21, 34], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 21, 34], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 51, 58], ["SINTBAD", "PROTEIN", 51, 58], ["interacting proteins", "PROTEIN", 84, 104]]], ["These experiments revealed that some of the proteins such as PTPN23 exactly mirrored the behavior of SINTBAD, as shown in Figure 5F .", [["PTPN23", "GENE_OR_GENE_PRODUCT", 61, 67], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 101, 108], ["PTPN23", "PROTEIN", 61, 67], ["SINTBAD", "PROTEIN", 101, 108], ["These experiments", "TEST", 0, 17]]], ["PTPN23 localizes in the cytosol of control cells and forms speckles after induction of cell stress.", [["cytosol", "ANATOMY", 24, 31], ["cells", "ANATOMY", 43, 48], ["speckles", "ANATOMY", 59, 67], ["cell", "ANATOMY", 87, 91], ["PTPN23", "GENE_OR_GENE_PRODUCT", 0, 6], ["cytosol", "CELLULAR_COMPONENT", 24, 31], ["cells", "CELL", 43, 48], ["speckles", "CELLULAR_COMPONENT", 59, 67], ["cell", "CELL", 87, 91], ["PTPN23", "PROTEIN", 0, 6], ["control cells", "CELL_TYPE", 35, 48], ["PTPN23", "TREATMENT", 0, 6], ["cell stress", "PROBLEM", 87, 98]]], ["Costaining with SINTBAD revealed a complete colocalization in speckles after treatment with heat shock ( Figure 5F ) or arsenite ( Figure S8B ), confirming PTPN23 as a bona fide constituent of speckles.", [["speckles", "ANATOMY", 62, 70], ["speckles", "ANATOMY", 193, 201], ["SINTBAD", "CHEMICAL", 16, 23], ["shock", "DISEASE", 97, 102], ["arsenite", "CHEMICAL", 120, 128], ["PTPN23", "CHEMICAL", 156, 162], ["arsenite", "CHEMICAL", 120, 128], ["speckles", "CELLULAR_COMPONENT", 62, 70], ["arsenite", "SIMPLE_CHEMICAL", 120, 128], ["PTPN23", "GENE_OR_GENE_PRODUCT", 156, 162], ["speckles", "CELLULAR_COMPONENT", 193, 201], ["SINTBAD", "PROTEIN", 16, 23], ["PTPN23", "PROTEIN", 156, 162], ["a complete colocalization in speckles", "PROBLEM", 33, 70], ["heat shock ( Figure 5F", "TREATMENT", 92, 114], ["speckles", "OBSERVATION", 193, 201]]], ["According to the ability of SINTBAD to bind and colocalize with further proteins we term these speckles inducible SINT-speckles.Regulation of SINT-Speckle Formation by KAT2A and ULK1/2Further costaining experiments revealed that some interactors can trigger the formation of SINT-speckles even in unstressed cells.", [["cells", "ANATOMY", 308, 313], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 28, 35], ["SINT", "GENE_OR_GENE_PRODUCT", 114, 118], ["SINT", "GENE_OR_GENE_PRODUCT", 142, 146], ["KAT2A", "GENE_OR_GENE_PRODUCT", 168, 173], ["ULK1", "GENE_OR_GENE_PRODUCT", 178, 182], ["SINT", "GENE_OR_GENE_PRODUCT", 275, 279], ["cells", "CELL", 308, 313], ["SINTBAD", "PROTEIN", 28, 35], ["SINT", "PROTEIN", 114, 118], ["SINT", "PROTEIN", 142, 146], ["KAT2A", "PROTEIN", 168, 173], ["ULK1", "PROTEIN", 178, 182], ["SINT", "PROTEIN", 275, 279], ["unstressed cells", "CELL_TYPE", 297, 313], ["further proteins", "TREATMENT", 64, 80], ["ULK1", "TEST", 178, 182], ["some interactors", "PROBLEM", 229, 245], ["unstressed cells", "OBSERVATION", 297, 313]]], ["An example of such a positive regulator is the lysine acetyltransferase KAT2A.", [["lysine", "CHEMICAL", 47, 53], ["lysine", "CHEMICAL", 47, 53], ["KAT2A", "GENE_OR_GENE_PRODUCT", 72, 77], ["lysine acetyltransferase", "PROTEIN", 47, 71], ["KAT2A", "PROTEIN", 72, 77], ["the lysine acetyltransferase KAT2A", "TREATMENT", 43, 77]]], ["Expression of this predominantly nuclear protein triggered the formation of SINT-speckles even in unstressed cells and also increased the fraction of nuclear speckles ( Figure 6A ).", [["nuclear", "ANATOMY", 33, 40], ["SINT-speckles", "ANATOMY", 76, 89], ["cells", "ANATOMY", 109, 114], ["nuclear speckles", "ANATOMY", 150, 166], ["nuclear", "CELLULAR_COMPONENT", 33, 40], ["SINT", "GENE_OR_GENE_PRODUCT", 76, 80], ["cells", "CELL", 109, 114], ["nuclear", "CELLULAR_COMPONENT", 150, 157], ["SINT", "PROTEIN", 76, 80], ["unstressed cells", "CELL_TYPE", 98, 114], ["this predominantly nuclear protein", "PROBLEM", 14, 48], ["SINT-speckles", "PROBLEM", 76, 89], ["unstressed cells", "PROBLEM", 98, 114], ["unstressed cells", "OBSERVATION", 98, 114], ["increased", "OBSERVATION_MODIFIER", 124, 133], ["nuclear speckles", "OBSERVATION", 150, 166]]], ["Another interactor triggering the formation of SINT-speckles was ABIN2, as its expression resulted in SINT-speckle formation even in unstressed cells ( Figure 6B ).", [["SINT-speckles", "ANATOMY", 47, 60], ["cells", "ANATOMY", 144, 149], ["SINT", "GENE_OR_GENE_PRODUCT", 47, 51], ["ABIN2", "GENE_OR_GENE_PRODUCT", 65, 70], ["SINT", "GENE_OR_GENE_PRODUCT", 102, 106], ["cells", "CELL", 144, 149], ["SINT", "PROTEIN", 47, 51], ["ABIN2", "PROTEIN", 65, 70], ["SINT", "PROTEIN", 102, 106], ["unstressed cells", "CELL_TYPE", 133, 149], ["SINT-speckle formation", "PROBLEM", 102, 124], ["unstressed cells", "PROBLEM", 133, 149], ["unstressed cells", "OBSERVATION", 133, 149]]], ["The dominant effect of ABIN2 also occurred for PTPN23 ( Figure 6B , lower) and resembles that of AZI2, which was sufficient to trigger incorporation of SINTBAD into speckles (see Fig Figure S10 ).", [["speckles", "ANATOMY", 165, 173], ["ABIN2", "GENE_OR_GENE_PRODUCT", 23, 28], ["AZI2", "GENE_OR_GENE_PRODUCT", 97, 101], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 152, 159], ["ABIN2", "PROTEIN", 23, 28], ["PTPN23", "PROTEIN", 47, 53], ["AZI2", "PROTEIN", 97, 101], ["SINTBAD", "PROTEIN", 152, 159], ["ABIN2", "PROBLEM", 23, 28], ["PTPN23", "TEST", 47, 53], ["dominant", "OBSERVATION_MODIFIER", 4, 12], ["effect", "OBSERVATION_MODIFIER", 13, 19]]], ["A kinase-inactive ULK1 K46I point mutant (Chan et al., 2009) , in contrast to the ULK1 wild-type, formed speckles upon cellular stress when expressed alone ( Figure 6D ).", [["speckles", "ANATOMY", 105, 113], ["cellular", "ANATOMY", 119, 127], ["ULK1", "GENE_OR_GENE_PRODUCT", 18, 22], ["ULK1", "GENE_OR_GENE_PRODUCT", 82, 86], ["speckles", "CELLULAR_COMPONENT", 105, 113], ["cellular", "CELL", 119, 127], ["ULK1 K46I point mutant", "PROTEIN", 18, 40], ["ULK1", "PROTEIN", 82, 86], ["A kinase", "TEST", 0, 8], ["cellular stress", "PROBLEM", 119, 134], ["cellular stress", "OBSERVATION", 119, 134]]], ["Coexpression of the kinase-inactive mutant with SINTBAD resulted in the formation of SINTspeckles even in unstressed cells, emphasizing the importance of ULK1 kinase activity for controlling SINTspeckle formation.", [["cells", "ANATOMY", 117, 122], ["SINTBAD", "CHEMICAL", 48, 55], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 48, 55], ["SINTspeckles", "GENE_OR_GENE_PRODUCT", 85, 97], ["cells", "CELL", 117, 122], ["ULK1", "GENE_OR_GENE_PRODUCT", 154, 158], ["SINTspeckle", "GENE_OR_GENE_PRODUCT", 191, 202], ["kinase-inactive mutant", "PROTEIN", 20, 42], ["SINTBAD", "PROTEIN", 48, 55], ["SINTspeckles", "PROTEIN", 85, 97], ["unstressed cells", "CELL_TYPE", 106, 122], ["ULK1 kinase", "PROTEIN", 154, 165], ["SINTspeckle", "PROTEIN", 191, 202], ["the kinase", "TEST", 16, 26], ["inactive mutant with SINTBAD", "PROBLEM", 27, 55], ["SINTspeckles", "PROBLEM", 85, 97], ["unstressed cells", "PROBLEM", 106, 122], ["ULK1 kinase activity", "TREATMENT", 154, 174], ["controlling SINTspeckle formation", "PROBLEM", 179, 212], ["unstressed cells", "OBSERVATION", 106, 122]]], ["To determine the consequences of ULK knockdown on SINT-speckle formation we interfered with the expression of ULK1 and also ULK2, as both kinases can have redundant functions (Lee and Tournier, 2011; Li et al., 2016) .", [["ULK", "GENE_OR_GENE_PRODUCT", 33, 36], ["SINT", "GENE_OR_GENE_PRODUCT", 50, 54], ["ULK1", "GENE_OR_GENE_PRODUCT", 110, 114], ["ULK2", "GENE_OR_GENE_PRODUCT", 124, 128], ["ULK", "PROTEIN", 33, 36], ["SINT", "PROTEIN", 50, 54], ["ULK1", "PROTEIN", 110, 114], ["ULK2", "PROTEIN", 124, 128], ["kinases", "PROTEIN", 138, 145], ["ULK knockdown", "PROBLEM", 33, 46], ["ULK1", "PROBLEM", 110, 114]]], ["Loss of both kinases already triggered the formation of SINTspeckles even in unstressed cells ( Figure 6E ), supporting the finding that constitutive ULK signaling is important for restriction of SINT-speckle formation.", [["cells", "ANATOMY", 88, 93], ["SINTspeckles", "GENE_OR_GENE_PRODUCT", 56, 68], ["cells", "CELL", 88, 93], ["ULK", "GENE_OR_GENE_PRODUCT", 150, 153], ["SINT", "GENE_OR_GENE_PRODUCT", 196, 200], ["kinases", "PROTEIN", 13, 20], ["SINTspeckles", "PROTEIN", 56, 68], ["unstressed cells", "CELL_TYPE", 77, 93], ["ULK", "PROTEIN", 150, 153], ["SINT", "PROTEIN", 196, 200], ["Loss of both kinases", "PROBLEM", 0, 20], ["SINTspeckles", "PROBLEM", 56, 68], ["constitutive ULK signaling", "PROBLEM", 137, 163], ["SINT-speckle formation", "PROBLEM", 196, 218], ["both kinases", "OBSERVATION", 8, 20], ["unstressed cells", "OBSERVATION", 77, 93]]], ["These kinase-dependent regulatory processes could enable regulation of SINT-speckle formation, as MLOs are highly dynamic and their formation is typically also regulated during the cell cycle (Rai et al., 2018) .", [["cell", "ANATOMY", 181, 185], ["SINT", "GENE_OR_GENE_PRODUCT", 71, 75], ["MLOs", "GENE_OR_GENE_PRODUCT", 98, 102], ["cell", "CELL", 181, 185], ["SINT", "PROTEIN", 71, 75], ["MLOs", "PROTEIN", 98, 102], ["These kinase-dependent regulatory processes", "PROBLEM", 0, 43], ["SINT-speckle formation", "PROBLEM", 71, 93]]], ["This also applies to SINT-speckles, which do not occur in unstressed or stressed mitotic cells ( Figure 6F ).SINT-Speckle Components Control the Amplitude and Localization of Activated TBK1As expression of ULK1 can trigger TBK1 phosphorylation , we tested the effect of ULK1 expression on the localization of phosphorylated TBK1.", [["mitotic cells", "ANATOMY", 81, 94], ["SINT", "GENE_OR_GENE_PRODUCT", 21, 25], ["mitotic cells", "CELL", 81, 94], ["TBK1As", "GENE_OR_GENE_PRODUCT", 185, 191], ["ULK1", "GENE_OR_GENE_PRODUCT", 206, 210], ["TBK1", "GENE_OR_GENE_PRODUCT", 223, 227], ["ULK1", "GENE_OR_GENE_PRODUCT", 270, 274], ["TBK1", "GENE_OR_GENE_PRODUCT", 324, 328], ["SINT", "PROTEIN", 21, 25], ["stressed mitotic cells", "CELL_TYPE", 72, 94], ["SINT", "PROTEIN", 109, 113], ["TBK1As", "PROTEIN", 185, 191], ["ULK1", "PROTEIN", 206, 210], ["TBK1", "PROTEIN", 223, 227], ["ULK1", "PROTEIN", 270, 274], ["phosphorylated TBK1", "PROTEIN", 309, 328], ["SINT-speckles", "PROBLEM", 21, 34], ["the Amplitude", "TEST", 141, 154], ["Activated TBK1As expression of ULK1", "TREATMENT", 175, 210], ["TBK1 phosphorylation", "PROBLEM", 223, 243], ["ULK1 expression", "TREATMENT", 270, 285], ["phosphorylated TBK1", "TREATMENT", 309, 328], ["mitotic cells", "OBSERVATION", 81, 94], ["phosphorylated TBK1", "OBSERVATION", 309, 328]]], ["ULK1-expressing cells lacked any areas with focal TBK1 phosphorylation, as the activated kinase was found in the cytosol ( Figure 7A ), revealing that ULK1 can control the distribution of phosphorylated TBK1.", [["cells", "ANATOMY", 16, 21], ["cytosol", "ANATOMY", 113, 120], ["ULK1", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 16, 21], ["TBK1", "GENE_OR_GENE_PRODUCT", 50, 54], ["cytosol", "CELLULAR_COMPONENT", 113, 120], ["ULK1", "GENE_OR_GENE_PRODUCT", 151, 155], ["TBK1", "GENE_OR_GENE_PRODUCT", 203, 207], ["ULK1", "PROTEIN", 0, 4], ["expressing cells", "CELL_TYPE", 5, 21], ["TBK1", "PROTEIN", 50, 54], ["activated kinase", "PROTEIN", 79, 95], ["ULK1", "PROTEIN", 151, 155], ["phosphorylated TBK1", "PROTEIN", 188, 207], ["ULK1", "TEST", 0, 4], ["expressing cells", "PROBLEM", 5, 21], ["focal TBK1 phosphorylation", "PROBLEM", 44, 70], ["the activated kinase", "TEST", 75, 95], ["ULK1", "PROBLEM", 151, 155], ["phosphorylated TBK1", "PROBLEM", 188, 207], ["expressing cells", "OBSERVATION", 5, 21], ["areas", "OBSERVATION_MODIFIER", 33, 38], ["focal", "OBSERVATION_MODIFIER", 44, 49], ["TBK1 phosphorylation", "OBSERVATION", 50, 70], ["phosphorylated TBK1", "OBSERVATION", 188, 207]]], ["To test whether loss of ULK1 and ULK2 affects TBK1 phosphorylation in response to thermal stress, the expression of both kinases was downregulated with specific siRNAs ( Figure S11 ).", [["ULK1", "GENE_OR_GENE_PRODUCT", 24, 28], ["ULK2", "GENE_OR_GENE_PRODUCT", 33, 37], ["TBK1", "GENE_OR_GENE_PRODUCT", 46, 50], ["ULK1", "PROTEIN", 24, 28], ["ULK2", "PROTEIN", 33, 37], ["TBK1", "PROTEIN", 46, 50], ["kinases", "PROTEIN", 121, 128], ["loss of ULK1", "PROBLEM", 16, 28], ["TBK1 phosphorylation", "PROBLEM", 46, 66], ["thermal stress", "PROBLEM", 82, 96]]], ["Immunofluorescence analysis of control cells revealed the heat shock-activated TBK1 in focal structures mainly in the nucleus with a partial overlap with cytosolic SINT-speckles.", [["cells", "ANATOMY", 39, 44], ["focal structures", "ANATOMY", 87, 103], ["nucleus", "ANATOMY", 118, 125], ["cytosolic", "ANATOMY", 154, 163], ["cells", "CELL", 39, 44], ["TBK1", "GENE_OR_GENE_PRODUCT", 79, 83], ["focal structures", "PATHOLOGICAL_FORMATION", 87, 103], ["nucleus", "CELLULAR_COMPONENT", 118, 125], ["SINT", "GENE_OR_GENE_PRODUCT", 164, 168], ["heat shock-activated TBK1", "PROTEIN", 58, 83], ["SINT", "PROTEIN", 164, 168], ["Immunofluorescence analysis", "TEST", 0, 27], ["control cells", "PROBLEM", 31, 44], ["the heat shock", "PROBLEM", 54, 68], ["activated TBK1 in focal structures", "PROBLEM", 69, 103], ["shock", "OBSERVATION", 63, 68], ["TBK1", "OBSERVATION", 79, 83], ["focal", "OBSERVATION_MODIFIER", 87, 92], ["nucleus", "ANATOMY", 118, 125], ["partial overlap", "OBSERVATION", 133, 148], ["cytosolic SINT", "OBSERVATION", 154, 168]]], ["Downregulation of ULK1/2 largely inhibited the heat shock-induced phosphorylation of TBK1 ( Figure 7B ), suggesting an important contribution of these kinases for this activation pathway.", [["shock", "DISEASE", 52, 57], ["ULK1/2", "GENE_OR_GENE_PRODUCT", 18, 24], ["TBK1", "GENE_OR_GENE_PRODUCT", 85, 89], ["Figure 7B", "GENE_OR_GENE_PRODUCT", 92, 101], ["ULK1/2", "PROTEIN", 18, 24], ["TBK1", "PROTEIN", 85, 89], ["Figure 7B", "PROTEIN", 92, 101], ["kinases", "PROTEIN", 151, 158], ["Downregulation of ULK1/2", "PROBLEM", 0, 24], ["the heat shock", "PROBLEM", 43, 57], ["TBK1", "PROBLEM", 85, 89], ["this activation pathway", "TREATMENT", 163, 186], ["ULK1", "OBSERVATION", 18, 22], ["heat", "OBSERVATION_MODIFIER", 47, 51], ["shock", "OBSERVATION", 52, 57]]], ["In contrast, arsenite-induced TBK1 phosphorylation was not changed by ULK1/2 knockdown and occurred to a significant part in SINTspeckles ( Figure 7B) , showing that the ULK kinases control phosphorylation of TBK1 in a pathway-specific manner.SINT-Speckle Components Control the Amplitude and Localization of Activated TBK1It was then interesting to test whether cell stress also leads to changes in the intracellular distribution of TBK1.", [["cell", "ANATOMY", 363, 367], ["intracellular", "ANATOMY", 404, 417], ["arsenite", "CHEMICAL", 13, 21], ["arsenite", "CHEMICAL", 13, 21], ["arsenite", "SIMPLE_CHEMICAL", 13, 21], ["TBK1", "GENE_OR_GENE_PRODUCT", 30, 34], ["ULK1/2", "GENE_OR_GENE_PRODUCT", 70, 76], ["ULK kinases", "GENE_OR_GENE_PRODUCT", 170, 181], ["TBK1", "GENE_OR_GENE_PRODUCT", 209, 213], ["TBK1It", "GENE_OR_GENE_PRODUCT", 319, 325], ["cell", "CELL", 363, 367], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 404, 417], ["TBK1", "GENE_OR_GENE_PRODUCT", 434, 438], ["TBK1", "PROTEIN", 30, 34], ["ULK1", "PROTEIN", 70, 74], ["SINTspeckles", "PROTEIN", 125, 137], ["ULK kinases", "PROTEIN", 170, 181], ["TBK1", "PROTEIN", 209, 213], ["SINT", "PROTEIN", 243, 247], ["Activated TBK1It", "PROTEIN", 309, 325], ["TBK1", "PROTEIN", 434, 438], ["TBK1 phosphorylation", "PROBLEM", 30, 50], ["ULK1", "TEST", 70, 74], ["the ULK kinases", "TEST", 166, 181], ["TBK1", "PROBLEM", 209, 213], ["Activated TBK1It", "TREATMENT", 309, 325], ["cell stress", "PROBLEM", 363, 374], ["TBK1", "PROBLEM", 434, 438], ["intracellular distribution", "OBSERVATION", 404, 430], ["TBK1", "OBSERVATION", 434, 438]]], ["Treatment with arsenite or heat shock resulted in a partial recruitment of TBK1 to SINT-speckles (Figure 7C) , suggesting that this previously identified interaction (Ryzhakov and Randow, 2007) also occurs in MLOs.", [["arsenite", "CHEMICAL", 15, 23], ["shock", "DISEASE", 32, 37], ["arsenite", "CHEMICAL", 15, 23], ["arsenite", "SIMPLE_CHEMICAL", 15, 23], ["TBK1", "GENE_OR_GENE_PRODUCT", 75, 79], ["SINT", "GENE_OR_GENE_PRODUCT", 83, 87], ["MLOs", "PATHOLOGICAL_FORMATION", 209, 213], ["TBK1", "PROTEIN", 75, 79], ["SINT", "PROTEIN", 83, 87], ["arsenite", "TREATMENT", 15, 23], ["heat shock", "PROBLEM", 27, 37], ["a partial recruitment of TBK1", "TREATMENT", 50, 79], ["partial", "OBSERVATION_MODIFIER", 52, 59], ["recruitment", "OBSERVATION_MODIFIER", 60, 71]]], ["To investigate a possible contribution of SINTBAD for the activation of TBK1, SINTBAD and AZI2 double-deficient U2OS cells were treated for various periods with arsenite and TBK1 activation was assessed with a phospho-specific antibody by immunoblotting.", [["U2OS cells", "ANATOMY", 112, 122], ["arsenite", "CHEMICAL", 161, 169], ["arsenite", "CHEMICAL", 161, 169], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 42, 49], ["TBK1", "GENE_OR_GENE_PRODUCT", 72, 76], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 78, 85], ["AZI2", "GENE_OR_GENE_PRODUCT", 90, 94], ["U2OS cells", "CELL", 112, 122], ["arsenite", "SIMPLE_CHEMICAL", 161, 169], ["TBK1", "GENE_OR_GENE_PRODUCT", 174, 178], ["SINTBAD", "PROTEIN", 42, 49], ["TBK1", "PROTEIN", 72, 76], ["SINTBAD", "PROTEIN", 78, 85], ["AZI2 double-deficient U2OS cells", "CELL_LINE", 90, 122], ["TBK1", "PROTEIN", 174, 178], ["phospho-specific antibody", "PROTEIN", 210, 235], ["SINTBAD", "PROBLEM", 42, 49], ["TBK1", "PROBLEM", 72, 76], ["SINTBAD", "TEST", 78, 85], ["AZI2 double-deficient U2OS cells", "TREATMENT", 90, 122], ["arsenite", "TREATMENT", 161, 169], ["TBK1 activation", "TEST", 174, 189], ["a phospho-specific antibody", "TEST", 208, 235], ["U2OS cells", "OBSERVATION", 112, 122]]], ["Knockout of SINTBAD alone had no effect (data not shown), whereas cells lacking SINTBAD and AZI2 ( Figure S2 ) showed reduced TBK1 phosphorylation ( Figure 7D ).", [["cells", "ANATOMY", 66, 71], ["SINTBAD", "CHEMICAL", 12, 19], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 12, 19], ["cells", "CELL", 66, 71], ["AZI2 ( Figure S2", "GENE_OR_GENE_PRODUCT", 92, 108], ["TBK1", "GENE_OR_GENE_PRODUCT", 126, 130], ["SINTBAD", "PROTEIN", 12, 19], ["SINTBAD", "PROTEIN", 80, 87], ["AZI2", "PROTEIN", 92, 96], ["Figure S2", "PROTEIN", 99, 108], ["TBK1", "PROTEIN", 126, 130], ["reduced TBK1 phosphorylation", "PROBLEM", 118, 146], ["reduced", "OBSERVATION_MODIFIER", 118, 125], ["TBK1 phosphorylation", "OBSERVATION", 126, 146]]], ["To investigate the contribution of SINTBAD and AZI2 for ULK1-induced TBK1 phosphorylation by an independent experimental approach, cells were transfected to express ULK1 together with SINTBAD and/or AZI2.", [["cells", "ANATOMY", 131, 136], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 35, 42], ["AZI2", "GENE_OR_GENE_PRODUCT", 47, 51], ["ULK1", "GENE_OR_GENE_PRODUCT", 56, 60], ["TBK1", "GENE_OR_GENE_PRODUCT", 69, 73], ["cells", "CELL", 131, 136], ["ULK1", "GENE_OR_GENE_PRODUCT", 165, 169], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 184, 191], ["AZI2", "GENE_OR_GENE_PRODUCT", 199, 203], ["SINTBAD", "PROTEIN", 35, 42], ["AZI2", "PROTEIN", 47, 51], ["ULK1", "PROTEIN", 56, 60], ["TBK1", "PROTEIN", 69, 73], ["ULK1", "PROTEIN", 165, 169], ["SINTBAD", "PROTEIN", 184, 191], ["AZI2", "PROTEIN", 199, 203], ["SINTBAD and AZI2", "TREATMENT", 35, 51], ["ULK1", "TEST", 56, 60], ["TBK1 phosphorylation", "PROBLEM", 69, 89], ["ULK1", "TEST", 165, 169], ["AZI2", "TREATMENT", 199, 203]]], ["Immunoblotting revealed that ULK1-triggered TBK1 phosphorylation was further enhanced by SINTBAD and AZI2 ( Figure 7E ), corroborating the finding that both adaptor proteins contribute to control of the TBK1 activation threshold.", [["ULK1", "GENE_OR_GENE_PRODUCT", 29, 33], ["TBK1", "GENE_OR_GENE_PRODUCT", 44, 48], ["AZI2 ( Figure 7E", "GENE_OR_GENE_PRODUCT", 101, 117], ["TBK1", "GENE_OR_GENE_PRODUCT", 203, 207], ["ULK1", "PROTEIN", 29, 33], ["TBK1", "PROTEIN", 44, 48], ["SINTBAD", "PROTEIN", 89, 96], ["AZI2", "PROTEIN", 101, 105], ["adaptor proteins", "PROTEIN", 157, 173], ["TBK1", "PROTEIN", 203, 207], ["Immunoblotting", "TEST", 0, 14], ["ULK1", "TEST", 29, 33], ["TBK1 phosphorylation", "PROBLEM", 44, 64], ["adaptor proteins", "TREATMENT", 157, 173]]], ["(B) 293T cells were transfected to express hemagglutinin (HA)-SINTBAD along with GFP-AMBRA1 or GFP-PTPN23.", [["(B) 293T cells", "ANATOMY", 0, 14], ["B) 293T cells", "CELL", 1, 14], ["hemagglutinin (HA)-SINTBAD", "GENE_OR_GENE_PRODUCT", 43, 69], ["GFP-AMBRA1", "GENE_OR_GENE_PRODUCT", 81, 91], ["GFP-PTPN23", "GENE_OR_GENE_PRODUCT", 95, 105], ["293T cells", "CELL_LINE", 4, 14], ["hemagglutinin (HA)-SINTBAD", "PROTEIN", 43, 69], ["GFP-AMBRA1", "PROTEIN", 81, 91], ["GFP", "PROTEIN", 95, 98], ["PTPN23", "PROTEIN", 99, 105], ["hemagglutinin (HA)", "PROBLEM", 43, 61], ["SINTBAD", "PROBLEM", 62, 69], ["GFP-AMBRA1", "TEST", 81, 91], ["GFP", "TEST", 95, 98], ["PTPN23", "TREATMENT", 99, 105]]], ["One day later, immunoprecipitation (IP) was performed using GFP-Trap beads.", [["GFP", "GENE_OR_GENE_PRODUCT", 60, 63], ["GFP", "PROTEIN", 60, 63], ["GFP", "TEST", 60, 63], ["Trap beads", "TREATMENT", 64, 74]]], ["IP and input samples were further analyzed by western blot using appropriate antibodies as indicated.SINT-Speckle Components Control the Amplitude and Localization of Activated TBK1(C) An expression plasmid encoding HA-tagged ABIN2 was transfected into 293T cells together with various FLAG-SINTBAD truncation mutants (DN1: 106-615 amino acid [aa], DN2: 165-615 aa, DC: 1-520 aa).", [["samples", "ANATOMY", 13, 20], ["293T cells", "ANATOMY", 253, 263], ["DC", "ANATOMY", 366, 368], ["amino acid", "CHEMICAL", 332, 342], ["amino acid", "CHEMICAL", 332, 342], ["IP", "SIMPLE_CHEMICAL", 0, 2], ["TBK1", "GENE_OR_GENE_PRODUCT", 177, 181], ["HA", "GENE_OR_GENE_PRODUCT", 216, 218], ["ABIN2", "GENE_OR_GENE_PRODUCT", 226, 231], ["293T cells", "CELL", 253, 263], ["FLAG", "GENE_OR_GENE_PRODUCT", 286, 290], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 291, 298], ["amino acid", "AMINO_ACID", 332, 342], ["antibodies", "PROTEIN", 77, 87], ["SINT", "PROTEIN", 101, 105], ["Activated TBK1(C) An expression plasmid", "DNA", 167, 206], ["HA", "PROTEIN", 216, 218], ["ABIN2", "PROTEIN", 226, 231], ["293T cells", "CELL_LINE", 253, 263], ["FLAG", "PROTEIN", 286, 290], ["SINTBAD truncation mutants", "PROTEIN", 291, 317], ["input samples", "TEST", 7, 20], ["appropriate antibodies", "TREATMENT", 65, 87], ["the Amplitude", "TEST", 133, 146], ["Activated TBK1(C", "TREATMENT", 167, 183], ["An expression plasmid encoding HA", "TREATMENT", 185, 218], ["various FLAG", "TEST", 278, 290], ["amino acid", "TEST", 332, 342], ["aa", "TEST", 344, 346], ["DN2", "TEST", 349, 352], ["aa", "TEST", 362, 364], ["DC", "TEST", 366, 368], ["aa", "TEST", 376, 378]]], ["After IP, samples were analyzed by western blot as shown.SINT-Speckle Components Control the Amplitude and Localization of Activated TBK1(D) Known functions of the respective SINTBAD interactors were retrieved from databases and Pubmed searches.", [["samples", "ANATOMY", 10, 17], ["TBK1", "GENE_OR_GENE_PRODUCT", 133, 137], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 175, 182], ["SINT", "PROTEIN", 57, 61], ["TBK1", "PROTEIN", 133, 137], ["SINTBAD interactors", "PROTEIN", 175, 194], ["samples", "TEST", 10, 17], ["the Amplitude", "TEST", 89, 102], ["Activated TBK1(D)", "TREATMENT", 123, 140]]], ["Proteins were assigned to the functional groups as displayed; proteins with several functions are found in more than one group.", [["Proteins", "TEST", 0, 8]]], ["Only the five largest functional groups (>10 proteins per group) are shown.SINT-Speckle Components Control the Amplitude and Localization of Activated TBK1(E) Visualization of interacting protein networks in the SINTBAD interactome using the STRING database (Version 11.0).", [["TBK1", "GENE_OR_GENE_PRODUCT", 151, 155], ["SINT", "PROTEIN", 75, 79], ["TBK1", "PROTEIN", 151, 155], ["E", "PROTEIN", 156, 157], ["interacting protein networks", "PROTEIN", 176, 204], ["SINTBAD", "PROTEIN", 212, 219], ["interacting protein networks", "PROBLEM", 176, 204], ["five", "OBSERVATION_MODIFIER", 9, 13], ["largest", "OBSERVATION_MODIFIER", 14, 21]]], ["Line thickness indicates the strength of data support.", [["Line thickness", "TREATMENT", 0, 14], ["thickness", "OBSERVATION_MODIFIER", 5, 14]]], ["SINTBAD (TBKBP1) is highlighted in dark green and written in bold.", [["TBKBP1", "GENE_OR_GENE_PRODUCT", 9, 15], ["TBKBP1", "PROTEIN", 9, 15]]], ["Proteins that were tested for their interaction with SINTBAD by co-IP (data not shown) are marked in green or red, indicating a confirmed or unconfirmed interaction, respectively.", [["SINTBAD", "GENE_OR_GENE_PRODUCT", 53, 60], ["SINTBAD", "PROTEIN", 53, 60], ["marked", "OBSERVATION_MODIFIER", 91, 97]]], ["(F) U2OS cells were transfected to express the SINTBAD interactor PTPN23 alone and were left untreated or exposed to heat shock, followed by the analysis of GFP-PTPN23 localization by fluorescence microscopy.", [["U2OS cells", "ANATOMY", 4, 14], ["shock", "DISEASE", 122, 127], ["F) U2OS cells", "CELL", 1, 14], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 47, 54], ["PTPN23", "GENE_OR_GENE_PRODUCT", 66, 72], ["GFP", "GENE_OR_GENE_PRODUCT", 157, 160], ["PTPN23", "GENE_OR_GENE_PRODUCT", 161, 167], ["U2OS cells", "CELL_LINE", 4, 14], ["SINTBAD interactor", "PROTEIN", 47, 65], ["PTPN23", "PROTEIN", 66, 72], ["GFP", "PROTEIN", 157, 160], ["PTPN23", "PROTEIN", 161, 167], ["U2OS cells", "PROBLEM", 4, 14], ["heat shock", "PROBLEM", 117, 127], ["the analysis", "TEST", 141, 153], ["GFP", "TEST", 157, 160], ["fluorescence microscopy", "TEST", 184, 207], ["shock", "OBSERVATION", 122, 127]]], ["In addition, cells cotransfected to express GFP-PTPN23 and FLAG-SINTBAD were treated the same way.", [["cells", "ANATOMY", 13, 18], ["GFP-", "ANATOMY", 44, 48], ["cells", "CELL", 13, 18], ["GFP-", "CELL", 44, 48], ["FLAG-SINTBAD", "GENE_OR_GENE_PRODUCT", 59, 71], ["GFP-PTPN23", "PROTEIN", 44, 54], ["FLAG", "PROTEIN", 59, 63], ["SINTBAD", "PROTEIN", 64, 71], ["cells cotransfected", "PROBLEM", 13, 32], ["GFP-PTPN23", "TREATMENT", 44, 54], ["FLAG-SINTBAD", "TREATMENT", 59, 71]]], ["Scale bar, 10 mm; the percentage of cells showing the displayed phenotype is indicated.", [["cells", "ANATOMY", 36, 41], ["cells", "CELL", 36, 41], ["the percentage of cells", "TEST", 18, 41], ["10 mm", "OBSERVATION_MODIFIER", 11, 16]]], ["The right part schematically summarizes the intracellular localization of the proteins. .", [["right part", "ANATOMY", 4, 14], ["intracellular", "ANATOMY", 44, 57], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 44, 57], ["right", "ANATOMY_MODIFIER", 4, 9]]], ["Characterization and Regulation of SINT-Speckles (A) U2OS cells were transfected to express the SINTBAD interactor KAT2A alone and were left untreated or exposed to heat shock, followed by the analysis of FLAG-KAT2A localization by fluorescence microscopy.", [["SINT-Speckles (A) U2OS cells", "ANATOMY", 35, 63], ["shock", "DISEASE", 170, 175], ["U2OS cells", "CELL", 53, 63], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 96, 103], ["KAT2A", "GENE_OR_GENE_PRODUCT", 115, 120], ["FLAG-KAT2A", "GENE_OR_GENE_PRODUCT", 205, 215], ["SINT-Speckles (A) U2OS cells", "CELL_LINE", 35, 63], ["SINTBAD interactor", "PROTEIN", 96, 114], ["KAT2A", "PROTEIN", 115, 120], ["FLAG-KAT2A", "PROTEIN", 205, 215], ["Characterization", "TEST", 0, 16], ["SINT-Speckles (A) U2OS cells", "TREATMENT", 35, 63], ["the SINTBAD interactor KAT2A", "TREATMENT", 92, 120], ["heat shock", "PROBLEM", 165, 175], ["FLAG-KAT2A localization", "TEST", 205, 228], ["fluorescence microscopy", "TEST", 232, 255], ["shock", "OBSERVATION", 170, 175]]], ["In addition, cellsA Fraction of Phlebovirus Non-structural Protein S Associates with SINT-SpecklesThe severe fever thrombocytopenia syndrome phlebovirus non-structural protein S (NSs) targets the ABIN2/p105 complex to activate proviral signaling cascades (Choi et al., 2019) .", [["fever", "DISEASE", 109, 114], ["thrombocytopenia", "DISEASE", 115, 131], ["SINT-Speckles", "GENE_OR_GENE_PRODUCT", 85, 98], ["non-structural protein S", "GENE_OR_GENE_PRODUCT", 153, 177], ["NSs", "GENE_OR_GENE_PRODUCT", 179, 182], ["ABIN2", "GENE_OR_GENE_PRODUCT", 196, 201], ["Phlebovirus Non-structural Protein S", "PROTEIN", 32, 68], ["SINT", "PROTEIN", 85, 89], ["phlebovirus non-structural protein S", "PROTEIN", 141, 177], ["NSs", "PROTEIN", 179, 182], ["ABIN2/p105 complex", "PROTEIN", 196, 214], ["cellsA Fraction", "TEST", 13, 28], ["Phlebovirus Non-structural Protein S", "PROBLEM", 32, 68], ["The severe fever thrombocytopenia syndrome", "PROBLEM", 98, 140], ["phlebovirus non-structural protein S (NSs)", "TREATMENT", 141, 183], ["the ABIN2", "TEST", 192, 201], ["Phlebovirus", "OBSERVATION", 32, 43], ["severe", "OBSERVATION_MODIFIER", 102, 108], ["fever", "OBSERVATION_MODIFIER", 109, 114], ["thrombocytopenia", "OBSERVATION", 115, 131]]], ["As ABIN2 is a core component of SINT-speckles it was interesting to investigate whether the NSs protein also can be recruited to these MLOs.", [["ABIN2", "GENE_OR_GENE_PRODUCT", 3, 8], ["SINT", "GENE_OR_GENE_PRODUCT", 32, 36], ["NSs", "GENE_OR_GENE_PRODUCT", 92, 95], ["MLOs", "GENE_OR_GENE_PRODUCT", 135, 139], ["ABIN2", "PROTEIN", 3, 8], ["SINT", "PROTEIN", 32, 36], ["NSs protein", "PROTEIN", 92, 103], ["MLOs", "PROTEIN", 135, 139], ["SINT-speckles", "PROBLEM", 32, 45], ["the NSs protein", "PROBLEM", 88, 103]]], ["Immunofluorescence analysis not only confirmed the described cytosolic localization of NSs (Choi et al., 2019) but also revealed a fraction of NSs in colocalization with ABIN2 ( Figure 8A ).", [["cytosolic", "ANATOMY", 61, 70], ["NSs", "GENE_OR_GENE_PRODUCT", 143, 146], ["NSs", "PROTEIN", 87, 90], ["NSs", "PROTEIN", 143, 146], ["ABIN2", "PROTEIN", 170, 175], ["Figure 8A", "PROTEIN", 178, 187], ["Immunofluorescence analysis", "TEST", 0, 27], ["NSs", "OBSERVATION", 143, 146]]], ["Induction of cell stress by arsenite or heat shock resulted in an increased recruitment of NSs to SINT-speckles (Figure 8A ).", [["cell", "ANATOMY", 13, 17], ["arsenite", "CHEMICAL", 28, 36], ["shock", "DISEASE", 45, 50], ["arsenite", "CHEMICAL", 28, 36], ["cell", "CELL", 13, 17], ["arsenite", "SIMPLE_CHEMICAL", 28, 36], ["SINT", "GENE_OR_GENE_PRODUCT", 98, 102], ["NSs", "PROTEIN", 91, 94], ["SINT", "PROTEIN", 98, 102], ["cell stress", "PROBLEM", 13, 24], ["heat shock", "PROBLEM", 40, 50], ["an increased recruitment of NSs", "TREATMENT", 63, 94], ["increased", "OBSERVATION_MODIFIER", 66, 75], ["recruitment", "OBSERVATION_MODIFIER", 76, 87]]], ["The expression of NSs also increased UKL1-induced TBK1 phosphorylation ( Figure 8B ).", [["NSs", "GENE_OR_GENE_PRODUCT", 18, 21], ["UKL1", "GENE_OR_GENE_PRODUCT", 37, 41], ["TBK1", "GENE_OR_GENE_PRODUCT", 50, 54], ["NSs", "PROTEIN", 18, 21], ["UKL1", "PROTEIN", 37, 41], ["TBK1", "PROTEIN", 50, 54], ["NSs", "TREATMENT", 18, 21], ["increased UKL1", "PROBLEM", 27, 41], ["TBK1 phosphorylation", "PROBLEM", 50, 70]]], ["In summary, these data show that a virus-encoded protein affecting cellular signaling pathways such as NSs can inducibly associate with SINT-speckles.SINT-SpecklesHere we identified the stress-induced translocation of SINTBAD to SINT-speckles, as revealed by immunofluorescence and cell fractionation experiments.", [["cellular", "ANATOMY", 67, 75], ["cell", "ANATOMY", 282, 286], ["cellular", "CELL", 67, 75], ["NSs", "GENE_OR_GENE_PRODUCT", 103, 106], ["SINT", "GENE_OR_GENE_PRODUCT", 136, 140], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 218, 225], ["SINT", "GENE_OR_GENE_PRODUCT", 229, 233], ["cell", "CELL", 282, 286], ["virus-encoded protein", "PROTEIN", 35, 56], ["NSs", "PROTEIN", 103, 106], ["SINT", "PROTEIN", 136, 140], ["SINT", "PROTEIN", 150, 154], ["SINTBAD", "PROTEIN", 218, 225], ["SINT", "PROTEIN", 229, 233], ["these data", "TEST", 12, 22], ["a virus", "PROBLEM", 33, 40], ["cellular signaling pathways", "PROBLEM", 67, 94], ["SINT-speckles", "PROBLEM", 136, 149], ["the stress", "PROBLEM", 182, 192], ["immunofluorescence", "TEST", 259, 277], ["cell fractionation experiments", "TREATMENT", 282, 312], ["cell fractionation", "OBSERVATION", 282, 300]]], ["These SINT-speckles form a subcellular compartment with no significant overlap to other characterized MLOs (Darling et al., 2018) .", [["SINT-speckles", "ANATOMY", 6, 19], ["subcellular compartment", "ANATOMY", 27, 50], ["SINT", "GENE_OR_GENE_PRODUCT", 6, 10], ["MLOs", "PATHOLOGICAL_FORMATION", 102, 106], ["SINT", "PROTEIN", 6, 10], ["subcellular", "ANATOMY_MODIFIER", 27, 38], ["compartment", "ANATOMY", 39, 50], ["no", "UNCERTAINTY", 56, 58], ["significant", "OBSERVATION_MODIFIER", 59, 70], ["overlap", "OBSERVATION", 71, 78]]], ["SINTBAD contains two lowcomplexity domains containing 12.9% Gln (residues 106-346) and 27.7% Pro (residues 340-535).", [["Gln", "CHEMICAL", 60, 63], ["Gln", "CHEMICAL", 60, 63], ["SINTBAD", "PROTEIN", 0, 7], ["lowcomplexity domains", "PROTEIN", 21, 42], ["two lowcomplexity domains", "TEST", 17, 42], ["Gln (residues", "TEST", 60, 73], ["two", "OBSERVATION_MODIFIER", 17, 20], ["lowcomplexity", "OBSERVATION_MODIFIER", 21, 34]]], ["Core components of constitutive SINT-speckles such as ABIN2 and AZI2, and also the inducible interactor SINTBAD, are predicted to harbor long intrinsically disordered regions ( Figure 9A , Table S1 ), which are typical for MLO-resident proteins (Elbaum-Garfinkle et al., Nott et al., 2015; Uversky and Dunker, 2010) .", [["SINT", "GENE_OR_GENE_PRODUCT", 32, 36], ["ABIN2", "GENE_OR_GENE_PRODUCT", 54, 59], ["AZI2", "GENE_OR_GENE_PRODUCT", 64, 68], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 104, 111], ["Table S1", "GENE_OR_GENE_PRODUCT", 189, 197], ["MLO", "GENE_OR_GENE_PRODUCT", 223, 226], ["SINT", "PROTEIN", 32, 36], ["ABIN2", "PROTEIN", 54, 59], ["AZI2", "PROTEIN", 64, 68], ["SINTBAD", "PROTEIN", 104, 111], ["Figure 9A", "DNA", 177, 186], ["Table S1", "DNA", 189, 197], ["MLO", "PROTEIN", 223, 226], ["resident proteins", "PROTEIN", 227, 244], ["constitutive SINT-speckles", "PROBLEM", 19, 45], ["AZI2", "TEST", 64, 68], ["the inducible interactor SINTBAD", "PROBLEM", 79, 111], ["harbor long intrinsically disordered regions", "PROBLEM", 130, 174], ["constitutive SINT", "OBSERVATION", 19, 36], ["interactor SINTBAD", "OBSERVATION", 93, 111]]], ["Accordingly, about one-third of the SINT-speckle proteins (47 from 150) are predicted to have >40% disordered regions (Table S1 ).", [["SINT", "GENE_OR_GENE_PRODUCT", 36, 40], ["SINT-speckle proteins", "PROTEIN", 36, 57], ["disordered regions", "PROTEIN", 99, 117], ["speckle proteins", "TEST", 41, 57]]], ["The mechanisms controlling the formation of constitutive SINT-speckles are not known and might involve post-translational modifications such as ULK1/2-mediated phosphorylation.", [["SINT", "GENE_OR_GENE_PRODUCT", 57, 61], ["ULK1/2", "GENE_OR_GENE_PRODUCT", 144, 150], ["SINT", "PROTEIN", 57, 61], ["ULK1", "PROTEIN", 144, 148], ["constitutive SINT-speckles", "PROBLEM", 44, 70], ["ULK1/2-mediated phosphorylation", "TREATMENT", 144, 175]]], ["Another possible mechanism could involve the bridging of two ABIN2 dimers by binding to M1-linked tri-ubiquitin chains, which might facilitate ABIN2 assembly to higher-order signaling complexes (Lin et al., 2017) .", [["ABIN2", "GENE_OR_GENE_PRODUCT", 61, 66], ["ABIN2", "GENE_OR_GENE_PRODUCT", 143, 148], ["ABIN2 dimers", "PROTEIN", 61, 73], ["M1", "PROTEIN", 88, 90], ["tri-ubiquitin chains", "PROTEIN", 98, 118], ["ABIN2", "PROTEIN", 143, 148], ["signaling complexes", "PROTEIN", 174, 193]]], ["Also, changes in the relative expression levels of ABIN2 speckle components affect the formation of these MLOs, explaining the abundant finding that expression of a given protein such as ABIN2 or AZI2 can affect the intracellular localization of its interactors.", [["intracellular", "ANATOMY", 216, 229], ["ABIN2", "GENE_OR_GENE_PRODUCT", 51, 56], ["MLOs", "GENE_OR_GENE_PRODUCT", 106, 110], ["ABIN2", "GENE_OR_GENE_PRODUCT", 187, 192], ["AZI2", "GENE_OR_GENE_PRODUCT", 196, 200], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 216, 229], ["ABIN2", "PROTEIN", 51, 56], ["MLOs", "PROTEIN", 106, 110], ["ABIN2", "PROTEIN", 187, 192], ["AZI2", "PROTEIN", 196, 200], ["ABIN2 speckle components", "PROBLEM", 51, 75], ["ABIN2", "PROBLEM", 187, 192], ["AZI2", "TREATMENT", 196, 200]]], ["This behavior is characteristic for MLO formation, and accordingly, also overexpression of SG components such as TIA1 or G3BP1 is sufficient to trigger formation of SGs (Kedersha and Anderson, 2007) .", [["MLO", "GENE_OR_GENE_PRODUCT", 36, 39], ["SG components", "GENE_OR_GENE_PRODUCT", 91, 104], ["TIA1", "GENE_OR_GENE_PRODUCT", 113, 117], ["G3BP1", "GENE_OR_GENE_PRODUCT", 121, 126], ["SGs", "CELLULAR_COMPONENT", 165, 168], ["SG components", "PROTEIN", 91, 104], ["TIA1", "PROTEIN", 113, 117], ["G3BP1", "PROTEIN", 121, 126], ["MLO formation", "PROBLEM", 36, 49], ["SG components", "PROBLEM", 91, 104], ["TIA1 or G3BP1", "PROBLEM", 113, 126], ["SGs", "PROBLEM", 165, 168], ["characteristic for", "UNCERTAINTY", 17, 35], ["MLO formation", "OBSERVATION", 36, 49]]], ["This implies that physiological variations in the amounts of SINTspeckle proteins can already affect speckle formation.", [["SINTspeckle", "GENE_OR_GENE_PRODUCT", 61, 72], ["SINTspeckle proteins", "PROTEIN", 61, 81], ["physiological variations", "PROBLEM", 18, 42], ["SINTspeckle proteins", "PROBLEM", 61, 81], ["speckle formation", "PROBLEM", 101, 118], ["physiological variations", "OBSERVATION", 18, 42], ["amounts", "OBSERVATION_MODIFIER", 50, 57]]], ["Regulation of ABIN2 protein levels occurs in the presence of increased glucose levels or by the kinases TPL2 or IKKa/b (Chen et al., 2013; Leotoing et al., 2011; Nanda et al., 2018) , and it will thus be interesting to investigate whether these situations will affect the formation of SINT-speckles.", [["glucose", "CHEMICAL", 71, 78], ["glucose", "CHEMICAL", 71, 78], ["ABIN2", "GENE_OR_GENE_PRODUCT", 14, 19], ["glucose", "SIMPLE_CHEMICAL", 71, 78], ["TPL2", "GENE_OR_GENE_PRODUCT", 104, 108], ["IKKa/b", "GENE_OR_GENE_PRODUCT", 112, 118], ["SINT", "GENE_OR_GENE_PRODUCT", 285, 289], ["speckles", "CELLULAR_COMPONENT", 290, 298], ["ABIN2", "PROTEIN", 14, 19], ["kinases", "PROTEIN", 96, 103], ["TPL2", "PROTEIN", 104, 108], ["IKKa", "PROTEIN", 112, 116], ["SINT", "PROTEIN", 285, 289], ["ABIN2 protein levels", "TEST", 14, 34], ["increased glucose levels", "PROBLEM", 61, 85], ["these situations", "PROBLEM", 239, 255], ["increased", "OBSERVATION_MODIFIER", 61, 70], ["glucose levels", "OBSERVATION", 71, 85]]], ["The formation of inducible SINT-speckles is regulated by several mechanisms, as schematically shown in Figure 9B .", [["SINT", "GENE_OR_GENE_PRODUCT", 27, 31], ["SINT", "PROTEIN", 27, 31], ["inducible SINT-speckles", "PROBLEM", 17, 40], ["inducible SINT", "OBSERVATION", 17, 31]]], ["SINT-speckle formation is triggered by the acetyltransferase KAT2A.", [["acetyltransferase KAT2A", "GENE_OR_GENE_PRODUCT", 43, 66], ["SINT", "PROTEIN", 0, 4], ["acetyltransferase KAT2A", "PROTEIN", 43, 66], ["the acetyltransferase KAT2A", "TREATMENT", 39, 66], ["speckle formation", "OBSERVATION", 5, 22]]], ["A recent study showed the relevance of acetylation of low-complexity domains for the formation of SGs (Saito et al., 2019) , and it will be interesting to investigate whether the enzymatic activity of KAT2A contributes to its ability to promote inducible SINT-speckle formation.", [["KAT2A", "CHEMICAL", 201, 206], ["SGs", "CELLULAR_COMPONENT", 98, 101], ["KAT2A", "GENE_OR_GENE_PRODUCT", 201, 206], ["SINT", "GENE_OR_GENE_PRODUCT", 255, 259], ["low-complexity domains", "PROTEIN", 54, 76], ["KAT2A", "PROTEIN", 201, 206], ["SINT", "PROTEIN", 255, 259], ["A recent study", "TEST", 0, 14], ["acetylation of low-complexity domains", "TREATMENT", 39, 76], ["the enzymatic activity of KAT2A", "PROBLEM", 175, 206], ["inducible SINT-speckle formation", "PROBLEM", 245, 277], ["speckle formation", "OBSERVATION", 260, 277]]], ["Formation of inducible SINT-speckles is antagonized by the kinase activity of its component ULK1, raising the possibility of an autoregulatory control of speckle homeostasis.", [["SINT", "GENE_OR_GENE_PRODUCT", 23, 27], ["ULK1", "GENE_OR_GENE_PRODUCT", 92, 96], ["SINT", "PROTEIN", 23, 27], ["ULK1", "PROTEIN", 92, 96], ["inducible SINT-speckles", "PROBLEM", 13, 36], ["speckle homeostasis", "PROBLEM", 154, 173], ["inducible SINT", "OBSERVATION", 13, 27], ["kinase activity", "OBSERVATION", 59, 74], ["component", "OBSERVATION_MODIFIER", 82, 91], ["ULK1", "OBSERVATION", 92, 96], ["raising the possibility of", "UNCERTAINTY", 98, 124], ["speckle homeostasis", "OBSERVATION", 154, 173]]], ["Interestingly, a recent study showed that, vice versa, SINTBAD Figure 6 .", [["a recent study", "TEST", 15, 29]]], ["Continued cotransfected to express FLAG-KAT2A and hemagglutinin (HA)-SINTBAD were treated the same way.", [["FLAG-KAT2A", "GENE_OR_GENE_PRODUCT", 35, 45], ["hemagglutinin (HA)-SINTBAD", "GENE_OR_GENE_PRODUCT", 50, 76], ["FLAG-KAT2A", "PROTEIN", 35, 45], ["hemagglutinin (HA)-SINTBAD", "DNA", 50, 76], ["FLAG-KAT2A", "TREATMENT", 35, 45], ["hemagglutinin (HA)", "TREATMENT", 50, 68], ["SINTBAD", "TREATMENT", 69, 76]]], ["Scale bar, 10 mm.", [["10 mm", "OBSERVATION_MODIFIER", 11, 16]]], ["The right part schematically summarizes the intracellular localization of the proteins.SINT-Speckles(B) Upper: The experiment was done as in (A) with the difference that HA-ABIN2 was expressed either alone or together with FLAG-SINTBAD as shown.", [["right part", "ANATOMY", 4, 14], ["intracellular", "ANATOMY", 44, 57], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 44, 57], ["HA-ABIN2", "GENE_OR_GENE_PRODUCT", 170, 178], ["FLAG", "GENE_OR_GENE_PRODUCT", 223, 227], ["HA", "PROTEIN", 170, 172], ["ABIN2", "PROTEIN", 173, 178], ["FLAG", "PROTEIN", 223, 227], ["SINTBAD", "PROTEIN", 228, 235], ["HA", "PROBLEM", 170, 172], ["right", "ANATOMY_MODIFIER", 4, 9], ["Upper", "ANATOMY_MODIFIER", 104, 109]]], ["Lower: Cells were cotransfected to express GFP-PTPN23 and HA-ABIN2, followed by exposure to heat shock and the analysis of colocalization by immunofluorescence as shown.", [["Cells", "ANATOMY", 7, 12], ["GFP-", "ANATOMY", 43, 47], ["shock", "DISEASE", 97, 102], ["Cells", "CELL", 7, 12], ["GFP-", "CELL", 43, 47], ["PTPN23", "GENE_OR_GENE_PRODUCT", 47, 53], ["HA-ABIN2", "GENE_OR_GENE_PRODUCT", 58, 66], ["GFP-PTPN23", "PROTEIN", 43, 53], ["HA", "PROTEIN", 58, 60], ["ABIN2", "PROTEIN", 61, 66], ["HA", "PROBLEM", 58, 60], ["ABIN2", "PROBLEM", 61, 66], ["heat shock", "TREATMENT", 92, 102], ["the analysis", "TEST", 107, 119], ["immunofluorescence", "TEST", 141, 159], ["shock", "OBSERVATION", 97, 102]]], ["Scale bars, 10 mm.SINT-Speckles(C) U2OS cells were transfected to express HA-ULK1 alone or together with FLAG-SINTBAD.", [["SINT-Speckles(C) U2OS cells", "ANATOMY", 18, 45], ["U2OS cells", "CELL", 35, 45], ["HA-ULK1", "GENE_OR_GENE_PRODUCT", 74, 81], ["FLAG", "GENE_OR_GENE_PRODUCT", 105, 109], ["SINT-Speckles(C) U2OS cells", "CELL_LINE", 18, 45], ["HA", "PROTEIN", 74, 76], ["ULK1", "PROTEIN", 77, 81], ["FLAG", "PROTEIN", 105, 109], ["SINTBAD", "PROTEIN", 110, 117], ["Speckles(C) U2OS cells", "PROBLEM", 23, 45], ["HA", "PROBLEM", 74, 76], ["FLAG", "TEST", 105, 109], ["10 mm", "OBSERVATION_MODIFIER", 12, 17]]], ["Cells were left untreated or exposed to heat shock, stained, and analyzed by fluorescence microscopy.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["heat shock", "PROBLEM", 40, 50], ["fluorescence microscopy", "TEST", 77, 100], ["shock", "OBSERVATION", 45, 50]]], ["Scale bars, 10 mm.", [["10 mm", "OBSERVATION_MODIFIER", 12, 17]]], ["The right part schematically summarizes the results.", [["right", "ANATOMY_MODIFIER", 4, 9]]], ["(D) The experiment was performed as in (A), except that a kinase-inactive HA-ULK1-K46I mutant was transfected into U2OS cells.SINT-Speckles(E) Reconstituted SINTBAD-deficient U2OS cells were treated for three days with siRNAs specifically targeting ULK1 and ULK2 or alternatively with a control siRNA.", [["U2OS cells", "ANATOMY", 115, 125], ["U2OS cells", "ANATOMY", 175, 185], ["HA", "GENE_OR_GENE_PRODUCT", 74, 76], ["ULK1", "GENE_OR_GENE_PRODUCT", 77, 81], ["U2OS cells", "CELL", 115, 125], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 157, 164], ["U2OS cells", "CELL", 175, 185], ["ULK1", "GENE_OR_GENE_PRODUCT", 249, 253], ["ULK2", "GENE_OR_GENE_PRODUCT", 258, 262], ["kinase", "PROTEIN", 58, 64], ["HA", "PROTEIN", 74, 76], ["ULK1", "PROTEIN", 77, 81], ["K46I mutant", "PROTEIN", 82, 93], ["U2OS cells", "CELL_LINE", 115, 125], ["SINT-Speckles(E) Reconstituted SINTBAD-deficient U2OS cells", "CELL_LINE", 126, 185], ["ULK1", "PROTEIN", 249, 253], ["ULK2", "PROTEIN", 258, 262], ["a kinase", "TEST", 56, 64], ["inactive HA", "PROBLEM", 65, 76], ["ULK1", "PROBLEM", 77, 81], ["deficient U2OS cells", "PROBLEM", 165, 185], ["siRNAs", "TREATMENT", 219, 225], ["ULK1", "TEST", 249, 253], ["ULK2", "TREATMENT", 258, 262], ["a control siRNA", "TREATMENT", 285, 300], ["U2OS cells", "OBSERVATION", 115, 125], ["U2OS cells", "OBSERVATION", 175, 185]]], ["Cells were then analyzed by fluorescence microscopy for the intracellular distribution of SINTBAD as shown.", [["Cells", "ANATOMY", 0, 5], ["intracellular", "ANATOMY", 60, 73], ["Cells", "CELL", 0, 5], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 60, 73], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 90, 97], ["SINTBAD", "PROTEIN", 90, 97], ["fluorescence microscopy", "TEST", 28, 51], ["intracellular distribution", "OBSERVATION", 60, 86]]], ["Scale bars, 10 mm.SINT-Speckles(F) Reconstituted SINTBAD-deficient U2OS cells were exposed to arsenite or heat shock, and FLAG-SINTBAD was costained with antibodies against phosphorylated TBK1 (S172) as a centrosome marker (Pillai et al., 2015) .", [["U2OS cells", "ANATOMY", 67, 77], ["centrosome", "ANATOMY", 205, 215], ["arsenite", "CHEMICAL", 94, 102], ["shock", "DISEASE", 111, 116], ["arsenite", "CHEMICAL", 94, 102], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 49, 56], ["U2OS cells", "CELL", 67, 77], ["arsenite", "SIMPLE_CHEMICAL", 94, 102], ["FLAG", "GENE_OR_GENE_PRODUCT", 122, 126], ["TBK1", "GENE_OR_GENE_PRODUCT", 188, 192], ["S172", "GENE_OR_GENE_PRODUCT", 194, 198], ["centrosome", "CELLULAR_COMPONENT", 205, 215], ["SINT-Speckles(F) Reconstituted SINTBAD-deficient U2OS cells", "CELL_LINE", 18, 77], ["FLAG", "PROTEIN", 122, 126], ["SINTBAD", "PROTEIN", 127, 134], ["antibodies", "PROTEIN", 154, 164], ["phosphorylated TBK1", "PROTEIN", 173, 192], ["S172", "PROTEIN", 194, 198], ["deficient U2OS cells", "PROBLEM", 57, 77], ["heat shock", "PROBLEM", 106, 116], ["FLAG", "TEST", 122, 126], ["antibodies", "TEST", 154, 164], ["phosphorylated TBK1", "PROBLEM", 173, 192], ["10 mm", "OBSERVATION_MODIFIER", 12, 17], ["U2OS cells", "OBSERVATION", 67, 77], ["shock", "OBSERVATION", 111, 116]]], ["The DNA was stained with Hoechst, and only mitotic cells were analyzed.", [["mitotic cells", "ANATOMY", 43, 56], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["Hoechst", "SIMPLE_CHEMICAL", 25, 32], ["mitotic cells", "CELL", 43, 56], ["mitotic cells", "CELL_TYPE", 43, 56], ["Hoechst", "TREATMENT", 25, 32], ["mitotic cells", "OBSERVATION", 43, 56]]], ["Scale bars, 5 mm.SINT-SpecklesiScience 19, 527-544, September 27, 2019 537SINT-SpecklesA B E C D is required for ULK1 phosphorylation occurring during the cell type-specific induction of autophagy , suggesting a mutual cross talk between these SINT-speckle components.", [["cell", "ANATOMY", 155, 159], ["E C D", "GENE_OR_GENE_PRODUCT", 91, 96], ["ULK1", "GENE_OR_GENE_PRODUCT", 113, 117], ["cell", "CELL", 155, 159], ["SINT", "GENE_OR_GENE_PRODUCT", 244, 248], ["ULK1", "PROTEIN", 113, 117], ["SINT", "PROTEIN", 244, 248], ["SpecklesA B E C D", "TEST", 79, 96], ["ULK1 phosphorylation", "PROBLEM", 113, 133], ["5 mm", "OBSERVATION_MODIFIER", 12, 16]]], ["Depletion of ULK1/2 leads to the formation of SINT-speckles in unstimulated cells.", [["cells", "ANATOMY", 76, 81], ["ULK1/2", "GENE_OR_GENE_PRODUCT", 13, 19], ["SINT", "GENE_OR_GENE_PRODUCT", 46, 50], ["cells", "CELL", 76, 81], ["ULK1/2", "PROTEIN", 13, 19], ["SINT", "PROTEIN", 46, 50], ["unstimulated cells", "CELL_TYPE", 63, 81], ["Depletion of ULK1/2", "PROBLEM", 0, 19], ["SINT", "TEST", 46, 50], ["speckles in unstimulated cells", "PROBLEM", 51, 81], ["unstimulated cells", "OBSERVATION", 63, 81]]], ["As expression of a kinase-inactive ULK1 mutant results in the spontaneous formation of SINT-speckles it is reasonable to assume an important contribution of the kinase function for this process.", [["ULK1", "GENE_OR_GENE_PRODUCT", 35, 39], ["SINT", "GENE_OR_GENE_PRODUCT", 87, 91], ["kinase", "PROTEIN", 19, 25], ["ULK1 mutant", "PROTEIN", 35, 46], ["SINT", "PROTEIN", 87, 91], ["kinase", "PROTEIN", 161, 167], ["a kinase", "TEST", 17, 25], ["inactive ULK1 mutant", "PROBLEM", 26, 46]]], ["Also, other protein kinases function to restrict the formation of MLOs.", [["MLOs", "GENE_OR_GENE_PRODUCT", 66, 70], ["protein kinases", "PROTEIN", 12, 27], ["MLOs", "PROTEIN", 66, 70], ["other protein kinases function", "TEST", 6, 36]]], ["The related kinases HIPK1 and HIPK2 decrease the size and number of PML-NBs during the cell cycle (Berchtold et al., 2018) , and active DYRK3 facilitates the dissolution of several types of MLOs during mitosis (Rai et al., 2018) .", [["PML-NBs", "ANATOMY", 68, 75], ["cell", "ANATOMY", 87, 91], ["HIPK1", "GENE_OR_GENE_PRODUCT", 20, 25], ["HIPK2", "GENE_OR_GENE_PRODUCT", 30, 35], ["PML-NBs", "GENE_OR_GENE_PRODUCT", 68, 75], ["cell", "CELL", 87, 91], ["DYRK3", "GENE_OR_GENE_PRODUCT", 136, 141], ["MLOs", "GENE_OR_GENE_PRODUCT", 190, 194], ["kinases", "PROTEIN", 12, 19], ["HIPK1", "PROTEIN", 20, 25], ["HIPK2", "PROTEIN", 30, 35], ["PML", "PROTEIN", 68, 71], ["DYRK3", "PROTEIN", 136, 141], ["MLOs", "PROTEIN", 190, 194], ["The related kinases HIPK1", "TEST", 0, 25], ["HIPK2 decrease the size", "PROBLEM", 30, 53], ["PML", "TEST", 68, 71], ["the cell cycle", "TEST", 83, 97], ["active DYRK3", "PROBLEM", 129, 141], ["kinases", "OBSERVATION_MODIFIER", 12, 19], ["HIPK1", "OBSERVATION_MODIFIER", 20, 25], ["HIPK2", "OBSERVATION", 30, 35], ["decrease", "OBSERVATION_MODIFIER", 36, 44], ["size", "OBSERVATION_MODIFIER", 49, 53], ["number", "OBSERVATION_MODIFIER", 58, 64], ["PML", "OBSERVATION", 68, 71], ["active", "OBSERVATION_MODIFIER", 129, 135], ["DYRK3", "OBSERVATION", 136, 141]]], ["Kinase-dependent mechanisms might also contribute to the elimination of SINT-speckles during mitosis, a process that is accompanied by massive SINTBAD phosphorylation (Figures S12A and S12B).", [["Kinase", "GENE_OR_GENE_PRODUCT", 0, 6], ["SINT", "GENE_OR_GENE_PRODUCT", 72, 76], ["mitosis", "CELLULAR_COMPONENT", 93, 100], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 143, 150], ["SINT", "PROTEIN", 72, 76], ["SINTBAD", "PROTEIN", 143, 150], ["S12A", "PROTEIN", 176, 180], ["S12B", "PROTEIN", 185, 189], ["Kinase-dependent mechanisms", "PROBLEM", 0, 27], ["SINT-speckles", "PROBLEM", 72, 85], ["massive SINTBAD phosphorylation", "PROBLEM", 135, 166], ["massive", "OBSERVATION_MODIFIER", 135, 142], ["SINTBAD phosphorylation", "OBSERVATION", 143, 166]]], ["MLO composition can be modulated in response to stress (Boulon et al., 2010; Dellaire and Bazett-Jones, 2004) , and accordingly this study reveals the recruitment of SINTBAD to SINT-speckles in response to a variety of cell stresses or after inhibition of the chaperone function of HSPs.", [["cell", "ANATOMY", 219, 223], ["MLO", "SIMPLE_CHEMICAL", 0, 3], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 166, 173], ["SINT", "GENE_OR_GENE_PRODUCT", 177, 181], ["cell", "CELL", 219, 223], ["HSPs", "GENE_OR_GENE_PRODUCT", 282, 286], ["MLO", "PROTEIN", 0, 3], ["SINTBAD", "PROTEIN", 166, 173], ["SINT", "PROTEIN", 177, 181], ["HSPs", "PROTEIN", 282, 286], ["this study", "TEST", 128, 138], ["cell stresses", "PROBLEM", 219, 232]]], ["Heat shock-induced speckle incorporation of SINTBAD can probably also be explained by the temperature-regulated SINTBAD-HSP70 interaction.", [["shock", "DISEASE", 5, 10], ["SINTBAD", "CHEMICAL", 44, 51], ["SINTBAD", "SIMPLE_CHEMICAL", 44, 51], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 112, 119], ["HSP70", "GENE_OR_GENE_PRODUCT", 120, 125], ["SINTBAD", "PROTEIN", 44, 51], ["SINTBAD", "PROTEIN", 112, 119], ["HSP70", "PROTEIN", 120, 125], ["Heat shock", "PROBLEM", 0, 10], ["speckle incorporation of SINTBAD", "PROBLEM", 19, 51], ["the temperature", "TEST", 86, 101], ["shock", "OBSERVATION", 5, 10]]], ["The relevance of HSP70 was also shown for the prevention of aberrant SG formation (Mateju et al., 2017) , and it will be interesting to reveal whether HSPs play a general role in the control of MLO integrity, as recently implicated by the analysis of the cellular chaperone network (Rizzolo et al., 2017) .", [["cellular", "ANATOMY", 255, 263], ["HSP70", "GENE_OR_GENE_PRODUCT", 17, 22], ["SG", "PATHOLOGICAL_FORMATION", 69, 71], ["HSPs", "GENE_OR_GENE_PRODUCT", 151, 155], ["MLO", "GENE_OR_GENE_PRODUCT", 194, 197], ["cellular", "CELL", 255, 263], ["HSP70", "PROTEIN", 17, 22], ["HSPs", "PROTEIN", 151, 155], ["MLO", "PROTEIN", 194, 197], ["HSP70", "TEST", 17, 22], ["aberrant SG formation", "PROBLEM", 60, 81], ["aberrant", "OBSERVATION_MODIFIER", 60, 68], ["SG", "OBSERVATION", 69, 71]]], ["This study revealed the existence of a large functional chaperone supercomplex and its preferential interaction with proteins forming foci or condensates under stress conditions.Possible Functions of Inducible SINT-SpecklesSINTBAD together with AZI2 controls the threshold of TBK1 phosphorylation, as revealed by loss-of-function and gain-of-function experiments.", [["foci", "ANATOMY", 134, 138], ["foci", "CELLULAR_COMPONENT", 134, 138], ["SINT-SpecklesSINTBAD", "GENE_OR_GENE_PRODUCT", 210, 230], ["AZI2", "GENE_OR_GENE_PRODUCT", 245, 249], ["TBK1", "GENE_OR_GENE_PRODUCT", 276, 280], ["chaperone supercomplex", "PROTEIN", 56, 78], ["SINT", "PROTEIN", 210, 214], ["SpecklesSINTBAD", "PROTEIN", 215, 230], ["AZI2", "PROTEIN", 245, 249], ["TBK1", "PROTEIN", 276, 280], ["This study", "TEST", 0, 10], ["a large functional chaperone supercomplex", "PROBLEM", 37, 78], ["proteins forming foci", "PROBLEM", 117, 138], ["Inducible SINT", "PROBLEM", 200, 214], ["AZI2 controls", "TREATMENT", 245, 258], ["TBK1 phosphorylation", "TEST", 276, 296], ["large", "OBSERVATION_MODIFIER", 39, 44], ["functional chaperone supercomplex", "OBSERVATION", 45, 78], ["foci", "OBSERVATION", 134, 138], ["stress conditions", "OBSERVATION", 160, 177]]], ["Active and phosphorylated TBK1 in arsenite-treated cells was largely occurring in the cytosol and showed considerable colocalization with SINT-speckles.", [["cells", "ANATOMY", 51, 56], ["cytosol", "ANATOMY", 86, 93], ["arsenite", "CHEMICAL", 34, 42], ["arsenite", "CHEMICAL", 34, 42], ["TBK1", "GENE_OR_GENE_PRODUCT", 26, 30], ["arsenite", "SIMPLE_CHEMICAL", 34, 42], ["cells", "CELL", 51, 56], ["cytosol", "ORGANISM_SUBSTANCE", 86, 93], ["SINT", "GENE_OR_GENE_PRODUCT", 138, 142], ["TBK1", "PROTEIN", 26, 30], ["arsenite-treated cells", "CELL_LINE", 34, 56], ["SINT", "PROTEIN", 138, 142], ["treated cells", "PROBLEM", 43, 56], ["the cytosol", "TEST", 82, 93], ["phosphorylated TBK1", "OBSERVATION", 11, 30]]], ["In contrast, heat shock-induced TBK1 phosphorylation was mainly nuclear and showed only a partial overlap with SINT-speckles.", [["nuclear", "ANATOMY", 64, 71], ["shock", "DISEASE", 18, 23], ["TBK1", "GENE_OR_GENE_PRODUCT", 32, 36], ["nuclear", "CELLULAR_COMPONENT", 64, 71], ["SINT", "GENE_OR_GENE_PRODUCT", 111, 115], ["TBK1", "PROTEIN", 32, 36], ["SINT", "PROTEIN", 111, 115], ["heat shock", "TEST", 13, 23], ["TBK1 phosphorylation", "PROBLEM", 32, 52], ["a partial overlap with SINT-speckles", "PROBLEM", 88, 124], ["partial overlap", "OBSERVATION", 90, 105]]], ["These differential intracellular localizations together with their distinct dependency on upstream UKL1/2 signals suggest that several pathways lead to TBK1 phosphorylation.", [["intracellular", "ANATOMY", 19, 32], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 19, 32], ["UKL1", "GENE_OR_GENE_PRODUCT", 99, 103], ["2", "GENE_OR_GENE_PRODUCT", 104, 105], ["TBK1", "GENE_OR_GENE_PRODUCT", 152, 156], ["UKL1", "PROTEIN", 99, 103], ["TBK1", "PROTEIN", 152, 156], ["their distinct dependency", "PROBLEM", 61, 86], ["upstream UKL1/2 signals", "TEST", 90, 113], ["TBK1 phosphorylation", "PROBLEM", 152, 172], ["intracellular localizations", "OBSERVATION", 19, 46], ["distinct", "OBSERVATION_MODIFIER", 67, 75], ["dependency", "OBSERVATION_MODIFIER", 76, 86], ["TBK1 phosphorylation", "OBSERVATION", 152, 172]]], ["Thus it is conceivable that SINT-speckles serve as sites of TBK1 phosphorylation in a stimulus-and context-specific manner.", [["SINT", "GENE_OR_GENE_PRODUCT", 28, 32], ["TBK1", "GENE_OR_GENE_PRODUCT", 60, 64], ["SINT", "PROTEIN", 28, 32], ["TBK1", "PROTEIN", 60, 64], ["TBK1 phosphorylation", "TEST", 60, 80], ["a stimulus", "TEST", 84, 94]]], ["The occurrence of phosphorylated TBK1 in SINT-speckles and also outside from these MLOs can be explained by the fact that only a fraction of TBK1 is found in SINT-speckles at a given time point.", [["SINT-speckles", "ANATOMY", 41, 54], ["TBK1", "GENE_OR_GENE_PRODUCT", 33, 37], ["SINT", "GENE_OR_GENE_PRODUCT", 41, 45], ["MLOs", "GENE_OR_GENE_PRODUCT", 83, 87], ["TBK1", "GENE_OR_GENE_PRODUCT", 141, 145], ["SINT", "GENE_OR_GENE_PRODUCT", 158, 162], ["phosphorylated TBK1", "PROTEIN", 18, 37], ["SINT", "PROTEIN", 41, 45], ["MLOs", "PROTEIN", 83, 87], ["TBK1", "PROTEIN", 141, 145], ["SINT", "PROTEIN", 158, 162], ["phosphorylated TBK1", "PROBLEM", 18, 37], ["TBK1", "PROBLEM", 141, 145], ["phosphorylated TBK1", "OBSERVATION", 18, 37], ["TBK1", "OBSERVATION", 141, 145]]], ["A further possible explanation is derived from the mechanism of TBK1 activation, where the initial activation of the kinase leads to rapid interdimer trans-autophosphorylation of its activation loop (Ma et al., 2012) .", [["TBK1", "GENE_OR_GENE_PRODUCT", 64, 68], ["TBK1", "PROTEIN", 64, 68], ["kinase", "PROTEIN", 117, 123], ["TBK1 activation", "PROBLEM", 64, 79]]], ["This implies that after primary activation of the kinase (probably facilitated by the high local protein density in SINTspeckles) active TBK1 can rapidly spread to create high local concentrations at substrate sides.", [["TBK1", "GENE_OR_GENE_PRODUCT", 137, 141], ["kinase", "PROTEIN", 50, 56], ["SINTspeckles", "PROTEIN", 116, 128], ["TBK1", "PROTEIN", 137, 141], ["the high local protein density in SINTspeckles", "PROBLEM", 82, 128], ["active TBK1", "PROBLEM", 130, 141], ["active", "OBSERVATION_MODIFIER", 130, 136], ["TBK1", "OBSERVATION", 137, 141]]], ["This local enrichment of phosphorylated TBK1 is frequently seen by immunofluorescence and can occur in diverse subcellular localizations (Moharir et al., 2018; Pourcelot et al., 2016) .", [["subcellular", "ANATOMY", 111, 122], ["TBK1", "GENE_OR_GENE_PRODUCT", 40, 44], ["phosphorylated TBK1", "PROTEIN", 25, 44], ["phosphorylated TBK1", "PROBLEM", 25, 44], ["immunofluorescence", "TEST", 67, 85], ["phosphorylated TBK1", "OBSERVATION", 25, 44]]], ["The localization of TBK1 is also controlled by differential interaction with adaptor proteins including SINTBAD, TANK, and AZI2, which compete for binding to a C-terminal interaction domain in TBK1 (Goncalves et al., 2011) .", [["C", "CHEMICAL", 160, 161], ["TBK1", "GENE_OR_GENE_PRODUCT", 20, 24], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 104, 111], ["TANK", "GENE_OR_GENE_PRODUCT", 113, 117], ["AZI2", "GENE_OR_GENE_PRODUCT", 123, 127], ["TBK1", "GENE_OR_GENE_PRODUCT", 193, 197], ["TBK1", "PROTEIN", 20, 24], ["adaptor proteins", "PROTEIN", 77, 93], ["SINTBAD", "PROTEIN", 104, 111], ["TANK", "PROTEIN", 113, 117], ["AZI2", "PROTEIN", 123, 127], ["C-terminal interaction domain", "PROTEIN", 160, 189], ["TBK1", "PROTEIN", 193, 197], ["TBK1", "PROBLEM", 20, 24], ["adaptor proteins", "TREATMENT", 77, 93], ["AZI2", "TREATMENT", 123, 127], ["a C-terminal interaction domain", "PROBLEM", 158, 189], ["TBK1", "OBSERVATION", 20, 24]]], ["Contrary to the initial assumption that the TBK1 adaptor proteins control the antiviral function of the kinase, recent publications have shown their dispensability for IRF3 activation (Fang et al., 2017) .Possible Functions of Inducible SINT-SpecklesFurther possible functions of inducible SINT-speckles might be derived from a set of SINTBAD interactors, which fall into several categories (see Figure 5D ).", [["TBK1", "GENE_OR_GENE_PRODUCT", 44, 48], ["IRF3", "GENE_OR_GENE_PRODUCT", 168, 172], ["SINT", "GENE_OR_GENE_PRODUCT", 290, 294], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 335, 342], ["TBK1 adaptor proteins", "PROTEIN", 44, 65], ["kinase", "PROTEIN", 104, 110], ["IRF3", "PROTEIN", 168, 172], ["SINT", "PROTEIN", 237, 241], ["SINT", "PROTEIN", 290, 294], ["SINTBAD interactors", "PROTEIN", 335, 354], ["the TBK1 adaptor proteins", "TREATMENT", 40, 65], ["IRF3 activation", "PROBLEM", 168, 183], ["Inducible SINT", "PROBLEM", 227, 241], ["inducible SINT-speckles", "PROBLEM", 280, 303], ["SINTBAD interactors", "PROBLEM", 335, 354]]], ["The smallest group of SINTBAD interactors comprises the expected group of innate immune regulators, but interestingly the largest group is formed by enzymes and Figure 7 .", [["SINTBAD", "GENE_OR_GENE_PRODUCT", 22, 29], ["SINTBAD interactors", "PROTEIN", 22, 41], ["innate immune regulators", "PROTEIN", 74, 98], ["enzymes", "PROTEIN", 149, 156], ["SINTBAD interactors", "PROBLEM", 22, 41], ["enzymes", "TEST", 149, 156], ["smallest", "OBSERVATION_MODIFIER", 4, 12], ["SINTBAD interactors", "OBSERVATION", 22, 41], ["largest", "OBSERVATION_MODIFIER", 122, 129]]], ["Regulation of TBK1 Phosphorylation by Inducible SINT-Speckles (A) U2OS cells were transfected to express hemagglutinin (HA)-ULK1 and stained for the localization of HA-ULK1 and phosphorylated TBK1 (S172) as shown.Possible Functions of Inducible SINT-Speckles(B) U2OS cells stably expressing FLAG-SINTBAD were treated for 3 days with siRNAs specifically targeting ULK1 and ULK2 or alternatively with a scrambled siRNA (siSCR).", [["SINT-Speckles (A) U2OS cells", "ANATOMY", 48, 76], ["SINT-Speckles(B) U2OS cells", "ANATOMY", 245, 272], ["TBK1", "GENE_OR_GENE_PRODUCT", 14, 18], ["U2OS cells", "CELL", 66, 76], ["hemagglutinin (HA)-ULK1", "GENE_OR_GENE_PRODUCT", 105, 128], ["HA-ULK1", "GENE_OR_GENE_PRODUCT", 165, 172], ["TBK1", "GENE_OR_GENE_PRODUCT", 192, 196], ["S172", "GENE_OR_GENE_PRODUCT", 198, 202], ["U2OS cells", "CELL", 262, 272], ["FLAG-SINTBAD", "GENE_OR_GENE_PRODUCT", 291, 303], ["ULK1", "GENE_OR_GENE_PRODUCT", 363, 367], ["ULK2", "GENE_OR_GENE_PRODUCT", 372, 376], ["TBK1", "PROTEIN", 14, 18], ["Inducible SINT-Speckles (A) U2OS cells", "CELL_LINE", 38, 76], ["hemagglutinin", "PROTEIN", 105, 118], ["HA", "PROTEIN", 120, 122], ["ULK1", "PROTEIN", 124, 128], ["HA", "PROTEIN", 165, 167], ["ULK1", "PROTEIN", 168, 172], ["TBK1", "PROTEIN", 192, 196], ["S172", "PROTEIN", 198, 202], ["Inducible SINT-Speckles(B) U2OS cells", "CELL_LINE", 235, 272], ["FLAG", "PROTEIN", 291, 295], ["SINTBAD", "PROTEIN", 296, 303], ["ULK1", "PROTEIN", 363, 367], ["ULK2", "PROTEIN", 372, 376], ["siSCR", "DNA", 418, 423], ["TBK1 Phosphorylation", "TEST", 14, 34], ["Inducible SINT", "TEST", 38, 52], ["A) U2OS cells", "TEST", 63, 76], ["hemagglutinin (HA)", "TEST", 105, 123], ["ULK1", "PROBLEM", 124, 128], ["HA", "PROBLEM", 165, 167], ["ULK1", "PROBLEM", 168, 172], ["phosphorylated TBK1", "TEST", 177, 196], ["Inducible SINT", "PROBLEM", 235, 249], ["Speckles(B) U2OS cells", "TEST", 250, 272], ["siRNAs specifically targeting ULK1 and ULK2", "PROBLEM", 333, 376], ["a scrambled siRNA", "PROBLEM", 399, 416], ["TBK1 Phosphorylation", "OBSERVATION", 14, 34], ["phosphorylated TBK1", "OBSERVATION", 177, 196], ["scrambled siRNA", "OBSERVATION", 401, 416]]], ["Cells were left untreated or exposed to arsenite or heat shock and analyzed by immunofluorescence microscopy for the intracellular distribution of SINTBAD and phosphorylated TBK1 with specific antibodies.", [["Cells", "ANATOMY", 0, 5], ["intracellular", "ANATOMY", 117, 130], ["arsenite", "CHEMICAL", 40, 48], ["shock", "DISEASE", 57, 62], ["arsenite", "CHEMICAL", 40, 48], ["Cells", "CELL", 0, 5], ["arsenite", "SIMPLE_CHEMICAL", 40, 48], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 117, 130], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 147, 154], ["TBK1", "GENE_OR_GENE_PRODUCT", 174, 178], ["SINTBAD", "PROTEIN", 147, 154], ["TBK1", "PROTEIN", 174, 178], ["specific antibodies", "PROTEIN", 184, 203], ["heat shock", "PROBLEM", 52, 62], ["immunofluorescence microscopy", "TEST", 79, 108], ["SINTBAD", "PROBLEM", 147, 154], ["phosphorylated TBK1", "PROBLEM", 159, 178], ["phosphorylated TBK1", "OBSERVATION", 159, 178]]], ["Areas of colocalization are shown by arrows.", [["colocalization", "OBSERVATION", 9, 23], ["arrows", "OBSERVATION", 37, 43]]], ["Scale bar, 10 mm; the percentage of cells showing the displayed phenotype is given.Possible Functions of Inducible SINT-Speckles(C) U2OS cells stably expressing FLAG-SINTBAD were treated with arsenite or heat shock and stained for the intracellular localization of SINTBAD and TBK1 with specific antibodies.", [["cells", "ANATOMY", 36, 41], ["SINT-Speckles(C) U2OS cells", "ANATOMY", 115, 142], ["intracellular", "ANATOMY", 235, 248], ["arsenite", "CHEMICAL", 192, 200], ["arsenite", "CHEMICAL", 192, 200], ["cells", "CELL", 36, 41], ["U2OS cells", "CELL", 132, 142], ["FLAG-SINTBAD", "GENE_OR_GENE_PRODUCT", 161, 173], ["arsenite", "SIMPLE_CHEMICAL", 192, 200], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 235, 248], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 265, 272], ["TBK1", "GENE_OR_GENE_PRODUCT", 277, 281], ["Inducible SINT-Speckles(C) U2OS cells", "CELL_LINE", 105, 142], ["FLAG", "PROTEIN", 161, 165], ["SINTBAD", "PROTEIN", 166, 173], ["SINTBAD", "PROTEIN", 265, 272], ["TBK1", "PROTEIN", 277, 281], ["specific antibodies", "PROTEIN", 287, 306], ["Inducible SINT", "PROBLEM", 105, 119], ["Speckles(C) U2OS cells", "PROBLEM", 120, 142], ["arsenite", "TREATMENT", 192, 200], ["heat shock", "TREATMENT", 204, 214], ["the intracellular localization", "TEST", 231, 261], ["SINTBAD", "PROBLEM", 265, 272], ["TBK1", "PROBLEM", 277, 281], ["10 mm", "OBSERVATION_MODIFIER", 11, 16]]], ["Scale bar, 10 mm; the percentage of cells showing the displayed phenotype is given.Possible Functions of Inducible SINT-Speckles(D) U2OS wild-type (WT) cells and two U2OS cell clones (DKO #1 and #2) lacking SINTBAD and AZI2 expression due to CRISPR/Cas9-mediated gene editing were treated for the indicated periods with 0.5 mM arsenite.", [["cells", "ANATOMY", 36, 41], ["U2OS wild-type (WT) cells", "ANATOMY", 132, 157], ["U2OS cell clones", "ANATOMY", 166, 182], ["arsenite", "CHEMICAL", 327, 335], ["arsenite", "CHEMICAL", 327, 335], ["cells", "CELL", 36, 41], ["U2OS wild-type (WT) cells", "CELL", 132, 157], ["U2OS cell clones", "CELL", 166, 182], ["DKO #1", "CELL", 184, 190], ["#2", "CELL", 195, 197], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 207, 214], ["AZI2", "GENE_OR_GENE_PRODUCT", 219, 223], ["Cas9", "GENE_OR_GENE_PRODUCT", 249, 253], ["arsenite", "SIMPLE_CHEMICAL", 327, 335], ["Inducible SINT-Speckles(D) U2OS wild-type (WT) cells", "CELL_LINE", 105, 157], ["U2OS cell clones", "CELL_LINE", 166, 182], ["DKO #1", "CELL_LINE", 184, 190], ["AZI2", "PROTEIN", 219, 223], ["CRISPR", "DNA", 242, 248], ["Cas9", "DNA", 249, 253], ["Inducible SINT", "PROBLEM", 105, 119], ["Speckles(D) U2OS wild", "TEST", 120, 141], ["type (WT) cells", "PROBLEM", 142, 157], ["two U2OS cell clones", "TEST", 162, 182], ["lacking SINTBAD", "PROBLEM", 199, 214], ["AZI2 expression", "TREATMENT", 219, 234], ["CRISPR/Cas9", "PROBLEM", 242, 253], ["10 mm", "OBSERVATION_MODIFIER", 11, 16], ["U2OS cell clones", "OBSERVATION", 166, 182]]], ["Phosphorylation of TBK1 and MAP kinases (p38, ERK1/2) was determined by immunoblotting with phospho-specific antibodies as shown, to ensure successful cell stimulation.", [["cell", "ANATOMY", 151, 155], ["TBK1", "GENE_OR_GENE_PRODUCT", 19, 23], ["MAP kinases", "GENE_OR_GENE_PRODUCT", 28, 39], ["p38", "GENE_OR_GENE_PRODUCT", 41, 44], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 46, 52], ["cell", "CELL", 151, 155], ["TBK1", "PROTEIN", 19, 23], ["MAP kinases", "PROTEIN", 28, 39], ["p38, ERK1/2", "PROTEIN", 41, 52], ["phospho-specific antibodies", "PROTEIN", 92, 119], ["Phosphorylation", "TEST", 0, 15], ["TBK1", "TEST", 19, 23], ["MAP kinases", "TEST", 28, 39], ["p38", "TEST", 41, 44], ["ERK1", "TEST", 46, 50], ["phospho-specific antibodies", "TEST", 92, 119], ["successful cell stimulation", "TREATMENT", 140, 167], ["successful cell stimulation", "OBSERVATION", 140, 167]]], ["The position of a non-specific band is indicated by an asterisk.Possible Functions of Inducible SINT-Speckles(E) 293T cells were transfected to express HA-tagged ULK1 WT along with FLAG-tagged SINTBAD or AZI2 as shown.", [["SINT-Speckles(E) 293T cells", "ANATOMY", 96, 123], ["E) 293T cells", "CELL", 110, 123], ["HA", "GENE_OR_GENE_PRODUCT", 152, 154], ["ULK1", "GENE_OR_GENE_PRODUCT", 162, 166], ["FLAG", "GENE_OR_GENE_PRODUCT", 181, 185], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 193, 200], ["AZI2", "GENE_OR_GENE_PRODUCT", 204, 208], ["Inducible SINT-Speckles(E) 293T cells", "CELL_LINE", 86, 123], ["HA", "PROTEIN", 152, 154], ["ULK1 WT", "PROTEIN", 162, 169], ["FLAG", "PROTEIN", 181, 185], ["SINTBAD", "PROTEIN", 193, 200], ["AZI2", "PROTEIN", 204, 208], ["a non-specific band", "PROBLEM", 16, 35], ["HA", "PROBLEM", 152, 154], ["ULK1 WT", "TEST", 162, 169], ["FLAG", "TEST", 181, 185], ["AZI2", "TREATMENT", 204, 208], ["position", "OBSERVATION_MODIFIER", 4, 12]]], ["After 1 day cell lysates were prepared and analyzed by immunoblotting for the phosphorylation of TBK1.Possible Functions of Inducible SINT-Specklesregulators of cell metabolic pathways controlling glucose phosphorylation, pyruvate decarboxylation, fatty acid synthesis, and amino acid metabolism.", [["cell lysates", "ANATOMY", 12, 24], ["cell", "ANATOMY", 161, 165], ["glucose", "CHEMICAL", 197, 204], ["pyruvate", "CHEMICAL", 222, 230], ["fatty acid", "CHEMICAL", 248, 258], ["amino acid", "CHEMICAL", 274, 284], ["glucose", "CHEMICAL", 197, 204], ["pyruvate", "CHEMICAL", 222, 230], ["fatty acid", "CHEMICAL", 248, 258], ["amino acid", "CHEMICAL", 274, 284], ["cell lysates", "ORGANISM_SUBSTANCE", 12, 24], ["TBK1", "GENE_OR_GENE_PRODUCT", 97, 101], ["cell", "CELL", 161, 165], ["glucose", "SIMPLE_CHEMICAL", 197, 204], ["pyruvate", "SIMPLE_CHEMICAL", 222, 230], ["fatty acid", "SIMPLE_CHEMICAL", 248, 258], ["amino acid", "AMINO_ACID", 274, 284], ["TBK1", "PROTEIN", 97, 101], ["1 day cell lysates", "TREATMENT", 6, 24], ["the phosphorylation of TBK1", "TREATMENT", 74, 101], ["Inducible SINT", "PROBLEM", 124, 138], ["cell metabolic pathways", "PROBLEM", 161, 184], ["glucose phosphorylation", "TEST", 197, 220], ["pyruvate decarboxylation", "TREATMENT", 222, 246], ["fatty acid synthesis", "TREATMENT", 248, 268], ["amino acid metabolism", "PROBLEM", 274, 295]]], ["This might indicate a role of SINT-speckles in metabolic regulation as a mediator of the cross talk between innate immunity and metabolism (Hotamisligil, 2017; Joseph et al., 2018; Jung et al., 2019) .", [["SINT", "GENE_OR_GENE_PRODUCT", 30, 34], ["SINT", "PROTEIN", 30, 34], ["metabolic regulation", "OBSERVATION", 47, 67]]], ["Interestingly, the ULK kinases have also been implicated in the regulation of glucose metabolic fluxes and lipid metabolism (Ro et al., 2013) .", [["glucose", "CHEMICAL", 78, 85], ["glucose", "CHEMICAL", 78, 85], ["ULK kinases", "GENE_OR_GENE_PRODUCT", 19, 30], ["glucose", "SIMPLE_CHEMICAL", 78, 85], ["lipid", "SIMPLE_CHEMICAL", 107, 112], ["ULK kinases", "PROTEIN", 19, 30], ["the ULK kinases", "TEST", 15, 30], ["metabolic fluxes", "OBSERVATION", 86, 102]]], ["In addition, metabolic processes co-determine effector functions and cell fate decisions of cells from the innate and adaptive immune systems (Ganeshan and Chawla, 2014; Odegaard and Chawla, 2013) .", [["cell", "ANATOMY", 69, 73], ["cells", "ANATOMY", 92, 97], ["cell", "CELL", 69, 73], ["cells", "CELL", 92, 97], ["metabolic processes", "OBSERVATION", 13, 32]]], ["Vice versa, immunomodulatory signals such as cytokines directly regulate metabolic hormones or pathways (K\u00f6 nner and Br\u00fc ning, 2011; Matsuki et al., 2003) .", [["cytokines", "PROTEIN", 45, 54], ["immunomodulatory signals", "TEST", 12, 36]]], ["The second largest group is formed by proteins involved in vesicle trafficking and autophagy, which is consistent with a previous study identifying ABIN2 as a hub protein binding to components of the endosomal sorting complex (Banks et al., 2016) .", [["vesicle", "ANATOMY", 59, 66], ["endosomal", "ANATOMY", 200, 209], ["vesicle", "CELLULAR_COMPONENT", 59, 66], ["ABIN2", "GENE_OR_GENE_PRODUCT", 148, 153], ["endosomal", "CELLULAR_COMPONENT", 200, 209], ["ABIN2", "PROTEIN", 148, 153], ["endosomal sorting complex", "PROTEIN", 200, 225], ["a previous study", "TEST", 119, 135], ["a hub protein binding", "PROBLEM", 157, 178], ["largest", "OBSERVATION_MODIFIER", 11, 18], ["proteins", "OBSERVATION", 38, 46], ["vesicle trafficking", "OBSERVATION", 59, 78], ["consistent with", "UNCERTAINTY", 103, 118]]], ["This set of interactors might be also relevant for the recently uncovered role of SINTBAD as a regulator of IL-15-induced autophagy , adding to the emerging role of innate immune signaling proteins such as TBK1 and TRAF6 for the formation of autophagosomes Pilli et al., 2012; Shi and Kehrl, 2010; Thurston et al., 2009) .", [["SINTBAD", "GENE_OR_GENE_PRODUCT", 82, 89], ["IL-15", "GENE_OR_GENE_PRODUCT", 108, 113], ["TBK1", "GENE_OR_GENE_PRODUCT", 206, 210], ["TRAF6", "GENE_OR_GENE_PRODUCT", 215, 220], ["SINTBAD", "PROTEIN", 82, 89], ["IL-15", "PROTEIN", 108, 113], ["innate immune signaling proteins", "PROTEIN", 165, 197], ["TBK1", "PROTEIN", 206, 210], ["TRAF6", "PROTEIN", 215, 220], ["innate immune signaling proteins", "TREATMENT", 165, 197], ["TBK1 and TRAF6", "TREATMENT", 206, 220]]], ["The third largest group of the SINTBAD interactome comprises regulators of mitosis and components of the cytoskeleton, in line with previous reports, documenting a function of TBK1 as a centrosome-associated regulator of mitotic microtubule dynamics (Pillai et al., 2015; Kim et al., 2013) .", [["cytoskeleton", "ANATOMY", 105, 117], ["centrosome", "ANATOMY", 186, 196], ["microtubule", "ANATOMY", 229, 240], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 31, 38], ["mitosis", "CELLULAR_COMPONENT", 75, 82], ["cytoskeleton", "CELLULAR_COMPONENT", 105, 117], ["TBK1", "GENE_OR_GENE_PRODUCT", 176, 180], ["centrosome", "CELLULAR_COMPONENT", 186, 196], ["SINTBAD", "PROTEIN", 31, 38], ["TBK1", "PROTEIN", 176, 180], ["microtubule", "PROTEIN", 229, 240], ["TBK1", "PROBLEM", 176, 180], ["third", "OBSERVATION_MODIFIER", 4, 9], ["largest", "OBSERVATION_MODIFIER", 10, 17], ["mitosis", "OBSERVATION_MODIFIER", 75, 82], ["components", "OBSERVATION_MODIFIER", 87, 97], ["cytoskeleton", "OBSERVATION_MODIFIER", 105, 117], ["TBK1", "OBSERVATION", 176, 180], ["mitotic microtubule", "OBSERVATION", 221, 240]]], ["Although this study focuses on the identification and cell biological characterization of SINT-speckles, future studies must comprehensively characterize the function(s) of constitutive and inducible SINT-speckles.Possible Functions of Inducible SINT-SpecklesSINT-speckles might also be of pathophysiological relevance in virus infections or protein aggregation diseases.", [["cell", "ANATOMY", 54, 58], ["infections", "DISEASE", 328, 338], ["aggregation diseases", "DISEASE", 350, 370], ["cell", "CELL", 54, 58], ["SINT", "GENE_OR_GENE_PRODUCT", 90, 94], ["SINT", "GENE_OR_GENE_PRODUCT", 200, 204], ["SINT", "GENE_OR_GENE_PRODUCT", 246, 250], ["SINT", "PROTEIN", 90, 94], ["SINT", "PROTEIN", 200, 204], ["SINT", "PROTEIN", 246, 250], ["SpecklesSINT", "PROTEIN", 251, 263], ["this study", "TEST", 9, 19], ["the identification", "TEST", 31, 49], ["cell biological characterization", "TEST", 54, 86], ["future studies", "TEST", 105, 119], ["constitutive and inducible SINT-speckles", "PROBLEM", 173, 213], ["Inducible SINT", "PROBLEM", 236, 250], ["virus infections", "PROBLEM", 322, 338], ["protein aggregation diseases", "PROBLEM", 342, 370], ["might also be of", "UNCERTAINTY", 273, 289], ["protein aggregation diseases", "OBSERVATION", 342, 370]]], ["This study shows that a significant fraction of the phlebovirus NSs protein colocalize with ABIN2.", [["phlebovirus NSs", "GENE_OR_GENE_PRODUCT", 52, 67], ["ABIN2", "GENE_OR_GENE_PRODUCT", 92, 97], ["phlebovirus NSs protein", "PROTEIN", 52, 75], ["ABIN2", "PROTEIN", 92, 97], ["This study", "TEST", 0, 10], ["a significant fraction", "PROBLEM", 22, 44], ["the phlebovirus NSs protein colocalize", "PROBLEM", 48, 86], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["fraction", "OBSERVATION", 36, 44], ["phlebovirus", "OBSERVATION", 52, 63]]], ["It will be interesting to investigate the functional consequences of this association as well as the molecular mechanisms leading to this interaction, as the NSs protein is a structured protein (Barski et al., 2017) .", [["NSs", "GENE_OR_GENE_PRODUCT", 158, 161], ["NSs protein", "PROTEIN", 158, 169]]], ["ABIN2 is also bound by the rabies virus-encoded M protein, which in turn controls the expression of inflammatory target genes (Besson et al., 2017) , and also other components of SINT-speckles assigned to the functional group ''inflammation and infection'' (see Figure 5D ) is targeted by viruses or involved in the antiviral response (Schmitz et al., 2014) .", [["inflammation", "DISEASE", 228, 240], ["infection", "DISEASE", 245, 254], ["ABIN2", "GENE_OR_GENE_PRODUCT", 0, 5], ["rabies virus", "ORGANISM", 27, 39], ["M protein", "GENE_OR_GENE_PRODUCT", 48, 57], ["SINT", "GENE_OR_GENE_PRODUCT", 179, 183], ["see Figure 5D", "GENE_OR_GENE_PRODUCT", 258, 271], ["ABIN2", "PROTEIN", 0, 5], ["M protein", "PROTEIN", 48, 57], ["inflammatory target genes", "DNA", 100, 125], ["SINT", "PROTEIN", 179, 183], ["rabies virus", "SPECIES", 27, 39], ["rabies virus", "SPECIES", 27, 39], ["the rabies virus", "PROBLEM", 23, 39], ["inflammatory target genes", "PROBLEM", 100, 125], ["SINT-speckles", "PROBLEM", 179, 192], ["the functional group ''inflammation", "PROBLEM", 205, 240], ["infection''", "PROBLEM", 245, 256], ["inflammatory", "OBSERVATION_MODIFIER", 100, 112], ["viruses", "OBSERVATION", 289, 296]]], ["Another possible pathophysiological scenario is due to the function of MLOs as signaling hubs in a crowded microenvironment, which can come at the cost of unwanted protein aggregation.", [["MLOs", "GENE_OR_GENE_PRODUCT", 71, 75], ["MLOs", "PROTEIN", 71, 75], ["pathophysiological scenario", "PROBLEM", 17, 44], ["unwanted protein aggregation", "PROBLEM", 155, 183], ["possible", "UNCERTAINTY", 8, 16], ["pathophysiological scenario", "OBSERVATION", 17, 44], ["protein aggregation", "OBSERVATION", 164, 183]]], ["Interestingly, partial loss of TBK1 causes protein misfolding diseases, namely, familial amyotrophic lateral sclerosis and frontotemporal dementia (Freischmidt et al., 2015; Gijselinck et al., 2015) .", [["amyotrophic lateral sclerosis", "ANATOMY", 89, 118], ["misfolding diseases", "DISEASE", 51, 70], ["amyotrophic lateral sclerosis", "DISEASE", 89, 118], ["frontotemporal dementia", "DISEASE", 123, 146], ["TBK1", "GENE_OR_GENE_PRODUCT", 31, 35], ["TBK1", "PROTEIN", 31, 35], ["partial loss of TBK1", "PROBLEM", 15, 35], ["protein misfolding diseases", "PROBLEM", 43, 70], ["familial amyotrophic lateral sclerosis", "PROBLEM", 80, 118], ["frontotemporal dementia", "PROBLEM", 123, 146], ["partial", "OBSERVATION_MODIFIER", 15, 22], ["loss", "OBSERVATION_MODIFIER", 23, 27], ["TBK1", "OBSERVATION", 31, 35], ["protein misfolding diseases", "OBSERVATION", 43, 70], ["familial", "OBSERVATION_MODIFIER", 80, 88], ["amyotrophic", "OBSERVATION_MODIFIER", 89, 100], ["lateral", "OBSERVATION_MODIFIER", 101, 108], ["sclerosis", "OBSERVATION", 109, 118], ["frontotemporal", "OBSERVATION_MODIFIER", 123, 137], ["dementia", "OBSERVATION", 138, 146]]], ["Also, mutations in TBK1 and its substrate protein optineurin contribute to frontotemporal lobar degeneration (Le Ber et al., 2015; Pottier et al., 2015) .", [["lobar", "ANATOMY", 90, 95], ["frontotemporal lobar degeneration", "DISEASE", 75, 108], ["TBK1", "GENE_OR_GENE_PRODUCT", 19, 23], ["optineurin", "GENE_OR_GENE_PRODUCT", 50, 60], ["lobar", "MULTI-TISSUE_STRUCTURE", 90, 95], ["TBK1", "PROTEIN", 19, 23], ["substrate protein", "PROTEIN", 32, 49], ["optineurin", "PROTEIN", 50, 60], ["mutations in TBK1", "PROBLEM", 6, 23], ["its substrate protein optineurin", "PROBLEM", 28, 60], ["frontotemporal lobar degeneration", "PROBLEM", 75, 108], ["frontotemporal", "OBSERVATION_MODIFIER", 75, 89], ["lobar", "ANATOMY_MODIFIER", 90, 95], ["degeneration", "OBSERVATION", 96, 108]]], ["This disease is also associated with an elevated SINTBAD expression (Broce et al., 2018) , and it will be very interesting to reveal in future studies whether the formation and function of SINT-speckles is affected in neurodegenerative diseases.Limitations of the StudyIn the present study we define components of constitutive and inducible SINT-speckles and reveal their regulation by ULK1/2, HSPs, and KAT2A.", [["neurodegenerative diseases", "DISEASE", 218, 244], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 49, 56], ["SINT", "GENE_OR_GENE_PRODUCT", 189, 193], ["SINT", "GENE_OR_GENE_PRODUCT", 341, 345], ["ULK1/2", "GENE_OR_GENE_PRODUCT", 386, 392], ["HSPs", "GENE_OR_GENE_PRODUCT", 394, 398], ["KAT2A", "GENE_OR_GENE_PRODUCT", 404, 409], ["SINTBAD", "PROTEIN", 49, 56], ["SINT", "PROTEIN", 189, 193], ["SINT", "PROTEIN", 341, 345], ["ULK1", "PROTEIN", 386, 390], ["HSPs", "PROTEIN", 394, 398], ["KAT2A", "PROTEIN", 404, 409], ["This disease", "PROBLEM", 0, 12], ["an elevated SINTBAD expression", "PROBLEM", 37, 67], ["neurodegenerative diseases", "PROBLEM", 218, 244], ["the Study", "TEST", 260, 269], ["constitutive and inducible SINT-speckles", "PROBLEM", 314, 354], ["ULK1", "TEST", 386, 390], ["HSPs", "TEST", 394, 398], ["KAT2A", "TEST", 404, 409], ["disease", "OBSERVATION", 5, 12], ["elevated", "OBSERVATION_MODIFIER", 40, 48], ["SINTBAD expression", "OBSERVATION", 49, 67], ["neurodegenerative diseases", "OBSERVATION", 218, 244]]], ["We thank the following colleagues for providing plasmids:DECLARATION OF INTERESTSThe authors declare no competing interests.", [["plasmids", "ANATOMY", 48, 56], ["plasmids", "DNA", 48, 56]]], ["The disordered P granule protein LAF-1 drives phase separation into droplets with tunable viscosity and dynamics.", [["LAF-1", "GENE_OR_GENE_PRODUCT", 33, 38], ["P granule protein", "PROTEIN", 15, 32], ["LAF-1", "PROTEIN", 33, 38], ["The disordered P granule protein LAF", "TREATMENT", 0, 36], ["tunable viscosity", "OBSERVATION", 82, 99]]], ["Natl.", [["Natl", "CHEMICAL", 0, 4]]], ["Fig. S5 .", [["S5", "ANATOMY", 5, 7]]], ["Disaggregation of heat shock-induced SINT-speckles is independent of de novo protein expression and autophagy, Related to Figure 3 .", [["shock", "DISEASE", 23, 28], ["heat shock-induced SINT", "GENE_OR_GENE_PRODUCT", 18, 41], ["SINT", "PROTEIN", 37, 41], ["heat shock", "PROBLEM", 18, 28], ["induced SINT", "PROBLEM", 29, 41], ["de novo protein expression", "PROBLEM", 69, 95], ["autophagy", "PROBLEM", 100, 109], ["protein expression", "OBSERVATION", 77, 95]]], ["(A) SINTBAD-deficient U2OS cells reconstituted with Flag-SINTBAD were left untreated or exposed to heat shock.", [["U2OS cells", "ANATOMY", 22, 32], ["shock", "DISEASE", 104, 109], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 4, 11], ["U2OS cells", "CELL", 22, 32], ["Flag-SINTBAD", "GENE_OR_GENE_PRODUCT", 52, 64], ["SINTBAD-deficient U2OS cells", "CELL_LINE", 4, 32], ["Flag", "PROTEIN", 52, 56], ["SINTBAD", "PROTEIN", 57, 64], ["A) SINTBAD", "TEST", 1, 11], ["deficient U2OS cells", "PROBLEM", 12, 32], ["Flag-SINTBAD", "TREATMENT", 52, 64], ["heat shock", "PROBLEM", 99, 109], ["U2OS cells", "OBSERVATION", 22, 32], ["left", "ANATOMY_MODIFIER", 70, 74], ["shock", "OBSERVATION", 104, 109]]], ["Indicated cells were allowed to recover from heat shock at 37 \u00b0C for 3 h in the absence or presence of the translation inhibitor anisomycin (5 \u00b5g/ml).", [["cells", "ANATOMY", 10, 15], ["shock", "DISEASE", 50, 55], ["anisomycin", "CHEMICAL", 129, 139], ["anisomycin", "CHEMICAL", 129, 139], ["cells", "CELL", 10, 15], ["anisomycin", "SIMPLE_CHEMICAL", 129, 139], ["cells", "PROBLEM", 10, 15], ["heat shock", "PROBLEM", 45, 55], ["the translation inhibitor anisomycin", "TREATMENT", 103, 139]]], ["(B) SINTBAD-deficient U2OS cells stably expressing Flag-SINTBAD were left untreated or exposed to heat shock, followed by a 3 h long recovery period at 37 \u00b0C. Treatments and recovery were performed in the presence of the indicated autophagy inhibitors (0.5 \u00b5M Bafilomycin A, 20 mM NH 4 Cl, 20 \u00b5M Chloroquine).", [["U2OS cells", "ANATOMY", 22, 32], ["shock", "DISEASE", 103, 108], ["Bafilomycin A", "CHEMICAL", 260, 273], ["NH 4 Cl", "CHEMICAL", 281, 288], ["Chloroquine", "CHEMICAL", 296, 307], ["Bafilomycin A", "CHEMICAL", 260, 273], ["NH 4 Cl", "CHEMICAL", 281, 288], ["Chloroquine", "CHEMICAL", 296, 307], ["(B) SINTBAD", "GENE_OR_GENE_PRODUCT", 0, 11], ["U2OS cells", "CELL", 22, 32], ["Flag-SINTBAD", "GENE_OR_GENE_PRODUCT", 51, 63], ["Bafilomycin A", "SIMPLE_CHEMICAL", 260, 273], ["NH 4 Cl", "SIMPLE_CHEMICAL", 281, 288], ["Chloroquine", "SIMPLE_CHEMICAL", 296, 307], ["SINTBAD-deficient U2OS cells", "CELL_LINE", 4, 32], ["Flag", "PROTEIN", 51, 55], ["SINTBAD", "PROTEIN", 56, 63], ["SINTBAD", "TEST", 4, 11], ["deficient U2OS cells", "PROBLEM", 12, 32], ["heat shock", "PROBLEM", 98, 108], ["Treatments", "TREATMENT", 159, 169], ["autophagy inhibitors", "TREATMENT", 231, 251], ["Bafilomycin A, 20 mM NH", "TREATMENT", 260, 283], ["Chloroquine", "TREATMENT", 296, 307], ["U2OS cells", "OBSERVATION", 22, 32], ["left", "ANATOMY_MODIFIER", 69, 73], ["shock", "OBSERVATION", 103, 108]]], ["The percentage of cells showing the displayed phenotype is indicated. et al., 2013)) into the pEGFP-C2 vector (Clontech); PCR-amplified ABIN2 from pCAGGS-E-hABIN2, that was kindly provided by Dr. R. Beyaert (VIB-Ghent University, Belgium, (Van et al., 2001) ) was subcloned with a N terminal HA-tag into pcDNA6 (Invitrogen); pcDNA3.1-HA-ULK1 was obtained from Dr. S. H. Tooze (The Francis Crick Institute, London, UK, (Joachim et al., 2015) ) and its kinase-inactive K46I mutant was generated by site-directed mutagenesis (QuikChange II XL, Agilent, (Chan et al., 2009) ).", [["cells", "ANATOMY", 18, 23], ["1-HA-ULK1", "CHEMICAL", 332, 341], ["N", "CHEMICAL", 281, 282], ["cells", "CELL", 18, 23], ["pEGFP-C2", "GENE_OR_GENE_PRODUCT", 94, 102], ["Clontech", "GENE_OR_GENE_PRODUCT", 111, 119], ["ABIN2", "GENE_OR_GENE_PRODUCT", 136, 141], ["pCAGGS-E-hABIN2", "GENE_OR_GENE_PRODUCT", 147, 162], ["pcDNA6", "GENE_OR_GENE_PRODUCT", 304, 310], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 312, 322], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 325, 331], ["1-HA-ULK1", "GENE_OR_GENE_PRODUCT", 332, 341], ["K46I", "GENE_OR_GENE_PRODUCT", 467, 471], ["pEGFP-C2 vector", "DNA", 94, 109], ["Clontech", "DNA", 111, 119], ["PCR-amplified ABIN2", "DNA", 122, 141], ["pCAGGS", "DNA", 147, 153], ["E-hABIN2", "DNA", 154, 162], ["N terminal HA-tag", "DNA", 281, 298], ["pcDNA6 (Invitrogen); pcDNA3", "DNA", 304, 331], ["ULK1", "PROTEIN", 337, 341], ["kinase-inactive K46I mutant", "PROTEIN", 451, 478], ["PCR", "TEST", 122, 125], ["a N terminal HA-tag into pcDNA6 (Invitrogen)", "TREATMENT", 279, 323], ["pcDNA3", "TREATMENT", 325, 331], ["its kinase", "TEST", 447, 457], ["inactive K46I mutant", "TREATMENT", 458, 478]]], ["Flag-KAT2A was from Dr.DECLARATION OF INTERESTSEzra Burstein (UT Southwestern, Dallas, USA, (Mao et al., 2009) ) and pIRES-3x-Flag-NSs (SFTSV) from Dr. J. U. Jung (University of Southern California, Los Angeles, USA, (Choi et al., 2019) ).Cell culture, transfections and treatments293T, HEK-TLR4, HeLa and U2OS cells were cultured in DMEM (Gibco) containing high glucose (4.5 g/l), L-alanyl-glutamine (4 mM) and sodium pyruvate (110 mg/l) supplemented with 10 % fetal bovine serum (FBS), 100 U/ml penicillin and 100 \u00b5g/ml streptomycin.", [["Cell", "ANATOMY", 239, 243], ["293T", "ANATOMY", 281, 285], ["HEK", "ANATOMY", 287, 290], ["HeLa", "ANATOMY", 297, 301], ["U2OS cells", "ANATOMY", 306, 316], ["fetal bovine serum", "ANATOMY", 462, 480], ["FBS", "ANATOMY", 482, 485], ["glucose", "CHEMICAL", 363, 370], ["L-alanyl-glutamine", "CHEMICAL", 382, 400], ["sodium pyruvate", "CHEMICAL", 412, 427], ["penicillin", "CHEMICAL", 497, 507], ["streptomycin", "CHEMICAL", 522, 534], ["glucose", "CHEMICAL", 363, 370], ["L-alanyl-glutamine", "CHEMICAL", 382, 400], ["sodium pyruvate", "CHEMICAL", 412, 427], ["penicillin", "CHEMICAL", 497, 507], ["streptomycin", "CHEMICAL", 522, 534], ["pIRES-3x", "GENE_OR_GENE_PRODUCT", 117, 125], ["Cell", "CELL", 239, 243], ["293T", "CELL", 281, 285], ["HEK-", "CELL", 287, 291], ["TLR4", "GENE_OR_GENE_PRODUCT", 291, 295], ["HeLa", "CELL", 297, 301], ["U2OS cells", "CELL", 306, 316], ["glucose", "SIMPLE_CHEMICAL", 363, 370], ["L-alanyl-glutamine", "SIMPLE_CHEMICAL", 382, 400], ["sodium pyruvate", "SIMPLE_CHEMICAL", 412, 427], ["bovine", "ORGANISM", 468, 474], ["serum", "ORGANISM_SUBSTANCE", 475, 480], ["FBS", "ORGANISM_SUBSTANCE", 482, 485], ["penicillin", "SIMPLE_CHEMICAL", 497, 507], ["streptomycin", "SIMPLE_CHEMICAL", 522, 534], ["Flag", "PROTEIN", 126, 130], ["293T", "CELL_LINE", 281, 285], ["HEK", "CELL_LINE", 287, 290], ["TLR4", "CELL_LINE", 291, 295], ["HeLa", "CELL_LINE", 297, 301], ["U2OS cells", "CELL_LINE", 306, 316], ["bovine", "SPECIES", 468, 474], ["pIRES", "TEST", 117, 122], ["Cell culture", "TEST", 239, 251], ["transfections", "TEST", 253, 266], ["treatments", "TEST", 271, 281], ["HEK", "TEST", 287, 290], ["TLR4", "TEST", 291, 295], ["HeLa", "TEST", 297, 301], ["U2OS cells", "TEST", 306, 316], ["DMEM", "TEST", 334, 338], ["Gibco", "TEST", 340, 345], ["high glucose", "TEST", 358, 370], ["L-alanyl-glutamine", "TREATMENT", 382, 400], ["sodium pyruvate", "TREATMENT", 412, 427], ["10 % fetal bovine serum (FBS", "TREATMENT", 457, 485], ["penicillin", "TREATMENT", 497, 507], ["streptomycin", "TREATMENT", 522, 534]]], ["Cells were grown in a humidified incubator at 37 o C under 5 % CO 2 .", [["Cells", "ANATOMY", 0, 5], ["CO 2", "CHEMICAL", 63, 67], ["Cells", "CELL", 0, 5], ["a humidified incubator", "TREATMENT", 20, 42]]], ["Transient transfections of plasmids were performed using linear polyethylenimine (PEI, Polyscience Inc.) as described previously (Saul et al., 2015) .", [["plasmids", "ANATOMY", 27, 35], ["polyethylenimine", "CHEMICAL", 64, 80], ["PEI", "CHEMICAL", 82, 85], ["polyethylenimine", "CHEMICAL", 64, 80], ["PEI", "CHEMICAL", 82, 85], ["polyethylenimine", "SIMPLE_CHEMICAL", 64, 80], ["plasmids", "DNA", 27, 35], ["Transient transfections of plasmids", "TREATMENT", 0, 35], ["linear polyethylenimine (PEI", "TREATMENT", 57, 85]]], ["Unless indicated otherwise, cells were treated with 0.5 mM arsenite for 1 h or were exposed to heat shock at 43 \u00b0C in a humidified cell culture incubator with a 5 % CO 2 atmosphere for 1 h.", [["cells", "ANATOMY", 28, 33], ["cell", "ANATOMY", 131, 135], ["arsenite", "CHEMICAL", 59, 67], ["shock", "DISEASE", 100, 105], ["arsenite", "CHEMICAL", 59, 67], ["CO", "CHEMICAL", 165, 167], ["cells", "CELL", 28, 33], ["arsenite", "SIMPLE_CHEMICAL", 59, 67], ["cell", "CELL", 131, 135], ["0.5 mM arsenite", "TREATMENT", 52, 67], ["heat shock", "TREATMENT", 95, 105], ["a humidified cell culture incubator", "TREATMENT", 118, 153], ["a 5 % CO 2 atmosphere", "TREATMENT", 159, 180]]], ["Inhibitors were incubated 1 h prior cell stimulation.", [["cell", "ANATOMY", 36, 40], ["cell", "CELL", 36, 40], ["Inhibitors", "TREATMENT", 0, 10], ["prior cell stimulation", "TREATMENT", 30, 52]]], ["Cell stimulations for the experiments displayed in Fig. 1C were done as follows: HeLa cells were treated with 0.5 M sorbitol (30, 60, 90 min), 0.5 mM arsenite (20, 40, 60 min) or 4 % (v/v) ethanol (15, 30 and 60 min).", [["Cell", "ANATOMY", 0, 4], ["HeLa cells", "ANATOMY", 81, 91], ["sorbitol", "CHEMICAL", 116, 124], ["arsenite", "CHEMICAL", 150, 158], ["ethanol", "CHEMICAL", 189, 196], ["sorbitol", "CHEMICAL", 116, 124], ["arsenite", "CHEMICAL", 150, 158], ["ethanol", "CHEMICAL", 189, 196], ["Cell", "CELL", 0, 4], ["HeLa cells", "CELL", 81, 91], ["sorbitol", "SIMPLE_CHEMICAL", 116, 124], ["arsenite", "SIMPLE_CHEMICAL", 150, 158], ["ethanol", "SIMPLE_CHEMICAL", 189, 196], ["HeLa cells", "CELL_LINE", 81, 91], ["Cell stimulations", "TREATMENT", 0, 17], ["1C", "TEST", 56, 58], ["HeLa cells", "PROBLEM", 81, 91], ["0.5 M sorbitol", "TREATMENT", 110, 124]]], ["In addition, HEK-TLR4 cells were treated with 1 \u00b5g/ml LPS (1, 2, 4 h), U2OS cells with 10 ng/ml IL-1\u03b2 (0.5, 1.5, 5 h) and HEK293 cells with 20 ng/ml TNF\u03b1 (30, 60, 90 min).Generation of CRISPR/Cas9-mediated knockout cells and reconstitution of themIn order to generate SINTBAD-and/or AZI2-deficient U2OS cells, CRISPR/Cas9-mediated genome editing technology was performed as described (Ran et al., 2013) .", [["HEK-TLR4 cells", "ANATOMY", 13, 27], ["U2OS cells", "ANATOMY", 71, 81], ["HEK293 cells", "ANATOMY", 122, 134], ["cells", "ANATOMY", 215, 220], ["U2OS cells", "ANATOMY", 298, 308], ["LPS", "CHEMICAL", 54, 57], ["HEK-TLR4 cells", "CELL", 13, 27], ["U2OS cells", "CELL", 71, 81], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 96, 101], ["HEK293 cells", "CELL", 122, 134], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 149, 153], ["CRISPR/Cas9", "GENE_OR_GENE_PRODUCT", 185, 196], ["cells", "CELL", 215, 220], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 268, 275], ["AZI2", "GENE_OR_GENE_PRODUCT", 283, 287], ["U2OS cells", "CELL", 298, 308], ["CRISPR/Cas9", "GENE_OR_GENE_PRODUCT", 310, 321], ["HEK-TLR4 cells", "CELL_LINE", 13, 27], ["U2OS cells", "CELL_LINE", 71, 81], ["HEK293 cells", "CELL_LINE", 122, 134], ["TNF\u03b1", "PROTEIN", 149, 153], ["CRISPR", "DNA", 185, 191], ["Cas9", "DNA", 192, 196], ["mediated knockout cells", "CELL_TYPE", 197, 220], ["SINTBAD-and/or AZI2-deficient U2OS cells", "CELL_LINE", 268, 308], ["Cas9", "DNA", 317, 321], ["HEK", "TEST", 13, 16], ["U2OS cells", "TEST", 71, 81], ["IL", "TEST", 96, 98], ["HEK293 cells", "TEST", 122, 134], ["TNF", "TEST", 149, 152], ["CRISPR/Cas9", "TREATMENT", 185, 196], ["knockout cells", "PROBLEM", 206, 220], ["SINTBAD", "TEST", 268, 275], ["AZI2", "TEST", 283, 287], ["deficient U2OS cells", "PROBLEM", 288, 308], ["CRISPR/Cas9", "TREATMENT", 310, 321], ["TLR4 cells", "ANATOMY", 17, 27], ["U2OS cells", "OBSERVATION", 298, 308]]], ["The target site for human SINTBAD was designed as an anti-sense sgRNA (5\u00b4-CGTAGACTTTGAGGCGGCGT-3\u00b4) within the first exon of the SINTBAD gene.", [["human", "ORGANISM", 20, 25], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 26, 33], ["sgRNA", "GENE_OR_GENE_PRODUCT", 64, 69], ["5\u00b4-CGTAGACTTTGAGGCGGCGT-3", "GENE_OR_GENE_PRODUCT", 71, 96], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 128, 135], ["target site", "DNA", 4, 15], ["human SINTBAD", "DNA", 20, 33], ["anti-sense sgRNA", "DNA", 53, 69], ["SINTBAD gene", "DNA", 128, 140], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["human SINTBAD", "TREATMENT", 20, 33], ["an anti-sense sgRNA (5\u00b4-CGTAGACTTTGAGGCGGCGT-3\u00b4)", "TREATMENT", 50, 98], ["anti-sense sgRNA", "OBSERVATION", 53, 69]]], ["The target site for sgAZI2 was designed within the second exon as 5\u00b4-GGCCTATCATGCATATCGAG-3\u00b4.", [["sgAZI2", "GENE_OR_GENE_PRODUCT", 20, 26], ["target site", "DNA", 4, 15], ["sgAZI2", "DNA", 20, 26], ["exon", "DNA", 58, 62], ["5\u00b4-GGCCTATCATGCATATCGAG-3\u00b4", "DNA", 66, 92], ["sgAZI2", "TREATMENT", 20, 26], ["5\u00b4-GGCCTATCATGCATATCGAG", "TEST", 66, 89]]], ["Oligos were ligated into px459 V2.0 vector (Addgene plasmid #62988) using standard protocols and verified by sequencing.", [["Oligos", "SIMPLE_CHEMICAL", 0, 6], ["px459 V2.0 vector", "DNA", 25, 42], ["Addgene plasmid #62988", "DNA", 44, 66], ["standard protocols", "TREATMENT", 74, 92]]], ["U2OS cells, seeded in a 6 cm dish, were transfected with 1 \u00b5g of empty px459 or px459-sgRNA vector.", [["U2OS cells", "ANATOMY", 0, 10], ["U2OS cells", "CELL", 0, 10], ["px459", "GENE_OR_GENE_PRODUCT", 71, 76], ["px459", "GENE_OR_GENE_PRODUCT", 80, 85], ["U2OS cells", "CELL_LINE", 0, 10], ["empty px459 or px459-sgRNA vector", "DNA", 65, 98], ["U2OS cells", "PROBLEM", 0, 10], ["empty px459", "TREATMENT", 65, 76], ["6 cm", "OBSERVATION_MODIFIER", 24, 28], ["dish", "OBSERVATION_MODIFIER", 29, 33], ["sgRNA vector", "OBSERVATION", 86, 98]]], ["One day after transfection, cells were selected for 30 h using 1 \u00b5g/ml Puromycin (Invivogen), diluted and further grown to allow the formation of single-cell clones.", [["cells", "ANATOMY", 28, 33], ["single-cell clones", "ANATOMY", 146, 164], ["Puromycin", "CHEMICAL", 71, 80], ["Puromycin", "CHEMICAL", 71, 80], ["cells", "CELL", 28, 33], ["Puromycin", "SIMPLE_CHEMICAL", 71, 80], ["Invivogen", "SIMPLE_CHEMICAL", 82, 91], ["single-cell clones", "CELL", 146, 164], ["single-cell clones", "CELL_LINE", 146, 164], ["cells", "TREATMENT", 28, 33], ["Puromycin (Invivogen)", "TREATMENT", 71, 92], ["single-cell clones", "PROBLEM", 146, 164], ["cell clones", "OBSERVATION", 153, 164]]], ["These clones were picked and analyzed for SINTBAD, AZI2Generation of CRISPR/Cas9-mediated knockout cells and reconstitution of themand Cas9 expression and verified by sequencing of the genomic DNA at the appropriate locus.Generation of CRISPR/Cas9-mediated knockout cells and reconstitution of themTo obtain SINTBAD/AZI2 double-deficient cells, a SINTBAD-deficient cell clone was transfected with px459-sgAZI2 and selected as described above.", [["clones", "ANATOMY", 6, 12], ["cells", "ANATOMY", 99, 104], ["cells", "ANATOMY", 266, 271], ["cells", "ANATOMY", 338, 343], ["cell clone", "ANATOMY", 365, 375], ["clones", "CELL", 6, 12], ["CRISPR/Cas9", "GENE_OR_GENE_PRODUCT", 69, 80], ["cells", "CELL", 99, 104], ["Cas9", "GENE_OR_GENE_PRODUCT", 135, 139], ["DNA", "CELLULAR_COMPONENT", 193, 196], ["locus", "CELLULAR_COMPONENT", 216, 221], ["CRISPR/Cas9", "GENE_OR_GENE_PRODUCT", 236, 247], ["cells", "CELL", 266, 271], ["themTo", "GENE_OR_GENE_PRODUCT", 294, 300], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 308, 315], ["AZI2", "GENE_OR_GENE_PRODUCT", 316, 320], ["cells", "CELL", 338, 343], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 347, 354], ["cell clone", "CELL", 365, 375], ["px459-sgAZI2", "GENE_OR_GENE_PRODUCT", 397, 409], ["SINTBAD", "PROTEIN", 42, 49], ["CRISPR", "DNA", 69, 75], ["Cas9", "DNA", 76, 80], ["mediated knockout cells", "CELL_TYPE", 81, 104], ["Cas9", "PROTEIN", 135, 139], ["genomic DNA", "DNA", 185, 196], ["CRISPR", "DNA", 236, 242], ["Cas9", "DNA", 243, 247], ["mediated knockout cells", "CELL_TYPE", 248, 271], ["themTo", "DNA", 294, 300], ["SINTBAD", "PROTEIN", 308, 315], ["AZI2 double-deficient cells", "CELL_LINE", 316, 343], ["SINTBAD-deficient cell clone", "CELL_LINE", 347, 375], ["px459", "PROTEIN", 397, 402], ["sgAZI2", "PROTEIN", 403, 409], ["These clones", "TEST", 0, 12], ["SINTBAD", "PROBLEM", 42, 49], ["CRISPR/Cas9-mediated knockout cells", "TREATMENT", 69, 104], ["reconstitution of themand Cas9 expression", "TREATMENT", 109, 150], ["the genomic DNA", "PROBLEM", 181, 196], ["CRISPR/Cas9", "TREATMENT", 236, 247], ["knockout cells", "PROBLEM", 257, 271], ["themTo", "TEST", 294, 300], ["SINTBAD", "TEST", 308, 315], ["double-deficient cells", "TREATMENT", 321, 343], ["a SINTBAD-deficient cell clone", "PROBLEM", 345, 375], ["genomic DNA", "OBSERVATION", 185, 196], ["cell clone", "OBSERVATION", 365, 375]]], ["To reconstitute SINTBADdeficient U2OS cells, cells were transfected with an pcDNA3.1/zeo-Flag-SINTBAD expression construct and continuously selected using 400 \u00b5g/ml Zeocin (Invivogen).", [["U2OS cells", "ANATOMY", 33, 43], ["cells", "ANATOMY", 45, 50], ["Zeocin", "CHEMICAL", 165, 171], ["Zeocin", "CHEMICAL", 165, 171], ["SINTBADdeficient U2OS cells", "CELL", 16, 43], ["cells", "CELL", 45, 50], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 76, 84], ["zeo", "GENE_OR_GENE_PRODUCT", 85, 88], ["Flag", "GENE_OR_GENE_PRODUCT", 89, 93], ["Zeocin", "SIMPLE_CHEMICAL", 165, 171], ["Invivogen", "SIMPLE_CHEMICAL", 173, 182], ["SINTBADdeficient U2OS cells", "CELL_LINE", 16, 43], ["pcDNA3.1/zeo-Flag-SINTBAD expression construct", "DNA", 76, 122], ["an pcDNA3.1", "TREATMENT", 73, 84], ["zeo", "TEST", 85, 88], ["Flag-SINTBAD expression construct", "TREATMENT", 89, 122], ["U2OS cells", "OBSERVATION", 33, 43]]], ["Singlecell clones were picked an analyzed by Western blotting.Knockdown of ULK1 and ULK2Reconstituted U2OS cells stably expressing Flag-SINTBAD were treated with 1 \u00b5M ULK1 and ULK2-specific Accell siRNAs (Dharmacon #A-005049-13-0005 and #A-005396-14-0005) or with a scrambled control RNA (Seibert et al., 2019) according to the protocol using Accell siRNA Delivery Media (Dharmacon #B-005000-500).", [["Singlecell clones", "ANATOMY", 0, 17], ["U2OS cells", "ANATOMY", 102, 112], ["Singlecell clones", "CELL", 0, 17], ["ULK1", "GENE_OR_GENE_PRODUCT", 75, 79], ["U2OS cells", "CELL", 102, 112], ["Flag-SINTBAD", "GENE_OR_GENE_PRODUCT", 131, 143], ["ULK1", "GENE_OR_GENE_PRODUCT", 167, 171], ["ULK2", "GENE_OR_GENE_PRODUCT", 176, 180], ["Singlecell clones", "CELL_LINE", 0, 17], ["ULK1", "PROTEIN", 75, 79], ["ULK2Reconstituted U2OS cells", "CELL_LINE", 84, 112], ["Flag", "PROTEIN", 131, 135], ["SINTBAD", "PROTEIN", 136, 143], ["ULK2", "PROTEIN", 176, 180], ["Singlecell clones", "PROBLEM", 0, 17], ["ULK1", "TEST", 75, 79], ["ULK2Reconstituted U2OS cells", "TEST", 84, 112], ["ULK2", "TEST", 176, 180], ["a scrambled control RNA", "TREATMENT", 264, 287], ["Accell siRNA Delivery Media", "TREATMENT", 343, 370], ["ULK1", "OBSERVATION", 75, 79], ["U2OS cells", "OBSERVATION", 102, 112]]], ["Three days after siRNA transfection, half of the cells were seeded on coverslips and used for immunofluorescence staining and the remaining cells were analyzed for efficient knockdown by real time qPCR, using the following primers specific for ACTB (5\u00b4-CATGTACGTTGCTATCCAGGC-3\u00b4, 5\u00b4-CTCCTTAATGTCACGCACGAT-3\u00b4), ULK1 (5\u00b4-ACCCCATTACTGCGAACCTGGA-3\u00b4, 5\u00b4-GCACGAACAGCAGCGTGAAGC-3\u00b4) and ULK2 (5\u00b4-TCTGCATCACCATGTGCAAGAA-3\u00b4, 5\u00b4-AACATCTCATCCAGGGCT-3\u00b4).Cell lysis protocols and subcellular fractionationTo prepare cell lysates under native conditions, cells were lysed on ice for 20 min in IGEPAL buffer (20 M Tris/HCl pH 7.5, 150 mM NaCl, 1 % IGEPAL CA-630 (Sigma-Aldrich), 5 % glycerol and freshly added 10 mM NaF, 0.5 mM Na 3 VO 4 , 1 mM PMSF, 5 \u00b5g/ml leupeptin and 5 \u00b5g/ml aprotinin).", [["cells", "ANATOMY", 49, 54], ["cells", "ANATOMY", 140, 145], ["Cell", "ANATOMY", 440, 444], ["subcellular", "ANATOMY", 465, 476], ["cell lysates", "ANATOMY", 501, 513], ["cells", "ANATOMY", 539, 544], ["NaCl", "CHEMICAL", 621, 625], ["IGEPAL CA-630", "CHEMICAL", 631, 644], ["Sigma-Aldrich", "CHEMICAL", 646, 659], ["glycerol", "CHEMICAL", 666, 674], ["NaF", "CHEMICAL", 699, 702], ["Na", "CHEMICAL", 711, 713], ["Tris", "CHEMICAL", 597, 601], ["HCl", "CHEMICAL", 602, 605], ["NaCl", "CHEMICAL", 621, 625], ["glycerol", "CHEMICAL", 666, 674], ["NaF", "CHEMICAL", 699, 702], ["Na 3 VO 4", "CHEMICAL", 711, 720], ["PMSF", "CHEMICAL", 728, 732], ["leupeptin", "CHEMICAL", 742, 751], ["aprotinin", "CHEMICAL", 764, 773], ["cells", "CELL", 49, 54], ["cells", "CELL", 140, 145], ["ACTB", "GENE_OR_GENE_PRODUCT", 244, 248], ["Cell", "CELL", 440, 444], ["cell lysates", "CELL", 501, 513], ["cells", "CELL", 539, 544], ["CA-630", "SIMPLE_CHEMICAL", 638, 644], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 646, 659], ["glycerol", "SIMPLE_CHEMICAL", 666, 674], ["NaF", "SIMPLE_CHEMICAL", 699, 702], ["PMSF", "SIMPLE_CHEMICAL", 728, 732], ["leupeptin", "SIMPLE_CHEMICAL", 742, 751], ["aprotinin", "GENE_OR_GENE_PRODUCT", 764, 773], ["ACTB", "DNA", 244, 248], ["siRNA transfection", "TREATMENT", 17, 35], ["coverslips", "TREATMENT", 70, 80], ["immunofluorescence staining", "TEST", 94, 121], ["the following primers", "TREATMENT", 209, 230], ["ACTB", "TEST", 244, 248], ["CATGTACGTTGCTATCCAGGC", "TEST", 253, 274], ["CTCCTTAATGTCACGCACGAT", "TEST", 282, 303], ["ULK1", "TEST", 309, 313], ["ACCCCATTACTGCGAACCTGGA", "TEST", 318, 340], ["GCACGAACAGCAGCGTGAAGC", "TEST", 348, 369], ["ULK2", "TEST", 378, 382], ["TCTGCATCACCATGTGCAAGAA", "TEST", 387, 409], ["AACATCTCATCCAGGGCT", "TEST", 417, 435], ["Cell lysis protocols", "TREATMENT", 440, 460], ["subcellular fractionation", "TREATMENT", 465, 490], ["Tris", "TEST", 597, 601], ["pH", "TEST", 606, 608], ["NaCl", "TEST", 621, 625], ["CA", "TEST", 638, 640], ["5 % glycerol", "TREATMENT", 662, 674], ["leupeptin", "TREATMENT", 742, 751], ["aprotinin", "TREATMENT", 764, 773], ["subcellular fractionation", "OBSERVATION", 465, 490]]], ["The lysates were cleared by centrifugation and the supernatants were transferred into a fresh tube and either used for coimmunoprecipitation studies or mixed with sample buffer for Western blot analysis.", [["lysates", "ANATOMY", 4, 11], ["supernatants", "ANATOMY", 51, 63], ["tube", "ANATOMY", 94, 98], ["lysates", "ORGANISM_SUBSTANCE", 4, 11], ["tube", "TISSUE", 94, 98], ["The lysates", "TREATMENT", 0, 11], ["a fresh tube", "TREATMENT", 86, 98], ["coimmunoprecipitation studies", "TEST", 119, 148], ["sample buffer", "TREATMENT", 163, 176], ["Western blot analysis", "TEST", 181, 202]]], ["To lyse cells under denaturing conditions, the washed cell pellets were resuspended in 1 \uf0b4 SDS sample buffer and sonicated two times for 20 sec with a Branson sonifier to shear the genomic DNA.", [["cells", "ANATOMY", 8, 13], ["cell", "ANATOMY", 54, 58], ["cells", "CELL", 8, 13], ["cell", "CELL", 54, 58], ["DNA", "CELLULAR_COMPONENT", 189, 192], ["genomic DNA", "DNA", 181, 192], ["denaturing conditions", "TREATMENT", 20, 41], ["the washed cell pellets", "TREATMENT", 43, 66], ["a Branson sonifier", "TREATMENT", 149, 167], ["genomic DNA", "OBSERVATION", 181, 192]]], ["After boiling the samples for 5 min, the lysates were analyzed by Western blotting.", [["samples", "ANATOMY", 18, 25], ["lysates", "ANATOMY", 41, 48], ["lysates", "ORGANISM_SUBSTANCE", 41, 48], ["the lysates", "TREATMENT", 37, 48]]], ["For subcellular fractionation experiments, cells, grown and treated in a 6 cm dish, were lysed in 160 \u00b5l low-salt buffer (10 mM Hepes, pH 7.9, added PMSF) on ice for 10 min.", [["subcellular", "ANATOMY", 4, 15], ["cells", "ANATOMY", 43, 48], ["PMSF", "CHEMICAL", 149, 153], ["cells", "CELL", 43, 48], ["PMSF", "SIMPLE_CHEMICAL", 149, 153], ["subcellular fractionation experiments", "TEST", 4, 41], ["Hepes", "TEST", 128, 133], ["pH", "TEST", 135, 137], ["fractionation experiments", "OBSERVATION", 16, 41]]], ["NP-40 (Roche) was added to a final concentration of 0.25 %, samples were briefly vortexed and centrifuged for 10 sec at 16 000 \u00d7 g.", [["samples", "ANATOMY", 60, 67], ["NP-40", "CHEMICAL", 0, 5], ["NP-40", "SIMPLE_CHEMICAL", 0, 5], ["Roche", "ORGANISM", 7, 12]]], ["The supernatantsCell lysis protocols and subcellular fractionationrepresenting the cytoplasmic fractions were collected in fresh tubes and mixed with 5 \u00d7 SDS sample buffer.", [["supernatants", "ANATOMY", 4, 16], ["Cell", "ANATOMY", 16, 20], ["subcellular", "ANATOMY", 41, 52], ["cytoplasmic fractions", "ANATOMY", 83, 104], ["Cell", "CELL", 16, 20], ["cytoplasmic", "ORGANISM_SUBSTANCE", 83, 94], ["Cell lysis protocols", "TREATMENT", 16, 36], ["subcellular fractionationrepresenting the cytoplasmic fractions", "TREATMENT", 41, 104], ["fresh tubes", "TREATMENT", 123, 134], ["5 \u00d7 SDS sample buffer", "TREATMENT", 150, 171], ["cytoplasmic fractions", "OBSERVATION", 83, 104], ["fresh tubes", "OBSERVATION", 123, 134]]], ["The remaining pellets representing the nuclear/insoluble fractions were washed twice in low-salt buffer and then resuspended in 180 \u00b5l 1 \u00d7 SDS sample buffer, boiled and sheared two times for 20 sec with a sonifier.", [["nuclear", "ANATOMY", 39, 46], ["fractions", "ANATOMY", 57, 66], ["nuclear", "CELLULAR_COMPONENT", 39, 46], ["The remaining pellets", "TREATMENT", 0, 21], ["the nuclear/insoluble fractions", "TREATMENT", 35, 66], ["low-salt buffer", "TREATMENT", 88, 103], ["pellets", "OBSERVATION", 14, 21]]], ["The purity of the cellular fractions was confirmed by Western blotting, detecting Tubulin and histone H3 as markers for the cytosolic or nuclear/insoluble fraction, respectively.Coimmunoprecipitation experiments and Western blottingFor coimmunoprecipitation, cleared cell extracts lysed in IGEPAL lysis buffer were filled up to a volume of 600 \u03bcl with lysis buffer and supplemented with 1 \u03bcg precipitating antibody or control IgG.", [["cellular fractions", "ANATOMY", 18, 36], ["cytosolic", "ANATOMY", 124, 133], ["nuclear", "ANATOMY", 137, 144], ["cell extracts", "ANATOMY", 267, 280], ["cellular", "CELL", 18, 26], ["Tubulin", "GENE_OR_GENE_PRODUCT", 82, 89], ["histone H3", "GENE_OR_GENE_PRODUCT", 94, 104], ["cytosolic", "CELLULAR_COMPONENT", 124, 133], ["nuclear", "CELLULAR_COMPONENT", 137, 144], ["cell extracts", "ORGANISM_SUBSTANCE", 267, 280], ["IgG", "GENE_OR_GENE_PRODUCT", 426, 429], ["Tubulin", "PROTEIN", 82, 89], ["histone H3", "PROTEIN", 94, 104], ["IgG", "PROTEIN", 426, 429], ["Western blotting", "TEST", 54, 70], ["Tubulin and histone H3", "TREATMENT", 82, 104], ["nuclear/insoluble fraction", "TEST", 137, 163], ["Coimmunoprecipitation experiments", "TREATMENT", 178, 211], ["coimmunoprecipitation", "PROBLEM", 236, 257], ["cleared cell extracts", "TREATMENT", 259, 280], ["IGEPAL lysis buffer", "TREATMENT", 290, 309], ["lysis buffer", "TREATMENT", 352, 364], ["purity", "OBSERVATION_MODIFIER", 4, 10], ["cellular fractions", "OBSERVATION", 18, 36]]], ["After adding 20 \u03bcl protein A/G agarose (Millipore), the samples were incubated for 4 h at 4\u00b0C on a rotating wheel.", [["samples", "ANATOMY", 56, 63], ["G agarose", "SIMPLE_CHEMICAL", 29, 38], ["20 \u03bcl protein A/G agarose (Millipore", "TREATMENT", 13, 49], ["the samples", "TEST", 52, 63], ["a rotating wheel", "TREATMENT", 97, 113]]], ["Alternatively, covalently antibody-coupled affinity gels were used for coimmunoprecipitation (anti-Flag M2 affinity gel, A2220, Sigma-Aldrich;Coimmunoprecipitation experiments and Western blottingGFP-Trap_A, Chromotek).", [["GFP", "GENE_OR_GENE_PRODUCT", 196, 199], ["covalently antibody", "PROTEIN", 15, 34], ["Flag M2", "PROTEIN", 99, 106], ["GFP", "PROTEIN", 196, 199], ["Trap_A", "PROTEIN", 200, 206], ["Chromotek", "PROTEIN", 208, 217], ["covalently antibody", "TEST", 15, 34], ["coupled affinity gels", "TREATMENT", 35, 56], ["coimmunoprecipitation", "TEST", 71, 92], ["anti-Flag M2 affinity gel", "TREATMENT", 94, 119], ["Coimmunoprecipitation experiments", "TREATMENT", 142, 175]]], ["Agarose beads were then washed four times with 1 ml cold IGEPAL buffer.", [["Agarose beads", "TREATMENT", 0, 13], ["1 ml cold IGEPAL buffer", "TREATMENT", 47, 70], ["beads", "OBSERVATION_MODIFIER", 8, 13]]], ["Precipitated proteins were eluted by adding 1.5 \u00d7 SDS sample buffer.", [["Precipitated proteins", "PROBLEM", 0, 21]]], ["Equal amounts of protein were separated by SDS-PAGE, followed by semidry blotting to a PVDF membrane (IPVH00010, Millipore).", [["PVDF membrane", "ANATOMY", 87, 100], ["PVDF", "CHEMICAL", 87, 91], ["membrane", "CELLULAR_COMPONENT", 92, 100], ["a PVDF membrane", "TREATMENT", 85, 100], ["amounts", "OBSERVATION_MODIFIER", 6, 13]]], ["Further analysis was performed using standard methods.Coimmunoprecipitation experiments and Western blottingAfter blocking the membrane, primary antibodies, diluted in 2 % nonfat dry milk or 5 % BSA (Sigma-Aldrich) in TBST, were incubated overnight at 4 \u00b0C. Peroxidase-coupled antibodies (Jackson ImmuoResearch) were diluted 1:5000 in 2 % dry milk in TBST and incubated 2 h at room temperature.", [["membrane", "ANATOMY", 127, 135], ["milk", "ANATOMY", 183, 187], ["milk", "ANATOMY", 343, 347], ["BSA", "CHEMICAL", 195, 198], ["membrane", "CELLULAR_COMPONENT", 127, 135], ["milk", "ORGANISM_SUBSTANCE", 183, 187], ["BSA", "SIMPLE_CHEMICAL", 195, 198], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 200, 213], ["Peroxidase", "GENE_OR_GENE_PRODUCT", 258, 268], ["milk", "ORGANISM_SUBSTANCE", 343, 347], ["primary antibodies", "PROTEIN", 137, 155], ["Peroxidase-coupled antibodies", "PROTEIN", 258, 287], ["Jackson ImmuoResearch", "PROTEIN", 289, 310], ["Further analysis", "TEST", 0, 16], ["standard methods", "TREATMENT", 37, 53], ["Coimmunoprecipitation experiments", "TREATMENT", 54, 87], ["blocking the membrane", "TREATMENT", 114, 135], ["primary antibodies", "TREATMENT", 137, 155], ["Peroxidase", "TEST", 258, 268]]], ["Immunoreactive bands were detected using the Western Lightning Plus-ECL reagent (Perkin Elmer) and visualized on a ChemiDoc Imaging System (Bio-Rad).Immunofluorescence stainingU2OS cells or their derivatives were grown on coverslips in 12-or 24-well plates.", [["stainingU2OS cells", "ANATOMY", 168, 186], ["stainingU2OS cells", "CELL", 168, 186], ["stainingU2OS cells", "CELL_LINE", 168, 186], ["Immunoreactive bands", "PROBLEM", 0, 20], ["ECL reagent", "TREATMENT", 68, 79], ["a ChemiDoc Imaging System", "TEST", 113, 138], ["Immunofluorescence stainingU2OS cells", "PROBLEM", 149, 186], ["their derivatives", "PROBLEM", 190, 207], ["coverslips", "TEST", 222, 232]]], ["Cells were transfected and/or treated as indicated and described in the figure legend.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5]]], ["After washing the cells with PBS, cells were fixed for 1 min with ice-cold methanol/acetone (1:1).", [["cells", "ANATOMY", 18, 23], ["cells", "ANATOMY", 34, 39], ["ice-cold methanol/acetone", "CHEMICAL", 66, 91], ["methanol", "CHEMICAL", 75, 83], ["acetone", "CHEMICAL", 84, 91], ["cells", "CELL", 18, 23], ["cells", "CELL", 34, 39], ["methanol", "SIMPLE_CHEMICAL", 75, 83], ["acetone", "SIMPLE_CHEMICAL", 84, 91], ["PBS, cells", "TREATMENT", 29, 39], ["ice-cold methanol/acetone", "TREATMENT", 66, 91]]], ["After rehydration, the cells were blocked with 5 % BSA in PBS for 1 h at room temperature.Immunofluorescence stainingCoverslips were subsequently incubated with the indicated primary antibodies, diluted in PBS containing 1 % BSA and 0.1 % Triton X-100, for 90 min at room temperature or at 4 \u00b0C overnight.", [["cells", "ANATOMY", 23, 28], ["BSA", "CHEMICAL", 51, 54], ["BSA", "CHEMICAL", 225, 228], ["Triton X-100", "CHEMICAL", 239, 251], ["cells", "CELL", 23, 28], ["BSA", "SIMPLE_CHEMICAL", 51, 54], ["BSA", "SIMPLE_CHEMICAL", 225, 228], ["Triton X-100", "SIMPLE_CHEMICAL", 239, 251], ["primary antibodies", "PROTEIN", 175, 193], ["rehydration", "TREATMENT", 6, 17], ["the cells", "TREATMENT", 19, 28], ["5 % BSA in PBS", "TREATMENT", 47, 61], ["Immunofluorescence stainingCoverslips", "TEST", 90, 127], ["primary antibodies", "TREATMENT", 175, 193], ["PBS", "TREATMENT", 206, 209], ["1 % BSA", "TREATMENT", 221, 228]]], ["After washing three times with PBS cells were incubated with the appropriate secondary Alexa488-or Cy3-conjugated antibodies (Jackson ImmunoResearch) diluted 1:3000 in 1 % BSA in PBS for 90 min in the dark.", [["cells", "ANATOMY", 35, 40], ["Alexa488", "CHEMICAL", 87, 95], ["BSA", "CHEMICAL", 172, 175], ["cells", "CELL", 35, 40], ["Alexa488", "SIMPLE_CHEMICAL", 87, 95], ["Cy3", "SIMPLE_CHEMICAL", 99, 102], ["BSA", "SIMPLE_CHEMICAL", 172, 175], ["PBS cells", "CELL_LINE", 31, 40], ["Alexa488", "PROTEIN", 87, 95], ["Cy3-conjugated antibodies", "PROTEIN", 99, 124], ["Jackson ImmunoResearch", "PROTEIN", 126, 148], ["PBS cells", "TREATMENT", 31, 40], ["Alexa488", "TEST", 87, 95], ["Cy3", "TEST", 99, 102]]], ["After incubation, cells were washed three times in PBS and the nuclear DNA was stained with Hoechst 33324 (Invitrogen).", [["cells", "ANATOMY", 18, 23], ["nuclear", "ANATOMY", 63, 70], ["Hoechst 33324", "CHEMICAL", 92, 105], ["Hoechst 33324", "CHEMICAL", 92, 105], ["cells", "CELL", 18, 23], ["nuclear", "CELLULAR_COMPONENT", 63, 70], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["Hoechst 33324", "SIMPLE_CHEMICAL", 92, 105], ["nuclear DNA", "DNA", 63, 74], ["cells", "TREATMENT", 18, 23], ["PBS", "TREATMENT", 51, 54], ["the nuclear DNA", "TEST", 59, 74], ["Hoechst", "TEST", 92, 99]]], ["The samples were mounted with Mowiol mounting medium and stored at 4 \u00b0C. Analysis of the stained cells was done using an Eclipse TE2000-E microscope (Nikon) and a 63 \u00d7 oil-immersion lens.", [["samples", "ANATOMY", 4, 11], ["cells", "ANATOMY", 97, 102], ["cells", "CELL", 97, 102], ["stained cells", "CELL_TYPE", 89, 102], ["The samples", "TEST", 0, 11], ["the stained cells", "TEST", 85, 102], ["an Eclipse TE2000-E microscope", "TREATMENT", 118, 148]]], ["For each condition >30 healthy individual cells were analyzed and pictures of one representative cell were taken with an OCRA-spark digital CMOS camera (C11440-36U, Hamamatsu).", [["cells", "ANATOMY", 42, 47], ["cell", "ANATOMY", 97, 101], ["cells", "CELL", 42, 47], ["cell", "CELL", 97, 101]]], ["For the quantification of protein localizations and cellular phenotypes, at least 100 cells for each condition were analyzed.Mass spectrometryTo identify SINTBAD interactors by mass spectrometry, 293T cells were either transfected with the pcDNA3.1-Flag-SINTBAD expression construct or the empty vector.", [["cellular", "ANATOMY", 52, 60], ["cells", "ANATOMY", 86, 91], ["293T cells", "ANATOMY", 196, 206], ["cellular", "CELL", 52, 60], ["cells", "CELL", 86, 91], ["SINTBAD", "GENE_OR_GENE_PRODUCT", 154, 161], ["293T cells", "CELL", 196, 206], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 240, 246], ["Flag-", "GENE_OR_GENE_PRODUCT", 249, 254], ["SINTBAD", "PROTEIN", 154, 161], ["293T cells", "CELL_LINE", 196, 206], ["pcDNA3.1-Flag-SINTBAD expression construct", "DNA", 240, 282], ["empty vector", "DNA", 290, 302], ["protein localizations", "PROBLEM", 26, 47], ["cellular phenotypes", "PROBLEM", 52, 71], ["Mass spectrometry", "PROBLEM", 125, 142], ["mass spectrometry", "TEST", 177, 194], ["the pcDNA3", "TREATMENT", 236, 246], ["cellular phenotypes", "OBSERVATION", 52, 71], ["spectrometry", "OBSERVATION", 130, 142], ["empty vector", "OBSERVATION", 290, 302]]], ["Four 10 cm dishes for each condition were taken for large-scale immunoprecipitation.", [["large-scale immunoprecipitation", "TREATMENT", 52, 83], ["10 cm", "OBSERVATION_MODIFIER", 5, 10]]], ["Washed cells were harvested and lysed in 1 ml low-salt buffer as described above.", [["cells", "ANATOMY", 7, 12], ["Washed cells", "CELL", 0, 12], ["Washed cells", "CELL_TYPE", 0, 12], ["Washed cells", "TREATMENT", 0, 12], ["low-salt buffer", "TREATMENT", 46, 61], ["harvested", "OBSERVATION_MODIFIER", 18, 27]]], ["The received cytosolic fraction was mixed with 1 ml IGEPAL lysis buffer, containing Complete Protease InhibitorMass spectrometryCocktail and PhosSTOP (Roche).", [["cytosolic", "ANATOMY", 13, 22], ["cytosolic fraction", "TREATMENT", 13, 31], ["1 ml IGEPAL lysis buffer", "TREATMENT", 47, 71], ["Complete Protease InhibitorMass spectrometryCocktail", "TREATMENT", 84, 136], ["PhosSTOP (Roche)", "TREATMENT", 141, 157]]], ["The remaining cell pellet was washed two times in low-salt buffer and then resuspended in 2 ml IGEPAL lysis buffer and sonified two times for 20 sec.Mass spectrometryThe two fractions were precleared by incubating them 1 h with 3 \u00b5g control mouse IgG (Santa Cruz Biotechnology) and 40 \u00b5l Protein A/G Agarose.", [["cell pellet", "ANATOMY", 14, 25], ["cell", "CELL", 14, 18], ["mouse", "ORGANISM", 241, 246], ["IgG", "GENE_OR_GENE_PRODUCT", 247, 250], ["mouse IgG", "PROTEIN", 241, 250], ["Santa Cruz Biotechnology", "PROTEIN", 252, 276], ["mouse", "SPECIES", 241, 246], ["mouse", "SPECIES", 241, 246], ["The remaining cell pellet", "TREATMENT", 0, 25], ["low-salt buffer", "TREATMENT", 50, 65], ["2 ml IGEPAL lysis buffer", "TREATMENT", 90, 114], ["Mass spectrometry", "PROBLEM", 149, 166], ["cell pellet", "OBSERVATION", 14, 25], ["spectrometry", "OBSERVATION", 154, 166], ["fractions", "OBSERVATION_MODIFIER", 174, 183]]], ["Afterwards, immunoprecipitation was performed by incubating the lysates with 6 \u00b5g anti-Flag M2 antibodies together with 80 \u00b5l Agarose beads for 4 h at 4 \u00b0C on a rotating wheel.", [["lysates", "ANATOMY", 64, 71], ["lysates", "ORGANISM_SUBSTANCE", 64, 71], ["anti-Flag M2 antibodies", "PROTEIN", 82, 105], ["immunoprecipitation", "TEST", 12, 31], ["the lysates", "TEST", 60, 71], ["6 \u00b5g anti-Flag M2 antibodies", "TREATMENT", 77, 105], ["80 \u00b5l Agarose beads", "TREATMENT", 120, 139], ["a rotating wheel", "TREATMENT", 159, 175]]], ["Beads were washed five times with 2 ml IGEPAL lysis buffer, transferred to a fresh tube and proteins were eluted at 70 \u00b0C for 10 min in LDS sample buffer (Invitrogen).", [["Beads", "CELL", 0, 5], ["tube", "TISSUE", 83, 87], ["2 ml IGEPAL lysis buffer", "TREATMENT", 34, 58], ["a fresh tube and proteins", "TREATMENT", 75, 100]]], ["Samples were separated on a 4-12 % Bis-Tris gradient-gel (NuPAGE, Invitrogen), stained with colloidal Coomassie (Invitrogen) and cut into small pieces (7 slides each lane).", [["Samples", "ANATOMY", 0, 7], ["Bis-Tris", "CHEMICAL", 35, 43], ["NuPAGE", "CHEMICAL", 58, 64], ["Coomassie", "CHEMICAL", 102, 111], ["Bis-Tris", "SIMPLE_CHEMICAL", 35, 43], ["Coomassie", "SIMPLE_CHEMICAL", 102, 111], ["Samples", "TEST", 0, 7], ["a 4-12 % Bis-Tris gradient", "TREATMENT", 26, 52], ["gel (NuPAGE, Invitrogen)", "TREATMENT", 53, 77], ["colloidal Coomassie (Invitrogen)", "TREATMENT", 92, 124], ["small pieces", "OBSERVATION_MODIFIER", 138, 150]]], ["In-gel digestion of the proteins with trypsin and purification of the peptides was performed as described (Seibert et al., 2019) .", [["trypsin", "GENE_OR_GENE_PRODUCT", 38, 45], ["trypsin", "PROTEIN", 38, 45], ["trypsin", "TREATMENT", 38, 45]]], ["Peptide solutions were desalted by stop and go extraction (STAGE) tips (Rappsilber et al., 2003) .", [["Peptide solutions", "TREATMENT", 0, 17]]], ["The purification and mass spectrometry of two individual experiments was performed with a time lag and therefore analyzed with different instrumental settings.", [["The purification", "TREATMENT", 0, 16], ["mass spectrometry", "TEST", 21, 38], ["a time lag", "TEST", 88, 98], ["different instrumental settings", "TREATMENT", 127, 158], ["mass", "OBSERVATION", 21, 25]]], ["Dissenting setting parameters of analysis 1 and 2 are indicated by a slash.", [["analysis", "TEST", 33, 41]]], ["Samples were eluted from STAGE tips with acetonitrile and applied to the UHPLC system (EASY-nLC 1000, Thermo Fisher Scientific) in 0.1 % formic acid.", [["Samples", "ANATOMY", 0, 7], ["acetonitrile", "CHEMICAL", 41, 53], ["formic acid", "CHEMICAL", 137, 148], ["acetonitrile", "CHEMICAL", 41, 53], ["formic acid", "CHEMICAL", 137, 148], ["acetonitrile", "SIMPLE_CHEMICAL", 41, 53], ["formic acid", "SIMPLE_CHEMICAL", 137, 148], ["Samples", "TEST", 0, 7], ["acetonitrile", "TREATMENT", 41, 53], ["tips", "OBSERVATION_MODIFIER", 31, 35]]], ["Separation of peptides by hydrophobicity was performed with 50/18 cm in-house packed C18 columns (1.9 \u00b5m C18 beads, Dr. Maisch GmbH).", [["hydrophobicity", "TEST", 26, 40], ["hydrophobicity", "OBSERVATION_MODIFIER", 26, 40]]], ["Peptide elution was achieved with a binary solvent system (solvent A: 0.1% formic acid; solvent B: 80% acetonitrile, 0.1% formic acid) by increasing the relative amount of B from 10 % to 38 % in a linear gradient within 35/20 min, followed by 5/3 min up to 60 % and another 5/2 min to 95%.", [["formic acid", "CHEMICAL", 75, 86], ["solvent B", "CHEMICAL", 88, 97], ["acetonitrile", "CHEMICAL", 103, 115], ["formic acid", "CHEMICAL", 122, 133], ["formic acid", "CHEMICAL", 75, 86], ["acetonitrile", "CHEMICAL", 103, 115], ["formic acid", "CHEMICAL", 122, 133], ["formic acid", "SIMPLE_CHEMICAL", 75, 86], ["acetonitrile", "SIMPLE_CHEMICAL", 103, 115], ["formic acid", "SIMPLE_CHEMICAL", 122, 133], ["Peptide elution", "TREATMENT", 0, 15], ["a binary solvent system", "TREATMENT", 34, 57], ["formic acid", "TREATMENT", 75, 86], ["80% acetonitrile", "TREATMENT", 99, 115]]], ["Re-equilibration was done within 5 min at 5 %.", [["Re-equilibration", "TEST", 0, 16]]], ["The samples were transferred to an in line coupled QExactive orbitrap/QExactive HF mass spectrometer (Thermo Fisher Scientific) using a nano electrospray ionization source.", [["samples", "ANATOMY", 4, 11], ["QExactive HF mass spectrometer", "TREATMENT", 70, 100], ["a nano electrospray ionization source", "TREATMENT", 134, 171]]], ["Full MS spectra were acquired with a data-dependent Top10/15 method that comprised a resolution of 70,000/60,000 at 200 m/z and an automatic gain control (AGC) target of 3e6 at a maximum injection time of 20 ms.", [["Top10", "PROTEIN", 52, 57], ["a data", "TEST", 35, 41]]], ["The 10/15 most intense ions were further fragmented with higher-energy collisional dissociation (HCD) at a normalized collision energy of 25/27 and MS\u00b2 spectra were generated at 35,000/30,000 resolution, AGC target of 5e5/1e5 and maximum injection time 120/64 ms.Mass spectrometryData from two biological replicates (2 \uf0b4 28 raw files of IgG control and anti-Flag-SINITBAD) were analyzed using MaxQuant (v1.5.5.18) (Cox and Mann, 2008) and the implemented Andromeda search engine (Cox et al., 2011) .", [["IgG", "PROTEIN", 337, 340], ["anti-Flag", "PROTEIN", 353, 362], ["SINITBAD", "PROTEIN", 363, 371], ["higher-energy collisional dissociation", "PROBLEM", 57, 95], ["a normalized collision energy", "TEST", 105, 134], ["MS\u00b2 spectra", "TEST", 148, 159], ["AGC target", "TEST", 204, 214], ["Mass spectrometry", "PROBLEM", 263, 280], ["IgG control", "TREATMENT", 337, 348], ["anti-Flag-SINITBAD)", "TREATMENT", 353, 372], ["fragmented", "OBSERVATION_MODIFIER", 41, 51], ["collisional dissociation", "OBSERVATION", 71, 95], ["spectrometry", "OBSERVATION", 268, 280]]], ["Protein assignment was accomplished with correlation of fragment spectra with the UniProt human database (July 2016).", [["human", "ORGANISM", 90, 95], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 90, 95], ["Protein assignment", "TEST", 0, 18]]], ["Common contaminants were excluded from the analysis.", [["Common contaminants", "PROBLEM", 0, 19], ["the analysis", "TEST", 39, 51], ["contaminants", "OBSERVATION", 7, 19]]], ["Data processing was performed with tryptic specifications and default settings for mass tolerance in MS and MS/MS spectra.", [["Data processing", "TEST", 0, 15], ["tryptic specifications", "TEST", 35, 57], ["default settings", "TEST", 62, 78], ["mass tolerance in MS", "PROBLEM", 83, 103], ["MS/MS spectra", "PROBLEM", 108, 121]]], ["The minimal peptide length was set to 7 amino acids by default and the false discovery rate on protein and peptide level was set to 1 %.", [["amino acids", "CHEMICAL", 40, 51], ["amino acids", "CHEMICAL", 40, 51], ["amino acids", "AMINO_ACID", 40, 51], ["The minimal peptide length", "PROBLEM", 0, 26], ["amino acids", "TEST", 40, 51], ["peptide level", "TEST", 107, 120], ["minimal", "OBSERVATION_MODIFIER", 4, 11], ["peptide length", "OBSERVATION", 12, 26]]], ["Prior to further processing of the data, contaminants, reverse entries and proteins that were only identified by a modification site were filtered out.", [["the data", "TEST", 31, 39], ["a modification site", "PROBLEM", 113, 132]]], ["In order to define high confidence interactors, identified proteins were classified according to criteria given in suppl.", [["high confidence interactors", "PROBLEM", 19, 46]]], ["Proteins from all three groups were combined and constitute the SINTBAD interactome.Bioinformatic analysisThe volcano plots for proteins of group 2a are displayed in suppl.", [["SINTBAD", "GENE_OR_GENE_PRODUCT", 64, 71], ["Proteins", "TEST", 0, 8], ["Bioinformatic analysis", "TEST", 84, 106], ["SINTBAD interactome", "OBSERVATION", 64, 83]]], ["The SINTBAD interactome was analysed by the STRING database version 11.0.", [["SINTBAD", "DNA", 4, 11]]], ["Only interactions with a medium confidence score of 0.4 were shown.", [["a medium confidence score", "TEST", 23, 48]]], ["Line thickness indicates the strength of data support.", [["Line thickness", "TREATMENT", 0, 14], ["thickness", "OBSERVATION_MODIFIER", 5, 14]]], ["The assignment of SINTBAD interactors to biological functions and processes was done by combined Genecards, Uniprot and Pubmed searches (www.genecards.org;Bioinformatic analysiswww.uniprot.org; www.ncbi.nlm.nih.gov/pubmed).", [["SINTBAD", "GENE_OR_GENE_PRODUCT", 18, 25], ["SINTBAD interactors", "PROTEIN", 18, 37], ["SINTBAD interactors", "PROBLEM", 18, 37]]], ["The intrinsic disorder was analyzed using the PONDR prediction tool (http://www.pondr.com) (Peng et al., 2005) and Espritz (Walsh et al., 2012) .", [["The intrinsic disorder", "PROBLEM", 0, 22], ["intrinsic disorder", "OBSERVATION", 4, 22]]]], "b8cd9cd3b6e4b6a6f80fc299809808169afba134": [["The Coronavirus Disease 2019 is an unprecedented pandemic with major life-threatening complications among people with serious underlying conditions, especially older adults.", [["Coronavirus Disease", "DISEASE", 4, 23], ["people", "ORGANISM", 106, 112], ["people", "SPECIES", 106, 112], ["The Coronavirus Disease", "PROBLEM", 0, 23], ["serious underlying conditions", "PROBLEM", 118, 147], ["Coronavirus Disease", "OBSERVATION", 4, 23]]], ["Today, in France, COVID-19 screening tests are performed on symptomatic individuals, inpatients, healthcare and emergency workers, but many individuals are asymptomatic and carry the virus.", [["individuals", "ORGANISM", 140, 151], ["COVID", "TEST", 18, 23], ["screening tests", "TEST", 27, 42], ["asymptomatic", "PROBLEM", 156, 168], ["the virus", "PROBLEM", 179, 188]]], ["Screening is currently established in hospitals or clinical laboratories by means of reverse transcription polymerase chain reaction (RT-PCR) tests that utilize deep nasopharyngeal swabs, with possibility of false negatives due to insufficient amount of viral material collection or laboratory error.", [["nasopharyngeal swabs", "ANATOMY", 166, 186], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 166, 186], ["reverse transcription polymerase chain reaction", "PROBLEM", 85, 132], ["RT-PCR) tests", "TEST", 134, 147], ["deep nasopharyngeal swabs", "TEST", 161, 186], ["false negatives", "PROBLEM", 208, 223], ["viral material collection", "PROBLEM", 254, 279], ["viral material", "OBSERVATION", 254, 268]]], ["The challenge is to define optimal screening strategies to identify both asymptomatic subjects and subgroups at risk of severe complications.", [["optimal screening strategies", "TREATMENT", 27, 55], ["severe complications", "PROBLEM", 120, 140], ["severe", "OBSERVATION_MODIFIER", 120, 126], ["complications", "OBSERVATION", 127, 140]]]], "PMC6817509": [["IntroductionPorcine epidemic diarrhea virus (PEDV) is an enteric coronavirus which causes diarrhea, vomiting, severe dehydration, and death in pigs.", [["IntroductionPorcine epidemic diarrhea", "DISEASE", 0, 37], ["enteric coronavirus", "DISEASE", 57, 76], ["diarrhea", "DISEASE", 90, 98], ["vomiting", "DISEASE", 100, 108], ["dehydration", "DISEASE", 117, 128], ["death", "DISEASE", 134, 139], ["IntroductionPorcine epidemic diarrhea virus", "ORGANISM", 0, 43], ["pigs", "ORGANISM", 143, 147], ["diarrhea virus", "SPECIES", 29, 43], ["coronavirus", "SPECIES", 65, 76], ["pigs", "SPECIES", 143, 147], ["IntroductionPorcine epidemic diarrhea virus", "SPECIES", 0, 43], ["PEDV", "SPECIES", 45, 49], ["pigs", "SPECIES", 143, 147], ["IntroductionPorcine epidemic diarrhea virus (PEDV", "PROBLEM", 0, 49], ["an enteric coronavirus", "PROBLEM", 54, 76], ["diarrhea", "PROBLEM", 90, 98], ["vomiting", "PROBLEM", 100, 108], ["severe dehydration", "PROBLEM", 110, 128], ["death", "PROBLEM", 134, 139], ["enteric coronavirus", "ANATOMY", 57, 76], ["diarrhea", "OBSERVATION", 90, 98], ["severe", "OBSERVATION_MODIFIER", 110, 116], ["dehydration", "OBSERVATION", 117, 128]]], ["Neonatal pigs are particularly susceptible, with mortality rates that can be as high as 90\u2013100%.", [["pigs", "ORGANISM", 9, 13], ["pigs", "SPECIES", 9, 13], ["pigs", "SPECIES", 9, 13], ["Neonatal pigs", "TREATMENT", 0, 13], ["mortality rates", "TEST", 49, 64], ["pigs", "OBSERVATION", 9, 13]]], ["In older pigs, manifestation of the disease is milder but growth and production parameters are affected (1, 2).", [["pigs", "ORGANISM", 9, 13], ["pigs", "SPECIES", 9, 13], ["pigs", "SPECIES", 9, 13], ["the disease", "PROBLEM", 32, 43], ["production parameters", "TEST", 69, 90], ["disease", "OBSERVATION", 36, 43], ["milder", "OBSERVATION_MODIFIER", 47, 53], ["growth", "OBSERVATION_MODIFIER", 58, 64]]], ["Classical strains of PEDV (G1 strains) were first detected in the UK in 1971, and spread to Asia and Europe.", [["PEDV", "GENE_OR_GENE_PRODUCT", 21, 25], ["PEDV", "SPECIES", 21, 25], ["Classical strains of PEDV (G1 strains", "PROBLEM", 0, 37]]], ["More recently, highly virulent strains (G2 strains) which emerged in China have spread to other countries, with the first case in the US being recorded in 2013 (1, 3, 4).", [["highly virulent strains (G2 strains", "PROBLEM", 15, 50], ["virulent", "OBSERVATION_MODIFIER", 22, 30]]], ["It is estimated that the outbreak resulted in the losses of $0.9\u20131.8 billion and the death of 7 million pigs (5, 6).", [["death", "DISEASE", 85, 90], ["pigs", "ORGANISM", 104, 108], ["pigs", "SPECIES", 104, 108], ["losses", "OBSERVATION_MODIFIER", 50, 56]]], ["The availability of effective vaccines and the practice of stringent biosecurity measures are critical for the prevention of PEDV.", [["PEDV", "CHEMICAL", 125, 129], ["PEDV", "SIMPLE_CHEMICAL", 125, 129], ["PEDV", "SPECIES", 125, 129], ["effective vaccines", "TREATMENT", 20, 38], ["stringent biosecurity measures", "TREATMENT", 59, 89], ["PEDV", "PROBLEM", 125, 129]]], ["However, the development of effective vaccines has been complicated by frequent viral evolution and the fact that PED is most severe in immunologically na\u00efve neonates.", [["PED", "DISEASE", 114, 117], ["neonates", "ORGANISM", 158, 166], ["effective vaccines", "TREATMENT", 28, 46], ["frequent viral evolution", "PROBLEM", 71, 95], ["immunologically na\u00efve neonates", "PROBLEM", 136, 166], ["effective", "OBSERVATION_MODIFIER", 28, 37], ["vaccines", "OBSERVATION", 38, 46], ["frequent", "OBSERVATION_MODIFIER", 71, 79], ["viral", "OBSERVATION", 80, 85], ["most severe", "OBSERVATION_MODIFIER", 121, 132]]], ["Effective and safe vaccines development was also challenging because active vaccine replication in the gut is required to induce good and lasting mucosal immunity.IntroductionBoth attenuated and inactivated PEDV vaccines have been routinely used in Asian countries for several years.", [["gut", "ANATOMY", 103, 106], ["mucosal", "ANATOMY", 146, 153], ["PEDV", "CHEMICAL", 207, 211], ["gut", "ORGANISM_SUBDIVISION", 103, 106], ["mucosal", "ORGAN", 146, 153], ["PEDV", "SPECIES", 207, 211], ["Effective and safe vaccines", "TREATMENT", 0, 27], ["active vaccine replication", "TREATMENT", 69, 95], ["inactivated PEDV vaccines", "TREATMENT", 195, 220]]], ["Vaccination of sows prior to farrowing induces lactogenic immunity which is transferred to neonatal piglets via colostrum.", [["colostrum", "ANATOMY", 112, 121], ["sows", "ORGANISM", 15, 19], ["piglets", "ORGANISM", 100, 107], ["colostrum", "ORGANISM_SUBSTANCE", 112, 121], ["piglets", "SPECIES", 100, 107], ["Vaccination", "TREATMENT", 0, 11], ["lactogenic immunity", "TREATMENT", 47, 66]]], ["Inactivated vaccines are very safe but have a low duration of immunity and appear to produce a predominantly Th2 type immune response (7).", [["Inactivated vaccines", "TREATMENT", 0, 20], ["low duration", "OBSERVATION_MODIFIER", 46, 58]]], ["Attenuated vaccines, produced by serially passaging field strains between 83 and 100 passages, are more effective against homologous strains but have a long lead development time and have been associated with safety concerns of recombination with field strains (2).", [["Attenuated vaccines", "TREATMENT", 0, 19], ["homologous strains", "PROBLEM", 122, 140]]], ["Regardless of the type of vaccine used, viremia and transmission of PEDV is not prevented in vaccinated animals.", [["viremia", "DISEASE", 40, 47], ["PEDV", "CHEMICAL", 68, 72], ["PEDV", "GENE_OR_GENE_PRODUCT", 68, 72], ["PEDV", "SPECIES", 68, 72], ["vaccine", "TREATMENT", 26, 33], ["viremia", "PROBLEM", 40, 47], ["PEDV", "PROBLEM", 68, 72], ["not prevented", "UNCERTAINTY", 76, 89]]], ["Outbreaks in vaccinated herds and the periodical emergence of new, highly pathogenic strains are not uncommon in countries were vaccines have been routinely used for many years (2, 7\u20139).IntroductionIn North America, a S-protein based subunit vaccine (iPED plus, Harris Vaccines Inc.) and inactivated vaccines produced by Zoetis and VIDO-Intervac were conditionally licensed.", [["iPED", "CHEMICAL", 251, 255], ["Zoetis", "CHEMICAL", 321, 327], ["Zoetis", "SIMPLE_CHEMICAL", 321, 327], ["VIDO-Intervac", "SIMPLE_CHEMICAL", 332, 345], ["highly pathogenic strains", "PROBLEM", 67, 92], ["vaccines", "TREATMENT", 128, 136], ["a S-protein based subunit vaccine", "TREATMENT", 216, 249], ["Harris Vaccines", "TREATMENT", 262, 277], ["inactivated vaccines", "TREATMENT", 288, 308], ["VIDO", "TREATMENT", 332, 336], ["Intervac", "TREATMENT", 337, 345]]], ["However, their efficacy has also been questioned by independent studies, as vaccination of PEDV na\u00efve sows did not result in strong protection in neonatal piglets (8, 10, 11).", [["PEDV", "ORGANISM", 91, 95], ["sows", "ORGANISM", 102, 106], ["piglets", "ORGANISM", 155, 162], ["piglets", "SPECIES", 155, 162], ["PEDV", "SPECIES", 91, 95], ["independent studies", "TEST", 52, 71]]], ["As the strong need for effective PEDV vaccines remains unmet, the practice of feeding back minced intestines from infected piglets to sows, in an attempt to induce more effective immunity against PEDV, is common in the field (8, 10, 11).", [["intestines", "ANATOMY", 98, 108], ["PEDV", "CHEMICAL", 33, 37], ["PEDV", "CHEMICAL", 196, 200], ["intestines", "ORGAN", 98, 108], ["piglets", "ORGANISM", 123, 130], ["piglets", "SPECIES", 123, 130], ["PEDV", "SPECIES", 33, 37], ["PEDV", "SPECIES", 196, 200], ["effective PEDV vaccines", "TREATMENT", 23, 46], ["PEDV", "PROBLEM", 196, 200], ["intestines", "ANATOMY", 98, 108], ["infected", "OBSERVATION", 114, 122], ["common", "OBSERVATION_MODIFIER", 205, 211]]], ["The use of autogenous vaccines, where a custom inactivated vaccine tailored to each herd is prepared using a sample provided from the production unit, is also practiced (8, 12, 13).", [["autogenous vaccines", "TREATMENT", 11, 30], ["a custom inactivated vaccine", "TREATMENT", 38, 66]]], ["Both the feedback and autogenous vaccine approaches are, once again, associated with significant safety and efficacy issues but natural or intentional exposure of pigs of all ages to PEDV provides stronger homologous and partial heterologous protection (2, 8).", [["PEDV", "CHEMICAL", 183, 187], ["pigs", "ORGANISM", 163, 167], ["pigs", "SPECIES", 163, 167], ["PEDV", "SPECIES", 183, 187], ["autogenous vaccine approaches", "TREATMENT", 22, 51], ["significant safety and efficacy issues", "PROBLEM", 85, 123], ["PEDV", "PROBLEM", 183, 187], ["partial heterologous protection", "TREATMENT", 221, 252]]], ["Further, vaccination of na\u00efve animals is less effective than vaccination of previously exposed pigs, indicating that current vaccines are less effective than natural infection at priming the immune response but can effectively boost the memory response (14).", [["infection", "DISEASE", 166, 175], ["pigs", "ORGANISM", 95, 99], ["pigs", "SPECIES", 95, 99], ["pigs", "SPECIES", 95, 99], ["vaccination of na\u00efve animals", "TREATMENT", 9, 37], ["vaccination", "TREATMENT", 61, 72], ["previously exposed pigs", "TREATMENT", 76, 99], ["current vaccines", "TREATMENT", 117, 133], ["natural infection", "PROBLEM", 158, 175], ["less effective", "OBSERVATION_MODIFIER", 41, 55], ["infection", "OBSERVATION", 166, 175]]], ["It is established that the viral spike protein is a critical protective antigen, as anti-spike protein-specific serum IgG levels correlate well with protection against PEDV and virus neutralizing responses (15).", [["serum", "ANATOMY", 112, 117], ["serum", "ORGANISM_SUBSTANCE", 112, 117], ["IgG", "GENE_OR_GENE_PRODUCT", 118, 121], ["PEDV", "GENE_OR_GENE_PRODUCT", 168, 172], ["viral spike protein", "PROTEIN", 27, 46], ["anti-spike protein", "PROTEIN", 84, 102], ["serum IgG", "PROTEIN", 112, 121], ["PEDV", "SPECIES", 168, 172], ["the viral spike protein", "TEST", 23, 46], ["a critical protective antigen", "PROBLEM", 50, 79], ["anti-spike protein", "TEST", 84, 102], ["specific serum IgG levels", "TEST", 103, 128], ["protection", "TREATMENT", 149, 159], ["PEDV", "PROBLEM", 168, 172], ["virus neutralizing responses", "TEST", 177, 205], ["viral spike", "OBSERVATION", 27, 38]]], ["However, the S-protein based subunit vaccine (iPED plus, Harris Vaccines Inc.) is of questionable efficacy, indicating that other viral components could contribute to protection.IntroductionBased on the above, we hypothesized that development of a process whereby the structural integrity of the virus was maintained but viral replication was highly diminished but not abrogated, would result in a vaccine with the combined advantages of inactivated and attenuated vaccines, namely, high safety and efficacy margins.", [["iPED", "CHEMICAL", 46, 50], ["the S-protein based subunit vaccine (iPED plus, Harris Vaccines", "TREATMENT", 9, 72], ["other viral components", "PROBLEM", 124, 146], ["a process", "PROBLEM", 246, 255], ["the virus", "PROBLEM", 292, 301], ["viral replication", "PROBLEM", 321, 338], ["a vaccine", "TREATMENT", 396, 405], ["attenuated vaccines", "TREATMENT", 454, 473], ["high safety and efficacy margins", "PROBLEM", 483, 515], ["viral", "OBSERVATION", 130, 135], ["virus", "OBSERVATION", 296, 301]]], ["Previously published data shows that the SARS coronavirus capsid is metastable and can be reversibly denatured by changes in temperature or pH, with unfolding commencing at 35\u00b0C and complete denaturation occurring at 55\u00b0C (16).", [["SARS", "DISEASE", 41, 45], ["SARS coronavirus", "ORGANISM", 41, 57], ["C", "GENE_OR_GENE_PRODUCT", 176, 177], ["SARS coronavirus capsid", "PROTEIN", 41, 64], ["SARS coronavirus", "SPECIES", 41, 57], ["Previously published data", "TEST", 0, 25], ["the SARS coronavirus capsid", "PROBLEM", 37, 64], ["changes in temperature or pH", "PROBLEM", 114, 142], ["complete denaturation", "PROBLEM", 182, 203], ["complete", "OBSERVATION_MODIFIER", 182, 190], ["denaturation", "OBSERVATION", 191, 203]]], ["Hence, in this study, our vaccine development approach consisted of exposing PEDV virions to 44\u00b0C to unfold the capsid, followed by fragmentation or digestion of the genome with RNAse to diminish viral replication and subsequent refolding of the capsid at 25\u00b0C. Gamma-irradiated PEDV virions were used as an inactivated control vaccine (17).", [["virions", "ANATOMY", 284, 291], ["PEDV", "ORGANISM", 77, 81], ["C", "GENE_OR_GENE_PRODUCT", 96, 97], ["genome", "CELLULAR_COMPONENT", 166, 172], ["RNAse", "GENE_OR_GENE_PRODUCT", 178, 183], ["PEDV virions", "CELL", 279, 291], ["RNAse", "PROTEIN", 178, 183], ["25\u00b0C", "PROTEIN", 256, 260], ["PEDV", "SPECIES", 77, 81], ["PEDV", "SPECIES", 279, 283], ["this study", "TEST", 10, 20], ["our vaccine development approach", "TREATMENT", 22, 54], ["unfold the capsid", "PROBLEM", 101, 118], ["RNAse", "TREATMENT", 178, 183], ["viral replication", "TREATMENT", 196, 213], ["the capsid", "TREATMENT", 242, 252], ["Gamma-irradiated PEDV virions", "TREATMENT", 262, 291], ["an inactivated control vaccine", "TREATMENT", 305, 335], ["capsid", "OBSERVATION", 112, 118]]], ["The objective of this study was to evaluate the heat and RNAse treated PEDV vaccine for its safety, immunogenicity and ability to reduce viremia in a weanling piglet model, with the ultimate goal of developing a process which can potentially reduce lead vaccine development time, is safe and be easily applied to newly emerging strains.Cells and Viruses ::: Materials and MethodsPorcine epidemic diarrhea virus (PEDV) strain PEDV CO2013 [National Veterinary Services Laboratory (NVSL), Ames, IA] was cultured at a multiplicity index (MOI) of 0.1 using Vero cells in the presence of trypsin as previously described (18, 19).", [["Cells", "ANATOMY", 336, 341], ["Vero cells", "ANATOMY", 552, 562], ["PEDV", "CHEMICAL", 71, 75], ["viremia", "DISEASE", 137, 144], ["MethodsPorcine epidemic diarrhea", "DISEASE", 372, 404], ["CO2013", "CHEMICAL", 430, 436], ["RNAse", "GENE_OR_GENE_PRODUCT", 57, 62], ["piglet", "ORGANISM", 159, 165], ["Cells", "CELL", 336, 341], ["MethodsPorcine epidemic diarrhea virus", "ORGANISM", 372, 410], ["Vero cells", "CELL", 552, 562], ["trypsin", "GENE_OR_GENE_PRODUCT", 582, 589], ["Vero cells", "CELL_LINE", 552, 562], ["trypsin", "PROTEIN", 582, 589], ["epidemic diarrhea virus", "SPECIES", 387, 410], ["PEDV", "SPECIES", 71, 75], ["weanling", "SPECIES", 150, 158], ["MethodsPorcine epidemic diarrhea virus", "SPECIES", 372, 410], ["PEDV", "SPECIES", 412, 416], ["PEDV", "SPECIES", 425, 429], ["this study", "TEST", 17, 27], ["RNAse", "TREATMENT", 57, 62], ["PEDV vaccine", "TREATMENT", 71, 83], ["viremia", "PROBLEM", 137, 144], ["a weanling piglet model", "TREATMENT", 148, 171], ["lead vaccine development", "TREATMENT", 249, 273], ["Materials", "TREATMENT", 358, 367], ["MethodsPorcine epidemic diarrhea virus", "PROBLEM", 372, 410], ["Vero cells", "TREATMENT", 552, 562], ["trypsin", "PROBLEM", 582, 589], ["Viruses", "OBSERVATION", 346, 353], ["trypsin", "OBSERVATION", 582, 589]]], ["The stock virus was titrated three times to obtain the mean 50% tissue culture infectious dose [TCID50] using the Spearman and Karber formula (20) and stored in aliquots at \u221280\u00b0C until further use.Vaccine Preparation ::: Materials and MethodsTo optimize the temperature, time of incubation, and dose of RNAse treatment, the virus stock was resuspended to 1 \u00d7 105 TCID50//ml in media (pH 7.2).", [["tissue", "ANATOMY", 64, 70], ["tissue", "TISSUE", 64, 70], ["RNAse", "GENE_OR_GENE_PRODUCT", 303, 308], ["RNAse", "PROTEIN", 303, 308], ["The stock virus", "TREATMENT", 0, 15], ["the Spearman and Karber formula", "TREATMENT", 110, 141], ["Methods", "TREATMENT", 235, 242], ["the temperature", "TEST", 254, 269], ["incubation", "TREATMENT", 279, 289], ["RNAse treatment", "TREATMENT", 303, 318], ["the virus stock", "TREATMENT", 320, 335], ["pH", "TEST", 384, 386], ["stock virus", "OBSERVATION", 4, 15]]], ["Diluted virus culture was exposed to temperatures ranging from 37 to 60\u00b0C for 10 min for unfolding, followed by incubation at 25\u00b0C for 30 min for refolding, and then moved to 4\u00b0C for 1 h, as previously described for the SARS coronavirus (16).", [["SARS coronavirus", "DISEASE", 220, 236], ["SARS coronavirus", "SPECIES", 220, 236], ["Diluted virus culture", "TEST", 0, 21], ["temperatures", "TEST", 37, 49], ["unfolding", "PROBLEM", 89, 98], ["the SARS coronavirus", "PROBLEM", 216, 236]]], ["Cultures were visualized by electron microscopy to ensure structural integrity.", [["Cultures", "TEST", 0, 8], ["electron microscopy", "TEST", 28, 47], ["structural integrity", "OBSERVATION", 58, 78]]], ["A temperature of 44\u00b0C for 10 min was selected for unfolding.", [["A temperature", "TEST", 0, 13], ["unfolding", "PROBLEM", 50, 59]]], ["Similarly, to fragment the genomic RNA, varying combinations of concentrations of RNAse A (Ameresco) and RNAse T (Thermo Scientific) were tested by adding them to the unfolded virus cultures, followed by incubation for 5, 4, 3, or 2 h at 44\u00b0C. Treated cultures were then exposed to 25\u00b0C for 30 min for refolding and cooled down on ice for 1 h.", [["cultures", "ANATOMY", 252, 260], ["RNAse A", "GENE_OR_GENE_PRODUCT", 82, 89], ["Ameresco", "SIMPLE_CHEMICAL", 91, 99], ["RNAse T", "GENE_OR_GENE_PRODUCT", 105, 112], ["genomic RNA", "RNA", 27, 38], ["RNAse A", "PROTEIN", 82, 89], ["Ameresco", "PROTEIN", 91, 99], ["RNAse T", "PROTEIN", 105, 112], ["unfolded virus cultures", "CELL_LINE", 167, 190], ["fragment the genomic RNA", "PROBLEM", 14, 38], ["RNAse A (Ameresco)", "TREATMENT", 82, 100], ["the unfolded virus cultures", "TEST", 163, 190], ["Treated cultures", "TEST", 244, 260], ["ice", "TREATMENT", 331, 334], ["fragment", "OBSERVATION_MODIFIER", 14, 22], ["genomic RNA", "OBSERVATION", 27, 38], ["varying", "OBSERVATION_MODIFIER", 40, 47], ["combinations", "OBSERVATION_MODIFIER", 48, 60], ["concentrations", "OBSERVATION_MODIFIER", 64, 78]]], ["The final optimized protocol consisted of exposing the virus culture, resuspended to 105 TCID50/ml, to 44\u00b0C for 10 min, followed by 0.1 mg/ml of RNase A and 1 \u03bcl/ml of RNase T1 (equivalent to 10 units/ml RNase A or 1,000 units/ml of RNAse T1), incubation at 44\u00b0C for 4 h, exposure to 25\u00b0C for 30 min and cooling down on ice for 1 h before storage at \u221280\u00b0C for further testing.", [["RNase A", "GENE_OR_GENE_PRODUCT", 145, 152], ["RNase", "GENE_OR_GENE_PRODUCT", 168, 173], ["RNase", "GENE_OR_GENE_PRODUCT", 204, 209], ["RNAse", "GENE_OR_GENE_PRODUCT", 233, 238], ["C", "GENE_OR_GENE_PRODUCT", 354, 355], ["RNase A", "PROTEIN", 145, 152], ["RNase T1", "PROTEIN", 168, 176], ["RNase A", "PROTEIN", 204, 211], ["RNAse T1", "PROTEIN", 233, 241], ["the virus culture", "TEST", 51, 68], ["RNase A", "TREATMENT", 145, 152], ["RNase T1", "TREATMENT", 168, 176], ["RNAse T1", "TREATMENT", 233, 241], ["incubation", "TREATMENT", 244, 254], ["further testing", "TEST", 360, 375]]], ["The final process was tested 3 times to ensure reproducibility.Vaccine Preparation ::: Materials and MethodsTo prepare the inactivated control vaccine, 1 \u00d7 105 TCID50//ml of PEDV was irradiated in a Cesium-137 source gamma (\u03b3) irradiator at time points of 8 h to 24 h at 753 rad/min.", [["PEDV", "CHEMICAL", 174, 178], ["Cesium-137", "CHEMICAL", 199, 209], ["PEDV", "ORGANISM", 174, 178], ["PEDV", "SPECIES", 174, 178], ["Methods", "TREATMENT", 101, 108], ["the inactivated control vaccine", "TREATMENT", 119, 150], ["PEDV", "PROBLEM", 174, 178], ["a Cesium", "TREATMENT", 197, 205]]], ["An effective dose of 24 h (1,084,320 rad), was used to prepare the irradiated vaccine, after validation as described above.Viral Amplification Test ::: Materials and MethodsTo determine the effect of the treatment on viability, the treated virus and an untreated control were serially passaged 3 times in Vero cells as described above.", [["Vero cells", "ANATOMY", 305, 315], ["Vero cells", "CELL", 305, 315], ["Vero cells", "CELL_LINE", 305, 315], ["the irradiated vaccine", "TREATMENT", 63, 85], ["Methods", "TREATMENT", 166, 173], ["the treatment", "TREATMENT", 200, 213], ["viability", "TREATMENT", 217, 226], ["the treated virus", "PROBLEM", 228, 245], ["an untreated control", "TREATMENT", 250, 270]]], ["The culture obtained was centrifuged at 10,000 \u00d7 g for 10 min 4\u00b0C to remove debris.", [["C", "SIMPLE_CHEMICAL", 64, 65], ["The culture", "TEST", 0, 11], ["debris", "PROBLEM", 76, 82], ["debris", "OBSERVATION", 76, 82]]], ["One ml of the supernatant was used to infect Vero cell monolayers and also infect 8 well chamber slides (Nunc) to visualize viral replication by an indirect immunofluorescence assay (IFA) as described below.Immunofluorescence Assay ::: Materials and MethodsVisualization of viral replication in treated and untreated cultures was achieved using an indirect immunofluorescence assay (IFA), performed essentially as described previously (18, 19).", [["supernatant", "ANATOMY", 14, 25], ["Vero cell monolayers", "ANATOMY", 45, 65], ["cultures", "ANATOMY", 317, 325], ["Vero cell monolayers", "CELL", 45, 65], ["Vero cell monolayers", "CELL_LINE", 45, 65], ["the supernatant", "TREATMENT", 10, 25], ["Vero cell monolayers", "TREATMENT", 45, 65], ["viral replication", "TREATMENT", 124, 141], ["an indirect immunofluorescence assay", "TEST", 145, 181], ["Materials", "TREATMENT", 236, 245], ["viral replication", "TREATMENT", 274, 291], ["untreated cultures", "TEST", 307, 325], ["an indirect immunofluorescence assay", "TEST", 345, 381], ["Vero cell monolayers", "OBSERVATION", 45, 65], ["viral replication", "OBSERVATION", 274, 291]]], ["Cultured and fixed cells were stained with polyclonal swine anti-PEDV sera (NVSL) and examined with a fluorescent microscope for green cytoplasmic fluorescence characteristic of RNA viral replication.Electron Microscopy ::: Materials and MethodsTo visualize structure, treated, and untreated viral cultures were negatively stained by standard methods (21).", [["cells", "ANATOMY", 19, 24], ["sera", "ANATOMY", 70, 74], ["NVSL", "ANATOMY", 76, 80], ["cytoplasmic", "ANATOMY", 135, 146], ["cells", "CELL", 19, 24], ["swine", "ORGANISM", 54, 59], ["anti-PEDV", "ORGANISM_SUBSTANCE", 60, 69], ["sera", "ORGANISM_SUBSTANCE", 70, 74], ["NVSL", "CELL", 76, 80], ["cytoplasmic", "ORGANISM_SUBSTANCE", 135, 146], ["swine", "SPECIES", 54, 59], ["swine", "SPECIES", 54, 59], ["anti-PEDV", "SPECIES", 60, 69], ["fixed cells", "PROBLEM", 13, 24], ["polyclonal swine anti-PEDV sera", "TEST", 43, 74], ["a fluorescent microscope", "TEST", 100, 124], ["green cytoplasmic fluorescence", "TEST", 129, 159], ["RNA viral replication", "TREATMENT", 178, 199], ["Electron Microscopy", "TEST", 200, 219], ["untreated viral cultures", "TEST", 282, 306], ["fixed cells", "OBSERVATION", 13, 24], ["RNA viral replication", "OBSERVATION", 178, 199]]], ["Stained grids were examined with a JEOL JEM-100CX II transmission electron microscope (Figure 1).Deep Sequencing of Treated PEDV Virions ::: Materials and MethodsPossible genetic differences between untreated and treated vaccine virions were assessed by deep sequencing.", [["PEDV", "SPECIES", 124, 128], ["Stained grids", "TEST", 0, 13], ["Materials", "TREATMENT", 141, 150], ["MethodsPossible genetic differences", "PROBLEM", 155, 190], ["treated vaccine virions", "TREATMENT", 213, 236]]], ["Heat and RNAse treated and untreated viral particles were purified from infected cells by ultra-centrifugation at 100,000 \u00d7 g for 2.50 h and re-suspended in PBS.", [["cells", "ANATOMY", 81, 86], ["Heat", "GENE_OR_GENE_PRODUCT", 0, 4], ["RNAse", "GENE_OR_GENE_PRODUCT", 9, 14], ["cells", "CELL", 81, 86], ["infected cells", "CELL_TYPE", 72, 86], ["Heat and RNAse", "TREATMENT", 0, 14], ["untreated viral particles", "PROBLEM", 27, 52], ["RNAse treated", "OBSERVATION_MODIFIER", 9, 22], ["viral particles", "OBSERVATION", 37, 52], ["infected cells", "OBSERVATION", 72, 86]]], ["Unpackaged RNA and DNA were removed by a RNase and DNase cocktail containing 20 units of RNase One (Promega), 20 units Benzonase (Novagen), and 14 units of turbo DNase (Ambion) incubated in 1X buffer (Ambion) for 37\u00b0C for 1.5 h.", [["DNA", "CELLULAR_COMPONENT", 19, 22], ["RNase", "GENE_OR_GENE_PRODUCT", 41, 46], ["DNase", "GENE_OR_GENE_PRODUCT", 51, 56], ["RNase", "GENE_OR_GENE_PRODUCT", 89, 94], ["Benzonase", "SIMPLE_CHEMICAL", 119, 128], ["Novagen", "GENE_OR_GENE_PRODUCT", 130, 137], ["DNase", "GENE_OR_GENE_PRODUCT", 162, 167], ["Ambion", "ORGANISM", 169, 175], ["RNase", "PROTEIN", 41, 46], ["DNase cocktail", "PROTEIN", 51, 65], ["RNase", "PROTEIN", 89, 94], ["Novagen", "PROTEIN", 130, 137], ["turbo DNase", "PROTEIN", 156, 167], ["Unpackaged RNA", "TREATMENT", 0, 14], ["DNA", "TREATMENT", 19, 22], ["a RNase and DNase cocktail", "TREATMENT", 39, 65], ["RNase", "TREATMENT", 89, 94], ["Benzonase (Novagen)", "TREATMENT", 119, 138], ["turbo DNase (Ambion)", "TREATMENT", 156, 176]]], ["Viral RNA was then isolated by using the Qiamp Viral RNA isolation kit (Qiagen) according to the manufacturer's protocol.Deep Sequencing of Treated PEDV Virions ::: Materials and MethodsPurified viral RNA was deep sequenced by a commercial vendor (BGI Genomic).", [["Viral", "ORGANISM", 0, 5], ["Viral RNA", "RNA", 0, 9], ["MethodsPurified viral RNA", "RNA", 179, 204], ["PEDV", "SPECIES", 148, 152], ["Viral RNA", "PROBLEM", 0, 9], ["the Qiamp Viral RNA isolation kit", "TREATMENT", 37, 70], ["the manufacturer's protocol", "TREATMENT", 93, 120], ["MethodsPurified viral RNA", "PROBLEM", 179, 204], ["RNA", "OBSERVATION", 6, 9], ["viral RNA", "OBSERVATION", 195, 204]]], ["The cDNA library was prepared using TruSeq library construction kit (Illumina Inc., USA) with random hexamer primers.", [["cDNA library", "DNA", 4, 16], ["TruSeq library construction kit", "TREATMENT", 36, 67], ["random hexamer primers", "TREATMENT", 94, 116]]], ["The prepared cDNA library was then sequenced using HiSeq 4000 PE100 platform (Illumina Inc., USA) and raw reads (100 bp) were obtained.", [["cDNA library", "DNA", 13, 25], ["HiSeq 4000 PE100 platform", "DNA", 51, 76]]], ["The resultant sequences reads were analyzed by BGI Genomic, Philadelphia, PA.", [["The resultant sequences reads", "TEST", 0, 29]]], ["The raw reads were filtered out using SOAPnuke to get \u201cClean reads\u201d by removing the reads with adaptors, reads with more than 5% of unknown bases (N), and low-quality reads (22).", [["SOAPnuke", "TREATMENT", 38, 46], ["bases", "ANATOMY_MODIFIER", 140, 145]]], ["Clean reads were mapped to reference PEDV genome (GenBank: KF267450.1) using HISAT (Hierarchical Indexing for Spliced Alignment of Transcripts) (23).", [["PEDV genome", "DNA", 37, 48], ["HISAT", "DNA", 77, 82], ["HISAT", "TREATMENT", 77, 82]]], ["The genome mapping results further analyzed using the Genome Analysis Toolkit (GATK) to call single nucleotide polymorphism (SNP) and INDEL (insertion and deletion of bases) (24).", [["SNP", "CHEMICAL", 125, 128], ["INDEL", "DNA", 134, 139], ["The genome mapping", "TEST", 0, 18], ["single nucleotide polymorphism (SNP)", "TREATMENT", 93, 129], ["INDEL (insertion and deletion of bases", "TREATMENT", 134, 172], ["bases", "ANATOMY_MODIFIER", 167, 172]]], ["Only SNPs with a quality score above the threshold (Qpred > 20) and with a SNP frequency of over 85% were included in assembling the consensus sequences.", [["SNP", "CHEMICAL", 75, 78], ["consensus sequences", "DNA", 133, 152], ["a SNP frequency", "TEST", 73, 88]]], ["The consensus sequences of the treated and untreated samples were compared by alignment with Clustal Omega (25) to obtain changes which could be attributed to the treatment.", [["samples", "ANATOMY", 53, 60], ["consensus sequences", "DNA", 4, 23], ["The consensus sequences", "TEST", 0, 23], ["untreated samples", "TEST", 43, 60], ["Clustal Omega", "TREATMENT", 93, 106], ["the treatment", "TREATMENT", 159, 172]]], ["Clean reads were mapped to the reference genome using BOWTIE2 to detect differentially expressed genes.", [["BOWTIE2", "GENE_OR_GENE_PRODUCT", 54, 61], ["reference genome", "DNA", 31, 47], ["BOWTIE2", "DNA", 54, 61], ["differentially expressed genes", "DNA", 72, 102]]], ["Gene expression levels were calculated with RSEM version 1.2.12 (26).", [["Gene expression levels", "TEST", 0, 22], ["RSEM version", "TEST", 44, 56]]], ["Differentially expressed genes were identified by the possionDis, EBSeq software for samples without replicates (27).Ethics Statement ::: Materials and MethodsAll animal experimentation was approved by the Institutional Animal Care and Use Committee (IACUC) of S. Dakota State Universities (SDSU) (Protocol number: 15-013A).", [["samples", "ANATOMY", 85, 92], ["Materials", "TREATMENT", 138, 147], ["Methods", "TREATMENT", 152, 159]]], ["This study did not involve endangered or protected species.Swine Vaccine and Challenge ::: Materials and MethodsTwenty-four, 2 to 3-week-old piglets which were negative for PEDV by PCR and serology were divided into 3 groups; Group 1\u2014unvaccinated control group (N = 8) (2 ml of PBS intramuscular and oral route each), Group 2\u2014RNase and Heat treated PEDV vaccine group (PEDV-VAC) group (N = 8) (2 ml of 105 TCID50/ml, intramuscular and oral route each) and Group 3\u2014irradiated PEDV vaccine group (N = 8) (2 ml of 105 TCID50/ml, intramuscular and oral route each).", [["intramuscular", "ANATOMY", 282, 295], ["oral", "ANATOMY", 300, 304], ["intramuscular", "ANATOMY", 417, 430], ["oral", "ANATOMY", 435, 439], ["intramuscular", "ANATOMY", 526, 539], ["oral", "ANATOMY", 544, 548], ["PEDV", "CHEMICAL", 349, 353], ["PEDV-VAC", "CHEMICAL", 369, 377], ["PEDV", "CHEMICAL", 475, 479], ["piglets", "ORGANISM", 141, 148], ["PEDV", "SIMPLE_CHEMICAL", 173, 177], ["oral", "ORGANISM_SUBDIVISION", 300, 304], ["RNase", "GENE_OR_GENE_PRODUCT", 326, 331], ["oral", "ORGANISM_SUBDIVISION", 435, 439], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 526, 539], ["oral", "ORGANISM_SUBDIVISION", 544, 548], ["RNase", "PROTEIN", 326, 331], ["Swine", "SPECIES", 59, 64], ["piglets", "SPECIES", 141, 148], ["PEDV", "SPECIES", 173, 177], ["This study", "TEST", 0, 10], ["endangered or protected species", "PROBLEM", 27, 58], ["Swine Vaccine", "TREATMENT", 59, 72], ["PEDV", "PROBLEM", 173, 177], ["PCR", "TEST", 181, 184], ["serology", "TEST", 189, 197], ["Group 1\u2014unvaccinated control group (N", "TREATMENT", 226, 263], ["PBS intramuscular and oral route each", "TREATMENT", 278, 315], ["Group 2\u2014RNase", "TREATMENT", 318, 331], ["Heat", "TREATMENT", 336, 340], ["PEDV vaccine group (PEDV-VAC) group (N", "TREATMENT", 349, 387], ["intramuscular and oral route each", "TREATMENT", 417, 450], ["Group 3\u2014irradiated PEDV vaccine group", "TREATMENT", 456, 493], ["intramuscular and oral route each", "TREATMENT", 526, 559], ["VAC", "ANATOMY", 374, 377]]], ["Piglets were boosted by the same route and dose at DPV 14 and 28.", [["Piglets", "ORGANISM", 0, 7], ["Piglets", "SPECIES", 0, 7], ["Piglets", "TREATMENT", 0, 7]]], ["On DPV 43, small intestine, heart, liver, and spleen were collected 2 piglets from each group (N = 2/group) to assess vaccine safety.", [["small intestine", "ANATOMY", 11, 26], ["heart", "ANATOMY", 28, 33], ["liver", "ANATOMY", 35, 40], ["spleen", "ANATOMY", 46, 52], ["small intestine", "ORGAN", 11, 26], ["heart", "ORGAN", 28, 33], ["liver", "ORGAN", 35, 40], ["spleen", "ORGAN", 46, 52], ["piglets", "ORGANISM", 70, 77], ["DPV 43", "SPECIES", 3, 9], ["DPV", "TEST", 3, 6], ["vaccine safety", "TREATMENT", 118, 132], ["small intestine", "ANATOMY", 11, 26], ["heart", "ANATOMY", 28, 33], ["liver", "ANATOMY", 35, 40], ["spleen", "ANATOMY", 46, 52]]], ["The remaining piglets (N = 6/group) were challenged orally with 105 TCID50/ml of PEDV CO2013, as previously described (28, 29).", [["PEDV CO2013", "CHEMICAL", 81, 92], ["piglets", "ORGANISM", 14, 21], ["piglets", "SPECIES", 14, 21], ["PEDV", "SPECIES", 81, 85], ["PEDV", "TREATMENT", 81, 85]]], ["Post-challenge, the piglets were observed daily for clinical signs of PED.", [["PED", "DISEASE", 70, 73], ["piglets", "ORGANISM", 20, 27], ["piglets", "SPECIES", 20, 27], ["the piglets", "TREATMENT", 16, 27], ["PED", "PROBLEM", 70, 73]]], ["All piglets were euthanized 1-week post challenge (DPC) or at DPV 49 and three sections of the small intestine (duodenum, jejunum, and ileum) were collected for histopathological (HP) and immunohistochemical (IHC) analysis.", [["sections", "ANATOMY", 79, 87], ["small intestine", "ANATOMY", 95, 110], ["duodenum", "ANATOMY", 112, 120], ["jejunum", "ANATOMY", 122, 129], ["ileum", "ANATOMY", 135, 140], ["piglets", "ORGANISM", 4, 11], ["small intestine", "MULTI-TISSUE_STRUCTURE", 95, 110], ["duodenum", "MULTI-TISSUE_STRUCTURE", 112, 120], ["jejunum", "MULTI-TISSUE_STRUCTURE", 122, 129], ["ileum", "ORGAN", 135, 140], ["piglets", "SPECIES", 4, 11], ["DPV", "SPECIES", 62, 65], ["DPC", "TEST", 51, 54], ["DPV", "TEST", 62, 65], ["histopathological (HP", "TEST", 161, 182], ["immunohistochemical (IHC) analysis", "TEST", 188, 222], ["small intestine", "ANATOMY", 95, 110], ["duodenum", "ANATOMY", 112, 120], ["jejunum", "ANATOMY", 122, 129], ["ileum", "ANATOMY", 135, 140]]], ["Serum was collected from all piglets on DPV 0, 14, 28, 43, and 49 to measure binding and neutralizing Ab responses.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["piglets", "ORGANISM", 29, 36], ["piglets", "SPECIES", 29, 36], ["Serum", "TEST", 0, 5], ["DPV", "TEST", 40, 43]]], ["Fecal swabs were collected at DPV 7, 21, 38, and 42 from all piglets to measure shedding of the vaccine virus by RT-qPCR.", [["Fecal swabs", "ANATOMY", 0, 11], ["Fecal swabs", "ORGANISM_SUBSTANCE", 0, 11], ["piglets", "ORGANISM", 61, 68], ["piglets", "SPECIES", 61, 68], ["DPV", "SPECIES", 30, 33], ["Fecal swabs", "TEST", 0, 11], ["DPV", "TEST", 30, 33], ["the vaccine virus", "TREATMENT", 92, 109]]], ["Fecal swabs were collected on DPV 45 and 49 (DPC day 3 and 7) from all piglets to measure protection against shedding of the challenge virus by RT-qPCR.Antibody Responses to the PEDV Spike and Nucleoproteins ::: Materials and MethodsSpike protein-specific IgG responses in pigs were measured in duplicate by an indirect ELISA as previously described, using the PEDV S antigen or NP antigen for capture (18).", [["Fecal swabs", "ANATOMY", 0, 11], ["Fecal swabs", "ORGANISM_SUBSTANCE", 0, 11], ["piglets", "ORGANISM", 71, 78], ["Nucleoproteins", "GENE_OR_GENE_PRODUCT", 193, 207], ["Spike", "GENE_OR_GENE_PRODUCT", 233, 238], ["IgG", "GENE_OR_GENE_PRODUCT", 256, 259], ["pigs", "ORGANISM", 273, 277], ["PEDV S antigen", "GENE_OR_GENE_PRODUCT", 361, 375], ["NP antigen", "GENE_OR_GENE_PRODUCT", 379, 389], ["PEDV Spike", "PROTEIN", 178, 188], ["Nucleoproteins", "PROTEIN", 193, 207], ["Spike protein", "PROTEIN", 233, 246], ["IgG", "PROTEIN", 256, 259], ["PEDV S antigen", "PROTEIN", 361, 375], ["NP antigen", "PROTEIN", 379, 389], ["piglets", "SPECIES", 71, 78], ["pigs", "SPECIES", 273, 277], ["DPV 45", "SPECIES", 30, 36], ["PEDV", "SPECIES", 178, 182], ["pigs", "SPECIES", 273, 277], ["Fecal swabs", "TEST", 0, 11], ["DPV", "TEST", 30, 33], ["DPC", "TEST", 45, 48], ["the challenge virus", "TREATMENT", 121, 140], ["Antibody", "TEST", 152, 160], ["MethodsSpike protein", "TEST", 226, 246], ["IgG responses", "TEST", 256, 269], ["an indirect ELISA", "TEST", 308, 325], ["the PEDV S antigen", "TEST", 357, 375]]], ["The assay format was pre-validated at the Animal Disease Research and Diagnostic Laboratory (ADRDL), SDSU, using serum samples from animals of known serological status.", [["serum samples", "ANATOMY", 113, 126], ["serum samples", "ORGANISM_SUBSTANCE", 113, 126], ["The assay format", "TEST", 0, 16], ["serum samples", "TEST", 113, 126], ["known serological status", "PROBLEM", 143, 167], ["serological status", "OBSERVATION", 149, 167]]], ["A standardized operating procedure was followed in sample analysis.", [["A standardized operating procedure", "TREATMENT", 0, 34], ["sample analysis", "TEST", 51, 66]]], ["The results were calculated as sample to positive (S/P) ratios as follows: S/P = optical density (OD) of the sample\u2014OD of buffer/OD of positive control\u2014OD of the buffer.Fluorescent Focus Neutralization Assay ::: Materials and MethodsTo assess the neutralizing antibody responses elicited by vaccination, a pre-validated fluorescent focus neutralization (FFN) assay was used as previously described (18), following the standard operating procedures of the ADRDL, SDSU.", [["the buffer", "TREATMENT", 158, 168], ["Methods", "TREATMENT", 226, 233], ["the neutralizing antibody responses", "TEST", 243, 278], ["a pre-validated fluorescent focus neutralization (FFN) assay", "TEST", 304, 364], ["density", "OBSERVATION", 89, 96]]], ["Briefly, doubling dilutions of heat inactivated sera were incubated with 100 foci forming units, incubated for 1 h and cultured on Vero cell monolayers.", [["sera", "ANATOMY", 48, 52], ["Vero cell monolayers", "ANATOMY", 131, 151], ["sera", "ORGANISM_SUBSTANCE", 48, 52], ["Vero cell monolayers", "CELL", 131, 151], ["Vero cell monolayers", "CELL_LINE", 131, 151], ["doubling dilutions of heat", "TREATMENT", 9, 35], ["Vero cell monolayers", "TREATMENT", 131, 151], ["Vero cell monolayers", "OBSERVATION", 131, 151]]], ["Plates were stained with a PEDV-specific fluorescein-labeled monoclonal antibody (SD6-29) to visualize the end point, which was defined as a 90% reduction of foci compared to the controls.RT-qPCR for Vaccine and Challenge Virus Shedding ::: Materials and MethodsVirus shedding through fecal route was assessed by a RT-qPCR performed by the NDSU Veterinary Diagnostic Laboratory, using pre-validated standard operating procedures, and a commercial PCR kit called the Swine Enteric PCR Panel (Thermo Fisher) following the manufacturer's instructions.", [["foci", "ANATOMY", 158, 162], ["fluorescein", "CHEMICAL", 41, 52], ["fluorescein", "CHEMICAL", 41, 52], ["PEDV", "SIMPLE_CHEMICAL", 27, 31], ["fluorescein", "SIMPLE_CHEMICAL", 41, 52], ["MethodsVirus", "GENE_OR_GENE_PRODUCT", 255, 267], ["PEDV-specific fluorescein-labeled monoclonal antibody", "PROTEIN", 27, 80], ["SD6", "PROTEIN", 82, 85], ["Plates", "TEST", 0, 6], ["a PEDV", "TEST", 25, 31], ["specific fluorescein", "TEST", 32, 52], ["monoclonal antibody", "TEST", 61, 80], ["SD6", "TEST", 82, 85], ["foci", "PROBLEM", 158, 162], ["Vaccine", "TREATMENT", 200, 207], ["fecal route", "TREATMENT", 285, 296], ["a RT-qPCR", "TEST", 313, 322], ["a commercial PCR kit", "TEST", 434, 454], ["foci", "OBSERVATION", 158, 162]]], ["Each pig was considered a biological replicate (N = 6, as 2 pigs/ group were sacrificed to assess vaccine safety prior to challenge), and each sample was assessed in duplicate.", [["pig", "ORGANISM", 5, 8], ["pigs", "ORGANISM", 60, 64], ["pig", "SPECIES", 5, 8], ["pigs", "SPECIES", 60, 64], ["pig", "SPECIES", 5, 8], ["2 pigs/ group", "TREATMENT", 58, 71], ["vaccine", "TREATMENT", 98, 105]]], ["The obtained Ct-values were converted to viral copy numbers using a standard curve and log transformed for representation.Histology ::: Materials and MethodsTissue samples, collected as described above, were fixed in neutral buffered formalin for 48 h, trimmed, processed, and embedded in paraffin.", [["MethodsTissue samples", "ANATOMY", 150, 171], ["formalin", "CHEMICAL", 234, 242], ["formalin", "CHEMICAL", 234, 242], ["paraffin", "CHEMICAL", 289, 297], ["formalin", "SIMPLE_CHEMICAL", 234, 242], ["The obtained Ct-values", "TEST", 0, 22], ["a standard curve", "TREATMENT", 66, 82], ["MethodsTissue samples", "TEST", 150, 171], ["neutral buffered formalin", "TREATMENT", 217, 242]]], ["Tissues were cut into 5 \u03bcm thick sections and stained with hematoxylin and eosin (HE) or a PEDV N protein-specific monoclonal antibody (SD6-29) for immunohistochemistry (IHC) following the standard operating procedures of the ADRDL, SDSU.", [["Tissues", "ANATOMY", 0, 7], ["sections", "ANATOMY", 33, 41], ["hematoxylin", "CHEMICAL", 59, 70], ["eosin", "CHEMICAL", 75, 80], ["Tissues", "CANCER", 0, 7], ["sections", "MULTI-TISSUE_STRUCTURE", 33, 41], ["hematoxylin", "SIMPLE_CHEMICAL", 59, 70], ["eosin", "SIMPLE_CHEMICAL", 75, 80], ["HE", "SIMPLE_CHEMICAL", 82, 84], ["PEDV N protein", "PROTEIN", 91, 105], ["monoclonal antibody", "PROTEIN", 115, 134], ["SD6", "PROTEIN", 136, 139], ["thick sections", "TEST", 27, 41], ["hematoxylin", "TEST", 59, 70], ["eosin", "TEST", 75, 80], ["a PEDV N protein", "TEST", 89, 105], ["specific monoclonal antibody", "TEST", 106, 134], ["SD6", "TEST", 136, 139], ["immunohistochemistry", "TEST", 148, 168]]], ["Scores were recorded in a blinded fashion by a board-certified veterinary pathologist.", [["Scores", "TEST", 0, 6]]], ["Scores to measure atrophic enteritis characteristic of PED were assigned as follows: 0 = negative, 2 = mild, 4 = moderate, 6 = severe.", [["enteritis", "DISEASE", 27, 36], ["PED", "DISEASE", 55, 58], ["Scores", "TEST", 0, 6], ["atrophic enteritis", "PROBLEM", 18, 36], ["atrophic", "OBSERVATION_MODIFIER", 18, 26], ["enteritis", "OBSERVATION", 27, 36], ["mild", "OBSERVATION_MODIFIER", 103, 107], ["moderate", "OBSERVATION_MODIFIER", 113, 121], ["severe", "OBSERVATION_MODIFIER", 127, 133]]], ["Sections with crypt hypertrophy were assigned an additional 2 points.", [["crypt", "ANATOMY", 14, 19], ["hypertrophy", "DISEASE", 20, 31], ["crypt", "MULTI-TISSUE_STRUCTURE", 14, 19], ["crypt hypertrophy", "PROBLEM", 14, 31], ["crypt", "ANATOMY", 14, 19], ["hypertrophy", "OBSERVATION", 20, 31]]], ["Antigen detection in enterocytes by IHC was semi-quantitatively scored based on the following criteria: 0 = negative, 2 = positive, \u2264 10%, 4 = positive, 11\u201350%, 6 = positive, >50%.", [["enterocytes", "ANATOMY", 21, 32], ["enterocytes", "CELL", 21, 32], ["enterocytes", "CELL_TYPE", 21, 32], ["Antigen detection", "TEST", 0, 17], ["IHC", "TEST", 36, 39], ["\u2264", "TEST", 132, 133], ["enterocytes", "ANATOMY", 21, 32]]], ["The consistency of fecal matter during necropsy was assigned scores as follows: Formed Feces = 0, Semi-formed feces = 3, Liquid feces = 6.", [["fecal matter", "ANATOMY", 19, 31], ["fecal matter", "MULTI-TISSUE_STRUCTURE", 19, 31], ["fecal matter", "PROBLEM", 19, 31], ["Feces", "TEST", 87, 92], ["consistency", "OBSERVATION_MODIFIER", 4, 15], ["fecal matter", "OBSERVATION", 19, 31], ["Feces", "OBSERVATION", 87, 92]]], ["Total scores were calculated as the mean sum of the histology and fecal scores (Table 1).Statistical Analysis ::: Materials and MethodsSignificant differences between treatments were assessed by ANOVA and when significant (p < 0.05) post-hoc analysis was used to determine differences between groups.", [["fecal", "ANATOMY", 66, 71], ["fecal", "ORGANISM_SUBSTANCE", 66, 71], ["Total scores", "TEST", 0, 12], ["treatments", "TREATMENT", 167, 177], ["post-hoc analysis", "TEST", 233, 250], ["fecal", "ANATOMY", 66, 71]]], ["The Student's T-test was used for the serology and RT-qPCR data and the Mann\u2013Whitney U-test for the pathology lesion scores.", [["lesion", "ANATOMY", 110, 116], ["The Student's T-test", "TEST", 0, 20], ["the serology", "TEST", 34, 46], ["RT-qPCR data", "TEST", 51, 63], ["the Mann\u2013Whitney U-test", "TEST", 68, 91], ["the pathology lesion scores", "PROBLEM", 96, 123], ["lesion", "OBSERVATION", 110, 116]]], ["The mean values of replicates, standard deviation and statistical significance are represented in the Figures and tables.Treatment With Heat and RNAse Diminishes Viral Replication While Maintaining Structural Integrity ::: ResultsTo achieve the targeted outcomes of maintaining structural integrity while achieving diminished viral replication, rather than complete inactivation, PEDV virus cultures were first exposed to temperatures ranging from 37 to 60\u00b0C for 10 min and visualized by electron microscopy.", [["PEDV virus", "ORGANISM", 380, 390], ["PEDV virus cultures", "CELL_LINE", 380, 399], ["PEDV virus", "SPECIES", 380, 390], ["The mean values", "TEST", 0, 15], ["standard deviation and statistical significance", "PROBLEM", 31, 78], ["Heat and RNAse", "TREATMENT", 136, 150], ["Viral Replication", "TREATMENT", 162, 179], ["diminished viral replication", "PROBLEM", 315, 343], ["PEDV virus cultures", "TEST", 380, 399], ["temperatures", "TEST", 422, 434], ["electron microscopy", "TEST", 488, 507], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["Structural Integrity", "OBSERVATION", 198, 218], ["viral replication", "OBSERVATION", 326, 343]]], ["However, increasing numbers of misshapen and fragmented virions were detected at 50\u00b0C and above.", [["virions", "ANATOMY", 56, 63], ["increasing numbers of misshapen", "PROBLEM", 9, 40], ["fragmented virions", "PROBLEM", 45, 63], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["numbers", "OBSERVATION_MODIFIER", 20, 27], ["fragmented", "OBSERVATION_MODIFIER", 45, 55], ["virions", "OBSERVATION", 56, 63]]], ["Cultures treated at 37 and 45\u00b0C remained viable as viral replication was visible by immunofluorescence (IFA) in infected Vero cells using a PEDV-specific antibody, without any amplification by serial passaging.", [["Vero cells", "ANATOMY", 121, 131], ["C", "GENE_OR_GENE_PRODUCT", 30, 31], ["Vero cells", "CELL", 121, 131], ["PEDV", "SIMPLE_CHEMICAL", 140, 144], ["Vero cells", "CELL_LINE", 121, 131], ["PEDV-specific antibody", "PROTEIN", 140, 162], ["Vero", "SPECIES", 121, 125], ["Cultures", "TEST", 0, 8], ["viral replication", "PROBLEM", 51, 68], ["immunofluorescence", "TEST", 84, 102], ["IFA", "TEST", 104, 107], ["infected Vero cells", "PROBLEM", 112, 131], ["a PEDV", "TEST", 138, 144], ["serial passaging", "TREATMENT", 193, 209], ["viral replication", "OBSERVATION", 51, 68], ["Vero cells", "OBSERVATION", 121, 131]]], ["Virus was detected after the 1st passage in the cultures treated at 50\u00b0C. Virus cultures treated at 55 and 60\u00b0C were not amplified even after four serial passages in Vero cells, indicating that complete inactivation occurred at these temperatures.", [["cultures", "ANATOMY", 48, 56], ["Vero cells", "ANATOMY", 166, 176], ["Virus", "ORGANISM", 0, 5], ["Virus", "ORGANISM", 74, 79], ["C", "GENE_OR_GENE_PRODUCT", 110, 111], ["Vero cells", "CELL", 166, 176], ["Vero cells", "CELL_LINE", 166, 176], ["Virus", "PROBLEM", 0, 5], ["the cultures", "TEST", 44, 56], ["Virus cultures", "TEST", 74, 88], ["four serial passages in Vero cells", "PROBLEM", 142, 176], ["complete inactivation", "PROBLEM", 194, 215], ["Vero cells", "OBSERVATION", 166, 176]]], ["Hence a temperature of 44\u00b0C for 10 min was chosen for reversible unfolding of the viral capsid (Figure 1B) without completely inactivating the virus.", [["viral capsid", "PROTEIN", 82, 94], ["Figure 1B", "PROTEIN", 96, 105], ["a temperature", "TEST", 6, 19], ["reversible unfolding of the viral capsid", "PROBLEM", 54, 94], ["the virus", "PROBLEM", 139, 148], ["viral capsid", "OBSERVATION", 82, 94], ["virus", "OBSERVATION", 143, 148]]], ["Untreated control virus culture remained structurally intact as expected (Figure 1A).", [["Untreated control virus culture", "TEST", 0, 31], ["intact", "OBSERVATION", 54, 60]]], ["Similarly, while RNAse treatment alone did not affect viability, the reduction in viral replication was proportional to the dose and time of exposure to RNase in the heat-treated virions.", [["virions", "ANATOMY", 179, 186], ["RNAse", "GENE_OR_GENE_PRODUCT", 17, 22], ["RNase", "GENE_OR_GENE_PRODUCT", 153, 158], ["RNAse", "PROTEIN", 17, 22], ["RNase", "PROTEIN", 153, 158], ["RNAse treatment", "TREATMENT", 17, 32], ["the reduction", "TREATMENT", 65, 78], ["viral replication", "TREATMENT", 82, 99], ["RNase", "TREATMENT", 153, 158], ["reduction", "OBSERVATION_MODIFIER", 69, 78], ["viral replication", "OBSERVATION", 82, 99]]], ["A dose of 10 units of RNase A and 1,000 units of RNase T with an exposure time of 4 h was chosen as optimal for the final vaccine preparation.", [["RNase A", "GENE_OR_GENE_PRODUCT", 22, 29], ["RNase T", "GENE_OR_GENE_PRODUCT", 49, 56], ["RNase A", "PROTEIN", 22, 29], ["RNase T", "PROTEIN", 49, 56], ["RNase A", "TREATMENT", 22, 29], ["RNase T", "TREATMENT", 49, 56], ["the final vaccine preparation", "TREATMENT", 112, 141]]], ["While the untreated virus control showed robust replication (Figure 2A), following the heat and RNAse treatment protocol, viral replication was detected only in the 3rd passage in Vero cells (Figure 2B).Treatment With Heat and RNAse Diminishes Viral Replication While Maintaining Structural Integrity ::: ResultsFor the gamma (\u03b3) irradiated, inactivated control vaccine, typical icosahedral structures were seen in electron microscopy after 23 h of exposure to radiation.", [["Vero cells", "ANATOMY", 180, 190], ["RNAse", "GENE_OR_GENE_PRODUCT", 96, 101], ["Vero cells", "CELL", 180, 190], ["Vero cells", "CELL_LINE", 180, 190], ["the untreated virus control", "TREATMENT", 6, 33], ["the heat and RNAse treatment protocol", "TREATMENT", 83, 120], ["viral replication", "TREATMENT", 122, 139], ["Heat and RNAse", "TREATMENT", 218, 232], ["the gamma (\u03b3) irradiated", "TREATMENT", 316, 340], ["inactivated control vaccine", "TREATMENT", 342, 369], ["typical icosahedral structures", "PROBLEM", 371, 401], ["electron microscopy", "TEST", 415, 434], ["radiation", "TREATMENT", 461, 470], ["Vero cells", "OBSERVATION", 180, 190]]], ["However, the corona-like layer containing the protective spike antigens appeared to be damaged (Figure 1C).", [["corona-like layer", "ANATOMY", 13, 30], ["protective spike antigens", "PROTEIN", 46, 71], ["the protective spike antigens", "PROBLEM", 42, 71], ["corona", "OBSERVATION_MODIFIER", 13, 19], ["layer", "OBSERVATION_MODIFIER", 25, 30], ["protective spike", "OBSERVATION", 46, 62]]], ["At this dose of radiation, the virus was not detected by the IFA with a PEDV-specific Ab at the third serial passage in cell culture (Figure 2C).", [["cell culture", "ANATOMY", 120, 132], ["PEDV", "CHEMICAL", 72, 76], ["Ab", "GENE_OR_GENE_PRODUCT", 86, 88], ["cell culture", "CELL", 120, 132], ["Ab", "PROTEIN", 86, 88], ["cell culture", "CELL_LINE", 120, 132], ["radiation", "TREATMENT", 16, 25], ["the virus", "PROBLEM", 27, 36], ["a PEDV", "TEST", 70, 76], ["cell culture", "TEST", 120, 132]]], ["Hence, a final dose of 24 h (1,084,320 rad) was selected to prepare the inactivated control vaccine.Vaccination of Pigs With the Heat and RNAse Treated Virions Elicits a Strong Protective Antibody (Ab) Response ::: ResultsMeasurement of Ab responses against the PEDV spike and nucleocapsid proteins (NP) by ELISA (18) showed that animals vaccinated with the heat and RNAse treated virions mounted strong Ab responses against the protective PEDV spike antigen following the booster vaccinations on DPV 14 and 28 (Figures 3A,B).", [["Pigs", "ORGANISM", 115, 119], ["nucleocapsid proteins", "GENE_OR_GENE_PRODUCT", 277, 298], ["animals", "ORGANISM", 330, 337], ["RNAse", "GENE_OR_GENE_PRODUCT", 367, 372], ["Ab", "GENE_OR_GENE_PRODUCT", 404, 406], ["PEDV spike antigen", "GENE_OR_GENE_PRODUCT", 440, 458], ["PEDV", "PROTEIN", 262, 266], ["nucleocapsid proteins", "PROTEIN", 277, 298], ["NP", "PROTEIN", 300, 302], ["PEDV spike antigen", "PROTEIN", 440, 458], ["Pigs", "SPECIES", 115, 119], ["PEDV", "SPECIES", 262, 266], ["PEDV", "SPECIES", 440, 444], ["DPV", "SPECIES", 497, 500], ["the inactivated control vaccine", "TREATMENT", 68, 99], ["Vaccination of Pigs", "TREATMENT", 100, 119], ["the Heat and RNAse", "TREATMENT", 125, 143], ["Ab responses", "TEST", 237, 249], ["the PEDV spike", "PROBLEM", 258, 272], ["nucleocapsid proteins", "TEST", 277, 298], ["ELISA", "TEST", 307, 312], ["the heat", "TREATMENT", 354, 362], ["RNAse treated virions", "TREATMENT", 367, 388], ["the protective PEDV spike antigen", "PROBLEM", 425, 458], ["the booster vaccinations", "TREATMENT", 469, 493], ["DPV", "TEST", 497, 500]]], ["However, Ab responses to non-structural nucleocapsid protein (NP) remained low prior to the challenge.", [["Ab", "GENE_OR_GENE_PRODUCT", 9, 11], ["non-structural nucleocapsid protein", "GENE_OR_GENE_PRODUCT", 25, 60], ["Ab", "PROTEIN", 9, 11], ["non-structural nucleocapsid protein", "PROTEIN", 25, 60], ["NP", "PROTEIN", 62, 64], ["non-structural nucleocapsid protein", "TEST", 25, 60]]], ["In pigs immunized with the irradiated vaccine, Ab responses to both viral antigens were low.", [["pigs", "ORGANISM", 3, 7], ["Ab", "GENE_OR_GENE_PRODUCT", 47, 49], ["viral antigens", "PROTEIN", 68, 82], ["pigs", "SPECIES", 3, 7], ["pigs", "SPECIES", 3, 7], ["the irradiated vaccine", "TREATMENT", 23, 45], ["both viral antigens", "TEST", 63, 82]]], ["The mean optical density values for the ELISAs were significantly different between the groups (Figures 3A,B).Vaccination of Pigs With the Heat and RNAse Treated Virions Elicits a Strong Protective Antibody (Ab) Response ::: ResultsMeasurement of virus neutralizing antibodies by a fluorescent focus inhibition test (FFN) (18) showed a trend which was similar to that of the spike protein-specific Abs.", [["Pigs", "ORGANISM", 125, 129], ["virus neutralizing antibodies", "PROTEIN", 247, 276], ["spike protein-specific Abs", "PROTEIN", 375, 401], ["Pigs", "SPECIES", 125, 129], ["The mean optical density values", "TEST", 0, 31], ["the ELISAs", "TEST", 36, 46], ["Vaccination of Pigs", "TREATMENT", 110, 129], ["the Heat and RNAse", "TREATMENT", 135, 153], ["virus neutralizing antibodies", "PROBLEM", 247, 276], ["a fluorescent focus inhibition test (FFN)", "TEST", 280, 321], ["the spike protein", "TEST", 371, 388], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["optical", "OBSERVATION_MODIFIER", 9, 16], ["density", "OBSERVATION", 17, 24]]], ["Strong virus neutralizing Ab responses, were detected in animals vaccinated with the heat and RNAse treated virions but not in the pigs which received the irradiated viral vaccine.", [["virions", "ANATOMY", 108, 115], ["Ab", "GENE_OR_GENE_PRODUCT", 26, 28], ["RNAse", "GENE_OR_GENE_PRODUCT", 94, 99], ["pigs", "ORGANISM", 131, 135], ["pigs", "SPECIES", 131, 135], ["pigs", "SPECIES", 131, 135], ["RNAse treated virions", "TREATMENT", 94, 115], ["the irradiated viral vaccine", "TREATMENT", 151, 179], ["virus", "OBSERVATION_MODIFIER", 7, 12], ["neutralizing", "OBSERVATION", 13, 25]]], ["The spike protein-specific Ab and virus neutralizing Ab levels were strongly correlated in the heat and RNAse treated PEDV vaccinated pigs, with a correlation coefficient of 95.11%.", [["Ab", "GENE_OR_GENE_PRODUCT", 27, 29], ["Ab", "GENE_OR_GENE_PRODUCT", 53, 55], ["RNAse", "GENE_OR_GENE_PRODUCT", 104, 109], ["pigs", "ORGANISM", 134, 138], ["spike protein", "PROTEIN", 4, 17], ["pigs", "SPECIES", 134, 138], ["PEDV", "SPECIES", 118, 122], ["pigs", "SPECIES", 134, 138], ["The spike protein", "TEST", 0, 17], ["Ab and virus neutralizing Ab levels", "TEST", 27, 62], ["RNAse", "TREATMENT", 104, 109], ["PEDV vaccinated pigs", "TREATMENT", 118, 138], ["a correlation coefficient", "TEST", 145, 170]]], ["As expected, the unvaccinated control pigs remained sero-negative for the duration of the study.Vaccination Protects Against Fecal Viral Shedding ::: ResultsTo assess the efficacy of the vaccine in protecting against challenge, shedding of the challenge viral RNA in fecal matter was assessed by a PEDV-specific RT-qPCR on days 0, 3, and 7 post-challenge.", [["fecal matter", "ANATOMY", 267, 279], ["pigs", "ORGANISM", 38, 42], ["challenge viral RNA", "RNA", 244, 263], ["pigs", "SPECIES", 38, 42], ["pigs", "SPECIES", 38, 42], ["the unvaccinated control pigs", "TREATMENT", 13, 42], ["the study", "TEST", 86, 95], ["Vaccination", "TREATMENT", 96, 107], ["the vaccine", "TREATMENT", 183, 194], ["the challenge viral RNA", "TREATMENT", 240, 263], ["a PEDV", "TEST", 296, 302], ["fecal matter", "OBSERVATION_MODIFIER", 267, 279]]], ["All experimental animals were RT-qPCR negative on day 0 post-challenge (DPC).", [["animals", "ORGANISM", 17, 24], ["All experimental animals", "TEST", 0, 24], ["RT-qPCR", "TEST", 30, 37]]], ["At DPC 3 and 7, challenge viral RNA was not detected in any of the pigs vaccinated with the heat and RNAse treated PEDV vaccine (Figure 4), while 4 of the 6 pigs administered the irradiated vaccine were positive by RT-qPCR on DPC3.", [["PEDV", "CHEMICAL", 115, 119], ["pigs", "ORGANISM", 67, 71], ["RNAse", "GENE_OR_GENE_PRODUCT", 101, 106], ["pigs", "ORGANISM", 157, 161], ["DPC3", "SIMPLE_CHEMICAL", 226, 230], ["challenge viral RNA", "RNA", 16, 35], ["pigs", "SPECIES", 67, 71], ["pigs", "SPECIES", 157, 161], ["pigs", "SPECIES", 67, 71], ["PEDV", "SPECIES", 115, 119], ["pigs", "SPECIES", 157, 161], ["DPC", "TEST", 3, 6], ["challenge viral RNA", "TREATMENT", 16, 35], ["the heat", "TREATMENT", 88, 96], ["RNAse", "TREATMENT", 101, 106], ["PEDV vaccine", "TREATMENT", 115, 127], ["the 6 pigs", "TREATMENT", 151, 161], ["the irradiated vaccine", "TREATMENT", 175, 197], ["DPC3", "TREATMENT", 226, 230], ["viral RNA", "OBSERVATION", 26, 35]]], ["All 6 pigs in the irradiated vaccine group turned positive by DPC7 (Figure 4).", [["pigs", "ORGANISM", 6, 10], ["DPC7", "PROTEIN", 62, 66], ["pigs", "SPECIES", 6, 10], ["pigs", "SPECIES", 6, 10], ["All 6 pigs", "TREATMENT", 0, 10], ["the irradiated vaccine group", "TREATMENT", 14, 42]]], ["As expected, viral RNA was detected in the fecal matter of all unvaccinated pigs on both sample collection days with titers increasing between DPC 3 and 7.", [["fecal matter", "ANATOMY", 43, 55], ["sample", "ANATOMY", 89, 95], ["pigs", "ORGANISM", 76, 80], ["viral RNA", "RNA", 13, 22], ["pigs", "SPECIES", 76, 80], ["pigs", "SPECIES", 76, 80], ["viral RNA", "PROBLEM", 13, 22], ["all unvaccinated pigs", "TREATMENT", 59, 80], ["titers", "TEST", 117, 123], ["DPC", "TEST", 143, 146], ["viral RNA", "OBSERVATION", 13, 22], ["fecal matter", "ANATOMY", 43, 55]]], ["While the viral RNA loads were significantly different between the two vaccine groups at both time points, there were no significant differences between the unvaccinated controls and pigs administered the irradiated vaccine at both the time points tested, indicating that the irradiated vaccine did not provide protection against viral replication and shedding in the host.Vaccination Protects Against Intestinal Pathology ::: ResultsExamination of the intestinal tissue of the experimental animals by histology and immunohistochemistry (IHC) showed that the heat and RNAse treated PEDV vaccine completely protected vaccinated pigs against the development of microscopic lesions following challenge.", [["intestinal tissue", "ANATOMY", 453, 470], ["lesions", "ANATOMY", 671, 678], ["PEDV", "CHEMICAL", 582, 586], ["pigs", "ORGANISM", 183, 187], ["intestinal tissue", "TISSUE", 453, 470], ["RNAse", "GENE_OR_GENE_PRODUCT", 568, 573], ["pigs", "ORGANISM", 627, 631], ["microscopic lesions", "PATHOLOGICAL_FORMATION", 659, 678], ["pigs", "SPECIES", 183, 187], ["pigs", "SPECIES", 627, 631], ["pigs", "SPECIES", 183, 187], ["PEDV", "SPECIES", 582, 586], ["pigs", "SPECIES", 627, 631], ["the viral RNA loads", "PROBLEM", 6, 25], ["the two vaccine groups", "TREATMENT", 63, 85], ["the unvaccinated controls", "TREATMENT", 153, 178], ["pigs", "TREATMENT", 183, 187], ["the irradiated vaccine", "TREATMENT", 201, 223], ["the irradiated vaccine", "TREATMENT", 272, 294], ["viral replication", "TREATMENT", 330, 347], ["immunohistochemistry", "TEST", 516, 536], ["IHC", "TEST", 538, 541], ["the heat and RNAse", "TREATMENT", 555, 573], ["PEDV vaccine", "TREATMENT", 582, 594], ["microscopic lesions", "PROBLEM", 659, 678], ["viral RNA loads", "OBSERVATION", 10, 25], ["no", "UNCERTAINTY", 118, 120], ["significant", "OBSERVATION_MODIFIER", 121, 132], ["intestinal tissue", "ANATOMY", 453, 470], ["microscopic", "OBSERVATION_MODIFIER", 659, 670], ["lesions", "OBSERVATION", 671, 678]]], ["Characteristic microscopic intestinal lesions of atrophic enteropathy and crypt hyperplasia were detected in the duodenum, jejunum, and ileum of animals in the control groups (Figures 5D\u2013G).", [["intestinal lesions", "ANATOMY", 27, 45], ["crypt hyperplasia", "ANATOMY", 74, 91], ["duodenum", "ANATOMY", 113, 121], ["jejunum", "ANATOMY", 123, 130], ["ileum", "ANATOMY", 136, 141], ["enteropathy", "DISEASE", 58, 69], ["intestinal lesions", "PATHOLOGICAL_FORMATION", 27, 45], ["atrophic enteropathy", "PATHOLOGICAL_FORMATION", 49, 69], ["crypt hyperplasia", "PATHOLOGICAL_FORMATION", 74, 91], ["duodenum", "MULTI-TISSUE_STRUCTURE", 113, 121], ["jejunum", "MULTI-TISSUE_STRUCTURE", 123, 130], ["ileum", "ORGAN", 136, 141], ["Characteristic microscopic intestinal lesions", "PROBLEM", 0, 45], ["atrophic enteropathy", "PROBLEM", 49, 69], ["crypt hyperplasia", "PROBLEM", 74, 91], ["microscopic", "OBSERVATION_MODIFIER", 15, 26], ["intestinal", "ANATOMY", 27, 37], ["lesions", "OBSERVATION", 38, 45], ["atrophic", "OBSERVATION_MODIFIER", 49, 57], ["enteropathy", "OBSERVATION", 58, 69], ["crypt hyperplasia", "OBSERVATION", 74, 91], ["duodenum", "ANATOMY", 113, 121], ["jejunum", "ANATOMY", 123, 130], ["ileum", "ANATOMY", 136, 141]]], ["Viral antigen was also detected in the enterocytes in all three sections using a PEDV-specific monoclonal Ab-based immunohistochemistry assay (Figures 6A\u2013E).", [["enterocytes", "ANATOMY", 39, 50], ["sections", "ANATOMY", 64, 72], ["Viral", "ORGANISM", 0, 5], ["enterocytes", "CELL", 39, 50], ["PEDV", "SIMPLE_CHEMICAL", 81, 85], ["Viral antigen", "PROTEIN", 0, 13], ["enterocytes", "CELL_TYPE", 39, 50], ["PEDV", "PROTEIN", 81, 85], ["monoclonal Ab", "PROTEIN", 95, 108], ["Viral antigen", "TEST", 0, 13], ["a PEDV", "TEST", 79, 85], ["enterocytes", "ANATOMY", 39, 50]]], ["There were no significant differences between the 3 sections, indicating the entire small intestine was affected.", [["sections", "ANATOMY", 52, 60], ["small intestine", "ANATOMY", 84, 99], ["small intestine", "ORGAN", 84, 99], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37], ["entire", "ANATOMY_MODIFIER", 77, 83], ["small intestine", "ANATOMY", 84, 99]]], ["The total microscopic score, including the histopathology and immunohistochemistry scores was 4.16 for the unvaccinated animals and 7.33 for the pigs immunized with the irradiated vaccine and 0 for pigs administered the heat and RNAse treated vaccine.", [["pigs", "ORGANISM", 145, 149], ["pigs", "ORGANISM", 198, 202], ["RNAse", "GENE_OR_GENE_PRODUCT", 229, 234], ["pigs", "SPECIES", 145, 149], ["pigs", "SPECIES", 198, 202], ["pigs", "SPECIES", 145, 149], ["pigs", "SPECIES", 198, 202], ["The total microscopic score", "TEST", 0, 27], ["the histopathology", "TEST", 39, 57], ["immunohistochemistry scores", "TEST", 62, 89], ["the pigs immunized", "TREATMENT", 141, 159], ["the irradiated vaccine", "TREATMENT", 165, 187], ["pigs", "TREATMENT", 198, 202], ["RNAse treated vaccine", "TREATMENT", 229, 250]]], ["While the difference between the unvaccinated group and irradiated vaccine group was not statistically significant, the irradiated vaccine appeared to enhance intestinal pathology (Table 1).", [["intestinal", "ANATOMY", 159, 169], ["intestinal", "ORGAN", 159, 169], ["irradiated vaccine group", "TREATMENT", 56, 80], ["the irradiated vaccine", "TREATMENT", 116, 138], ["intestinal", "ANATOMY", 159, 169]]], ["Similarly, the total necropsy scores, a sum of both the fecal and histology scores, were significantly different (p = 0.04) between the two vaccine groups but not between the unvaccinated group and the irradiated vaccine group (p = 0.37) (Table 1).The Experimental Vaccines Are Safe ::: ResultsNo side effects or clinical signs of PED were observed in vaccinated pigs after either the primary or booster vaccines.", [["fecal", "ANATOMY", 56, 61], ["PED", "DISEASE", 331, 334], ["fecal", "ORGANISM_SUBSTANCE", 56, 61], ["pigs", "ORGANISM", 363, 367], ["pigs", "SPECIES", 363, 367], ["pigs", "SPECIES", 363, 367], ["the total necropsy scores", "TEST", 11, 36], ["histology scores", "TEST", 66, 82], ["the two vaccine groups", "TREATMENT", 132, 154], ["the irradiated vaccine group", "TREATMENT", 198, 226], ["side effects", "PROBLEM", 297, 309], ["PED", "PROBLEM", 331, 334], ["booster vaccines", "TREATMENT", 396, 412], ["fecal", "ANATOMY", 56, 61], ["side effects", "OBSERVATION_MODIFIER", 297, 309]]], ["Vaccine viral RNA was not detected by RT-qPCR in the fecal matter of any of the vaccinated pigs from both groups at 7 days after the primary vaccination or at 1 week after the boosters.", [["fecal matter", "ANATOMY", 53, 65], ["fecal", "ORGANISM_SUBDIVISION", 53, 58], ["pigs", "ORGANISM", 91, 95], ["Vaccine viral RNA", "RNA", 0, 17], ["pigs", "SPECIES", 91, 95], ["pigs", "SPECIES", 91, 95], ["Vaccine viral RNA", "PROBLEM", 0, 17], ["the primary vaccination", "TREATMENT", 129, 152]]], ["All animals remained PCR negative until the day of challenge.", [["PCR", "TEST", 21, 24], ["negative", "OBSERVATION", 25, 33]]], ["Therefore, although the heat and RNase treated PEDV virions were detected by amplification after 3 serial passages in Vero cells, replication of the vaccine virus in the host appeared to be curtailed by its immune system.", [["Vero cells", "ANATOMY", 118, 128], ["RNase", "GENE_OR_GENE_PRODUCT", 33, 38], ["PEDV virions", "ORGANISM", 47, 59], ["Vero cells", "CELL", 118, 128], ["vaccine virus", "ORGANISM", 149, 162], ["RNase", "PROTEIN", 33, 38], ["Vero cells", "CELL_LINE", 118, 128], ["PEDV", "SPECIES", 47, 51], ["the heat and RNase", "TREATMENT", 20, 38], ["PEDV virions", "TREATMENT", 47, 59], ["3 serial passages in Vero cells", "TREATMENT", 97, 128], ["the vaccine virus", "TREATMENT", 145, 162], ["Vero cells", "OBSERVATION", 118, 128]]], ["In the 2 pigs euthanized from each group prior to challenge, stools were fully formed at necropsy (Table 1).", [["stools", "ANATOMY", 61, 67], ["pigs", "ORGANISM", 9, 13], ["stools", "ORGANISM", 61, 67], ["pigs", "SPECIES", 9, 13], ["pigs", "SPECIES", 9, 13], ["stools", "PROBLEM", 61, 67]]], ["No microscopic lesions or viral antigen were detected in the small intestine sections, heart, spleen, and liver of the 2 animals necropsied from each group prior to challenge (Table 1).", [["lesions", "ANATOMY", 15, 22], ["small intestine sections", "ANATOMY", 61, 85], ["heart", "ANATOMY", 87, 92], ["spleen", "ANATOMY", 94, 100], ["liver", "ANATOMY", 106, 111], ["lesions", "PATHOLOGICAL_FORMATION", 15, 22], ["intestine sections", "MULTI-TISSUE_STRUCTURE", 67, 85], ["heart", "ORGAN", 87, 92], ["spleen", "ORGAN", 94, 100], ["liver", "ORGAN", 106, 111], ["viral antigen", "PROTEIN", 26, 39], ["microscopic lesions", "PROBLEM", 3, 22], ["viral antigen", "PROBLEM", 26, 39], ["microscopic", "OBSERVATION_MODIFIER", 3, 14], ["lesions", "OBSERVATION", 15, 22], ["viral antigen", "OBSERVATION", 26, 39], ["small intestine", "ANATOMY", 61, 76], ["heart", "ANATOMY", 87, 92], ["spleen", "ANATOMY", 94, 100], ["liver", "ANATOMY", 106, 111]]], ["Representative images of the duodenum, jejunum, and ileum are depicted in Figure 5.Heat and RNAse Treatment Results in Genetic Changes ::: ResultsTo identify possible mutations that could explain the highly effective attenuation observed, deep sequencing of heat and RNAse treated virions from infected vero cells resulted in a total of 59.42 and 24.44 MB of raw reads were obtained by RNA seq for the treated and untreated samples, respectively.", [["duodenum", "ANATOMY", 29, 37], ["jejunum", "ANATOMY", 39, 46], ["ileum", "ANATOMY", 52, 57], ["virions", "ANATOMY", 281, 288], ["vero cells", "ANATOMY", 303, 313], ["samples", "ANATOMY", 424, 431], ["duodenum", "MULTI-TISSUE_STRUCTURE", 29, 37], ["jejunum", "MULTI-TISSUE_STRUCTURE", 39, 46], ["ileum", "MULTI-TISSUE_STRUCTURE", 52, 57], ["RNAse", "GENE_OR_GENE_PRODUCT", 267, 272], ["vero cells", "CELL", 303, 313], ["infected vero cells", "CELL_TYPE", 294, 313], ["RNA seq", "RNA", 386, 393], ["Representative images", "TEST", 0, 21], ["RNAse Treatment", "TREATMENT", 92, 107], ["mutations", "PROBLEM", 167, 176], ["the highly effective attenuation", "PROBLEM", 196, 228], ["heat and RNAse treated virions", "PROBLEM", 258, 288], ["infected vero cells", "PROBLEM", 294, 313], ["duodenum", "ANATOMY", 29, 37], ["jejunum", "ANATOMY", 39, 46], ["ileum", "ANATOMY", 52, 57], ["effective", "OBSERVATION_MODIFIER", 207, 216], ["attenuation", "OBSERVATION", 217, 228], ["vero cells", "OBSERVATION", 303, 313]]], ["Clean reads obtained after trimming were 26.94 and 19.53 GB, respectively.", [["trimming", "TEST", 27, 35]]], ["The Qphred20 values for the clean reads were 96.69 and 98.49 for the untreated and tread samples, respectively, indicating satisfactory quality of the data obtained.", [["samples", "ANATOMY", 89, 96], ["Qphred20", "GENE_OR_GENE_PRODUCT", 4, 12], ["Qphred20", "DNA", 4, 12], ["The Qphred20 values", "TEST", 0, 19], ["the clean reads", "TEST", 24, 39]]], ["As listed in Table 2 SNPs and insertions or deletions (INDELS) were detected in the polyprotein, spike and envelope proteins (Table 2, S1 Sequence File and Supplementary Figures 1\u20133) of heat and RNAse treated virions, when compared to the untreated virions.", [["virions", "ANATOMY", 249, 256], ["RNAse", "GENE_OR_GENE_PRODUCT", 195, 200], ["INDELS", "DNA", 55, 61], ["polyprotein, spike and envelope proteins", "PROTEIN", 84, 124], ["S1", "PROTEIN", 135, 137], ["insertions or deletions (INDELS)", "TREATMENT", 30, 62], ["the polyprotein", "PROBLEM", 80, 95], ["heat and RNAse treated virions", "TREATMENT", 186, 216]]], ["In addition, insertions and deletions were detected in the S1 region for the spike protein.", [["S1 region", "DNA", 59, 68], ["spike protein", "PROTEIN", 77, 90], ["insertions and deletions", "TREATMENT", 13, 37], ["the spike protein", "PROBLEM", 73, 90], ["S1", "ANATOMY", 59, 61]]], ["The N terminal signal peptide region of the spike protein had a 2 amino acid deletion and one non-synonymous change at position 355, changing the sequence from IGEN to K\u2014N. A conservative in-frame insertion was detected at position 355 in the S1 region, changing the amino acid sequence from L----AT to LKKKGAT (Table 2 and Supplementary Figure 2).DiscussionChemical methods for inactivation of viruses have long been in use for vaccine development.", [["amino acid", "CHEMICAL", 66, 76], ["amino acid", "CHEMICAL", 267, 277], ["N", "CHEMICAL", 4, 5], ["amino acid", "CHEMICAL", 66, 76], ["amino acid", "CHEMICAL", 267, 277], ["amino acid", "AMINO_ACID", 66, 76], ["amino acid", "AMINO_ACID", 267, 277], ["N terminal signal peptide region", "PROTEIN", 4, 36], ["spike protein", "PROTEIN", 44, 57], ["position 355", "PROTEIN", 119, 131], ["IGEN", "PROTEIN", 160, 164], ["K\u2014N", "PROTEIN", 168, 171], ["S1 region", "DNA", 243, 252], ["amino acid sequence", "PROTEIN", 267, 286], ["The N terminal signal peptide region", "PROBLEM", 0, 36], ["the spike protein", "PROBLEM", 40, 57], ["a 2 amino acid deletion", "PROBLEM", 62, 85], ["A conservative in-frame insertion", "TREATMENT", 173, 206], ["the amino acid sequence", "TEST", 263, 286], ["DiscussionChemical methods", "TREATMENT", 348, 374], ["inactivation of viruses", "PROBLEM", 379, 402], ["vaccine development", "TREATMENT", 429, 448], ["terminal", "OBSERVATION_MODIFIER", 6, 14], ["non-synonymous change", "OBSERVATION", 94, 115], ["conservative", "OBSERVATION_MODIFIER", 175, 187], ["S1", "ANATOMY", 243, 245], ["region", "ANATOMY_MODIFIER", 246, 252]]], ["While they are rapid and convenient, commonly used inactivation agents may not only affect nucleic acids but also protein structures and hence antigen presentation and vaccine efficacy.", [["nucleic acids", "CHEMICAL", 91, 104], ["nucleic acids", "SIMPLE_CHEMICAL", 91, 104], ["inactivation agents", "TREATMENT", 51, 70], ["nucleic acids", "TEST", 91, 104], ["protein structures", "PROBLEM", 114, 132], ["vaccine efficacy", "TREATMENT", 168, 184]]], ["Gamma irradiation has been traditionally used to inactivate viruses.", [["Gamma irradiation", "TREATMENT", 0, 17], ["viruses", "PROBLEM", 60, 67]]], ["The mechanisms involved include nucleic acid degradation, destruction of covalent bonds, and release of free radicals (30).", [["nucleic acid", "CHEMICAL", 32, 44], ["nucleic acid", "SIMPLE_CHEMICAL", 32, 44], ["free radicals", "SIMPLE_CHEMICAL", 104, 117], ["nucleic acid degradation", "PROBLEM", 32, 56], ["destruction of covalent bonds", "PROBLEM", 58, 87], ["nucleic acid", "OBSERVATION", 32, 44], ["covalent bonds", "OBSERVATION", 73, 87]]], ["As commercial inactivated vaccines were not available at the time of testing gamma irradiation was selected as the method of choice to prepare an inactivated control vaccine for this study.", [["commercial inactivated vaccines", "TREATMENT", 3, 34], ["testing gamma irradiation", "TREATMENT", 69, 94], ["an inactivated control vaccine", "TREATMENT", 143, 173], ["this study", "TEST", 178, 188]]], ["Moreover, similar to the heat and RNAse treated vaccine, the virus-like-particulate structure was more likely to be maintained by gamma irradiation, while achieving complete inactivation.DiscussionGamma irradiation had been previously used for vaccine development with varying success, depending on the pathogen (17).", [["RNAse", "GENE_OR_GENE_PRODUCT", 34, 39], ["RNAse", "PROTEIN", 34, 39], ["RNAse treated vaccine", "TREATMENT", 34, 55], ["the virus", "PROBLEM", 57, 66], ["gamma irradiation", "TREATMENT", 130, 147], ["Gamma irradiation", "TREATMENT", 197, 214], ["vaccine development", "TREATMENT", 244, 263], ["gamma irradiation", "OBSERVATION", 130, 147]]], ["For example, we have previously demonstrated that a gamma irradiated vaccine against Neospora caninum was effective in mice (31).", [["Neospora caninum", "DISEASE", 85, 101], ["Neospora caninum", "ORGANISM", 85, 101], ["mice", "ORGANISM", 119, 123], ["Neospora caninum", "SPECIES", 85, 101], ["mice", "SPECIES", 119, 123], ["Neospora caninum", "SPECIES", 85, 101], ["mice", "SPECIES", 119, 123], ["a gamma irradiated vaccine", "TREATMENT", 50, 76], ["Neospora caninum", "TREATMENT", 85, 101]]], ["However, a gamma irradiated, Lassa virus vaccine failed to protect vaccinated mice (32).", [["Lassa virus", "ORGANISM", 29, 40], ["mice", "ORGANISM", 78, 82], ["Lassa virus vaccine", "SPECIES", 29, 48], ["mice", "SPECIES", 78, 82], ["Lassa virus", "SPECIES", 29, 40], ["mice", "SPECIES", 78, 82], ["a gamma irradiated", "TREATMENT", 9, 27], ["Lassa virus vaccine", "TREATMENT", 29, 48]]], ["Although both approaches tested in this study targeted nucleic acids and preservation of structure, the protective outcomes varied significantly between the two vaccines tested.", [["nucleic acids", "CHEMICAL", 55, 68], ["nucleic acids", "SIMPLE_CHEMICAL", 55, 68], ["this study", "TEST", 35, 45], ["nucleic acids", "TEST", 55, 68], ["the two vaccines", "TREATMENT", 153, 169]]], ["It is possible that release of free radicals during the irradiation process could have a deleterious effect on integrity of antigenic structures and antigen presentation in vivo.", [["free radicals", "PROBLEM", 31, 44], ["the irradiation process", "TREATMENT", 52, 75], ["free radicals", "OBSERVATION", 31, 44], ["deleterious", "OBSERVATION", 89, 100]]], ["A more detailed characterization of these parameters will be the focus of future studies.", [["future studies", "TEST", 74, 88]]], ["Similar results for the gamma irradiated vaccine in this study, it has been shown that a dendritic cell targeted spike protein-based subunit vaccine against PEDV exacerbated intestinal pathology in vaccinated pigs, despite stimulating strong CD4+/CD8+ T cell responses (33).DiscussionWhile characterizing the exact physical interactions involved in the heat and RNAse treatment is not within the scope of this study, our finding that exposure of PEDV to temperatures below 50\u00b0C did not affect structure was similar to other studies showing that the SARS coronavirus structure is metastable and can be reversibly denatured by exposure to varying physical conditions such pH and temperature (16, 34).", [["dendritic cell", "ANATOMY", 89, 103], ["intestinal", "ANATOMY", 174, 184], ["CD4+/CD8+ T cell", "ANATOMY", 242, 258], ["PEDV", "CHEMICAL", 157, 161], ["SARS", "DISEASE", 549, 553], ["dendritic cell", "CELL", 89, 103], ["PEDV", "ORGANISM", 157, 161], ["intestinal", "ORGAN", 174, 184], ["pigs", "ORGANISM", 209, 213], ["CD4", "GENE_OR_GENE_PRODUCT", 242, 245], ["CD8", "GENE_OR_GENE_PRODUCT", 247, 250], ["RNAse", "GENE_OR_GENE_PRODUCT", 362, 367], ["SARS coronavirus", "ORGANISM", 549, 565], ["dendritic cell targeted spike protein", "PROTEIN", 89, 126], ["CD4", "PROTEIN", 242, 245], ["CD8", "PROTEIN", 247, 250], ["RNAse", "PROTEIN", 362, 367], ["pigs", "SPECIES", 209, 213], ["PEDV", "SPECIES", 157, 161], ["pigs", "SPECIES", 209, 213], ["SARS coronavirus", "SPECIES", 549, 565], ["the gamma irradiated vaccine", "TREATMENT", 20, 48], ["this study", "TEST", 52, 62], ["a dendritic cell targeted spike protein", "TREATMENT", 87, 126], ["subunit vaccine", "TREATMENT", 133, 148], ["PEDV exacerbated intestinal pathology", "PROBLEM", 157, 194], ["vaccinated pigs", "TREATMENT", 198, 213], ["RNAse treatment", "TREATMENT", 362, 377], ["this study", "TEST", 405, 415], ["PEDV", "PROBLEM", 446, 450], ["temperatures", "TEST", 454, 466], ["other studies", "TEST", 518, 531], ["the SARS coronavirus structure", "PROBLEM", 545, 575], ["temperature", "TEST", 677, 688], ["dendritic cell", "OBSERVATION", 89, 103], ["intestinal", "ANATOMY", 174, 184]]], ["Although the heat and RNAse treated virus culture was amplified after 3 passages in cell culture (Figure 2), the absence its detection by RT-qPCR (Figure 4), or immunohistochemistry (Table 1 and Figure 5) and the lack of strong Ab responses to the non-structural NP (Figure 3), in vaccinated pigs prior to challenge indicates that active vaccine viral replication was absent in the host or was undetectable by the techniques used.", [["cell culture", "ANATOMY", 84, 96], ["RNAse", "GENE_OR_GENE_PRODUCT", 22, 27], ["cell culture", "CELL", 84, 96], ["Ab", "GENE_OR_GENE_PRODUCT", 228, 230], ["pigs", "ORGANISM", 292, 296], ["pigs", "SPECIES", 292, 296], ["pigs", "SPECIES", 292, 296], ["the heat and RNAse treated virus culture", "PROBLEM", 9, 49], ["cell culture", "TEST", 84, 96], ["RT-qPCR", "TEST", 138, 145], ["immunohistochemistry", "TEST", 161, 181], ["active vaccine viral replication", "TREATMENT", 331, 363], ["active", "OBSERVATION_MODIFIER", 331, 337]]], ["Therefore, unlike other attenuated PEDV vaccines or vaccination strategies that rely on prior exposure to field strains, it is highly improbable that reversion to virulence or recombination with field strains could occur with the heat and RNAse treated vaccine.DiscussionViral genomes that were identical to the untreated parental virus were not detected by deep sequencing of the heat and RNAse treated virus from infected Vero cells.", [["Vero cells", "ANATOMY", 424, 434], ["PEDV", "CHEMICAL", 35, 39], ["RNAse", "GENE_OR_GENE_PRODUCT", 239, 244], ["RNAse", "GENE_OR_GENE_PRODUCT", 390, 395], ["Vero cells", "CELL", 424, 434], ["DiscussionViral genomes", "DNA", 261, 284], ["infected Vero cells", "CELL_LINE", 415, 434], ["PEDV", "SPECIES", 35, 39], ["attenuated PEDV vaccines", "TREATMENT", 24, 48], ["vaccination strategies", "TREATMENT", 52, 74], ["field strains", "PROBLEM", 106, 119], ["virulence", "PROBLEM", 163, 172], ["field strains", "PROBLEM", 195, 208], ["the heat and RNAse treated vaccine", "TREATMENT", 226, 260], ["DiscussionViral genomes", "PROBLEM", 261, 284], ["the untreated parental virus", "PROBLEM", 308, 336], ["the heat and RNAse treated virus", "PROBLEM", 377, 409], ["infected Vero cells", "PROBLEM", 415, 434], ["attenuated", "OBSERVATION_MODIFIER", 24, 34], ["PEDV", "OBSERVATION", 35, 39], ["Vero cells", "OBSERVATION", 424, 434]]], ["Insertions and deletions in the spike protein, especially the S1 region, influence pathogenicity, and immunogenicity of PEDV.", [["spike protein", "PROTEIN", 32, 45], ["S1 region", "DNA", 62, 71], ["PEDV", "PROTEIN", 120, 124], ["PEDV", "SPECIES", 120, 124], ["Insertions and deletions", "PROBLEM", 0, 24], ["the spike protein", "TEST", 28, 45], ["influence pathogenicity", "PROBLEM", 73, 96], ["PEDV", "PROBLEM", 120, 124], ["S1", "ANATOMY", 62, 64], ["region", "ANATOMY_MODIFIER", 65, 71]]], ["The core neutralizing epitope of the PEDV spike protein has been localized to amino acid positions 503\u2013568 (35, 36).", [["amino acid", "CHEMICAL", 78, 88], ["amino acid", "CHEMICAL", 78, 88], ["PEDV", "GENE_OR_GENE_PRODUCT", 37, 41], ["amino acid", "AMINO_ACID", 78, 88], ["PEDV spike protein", "PROTEIN", 37, 55], ["The core neutralizing epitope", "TREATMENT", 0, 29], ["the PEDV spike protein", "PROBLEM", 33, 55], ["amino acid positions", "TEST", 78, 98], ["neutralizing epitope", "OBSERVATION", 9, 29]]], ["The SNPs identified in the spike protein of the vaccine virions (Table 2) did not map to these residues.", [["spike protein", "PROTEIN", 27, 40], ["The SNPs", "PROBLEM", 0, 8], ["the vaccine virions", "TREATMENT", 44, 63]]], ["While a limitation of the described method is that genetic changes induced by treatment and repair are unpredictable, repair of mutations (37) or complementation in trans of the fragmented genome could have led to detection of a fluorescent signal in the 3rd passage after treatment.", [["genetic changes", "PROBLEM", 51, 66], ["treatment", "TREATMENT", 78, 87], ["repair", "TREATMENT", 92, 98], ["repair", "TREATMENT", 118, 124], ["mutations", "PROBLEM", 128, 137], ["a fluorescent signal", "PROBLEM", 227, 247], ["treatment", "TREATMENT", 273, 282], ["fragmented genome", "OBSERVATION", 178, 195]]], ["Indeed, it has been shown that replication deficient genomes with deletions or mutations are produced during serial passaging of foot and mouth disease virus (FMDV) for attenuation.", [["foot and mouth disease", "DISEASE", 129, 151], ["foot and mouth disease virus", "ORGANISM", 129, 157], ["FMDV", "ORGANISM", 159, 163], ["replication deficient genomes", "DNA", 31, 60], ["mouth disease virus", "SPECIES", 138, 157], ["FMDV", "SPECIES", 159, 163], ["foot and mouth disease virus", "SPECIES", 129, 157], ["FMDV", "SPECIES", 159, 163], ["replication deficient genomes", "PROBLEM", 31, 60], ["deletions or mutations", "PROBLEM", 66, 88], ["serial passaging of foot", "TREATMENT", 109, 133], ["mouth disease virus", "PROBLEM", 138, 157], ["attenuation", "PROBLEM", 169, 180], ["foot", "ANATOMY", 129, 133], ["mouth", "ANATOMY", 138, 143]]], ["They are not infective by themselves, but when present in the same cell, the mutations in the genomes can complement each other in trans to produce plaques in vitro.", [["cell", "ANATOMY", 67, 71], ["plaques", "ANATOMY", 148, 155], ["cell", "CELL", 67, 71], ["plaques", "PATHOLOGICAL_FORMATION", 148, 155], ["infective", "PROBLEM", 13, 22], ["plaques", "PROBLEM", 148, 155], ["not", "UNCERTAINTY", 9, 12], ["infective", "OBSERVATION", 13, 22], ["plaques", "OBSERVATION", 148, 155]]], ["When the defective-complementing virus system was used as a vaccine by Rodriguez-Calvo et al. vaccine virus replication was not detected but strong protection was elicited.", [["vaccine virus", "SPECIES", 94, 107], ["the defective", "PROBLEM", 5, 18], ["complementing virus system", "TREATMENT", 19, 45], ["a vaccine", "TREATMENT", 58, 67], ["vaccine virus replication", "TREATMENT", 94, 119]]], ["This observation can be explained by vaccine virus replication in the host being limited by the requirement of coinfection of the same cell.", [["cell", "ANATOMY", 135, 139], ["cell", "CELL", 135, 139], ["vaccine virus replication", "TREATMENT", 37, 62], ["coinfection of the same cell", "PROBLEM", 111, 139], ["coinfection", "OBSERVATION", 111, 122], ["same cell", "OBSERVATION", 130, 139]]], ["Even if such an unlikely coinfection event were to happen despite active host innate immunity, the recombined progeny viruses were more likely to be highly attenuated than acquire virulence, thus providing an additional vaccine safety barrier in vivo (38).", [["active host innate immunity", "TREATMENT", 66, 93], ["the recombined progeny viruses", "PROBLEM", 95, 125], ["an additional vaccine safety barrier", "TREATMENT", 206, 242], ["unlikely", "UNCERTAINTY", 16, 24], ["coinfection", "OBSERVATION", 25, 36]]], ["In vivo, the presence of the host innate immune system was likely able to effectively curtail replication, despite exposure to 105 TCID50 of the heat and RNAse treated virus culture.", [["RNAse", "GENE_OR_GENE_PRODUCT", 154, 159], ["the heat", "TREATMENT", 141, 149], ["RNAse", "TREATMENT", 154, 159], ["virus culture", "TEST", 168, 181]]], ["More detailed studies are required to confirm these hypotheses, but they are not within the scope of this manuscript.DiscussionThe importance of spike protein-specific antibodies for protection against PEDV is well-established (15).", [["PEDV", "CHEMICAL", 202, 206], ["spike protein", "PROTEIN", 145, 158], ["antibodies", "PROTEIN", 168, 178], ["PEDV", "SPECIES", 202, 206], ["More detailed studies", "TEST", 0, 21], ["spike protein", "PROBLEM", 145, 158], ["specific antibodies", "TREATMENT", 159, 178], ["PEDV", "PROBLEM", 202, 206]]], ["Several studies describing experimental subunit and vectored vaccines or commercial attenuated and inactivated vaccines against PEDV establish a strong correlation between spike protein-specific antibodies, virus neutralization titers and protection against infection (9, 29, 37, 39\u201343).", [["PEDV", "CHEMICAL", 128, 132], ["infection", "DISEASE", 258, 267], ["PEDV", "CANCER", 128, 132], ["spike protein", "PROTEIN", 172, 185], ["specific antibodies", "PROTEIN", 186, 205], ["PEDV", "SPECIES", 128, 132], ["Several studies", "TEST", 0, 15], ["experimental subunit", "TREATMENT", 27, 47], ["vectored vaccines", "TREATMENT", 52, 69], ["commercial attenuated and inactivated vaccines", "TREATMENT", 73, 119], ["PEDV", "PROBLEM", 128, 132], ["spike protein", "TEST", 172, 185], ["specific antibodies", "TEST", 186, 205], ["virus neutralization titers", "TREATMENT", 207, 234], ["infection", "PROBLEM", 258, 267]]], ["Similar to these studies, strong spike-protein specific Ab responses and virus neutralizing responses were noted in the pigs immunized with the heat and RNAse treated vaccine.", [["Ab", "GENE_OR_GENE_PRODUCT", 56, 58], ["pigs", "ORGANISM", 120, 124], ["RNAse", "GENE_OR_GENE_PRODUCT", 153, 158], ["pigs", "SPECIES", 120, 124], ["pigs", "SPECIES", 120, 124], ["these studies", "TEST", 11, 24], ["Ab responses", "TEST", 56, 68], ["virus neutralizing responses", "PROBLEM", 73, 101], ["the heat and RNAse treated vaccine", "TREATMENT", 140, 174]]], ["A commercial inactivated vaccine was able to reduce challenge viral shedding by 3\u20134 logs but an attenuated vaccine induced IgA responses but did not affect viral shedding (43).", [["IgA", "GENE_OR_GENE_PRODUCT", 123, 126], ["IgA", "PROTEIN", 123, 126], ["A commercial inactivated vaccine", "TREATMENT", 0, 32], ["an attenuated vaccine", "TREATMENT", 93, 114]]], ["Testing of two attenuated PEDV strains produced by serial passage in weanling pigs showed that the passaged viruses were attenuated but were not protected against challenge viral shedding or clinical signs (29).", [["PEDV strains", "ORGANISM", 26, 38], ["weanling pigs", "ORGANISM", 69, 82], ["weanling pigs", "SPECIES", 69, 82], ["PEDV", "SPECIES", 26, 30], ["weanling", "SPECIES", 69, 77], ["two attenuated PEDV strains", "PROBLEM", 11, 38], ["serial passage in weanling pigs", "TREATMENT", 51, 82], ["the passaged viruses", "PROBLEM", 95, 115], ["clinical signs", "TEST", 191, 205], ["attenuated", "OBSERVATION_MODIFIER", 15, 25], ["PEDV", "OBSERVATION", 26, 30]]], ["While direct comparisons are not possible due to differences in experimental conditions, unlike the other cited studies, intestinal lesions, or challenge virus was not detected by qPCR in the heat and RNAse treated vaccine group in this study.", [["intestinal lesions", "ANATOMY", 121, 139], ["intestinal lesions", "DISEASE", 121, 139], ["intestinal lesions", "PATHOLOGICAL_FORMATION", 121, 139], ["RNAse", "GENE_OR_GENE_PRODUCT", 201, 206], ["the other cited studies", "TEST", 96, 119], ["intestinal lesions", "PROBLEM", 121, 139], ["challenge virus", "PROBLEM", 144, 159], ["RNAse treated vaccine", "TREATMENT", 201, 222], ["this study", "TEST", 232, 242], ["intestinal", "ANATOMY", 121, 131], ["lesions", "OBSERVATION", 132, 139]]], ["Although boosters were incorporated in the study design to minimize risk, it is likely that they were not required to achieve adequate protection as strong spike protein specific antibody responses and virus neutralizing responses were detected after the first dose of the heat and RNAse treated vaccine, at DPV 14 (Figure 3).", [["RNAse", "GENE_OR_GENE_PRODUCT", 282, 287], ["strong spike protein specific antibody responses", "PROBLEM", 149, 197], ["virus neutralizing responses", "PROBLEM", 202, 230], ["the heat and RNAse treated vaccine", "TREATMENT", 269, 303]]], ["While cell mediated immunity was not assessed due to difficulties with transportation of cells, it is very likely that it was not compromised by the process used as the heat and RNAse treated vaccine was very effective in preventing challenge viral replication in vaccinated pigs.DiscussionWhile ideal for PEDV, studying vaccine efficacy in pregnant sows and neonatal pigs is expensive and procedurally tedious.", [["cell", "ANATOMY", 6, 10], ["cells", "ANATOMY", 89, 94], ["PEDV", "CHEMICAL", 306, 310], ["cell", "CELL", 6, 10], ["cells", "CELL", 89, 94], ["RNAse", "GENE_OR_GENE_PRODUCT", 178, 183], ["pigs", "ORGANISM", 275, 279], ["sows", "ORGANISM", 350, 354], ["pigs", "ORGANISM", 368, 372], ["pigs", "SPECIES", 275, 279], ["sows", "SPECIES", 350, 354], ["pigs", "SPECIES", 368, 372], ["pigs", "SPECIES", 275, 279], ["pigs", "SPECIES", 368, 372], ["difficulties with transportation of cells", "PROBLEM", 53, 94], ["the heat and RNAse treated vaccine", "TREATMENT", 165, 199], ["challenge viral replication", "TREATMENT", 233, 260], ["PEDV", "PROBLEM", 306, 310], ["studying vaccine efficacy", "TREATMENT", 312, 337], ["neonatal pigs", "TREATMENT", 359, 372], ["very likely", "UNCERTAINTY", 102, 113]]], ["Although clinical signs are less severe in older piglets (28) and virulence can vary between isolates used for challenge (44, 45), PEDV can infect and replicate well in pigs of all ages (14, 46).", [["PEDV", "CHEMICAL", 131, 135], ["piglets", "ORGANISM", 49, 56], ["PEDV", "ORGANISM", 131, 135], ["pigs", "ORGANISM", 169, 173], ["piglets", "SPECIES", 49, 56], ["pigs", "SPECIES", 169, 173], ["PEDV", "SPECIES", 131, 135], ["pigs", "SPECIES", 169, 173], ["clinical signs", "TEST", 9, 23], ["virulence", "PROBLEM", 66, 75], ["PEDV", "PROBLEM", 131, 135], ["less severe", "OBSERVATION_MODIFIER", 28, 39]]], ["Hence several researchers have used weanling piglets to screen vaccine candidates for efficacy and safety (9, 13, 29, 43, 47\u201352).", [["piglets", "ORGANISM", 45, 52], ["piglets", "SPECIES", 45, 52], ["weanling piglets", "TREATMENT", 36, 52]]], ["Several swine bioassay studies in growing piglets have reported that peak PEDV replication occurs between DPI 3 and DPI 7 after which viral loads decrease (28, 43, 47, 48).", [["DPI", "CHEMICAL", 106, 109], ["DPI", "CHEMICAL", 116, 119], ["DPI 7", "CHEMICAL", 116, 121], ["piglets", "ORGANISM", 42, 49], ["PEDV", "GENE_OR_GENE_PRODUCT", 74, 78], ["piglets", "SPECIES", 42, 49], ["swine", "SPECIES", 8, 13], ["PEDV", "SPECIES", 74, 78], ["Several swine bioassay studies", "TEST", 0, 30], ["peak PEDV replication", "PROBLEM", 69, 90], ["DPI", "TREATMENT", 106, 109], ["DPI", "TREATMENT", 116, 119], ["viral loads decrease", "TEST", 134, 154], ["viral loads", "OBSERVATION", 134, 145]]], ["Similar patterns of infectivity were observed in this study, as the uninfected control pigs had a mean fecal viral RNA load of 8.35 log copy numbers at DPI 7 (Figure 4) developed microscopic lesions, but not severe clinical signs.", [["lesions", "ANATOMY", 191, 198], ["DPI", "CHEMICAL", 152, 155], ["pigs", "ORGANISM", 87, 91], ["lesions", "PATHOLOGICAL_FORMATION", 191, 198], ["pigs", "SPECIES", 87, 91], ["pigs", "SPECIES", 87, 91], ["infectivity", "PROBLEM", 20, 31], ["this study", "TEST", 49, 59], ["a mean fecal viral RNA load", "PROBLEM", 96, 123], ["DPI", "TEST", 152, 155], ["microscopic lesions", "PROBLEM", 179, 198], ["severe clinical signs", "PROBLEM", 208, 229], ["infectivity", "OBSERVATION", 20, 31], ["viral RNA", "OBSERVATION", 109, 118], ["microscopic", "OBSERVATION_MODIFIER", 179, 190], ["lesions", "OBSERVATION", 191, 198], ["not", "UNCERTAINTY", 204, 207], ["severe", "OBSERVATION_MODIFIER", 208, 214]]], ["In comparison to the untreated control and irradiated vaccine groups, no fecal viral shedding or intestinal pathology was detected in the pigs immunized with the heat and RNase treated vaccine, indicating that vaccine induced immunity was highly effective against PEDV challenge, within the limits of this weanling pig study model.DiscussionThe primary advantages of this innovative approach are safety, efficacy, convenience and a short development time.", [["fecal", "ANATOMY", 73, 78], ["intestinal", "ANATOMY", 97, 107], ["PEDV", "CHEMICAL", 264, 268], ["fecal", "ORGANISM_SUBDIVISION", 73, 78], ["intestinal", "ORGAN", 97, 107], ["pigs", "ORGANISM", 138, 142], ["RNase", "GENE_OR_GENE_PRODUCT", 171, 176], ["PEDV", "ORGANISM", 264, 268], ["pig", "ORGANISM", 315, 318], ["RNase", "PROTEIN", 171, 176], ["pigs", "SPECIES", 138, 142], ["pigs", "SPECIES", 138, 142], ["PEDV", "SPECIES", 264, 268], ["pig", "SPECIES", 315, 318], ["irradiated vaccine groups", "TREATMENT", 43, 68], ["fecal viral shedding", "PROBLEM", 73, 93], ["intestinal pathology", "PROBLEM", 97, 117], ["the heat and RNase treated vaccine", "TREATMENT", 158, 192], ["vaccine", "TREATMENT", 210, 217], ["PEDV challenge", "PROBLEM", 264, 278], ["this weanling pig study model", "TREATMENT", 301, 330], ["this innovative approach", "TREATMENT", 367, 391], ["no", "UNCERTAINTY", 70, 72], ["fecal", "ANATOMY", 73, 78], ["viral", "OBSERVATION", 79, 84], ["intestinal", "ANATOMY", 97, 107], ["pathology", "OBSERVATION", 108, 117]]], ["As the method can be easily adapted to newly evolving strains, provided they are readily cultured, this approach is very relevant to current field immunization practices of feedback exposure and autogenous vaccination.", [["newly evolving strains", "PROBLEM", 39, 61], ["current field immunization practices", "TREATMENT", 133, 169], ["feedback exposure", "TREATMENT", 173, 190], ["autogenous vaccination", "TREATMENT", 195, 217]]], ["Our future goals include testing the heat and RNase treated vaccine in pregnant sows, and improving oral and respiratory mucosal vaccine delivery systems to target improved protection.Data Availability StatementThe datasets generated for this study are available on request to the corresponding author.Ethics StatementThe animal study was reviewed and approved by Institutional Animal Care and Use Committee (IACUC) of S. Dakota State Universities (SDSU) (Protocol number- 15-013A).Conflict of Interest ::: Author ContributionsThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [["oral", "ANATOMY", 100, 104], ["mucosal", "ANATOMY", 121, 128], ["RNase", "GENE_OR_GENE_PRODUCT", 46, 51], ["sows", "ORGANISM", 80, 84], ["oral", "ORGANISM_SUBDIVISION", 100, 104], ["mucosal", "ORGANISM_SUBDIVISION", 121, 128], ["RNase", "PROTEIN", 46, 51], ["the heat and RNase treated vaccine", "TREATMENT", 33, 67], ["oral and respiratory mucosal vaccine delivery systems", "TREATMENT", 100, 153], ["this study", "TEST", 238, 248], ["The animal study", "TEST", 318, 334], ["respiratory mucosal", "ANATOMY", 109, 128]]], ["The described technology is covered by a provisional U.S. Patent Application (Serial No. 15/906,685).", [["Patent", "OBSERVATION", 58, 64]]]], "5cbe07ac1439774aaaae482b7713cc9951ca0c5b": [["Different geographic applications require different levels of accuracy regarding the location of the events or phenomena of their interest.", [["the events", "PROBLEM", 97, 107]]], ["This observation indicates that, while using the same addressing system with the same kinds of address-based location procedures, the quality of the results may suffice for some applications, but may be inadequate for others.", [["This observation", "TEST", 0, 16]]], ["Locating precisely each provided address in a short time is essential for emergency dispatching, while an epidemiologist may be content if each West Nile virus case is located only well enough for it to be associated with a reasonably small spatial unit, such as a Census tract.", [["West Nile virus", "ORGANISM", 144, 159], ["West Nile virus", "SPECIES", 144, 159], ["small", "OBSERVATION_MODIFIER", 235, 240]]], ["Thus, in this paper, we introduce a measurement to evaluate the degree of certainty associated with geocoding, i.e., the location of events or phenomena using addresses.", [["a measurement", "TEST", 34, 47], ["geocoding", "TREATMENT", 100, 109], ["phenomena", "PROBLEM", 143, 152]]], ["This measurement, which we call Geocoding Certainty Indicator (GCI), shows how certain can the user be as to the actual position of the geocoded event.", [["This measurement", "TEST", 0, 16]]], ["The resulting GCI can be used as a threshold for a filter, to leave out less reliable data, or as a weight, allowing the user to take the uncertainty into consideration during the spatial analysis process.", [["a filter", "TREATMENT", 49, 57]]], ["1 In order to support geocoding activities and the determination of the GCI, we propose a conceptual schema for addressing databases.", [["geocoding activities", "TREATMENT", 22, 42]]]], "PMC7471497": [["IntroductionThe recent pandemic caused by unparalleled infectivity of the novel human coronavirus, referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly around the globe causing coronavirus disease 2019 (COVID-19) affecting our health care systems and economies.1,2 Phenomenally, symptoms observed in patients are similar to other previously reported viruses, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS).3,4 Many of these patients suffered from pneumonia-associated symptoms, such as acute respiratory distress syndrome (ARDS), cytokine release syndrome (CRS), multiple organ failure (MOF), and sepsis.5,6 The term cytokine storm is a physiological reaction in which the immune system causes an uncontrolled and excessive release of proinflammatory signaling molecules called cytokines.7 Aggressive inflammatory response with the sudden release of proinflammatory cytokines in large quantities can cause acute respiratory distress syndrome (ARDS) aggravation and widespread tissue damage resulting in multiple organ failure (MOF) and death.8 Recently, it has been reported that elevated serum cytokine levels and the severe complications correlate directly with coronavirus disease 2019 (COVID-19).9 Mortality in COVID-19 patients has been linked to the overproduction of the proinflammatory cytokines (IFN\u03b1, IFN\u03b3, IL-1\u03b2, IL-6, IL-12, IL-18, IL-33, TNF\u03b1, and TGF\u03b2) and chemokines (CXCL10, CXCL8, CXCL9, CCL2, CCL3, and CCL5) induced by the SARS-CoV-2 virus.10IntroductionThere are no approved therapies nor effective therapeutic agents available for the treatment of COVID-19 and the only available option is supportive treatment.11,12 In response to the COVID-19 pandemic, the global effort for research and development of a vaccine is unprecedented in terms of speed and scale.", [["respiratory", "ANATOMY", 581, 592], ["organ", "ANATOMY", 661, 666], ["immune system", "ANATOMY", 762, 775], ["respiratory", "ANATOMY", 1001, 1012], ["tissue", "ANATOMY", 1065, 1071], ["organ", "ANATOMY", 1101, 1106], ["serum", "ANATOMY", 1178, 1183], ["human coronavirus", "DISEASE", 80, 97], ["acute respiratory syndrome coronavirus", "DISEASE", 121, 159], ["coronavirus disease", "DISEASE", 220, 239], ["acute respiratory syndrome", "DISEASE", 417, 443], ["SARS", "DISEASE", 445, 449], ["Middle East respiratory syndrome", "DISEASE", 455, 487], ["MERS", "DISEASE", 489, 493], ["pneumonia", "DISEASE", 536, 545], ["acute respiratory distress syndrome", "DISEASE", 575, 610], ["ARDS", "DISEASE", 612, 616], ["CRS", "DISEASE", 646, 649], ["multiple organ failure", "DISEASE", 652, 674], ["MOF", "DISEASE", 676, 679], ["sepsis", "DISEASE", 686, 692], ["5,6", "CHEMICAL", 693, 696], ["acute respiratory distress syndrome", "DISEASE", 995, 1030], ["ARDS", "DISEASE", 1032, 1036], ["tissue damage", "DISEASE", 1065, 1078], ["multiple organ failure", "DISEASE", 1092, 1114], ["MOF", "DISEASE", 1116, 1119], ["death", "DISEASE", 1125, 1130], ["coronavirus disease", "DISEASE", 1253, 1272], ["COVID-19", "CHEMICAL", 1658, 1666], ["COVID-19", "CHEMICAL", 1658, 1666], ["human", "ORGANISM", 80, 85], ["coronavirus", "ORGANISM", 86, 97], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 114, 161], ["SARS-CoV-2", "ORGANISM", 163, 173], ["patients", "ORGANISM", 343, 351], ["patients", "ORGANISM", 513, 521], ["organ", "ORGAN", 661, 666], ["tissue", "TISSUE", 1065, 1071], ["organ", "ORGAN", 1101, 1106], ["serum", "ORGANISM_SUBSTANCE", 1178, 1183], ["patients", "ORGANISM", 1313, 1321], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 1394, 1398], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 1400, 1404], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 1406, 1411], ["IL-6", "GENE_OR_GENE_PRODUCT", 1413, 1417], ["IL-12", "GENE_OR_GENE_PRODUCT", 1419, 1424], ["IL-18", "GENE_OR_GENE_PRODUCT", 1426, 1431], ["IL-33", "GENE_OR_GENE_PRODUCT", 1433, 1438], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 1440, 1444], ["TGF\u03b2", "GENE_OR_GENE_PRODUCT", 1450, 1454], ["CXCL10", "GENE_OR_GENE_PRODUCT", 1472, 1478], ["CXCL8", "GENE_OR_GENE_PRODUCT", 1480, 1485], ["CXCL9", "GENE_OR_GENE_PRODUCT", 1487, 1492], ["CCL2", "GENE_OR_GENE_PRODUCT", 1494, 1498], ["CCL3", "GENE_OR_GENE_PRODUCT", 1500, 1504], ["CCL5", "GENE_OR_GENE_PRODUCT", 1510, 1514], ["SARS-CoV-2 virus", "ORGANISM", 1531, 1547], ["cytokine", "PROTEIN", 619, 627], ["cytokine", "PROTEIN", 706, 714], ["proinflammatory signaling molecules", "PROTEIN", 824, 859], ["cytokines", "PROTEIN", 867, 876], ["proinflammatory cytokines", "PROTEIN", 939, 964], ["cytokine", "PROTEIN", 1184, 1192], ["proinflammatory cytokines", "PROTEIN", 1367, 1392], ["IFN\u03b1", "PROTEIN", 1394, 1398], ["IFN\u03b3", "PROTEIN", 1400, 1404], ["IL", "PROTEIN", 1406, 1408], ["IL-33", "PROTEIN", 1433, 1438], ["TNF\u03b1", "PROTEIN", 1440, 1444], ["TGF\u03b2", "PROTEIN", 1450, 1454], ["chemokines", "PROTEIN", 1460, 1470], ["CXCL10", "PROTEIN", 1472, 1478], ["CXCL8", "PROTEIN", 1480, 1485], ["CXCL9", "PROTEIN", 1487, 1492], ["CCL2", "PROTEIN", 1494, 1498], ["CCL3", "PROTEIN", 1500, 1504], ["CCL5", "PROTEIN", 1510, 1514], ["human", "SPECIES", 80, 85], ["coronavirus", "SPECIES", 86, 97], ["patients", "SPECIES", 343, 351], ["patients", "SPECIES", 513, 521], ["patients", "SPECIES", 1313, 1321], ["CoV-2 virus", "SPECIES", 1536, 1547], ["human coronavirus", "SPECIES", 80, 97], ["severe acute respiratory syndrome coronavirus", "SPECIES", 114, 159], ["SARS-CoV-2", "SPECIES", 163, 173], ["Middle East respiratory syndrome (MERS)", "SPECIES", 455, 494], ["SARS-CoV-2 virus", "SPECIES", 1531, 1547], ["the novel human coronavirus", "PROBLEM", 70, 97], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 114, 159], ["SARS-CoV", "TEST", 163, 171], ["coronavirus disease", "PROBLEM", 220, 239], ["COVID", "TEST", 246, 251], ["symptoms", "PROBLEM", 322, 330], ["severe acute respiratory syndrome", "PROBLEM", 410, 443], ["SARS)", "PROBLEM", 445, 450], ["Middle East respiratory syndrome", "PROBLEM", 455, 487], ["pneumonia", "PROBLEM", 536, 545], ["associated symptoms", "PROBLEM", 546, 565], ["acute respiratory distress syndrome", "PROBLEM", 575, 610], ["ARDS)", "PROBLEM", 612, 617], ["cytokine release syndrome", "PROBLEM", 619, 644], ["CRS", "PROBLEM", 646, 649], ["multiple organ failure", "PROBLEM", 652, 674], ["sepsis", "PROBLEM", 686, 692], ["The term cytokine storm", "PROBLEM", 697, 720], ["a physiological reaction", "PROBLEM", 724, 748], ["proinflammatory signaling molecules", "PROBLEM", 824, 859], ["Aggressive inflammatory response", "PROBLEM", 879, 911], ["proinflammatory cytokines", "PROBLEM", 939, 964], ["acute respiratory distress syndrome", "PROBLEM", 995, 1030], ["ARDS)", "PROBLEM", 1032, 1037], ["aggravation", "PROBLEM", 1038, 1049], ["widespread tissue damage", "PROBLEM", 1054, 1078], ["multiple organ failure", "PROBLEM", 1092, 1114], ["death", "PROBLEM", 1125, 1130], ["elevated serum cytokine levels", "PROBLEM", 1169, 1199], ["the severe complications", "PROBLEM", 1204, 1228], ["coronavirus disease", "PROBLEM", 1253, 1272], ["COVID", "TEST", 1279, 1284], ["the proinflammatory cytokines", "TEST", 1363, 1392], ["IFN\u03b1", "TEST", 1394, 1398], ["IFN\u03b3", "TEST", 1400, 1404], ["IL", "TEST", 1406, 1408], ["IL", "TEST", 1413, 1415], ["IL", "TEST", 1419, 1421], ["IL", "TEST", 1426, 1428], ["IL", "TEST", 1433, 1435], ["TNF", "TEST", 1440, 1443], ["TGF", "TEST", 1450, 1453], ["chemokines", "TEST", 1460, 1470], ["CXCL10", "TEST", 1472, 1478], ["CXCL8", "TEST", 1480, 1485], ["CXCL9", "TEST", 1487, 1492], ["CCL2", "TEST", 1494, 1498], ["CCL3", "TEST", 1500, 1504], ["the SARS", "PROBLEM", 1527, 1535], ["CoV", "TEST", 1536, 1539], ["approved therapies", "TREATMENT", 1575, 1593], ["effective therapeutic agents", "TREATMENT", 1598, 1626], ["COVID", "TEST", 1658, 1663], ["supportive treatment", "TREATMENT", 1700, 1720], ["the COVID", "TEST", 1742, 1751], ["a vaccine", "TREATMENT", 1815, 1824], ["severe", "OBSERVATION_MODIFIER", 114, 120], ["acute", "OBSERVATION_MODIFIER", 121, 126], ["respiratory syndrome", "OBSERVATION", 127, 147], ["globe", "ANATOMY", 206, 211], ["coronavirus disease", "OBSERVATION", 220, 239], ["viruses", "OBSERVATION", 393, 400], ["severe", "OBSERVATION_MODIFIER", 410, 416], ["acute", "OBSERVATION_MODIFIER", 417, 422], ["respiratory syndrome", "OBSERVATION", 423, 443], ["Middle", "ANATOMY_MODIFIER", 455, 461], ["respiratory syndrome", "OBSERVATION", 467, 487], ["pneumonia", "OBSERVATION", 536, 545], ["acute", "OBSERVATION_MODIFIER", 575, 580], ["respiratory", "ANATOMY", 581, 592], ["distress syndrome", "OBSERVATION", 593, 610], ["multiple", "OBSERVATION_MODIFIER", 652, 660], ["organ", "ANATOMY", 661, 666], ["failure", "OBSERVATION", 667, 674], ["sepsis", "OBSERVATION", 686, 692], ["cytokine storm", "OBSERVATION", 706, 720], ["uncontrolled", "OBSERVATION_MODIFIER", 786, 798], ["proinflammatory signaling molecules", "OBSERVATION", 824, 859], ["inflammatory", "OBSERVATION", 890, 902], ["proinflammatory cytokines", "OBSERVATION", 939, 964], ["acute", "OBSERVATION_MODIFIER", 995, 1000], ["respiratory distress", "OBSERVATION", 1001, 1021], ["widespread tissue", "OBSERVATION_MODIFIER", 1054, 1071], ["damage", "OBSERVATION", 1072, 1078], ["multiple", "OBSERVATION_MODIFIER", 1092, 1100], ["organ", "ANATOMY", 1101, 1106], ["failure", "OBSERVATION", 1107, 1114], ["elevated", "OBSERVATION_MODIFIER", 1169, 1177], ["serum cytokine", "OBSERVATION_MODIFIER", 1178, 1192], ["severe", "OBSERVATION_MODIFIER", 1208, 1214], ["complications", "OBSERVATION", 1215, 1228], ["no", "UNCERTAINTY", 1572, 1574]]], ["Speed is a paramount factor and there is an indication that vaccines could be available under emergency use by early 2021.13 As it still requires time, this raises an important question about the urgent need for the development of effective therapies to lower the mortality rate of symptomatic COVID-19 patients.IntroductionSterol regulatory element binding proteins (SREBPs) were well documented as the basic-helix-loop helix-leucine zipper transcription factors that regulate the gene expressions involved in lipid cholesterol biosynthesis.14\u201316 These family of SREBP transcription factors have been reported to regulate the lipid cholesterol and fatty acid gene expressions17 via MAPK activation pathway.18 SREBP transcription factor is a critical regulator of lipid biosynthesis and sterol homeostasis in eukaryotes, where in mammals, SREBPs are highly active in the fed state to promote the expression of cholesterogenic and lipogenic genes involved in fat storage.19 For example, SREBP-2 has been shown to directly activates autophagy-related genes under sterol starvation condition.20,21 Recently, various pathogenic processes have been linked with SREBPs, such as endoplasmic reticulum (ER) stress, inflammation, apoptosis, and autophagy.22 Stiffening of diseased tissue has been linked with the SREBP levels as well.23IntroductionA recently published paper showed that Sestrin1 (SESN1) transcription is regulated by SREBP-2 in cells, demonstrating that SESN1 inhibits cholesterol biosynthesis.24 The results showed a significant reduction in plasma cholesterol levels in cholesterol-fed SESN1+/\u2212 and SESN1\u2212/\u2212 mice but not in control mice (Sesn1+/+), indicating that the SESN1 affects plasma cholesterol in a liver-specific manner via regulation of cholesterol biosynthesis.", [["fat", "ANATOMY", 958, 961], ["endoplasmic reticulum", "ANATOMY", 1172, 1193], ["ER", "ANATOMY", 1195, 1197], ["tissue", "ANATOMY", 1272, 1278], ["cells", "ANATOMY", 1436, 1441], ["plasma", "ANATOMY", 1551, 1557], ["plasma", "ANATOMY", 1693, 1699], ["liver", "ANATOMY", 1717, 1722], ["COVID", "DISEASE", 294, 299], ["cholesterol", "CHEMICAL", 517, 528], ["cholesterol", "CHEMICAL", 633, 644], ["fatty acid", "CHEMICAL", 649, 659], ["inflammation", "DISEASE", 1207, 1219], ["SESN1", "CHEMICAL", 1462, 1467], ["cholesterol", "CHEMICAL", 1477, 1488], ["cholesterol", "CHEMICAL", 1558, 1569], ["cholesterol", "CHEMICAL", 1580, 1591], ["cholesterol", "CHEMICAL", 1700, 1711], ["cholesterol", "CHEMICAL", 1757, 1768], ["leucine", "CHEMICAL", 427, 434], ["cholesterol", "CHEMICAL", 517, 528], ["cholesterol", "CHEMICAL", 633, 644], ["fatty acid", "CHEMICAL", 649, 659], ["sterol", "CHEMICAL", 787, 793], ["sterol", "CHEMICAL", 1061, 1067], ["cholesterol", "CHEMICAL", 1477, 1488], ["cholesterol", "CHEMICAL", 1558, 1569], ["cholesterol", "CHEMICAL", 1580, 1591], ["cholesterol", "CHEMICAL", 1700, 1711], ["cholesterol", "CHEMICAL", 1757, 1768], ["patients", "ORGANISM", 303, 311], ["IntroductionSterol regulatory element binding proteins", "GENE_OR_GENE_PRODUCT", 312, 366], ["SREBPs", "GENE_OR_GENE_PRODUCT", 368, 374], ["lipid", "SIMPLE_CHEMICAL", 511, 516], ["cholesterol", "SIMPLE_CHEMICAL", 517, 528], ["SREBP", "GENE_OR_GENE_PRODUCT", 564, 569], ["lipid", "SIMPLE_CHEMICAL", 627, 632], ["cholesterol", "SIMPLE_CHEMICAL", 633, 644], ["fatty acid", "SIMPLE_CHEMICAL", 649, 659], ["MAPK", "GENE_OR_GENE_PRODUCT", 683, 687], ["SREBP", "GENE_OR_GENE_PRODUCT", 710, 715], ["lipid", "SIMPLE_CHEMICAL", 764, 769], ["sterol", "SIMPLE_CHEMICAL", 787, 793], ["SREBPs", "GENE_OR_GENE_PRODUCT", 839, 845], ["fat", "TISSUE", 958, 961], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 986, 993], ["sterol", "SIMPLE_CHEMICAL", 1061, 1067], ["SREBPs", "GENE_OR_GENE_PRODUCT", 1156, 1162], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 1172, 1193], ["ER", "GENE_OR_GENE_PRODUCT", 1195, 1197], ["tissue", "TISSUE", 1272, 1278], ["SREBP", "GENE_OR_GENE_PRODUCT", 1304, 1309], ["Sestrin1", "GENE_OR_GENE_PRODUCT", 1378, 1386], ["SESN1", "GENE_OR_GENE_PRODUCT", 1388, 1393], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 1425, 1432], ["cells", "CELL", 1436, 1441], ["SESN1", "GENE_OR_GENE_PRODUCT", 1462, 1467], ["cholesterol", "SIMPLE_CHEMICAL", 1477, 1488], ["plasma", "ORGANISM_SUBSTANCE", 1551, 1557], ["cholesterol", "SIMPLE_CHEMICAL", 1558, 1569], ["cholesterol", "SIMPLE_CHEMICAL", 1580, 1591], ["SESN1", "GENE_OR_GENE_PRODUCT", 1596, 1601], ["SESN1\u2212", "GENE_OR_GENE_PRODUCT", 1609, 1615], ["mice", "ORGANISM", 1642, 1646], ["Sesn1", "GENE_OR_GENE_PRODUCT", 1648, 1653], ["SESN1", "GENE_OR_GENE_PRODUCT", 1679, 1684], ["plasma", "ORGANISM_SUBSTANCE", 1693, 1699], ["cholesterol", "SIMPLE_CHEMICAL", 1700, 1711], ["liver", "ORGAN", 1717, 1722], ["cholesterol", "SIMPLE_CHEMICAL", 1757, 1768], ["IntroductionSterol regulatory element binding proteins", "PROTEIN", 312, 366], ["SREBPs", "PROTEIN", 368, 374], ["basic-helix-loop helix-leucine zipper transcription factors", "PROTEIN", 404, 463], ["SREBP transcription factors", "PROTEIN", 564, 591], ["MAPK", "PROTEIN", 683, 687], ["SREBP transcription factor", "PROTEIN", 710, 736], ["SREBPs", "PROTEIN", 839, 845], ["cholesterogenic and lipogenic genes", "DNA", 910, 945], ["SREBP-2", "PROTEIN", 986, 993], ["SREBPs", "PROTEIN", 1156, 1162], ["SREBP", "PROTEIN", 1304, 1309], ["Sestrin1", "PROTEIN", 1378, 1386], ["SESN1", "PROTEIN", 1388, 1393], ["SREBP-2", "PROTEIN", 1425, 1432], ["SESN1", "PROTEIN", 1462, 1467], ["Sesn1", "PROTEIN", 1648, 1653], ["SESN1", "PROTEIN", 1679, 1684], ["patients", "SPECIES", 303, 311], ["mice", "SPECIES", 1618, 1622], ["mice", "SPECIES", 1642, 1646], ["mice", "SPECIES", 1618, 1622], ["mice", "SPECIES", 1642, 1646], ["vaccines", "TREATMENT", 60, 68], ["effective therapies", "TREATMENT", 231, 250], ["symptomatic COVID", "TREATMENT", 282, 299], ["IntroductionSterol regulatory element binding proteins", "TREATMENT", 312, 366], ["loop helix-leucine zipper transcription factors", "TREATMENT", 416, 463], ["lipid cholesterol biosynthesis", "TREATMENT", 511, 541], ["the lipid cholesterol", "TEST", 623, 644], ["fatty acid gene expressions", "PROBLEM", 649, 676], ["lipid biosynthesis", "TREATMENT", 764, 782], ["sterol homeostasis in eukaryotes", "TREATMENT", 787, 819], ["cholesterogenic and lipogenic genes", "PROBLEM", 910, 945], ["SREBP", "TEST", 986, 991], ["various pathogenic processes", "PROBLEM", 1105, 1133], ["endoplasmic reticulum (ER) stress", "PROBLEM", 1172, 1205], ["inflammation", "PROBLEM", 1207, 1219], ["apoptosis", "PROBLEM", 1221, 1230], ["autophagy", "PROBLEM", 1236, 1245], ["diseased tissue", "PROBLEM", 1263, 1278], ["the SREBP levels", "TEST", 1300, 1316], ["Sestrin1 (SESN1) transcription", "TREATMENT", 1378, 1408], ["SREBP", "TEST", 1425, 1430], ["cholesterol biosynthesis", "PROBLEM", 1477, 1501], ["a significant reduction", "PROBLEM", 1524, 1547], ["plasma cholesterol levels", "TEST", 1551, 1576], ["cholesterol", "TEST", 1580, 1591], ["SESN1", "TEST", 1596, 1601], ["SESN1\u2212", "TEST", 1609, 1615], ["Sesn1", "TEST", 1648, 1653], ["plasma cholesterol", "TEST", 1693, 1711], ["cholesterol biosynthesis", "TREATMENT", 1757, 1781], ["sterol homeostasis", "OBSERVATION", 787, 805], ["highly", "OBSERVATION_MODIFIER", 850, 856], ["active", "OBSERVATION", 857, 863], ["lipogenic genes", "OBSERVATION", 930, 945], ["various", "OBSERVATION_MODIFIER", 1105, 1112], ["pathogenic", "OBSERVATION", 1113, 1123], ["endoplasmic reticulum", "OBSERVATION", 1172, 1193], ["inflammation", "OBSERVATION", 1207, 1219], ["Stiffening", "OBSERVATION_MODIFIER", 1249, 1259], ["diseased tissue", "OBSERVATION", 1263, 1278], ["cholesterol biosynthesis", "OBSERVATION", 1477, 1501], ["significant", "OBSERVATION_MODIFIER", 1526, 1537], ["reduction", "OBSERVATION_MODIFIER", 1538, 1547], ["plasma cholesterol", "OBSERVATION", 1551, 1569], ["liver", "ANATOMY", 1717, 1722], ["cholesterol biosynthesis", "OBSERVATION", 1757, 1781]]], ["It is reported that SESN1 activates AMP kinase (AMPK) and inhibits rapamycin complex 1 (mTORC1).25\u201327 The recently published data demonstrated that after cholesterol feeding, SESN1\u2212/\u2212 mouse livers had significantly reduced phosphorylated AMPK and unchanged mTORC1, indicating that SESN1 functions to repress cholesterol biosynthesis via activating AMP kinase pathway.24 However, the exact mechanism of how cholesterol biosynthesis of SREBP-2 and SESN1 is associated with induction of inflammation during infections remain elusive.IntroductionIt is well-understood that cytokines, such as type I interferon (IFN) protects against viruses via suppressive effect on inflammation.", [["livers", "ANATOMY", 190, 196], ["AMP", "CHEMICAL", 36, 39], ["rapamycin", "CHEMICAL", 67, 76], ["cholesterol", "CHEMICAL", 154, 165], ["cholesterol", "CHEMICAL", 308, 319], ["AMP", "CHEMICAL", 348, 351], ["cholesterol", "CHEMICAL", 406, 417], ["inflammation", "DISEASE", 484, 496], ["infections", "DISEASE", 504, 514], ["inflammation", "DISEASE", 663, 675], ["AMP", "CHEMICAL", 36, 39], ["rapamycin", "CHEMICAL", 67, 76], ["cholesterol", "CHEMICAL", 154, 165], ["cholesterol", "CHEMICAL", 308, 319], ["AMP", "CHEMICAL", 348, 351], ["cholesterol", "CHEMICAL", 406, 417], ["SESN1", "GENE_OR_GENE_PRODUCT", 20, 25], ["AMP kinase", "GENE_OR_GENE_PRODUCT", 36, 46], ["AMPK", "GENE_OR_GENE_PRODUCT", 48, 52], ["rapamycin complex 1", "GENE_OR_GENE_PRODUCT", 67, 86], ["mTORC1", "GENE_OR_GENE_PRODUCT", 88, 94], ["cholesterol", "SIMPLE_CHEMICAL", 154, 165], ["SESN1\u2212", "GENE_OR_GENE_PRODUCT", 175, 181], ["mouse", "ORGANISM", 184, 189], ["AMPK", "GENE_OR_GENE_PRODUCT", 238, 242], ["mTORC1", "GENE_OR_GENE_PRODUCT", 257, 263], ["SESN1", "GENE_OR_GENE_PRODUCT", 281, 286], ["cholesterol", "SIMPLE_CHEMICAL", 308, 319], ["AMP kinase", "GENE_OR_GENE_PRODUCT", 348, 358], ["cholesterol", "SIMPLE_CHEMICAL", 406, 417], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 434, 441], ["SESN1", "GENE_OR_GENE_PRODUCT", 446, 451], ["type I interferon", "GENE_OR_GENE_PRODUCT", 588, 605], ["IFN", "GENE_OR_GENE_PRODUCT", 607, 610], ["SESN1", "PROTEIN", 20, 25], ["AMP kinase", "PROTEIN", 36, 46], ["AMPK", "PROTEIN", 48, 52], ["rapamycin complex 1", "PROTEIN", 67, 86], ["mTORC1", "PROTEIN", 88, 94], ["phosphorylated AMPK", "PROTEIN", 223, 242], ["mTORC1", "PROTEIN", 257, 263], ["SESN1", "PROTEIN", 281, 286], ["AMP kinase", "PROTEIN", 348, 358], ["SREBP-2", "PROTEIN", 434, 441], ["SESN1", "PROTEIN", 446, 451], ["cytokines", "PROTEIN", 569, 578], ["type I interferon", "PROTEIN", 588, 605], ["IFN", "PROTEIN", 607, 610], ["mouse", "SPECIES", 184, 189], ["mouse", "SPECIES", 184, 189], ["AMP kinase", "TEST", 36, 46], ["AMPK", "TEST", 48, 52], ["inhibits rapamycin complex", "TREATMENT", 58, 84], ["cholesterol feeding", "TEST", 154, 173], ["significantly reduced phosphorylated AMPK", "PROBLEM", 201, 242], ["SESN1 functions", "PROBLEM", 281, 296], ["cholesterol biosynthesis", "TREATMENT", 308, 332], ["activating AMP kinase pathway", "TREATMENT", 337, 366], ["SREBP", "TEST", 434, 439], ["SESN1", "TREATMENT", 446, 451], ["inflammation during infections", "PROBLEM", 484, 514], ["cytokines", "PROBLEM", 569, 578], ["type I interferon (IFN)", "TREATMENT", 588, 611], ["viruses", "PROBLEM", 629, 636], ["inflammation", "PROBLEM", 663, 675], ["livers", "ANATOMY", 190, 196], ["phosphorylated AMPK", "OBSERVATION", 223, 242], ["inflammation", "OBSERVATION", 484, 496], ["infections", "OBSERVATION", 504, 514], ["inflammation", "OBSERVATION", 663, 675]]], ["It was reported that hydroxylated form of cholesterol is a critical mediator in the negative-feedback pathway of IFN signaling on IL-1 family cytokine production and inflammasome activity.28 In addition, growing evidences show that hydroxycholesterols play an important role as regulators of immune function, demonstrating their roles are closely related to alteration of cholesterol content in plasma membrane that can have antiviral, anti-inflammatory, and proinflammatory effects.29 Hydroxycholesterol functions as an immune cell guidance signal by engaging the EBI2 receptor, a member of the G protein-coupled receptor, that it is required for innate and adaptive immunity.", [["plasma membrane", "ANATOMY", 395, 410], ["immune cell", "ANATOMY", 521, 532], ["cholesterol", "CHEMICAL", 42, 53], ["hydroxycholesterols", "CHEMICAL", 232, 251], ["cholesterol", "CHEMICAL", 372, 383], ["Hydroxycholesterol", "CHEMICAL", 486, 504], ["cholesterol", "CHEMICAL", 42, 53], ["hydroxycholesterols", "CHEMICAL", 232, 251], ["cholesterol", "CHEMICAL", 372, 383], ["Hydroxycholesterol", "CHEMICAL", 486, 504], ["cholesterol", "SIMPLE_CHEMICAL", 42, 53], ["IFN", "GENE_OR_GENE_PRODUCT", 113, 116], ["IL-1", "GENE_OR_GENE_PRODUCT", 130, 134], ["hydroxycholesterols", "SIMPLE_CHEMICAL", 232, 251], ["cholesterol", "SIMPLE_CHEMICAL", 372, 383], ["plasma membrane", "CELLULAR_COMPONENT", 395, 410], ["Hydroxycholesterol", "SIMPLE_CHEMICAL", 486, 504], ["immune cell", "CELL", 521, 532], ["EBI2 receptor", "GENE_OR_GENE_PRODUCT", 565, 578], ["G protein-coupled receptor", "GENE_OR_GENE_PRODUCT", 596, 622], ["IFN", "PROTEIN", 113, 116], ["cytokine", "PROTEIN", 142, 150], ["EBI2 receptor", "PROTEIN", 565, 578], ["G protein-coupled receptor", "PROTEIN", 596, 622], ["IFN signaling", "PROBLEM", 113, 126], ["inflammasome activity", "PROBLEM", 166, 187], ["hydroxycholesterols", "TREATMENT", 232, 251], ["immune function", "TEST", 292, 307], ["alteration of cholesterol content in plasma membrane", "PROBLEM", 358, 410], ["antiviral", "TREATMENT", 425, 434], ["anti-inflammatory", "TREATMENT", 436, 453], ["proinflammatory effects", "PROBLEM", 459, 482], ["Hydroxycholesterol functions", "TREATMENT", 486, 514], ["the G protein-coupled receptor", "TREATMENT", 592, 622], ["innate and adaptive immunity", "TREATMENT", 648, 676], ["inflammasome activity", "OBSERVATION", 166, 187], ["cholesterol content", "OBSERVATION", 372, 391]]], ["Specifically, cytokine production such as IFN induced by viral and bacterial infection along with toll-like receptor (TLR) signaling induces active nuclear translocation of hydrocycholesterol from ER, thus secretion of IL-6, IL-8, and M-CSF cytokines.", [["nuclear", "ANATOMY", 148, 155], ["ER", "ANATOMY", 197, 199], ["infection", "DISEASE", 77, 86], ["hydrocycholesterol", "CHEMICAL", 173, 191], ["hydrocycholesterol", "CHEMICAL", 173, 191], ["IFN", "GENE_OR_GENE_PRODUCT", 42, 45], ["toll-like receptor", "GENE_OR_GENE_PRODUCT", 98, 116], ["TLR", "GENE_OR_GENE_PRODUCT", 118, 121], ["nuclear", "CELLULAR_COMPONENT", 148, 155], ["hydrocycholesterol", "SIMPLE_CHEMICAL", 173, 191], ["ER", "GENE_OR_GENE_PRODUCT", 197, 199], ["IL-6", "GENE_OR_GENE_PRODUCT", 219, 223], ["IL-8", "GENE_OR_GENE_PRODUCT", 225, 229], ["M-CSF", "GENE_OR_GENE_PRODUCT", 235, 240], ["cytokine", "PROTEIN", 14, 22], ["IFN", "PROTEIN", 42, 45], ["toll-like receptor", "PROTEIN", 98, 116], ["TLR", "PROTEIN", 118, 121], ["hydrocycholesterol", "PROTEIN", 173, 191], ["ER", "PROTEIN", 197, 199], ["IL-6", "PROTEIN", 219, 223], ["IL-8", "PROTEIN", 225, 229], ["CSF cytokines", "PROTEIN", 237, 250], ["cytokine production", "PROBLEM", 14, 33], ["IFN", "PROBLEM", 42, 45], ["viral and bacterial infection", "PROBLEM", 57, 86], ["toll-like receptor (TLR)", "TREATMENT", 98, 122], ["active nuclear translocation of hydrocycholesterol", "PROBLEM", 141, 191], ["secretion of IL", "TEST", 206, 221], ["IL", "TEST", 225, 227], ["CSF cytokines", "TEST", 237, 250], ["cytokine production", "OBSERVATION", 14, 33], ["bacterial", "OBSERVATION_MODIFIER", 67, 76], ["infection", "OBSERVATION", 77, 86], ["active", "OBSERVATION_MODIFIER", 141, 147], ["nuclear translocation", "OBSERVATION", 148, 169]]], ["This is consistent with observations that cholesterol consumption leads to increase in inflammation and thus activates SREBP-2.", [["cholesterol", "CHEMICAL", 42, 53], ["inflammation", "DISEASE", 87, 99], ["cholesterol", "CHEMICAL", 42, 53], ["cholesterol", "SIMPLE_CHEMICAL", 42, 53], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 119, 126], ["SREBP-2", "PROTEIN", 119, 126], ["cholesterol consumption", "PROBLEM", 42, 65], ["inflammation", "PROBLEM", 87, 99], ["SREBP", "TEST", 119, 124], ["consistent with", "UNCERTAINTY", 8, 23], ["increase", "OBSERVATION_MODIFIER", 75, 83], ["inflammation", "OBSERVATION", 87, 99]]], ["Although the SREBP-2 is known to be a transcription factor for lipid synthesis, we found that the level of cholesterol maintained in a low level in COVID-19 patients, and even though the expression level of SREBP-2 is increased in plasma of COVID-19 patients.IntroductionA recent report has shown evidence of biological crosstalk between SREBP-2 and NF-\u03baB.30 It is known that that the cells secrete lipid and cholesterol to inactivate viruses.31\u201334 Recently, it has been reported that the activity of SREBP-2 increases as the concentration of cholesterol in the cell decreases.33,35 Based on these findings, we hypothesized that the activation of cholesterol biosynthesis is as a result of decrease in cellular cholesterol level and subsequent activation of SREBP-2.", [["plasma", "ANATOMY", 231, 237], ["cells", "ANATOMY", 385, 390], ["cell", "ANATOMY", 562, 566], ["cellular", "ANATOMY", 702, 710], ["cholesterol", "CHEMICAL", 107, 118], ["cholesterol", "CHEMICAL", 409, 420], ["cholesterol", "CHEMICAL", 543, 554], ["cholesterol", "CHEMICAL", 647, 658], ["cholesterol", "CHEMICAL", 711, 722], ["cholesterol", "CHEMICAL", 107, 118], ["cholesterol", "CHEMICAL", 409, 420], ["cholesterol", "CHEMICAL", 543, 554], ["cholesterol", "CHEMICAL", 647, 658], ["cholesterol", "CHEMICAL", 711, 722], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 13, 20], ["lipid", "SIMPLE_CHEMICAL", 63, 68], ["cholesterol", "SIMPLE_CHEMICAL", 107, 118], ["patients", "ORGANISM", 157, 165], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 207, 214], ["plasma", "ORGANISM_SUBSTANCE", 231, 237], ["patients", "ORGANISM", 250, 258], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 338, 345], ["NF-\u03ba", "GENE_OR_GENE_PRODUCT", 350, 354], ["cells", "CELL", 385, 390], ["lipid", "SIMPLE_CHEMICAL", 399, 404], ["cholesterol", "SIMPLE_CHEMICAL", 409, 420], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 501, 508], ["cholesterol", "SIMPLE_CHEMICAL", 543, 554], ["cell", "CELL", 562, 566], ["cholesterol", "SIMPLE_CHEMICAL", 647, 658], ["cellular", "CELL", 702, 710], ["cholesterol", "SIMPLE_CHEMICAL", 711, 722], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 758, 765], ["SREBP-2", "PROTEIN", 13, 20], ["transcription factor", "PROTEIN", 38, 58], ["SREBP-2", "PROTEIN", 207, 214], ["SREBP", "PROTEIN", 338, 343], ["NF-\u03baB.30", "PROTEIN", 350, 358], ["SREBP-2", "PROTEIN", 501, 508], ["SREBP-2", "PROTEIN", 758, 765], ["patients", "SPECIES", 157, 165], ["patients", "SPECIES", 250, 258], ["the SREBP", "TEST", 9, 18], ["lipid synthesis", "PROBLEM", 63, 78], ["cholesterol", "TEST", 107, 118], ["COVID", "TEST", 148, 153], ["SREBP", "TEST", 207, 212], ["COVID", "TEST", 241, 246], ["SREBP", "TEST", 338, 343], ["NF", "TEST", 350, 352], ["viruses", "PROBLEM", 435, 442], ["SREBP", "TEST", 501, 506], ["cholesterol biosynthesis", "PROBLEM", 647, 671], ["decrease in cellular cholesterol level", "PROBLEM", 690, 728], ["SREBP", "TEST", 758, 763], ["increased", "OBSERVATION_MODIFIER", 218, 227], ["cell decreases", "OBSERVATION", 562, 576], ["decrease", "OBSERVATION_MODIFIER", 690, 698], ["cellular cholesterol", "OBSERVATION", 702, 722]]], ["It is reported that SREBP-2-mediated biosynthesis of cholesterol is involved in the exocytosis process of SARS-CoV2, which explains its role in virus budding and envelop.31IntroductionHerein, we propose that the activated SREBP-2 and NF-\u03baB can cause vascular and organ damage, and believe that our study has proven its potential as a therapeutic target for the treatment of viral infections.", [["vascular", "ANATOMY", 250, 258], ["organ", "ANATOMY", 263, 268], ["cholesterol", "CHEMICAL", 53, 64], ["SARS", "DISEASE", 106, 110], ["vascular and organ damage", "DISEASE", 250, 275], ["viral infections", "DISEASE", 374, 390], ["cholesterol", "CHEMICAL", 53, 64], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 20, 27], ["cholesterol", "SIMPLE_CHEMICAL", 53, 64], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 106, 115], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 222, 229], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 234, 239], ["vascular", "MULTI-TISSUE_STRUCTURE", 250, 258], ["organ", "ORGAN", 263, 268], ["SREBP-2", "PROTEIN", 20, 27], ["SREBP-2", "PROTEIN", 222, 229], ["NF-\u03baB", "PROTEIN", 234, 239], ["SREBP", "TEST", 20, 25], ["SARS", "PROBLEM", 106, 110], ["the activated SREBP", "TEST", 208, 227], ["vascular and organ damage", "PROBLEM", 250, 275], ["our study", "TEST", 294, 303], ["viral infections", "PROBLEM", 374, 390], ["SARS", "OBSERVATION", 106, 110], ["virus", "OBSERVATION", 144, 149], ["vascular", "ANATOMY", 250, 258], ["organ", "ANATOMY", 263, 268], ["damage", "OBSERVATION", 269, 275], ["viral", "OBSERVATION_MODIFIER", 374, 379], ["infections", "OBSERVATION", 380, 390]]], ["We hypothesized that in infectious diseases, the role of mature SREBP-2 as an inflammatory transcription factor and its role as a diagnostic marker of SREBP-2 C-term.", [["infectious diseases", "DISEASE", 24, 43], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 64, 71], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 151, 158], ["SREBP-2", "PROTEIN", 64, 71], ["inflammatory transcription factor", "PROTEIN", 78, 111], ["SREBP", "PROTEIN", 151, 156], ["an inflammatory transcription factor", "PROBLEM", 75, 111], ["SREBP", "TEST", 151, 156], ["infectious", "OBSERVATION_MODIFIER", 24, 34], ["inflammatory", "OBSERVATION_MODIFIER", 78, 90]]], ["In this study, we traced SREBP-2 in COVID-19 patients and demonstrated for the first time that C-term fragment of SREBP-2 is found in the blood of COVID-19 patients.", [["blood", "ANATOMY", 138, 143], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 25, 32], ["COVID-19", "CELL", 36, 44], ["patients", "ORGANISM", 45, 53], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 114, 121], ["blood", "ORGANISM_SUBSTANCE", 138, 143], ["patients", "ORGANISM", 156, 164], ["SREBP-2", "PROTEIN", 25, 32], ["C-term fragment", "DNA", 95, 110], ["SREBP-2", "PROTEIN", 114, 121], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 156, 164], ["this study", "TEST", 3, 13], ["SREBP", "TEST", 25, 30], ["C-term fragment of SREBP", "PROBLEM", 95, 119], ["COVID", "TEST", 147, 152]]], ["Upon SARS-CoV-2 viral infection, SREBP-2 C-term fragment serves as an endotoxin, causing cytokine storm in COVID-19 septic patients.", [["infection", "DISEASE", 22, 31], ["septic", "DISEASE", 116, 122], ["SARS-CoV-2 viral", "ORGANISM", 5, 21], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 33, 40], ["endotoxin", "GENE_OR_GENE_PRODUCT", 70, 79], ["patients", "ORGANISM", 123, 131], ["SREBP-2 C-term fragment", "DNA", 33, 56], ["endotoxin", "PROTEIN", 70, 79], ["cytokine", "PROTEIN", 89, 97], ["patients", "SPECIES", 123, 131], ["SARS", "PROBLEM", 5, 9], ["CoV", "TEST", 10, 13], ["2 viral infection", "PROBLEM", 14, 31], ["SREBP", "TEST", 33, 38], ["2 C-term fragment serves", "TREATMENT", 39, 63], ["an endotoxin", "TEST", 67, 79], ["cytokine storm", "PROBLEM", 89, 103], ["COVID", "TEST", 107, 112], ["septic patients", "PROBLEM", 116, 131], ["viral", "OBSERVATION_MODIFIER", 16, 21], ["infection", "OBSERVATION", 22, 31], ["cytokine storm", "OBSERVATION", 89, 103], ["septic", "OBSERVATION", 116, 122]]], ["We monitored the level of SREBP-2 C-term fragment in these patients and identified the increase correlated with inflammatory cytokine release and vascular disruption.", [["vascular", "ANATOMY", 146, 154], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 26, 33], ["patients", "ORGANISM", 59, 67], ["vascular", "MULTI-TISSUE_STRUCTURE", 146, 154], ["SREBP-2 C-term fragment", "DNA", 26, 49], ["cytokine", "PROTEIN", 125, 133], ["patients", "SPECIES", 59, 67], ["SREBP", "TEST", 26, 31], ["inflammatory cytokine release", "PROBLEM", 112, 141], ["vascular disruption", "PROBLEM", 146, 165], ["inflammatory cytokine", "OBSERVATION", 112, 133], ["vascular", "ANATOMY", 146, 154], ["disruption", "OBSERVATION", 155, 165]]], ["Knockdown of the SREBP-2 rescued LPS-induced inflammatory cytokine levels.", [["LPS", "CHEMICAL", 33, 36], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 17, 24], ["LPS", "SIMPLE_CHEMICAL", 33, 36], ["SREBP-2", "PROTEIN", 17, 24], ["inflammatory cytokine", "PROTEIN", 45, 66], ["the SREBP", "TEST", 13, 22], ["LPS", "TEST", 33, 36], ["inflammatory cytokine levels", "PROBLEM", 45, 73], ["inflammatory cytokine levels", "OBSERVATION", 45, 73]]], ["We showed that an intravenous administration of short hairpin SREBP-2 (shSREBP2) alleviate lung damage and improve survival in a sepsis model.", [["intravenous", "ANATOMY", 18, 29], ["lung", "ANATOMY", 91, 95], ["lung damage", "DISEASE", 91, 102], ["sepsis", "DISEASE", 129, 135], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 18, 29], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 62, 69], ["shSREBP2", "GENE_OR_GENE_PRODUCT", 71, 79], ["lung", "ORGAN", 91, 95], ["short hairpin SREBP-2", "PROTEIN", 48, 69], ["shSREBP2", "PROTEIN", 71, 79], ["an intravenous administration", "TREATMENT", 15, 44], ["short hairpin SREBP", "TREATMENT", 48, 67], ["lung damage", "PROBLEM", 91, 102], ["a sepsis model", "PROBLEM", 127, 141], ["lung", "ANATOMY", 91, 95], ["damage", "OBSERVATION", 96, 102], ["sepsis model", "OBSERVATION", 129, 141]]], ["This is the first evidence that show secretion of SREBP-2 C-term in severe COVID-19 patients for the first time and propose as a biomarker for determination of the severity of the COVID-19.", [["SREBP-2", "GENE_OR_GENE_PRODUCT", 50, 57], ["patients", "ORGANISM", 84, 92], ["SREBP", "PROTEIN", 50, 55], ["patients", "SPECIES", 84, 92], ["SREBP", "TEST", 50, 55], ["a biomarker", "TEST", 127, 138], ["the COVID", "TEST", 176, 185]]], ["It is anticipated that targeting ubiquitously expressed transcription factors, SREBP-2 and NF-\u03baB may hamper and slow down the progression of the symptom and reduce the severity of the disease.", [["SREBP-2", "GENE_OR_GENE_PRODUCT", 79, 86], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 91, 96], ["transcription factors", "PROTEIN", 56, 77], ["SREBP-2", "PROTEIN", 79, 86], ["NF-\u03baB", "PROTEIN", 91, 96], ["SREBP", "TEST", 79, 84], ["the symptom", "PROBLEM", 141, 152], ["the disease", "PROBLEM", 180, 191], ["disease", "OBSERVATION", 184, 191]]], ["It is of vital importance to suppress the expression and secretion cytokines in severe COVID-19 patients.9 Antiviral drug such as remdesivir do not improve mortality in severe COVID-19, but it has been reported that anti-inflammatory drug such as dexamethasone ameliorates mortality.36,37 Steroid-based drugs have shown improvement in the mortality rate of COVID-19 severe patients, therefore regulation of uncontrolled inflammatory responses is a promising treatment strategy.", [["COVID", "DISEASE", 87, 92], ["remdesivir", "CHEMICAL", 130, 140], ["dexamethasone", "CHEMICAL", 247, 260], ["remdesivir", "CHEMICAL", 130, 140], ["dexamethasone", "CHEMICAL", 247, 260], ["Steroid", "CHEMICAL", 289, 296], ["patients", "ORGANISM", 96, 104], ["remdesivir", "SIMPLE_CHEMICAL", 130, 140], ["dexamethasone", "SIMPLE_CHEMICAL", 247, 260], ["Steroid", "SIMPLE_CHEMICAL", 289, 296], ["patients", "ORGANISM", 373, 381], ["secretion cytokines", "PROTEIN", 57, 76], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 373, 381], ["secretion cytokines", "TEST", 57, 76], ["severe COVID", "PROBLEM", 80, 92], ["Antiviral drug", "TREATMENT", 107, 121], ["remdesivir", "TREATMENT", 130, 140], ["severe COVID", "PROBLEM", 169, 181], ["anti-inflammatory drug", "TREATMENT", 216, 238], ["dexamethasone ameliorates mortality", "TREATMENT", 247, 282], ["Steroid-based drugs", "TREATMENT", 289, 308], ["COVID", "TEST", 357, 362], ["uncontrolled inflammatory responses", "PROBLEM", 407, 442], ["a promising treatment strategy", "TREATMENT", 446, 476], ["anti-inflammatory drug", "OBSERVATION", 216, 238], ["improvement", "OBSERVATION_MODIFIER", 320, 331], ["uncontrolled", "OBSERVATION_MODIFIER", 407, 419], ["inflammatory", "OBSERVATION", 420, 432]]], ["These finding indicate targeting SREBP-2 C-term fragment as a potential therapeutic strategy for SARS-CoV-2 that could play as a key factor for the treatment of severe COVID-19 patients with sepsis.SREBP-2 was highly activated in COVID-19 patients\u2019 PBMCs and affected subsequent cytotoxic effects on PBMCs ::: ResultsIn the blood of COVID-19 patients, the levels of total cholesterol (Ch), high-density lipoprotein (HDL)-Ch, and low-density lipoprotein (LDL)-Ch were lower compared to normal case, and the level was lower in intensive care unit (ICU) patient than nonICU patients (Supplementary Table S1).", [["COVID-19", "ANATOMY", 230, 238], ["PBMCs", "ANATOMY", 249, 254], ["PBMCs", "ANATOMY", 300, 305], ["blood", "ANATOMY", 324, 329], ["SARS", "DISEASE", 97, 101], ["COVID", "DISEASE", 168, 173], ["sepsis", "DISEASE", 191, 197], ["cholesterol", "CHEMICAL", 372, 383], ["Ch", "CHEMICAL", 385, 387], ["cholesterol", "CHEMICAL", 372, 383], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 33, 40], ["CoV-2", "ORGANISM", 102, 107], ["patients", "ORGANISM", 177, 185], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 198, 205], ["COVID-19", "CELL", 230, 238], ["patients", "ORGANISM", 239, 247], ["PBMCs", "CELL", 249, 254], ["PBMCs", "CELL", 300, 305], ["blood", "ORGANISM_SUBSTANCE", 324, 329], ["patients", "ORGANISM", 342, 350], ["cholesterol", "SIMPLE_CHEMICAL", 372, 383], ["Ch", "SIMPLE_CHEMICAL", 385, 387], ["high-density lipoprotein (HDL)-Ch", "SIMPLE_CHEMICAL", 390, 423], ["low-density lipoprotein (LDL)-Ch", "SIMPLE_CHEMICAL", 429, 461], ["patient", "ORGANISM", 551, 558], ["patients", "ORGANISM", 571, 579], ["SREBP-2 C-term fragment", "DNA", 33, 56], ["SREBP-2", "PROTEIN", 198, 205], ["PBMCs", "CELL_TYPE", 249, 254], ["PBMCs", "CELL_TYPE", 300, 305], ["high-density lipoprotein (HDL)-Ch", "PROTEIN", 390, 423], ["LDL", "PROTEIN", 454, 457], ["patients", "SPECIES", 177, 185], ["patients", "SPECIES", 239, 247], ["patients", "SPECIES", 342, 350], ["patient", "SPECIES", 551, 558], ["patients", "SPECIES", 571, 579], ["SARS-CoV", "SPECIES", 97, 105], ["SREBP", "TEST", 33, 38], ["2 C-term fragment", "PROBLEM", 39, 56], ["SARS", "PROBLEM", 97, 101], ["severe COVID", "PROBLEM", 161, 173], ["sepsis", "PROBLEM", 191, 197], ["SREBP", "TEST", 198, 203], ["COVID", "TEST", 230, 235], ["PBMCs", "PROBLEM", 249, 254], ["affected subsequent cytotoxic effects", "PROBLEM", 259, 296], ["COVID", "TEST", 333, 338], ["the levels", "TEST", 352, 362], ["total cholesterol", "TEST", 366, 383], ["high-density lipoprotein", "TEST", 390, 414], ["HDL", "TEST", 416, 419], ["LDL", "TEST", 454, 457], ["2 C-term fragment", "OBSERVATION_MODIFIER", 39, 56], ["sepsis", "OBSERVATION", 191, 197], ["density lipoprotein", "OBSERVATION", 433, 452]]], ["There were no notable comorbidities in each group.", [["notable comorbidities in each group", "PROBLEM", 14, 49], ["no", "UNCERTAINTY", 11, 13], ["notable", "OBSERVATION_MODIFIER", 14, 21], ["comorbidities", "OBSERVATION", 22, 35]]], ["According to the analysis, the SREBP-2 activity was increased as the severity of COVID-19 was increased from nonICU to ICU (Fig. 1a), which is inverse correlation with the trend of cholesterol level (Supplementary Table S1).", [["COVID-19", "CHEMICAL", 81, 89], ["cholesterol", "CHEMICAL", 181, 192], ["COVID-19", "CHEMICAL", 81, 89], ["cholesterol", "CHEMICAL", 181, 192], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 31, 38], ["cholesterol", "SIMPLE_CHEMICAL", 181, 192], ["SREBP", "PROTEIN", 31, 36], ["the analysis", "TEST", 13, 25], ["the SREBP", "TEST", 27, 36], ["COVID", "TEST", 81, 86]]], ["The activation level of SREBP-2 was higher in deceased patients than survival case (Fig. 1b), suggesting the SREBP-2 as an indicator for severity of COVID-19.", [["COVID-19", "CHEMICAL", 149, 157], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 24, 31], ["patients", "ORGANISM", 55, 63], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 109, 116], ["SREBP-2", "PROTEIN", 24, 31], ["SREBP-2", "PROTEIN", 109, 116], ["patients", "SPECIES", 55, 63], ["SREBP", "TEST", 24, 29], ["the SREBP", "TEST", 105, 114], ["COVID", "TEST", 149, 154]]], ["Furthermore, nuclear factor (NF)-\u03baB, which is known as a crosstalk molecule of SREBP-2,30 was exhibited similar increasing trend as the severity of COVID-19 increases (Fig. 1c, d).", [["COVID-19", "CHEMICAL", 148, 156], ["nuclear factor (NF)-\u03baB", "GENE_OR_GENE_PRODUCT", 13, 35], ["SREBP-2,30", "GENE_OR_GENE_PRODUCT", 79, 89], ["nuclear factor (NF)-\u03baB", "PROTEIN", 13, 35], ["SREBP", "PROTEIN", 79, 84], ["nuclear factor", "TEST", 13, 27], ["SREBP", "TEST", 79, 84], ["COVID", "TEST", 148, 153], ["increasing", "OBSERVATION_MODIFIER", 112, 122], ["trend", "OBSERVATION_MODIFIER", 123, 128]]], ["Production of inflammatory cytokines such as interleukin (IL)-1\u03b2 and tumor necrosis factor (TNF)-\u03b1 by SREBP-2 or NF-\u03baB were also increased as the severity of COVID-19 increases (Fig. 1e, f).", [["necrosis", "DISEASE", 75, 83], ["COVID-19", "CHEMICAL", 158, 166], ["interleukin (IL)-1\u03b2", "GENE_OR_GENE_PRODUCT", 45, 64], ["tumor necrosis factor (TNF)-\u03b1", "GENE_OR_GENE_PRODUCT", 69, 98], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 102, 109], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 113, 118], ["inflammatory cytokines", "PROTEIN", 14, 36], ["interleukin (IL)-1\u03b2", "PROTEIN", 45, 64], ["tumor necrosis factor (TNF)-\u03b1", "PROTEIN", 69, 98], ["SREBP-2", "PROTEIN", 102, 109], ["NF-\u03baB", "PROTEIN", 113, 118], ["inflammatory cytokines", "PROBLEM", 14, 36], ["interleukin (IL)", "TEST", 45, 61], ["tumor necrosis factor", "PROBLEM", 69, 90], ["TNF", "TEST", 92, 95], ["SREBP", "TEST", 102, 107], ["NF", "TEST", 113, 115], ["COVID", "TEST", 158, 163], ["inflammatory cytokines", "OBSERVATION", 14, 36], ["tumor", "OBSERVATION_MODIFIER", 69, 74], ["necrosis", "OBSERVATION", 75, 83]]], ["To determine whether SREBP-2 activation is as a direct cause of SARS-CoV-2 or SARS-CoV-2 viral proteins, we examined activation of SREBP-2 by treating recombinant SARS-CoV-2 spike RBD protein to high ACE2-expressing cells, HUVECs (Supplementary Fig. 1).", [["cells", "ANATOMY", 216, 221], ["HUVECs", "ANATOMY", 223, 229], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 21, 28], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 64, 74], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 78, 88], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 131, 138], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 163, 173], ["ACE2", "GENE_OR_GENE_PRODUCT", 200, 204], ["cells", "CELL", 216, 221], ["HUVECs", "CELL", 223, 229], ["SREBP-2", "PROTEIN", 21, 28], ["SARS-CoV-2 or SARS-CoV-2 viral proteins", "PROTEIN", 64, 103], ["SREBP-2", "PROTEIN", 131, 138], ["recombinant SARS-CoV-2 spike RBD protein", "PROTEIN", 151, 191], ["ACE2", "PROTEIN", 200, 204], ["expressing cells", "CELL_TYPE", 205, 221], ["HUVECs", "CELL_LINE", 223, 229], ["SREBP", "TEST", 21, 26], ["SARS", "PROBLEM", 64, 68], ["CoV", "TEST", 69, 72], ["SARS", "PROBLEM", 78, 82], ["CoV", "TEST", 83, 86], ["2 viral proteins", "PROBLEM", 87, 103], ["SREBP", "TEST", 131, 136], ["recombinant SARS", "TEST", 151, 167], ["CoV", "TEST", 168, 171], ["RBD protein", "TEST", 180, 191], ["high ACE2", "TEST", 195, 204], ["HUVECs (Supplementary Fig", "TREATMENT", 223, 248]]], ["The results showed no significant difference in the SREBP-2 level.", [["SREBP-2", "GENE_OR_GENE_PRODUCT", 52, 59], ["SREBP", "PROTEIN", 52, 57], ["significant difference in the SREBP", "PROBLEM", 22, 57], ["no", "UNCERTAINTY", 19, 21], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["difference", "OBSERVATION", 34, 44]]], ["According to qRT-PCR, SREBF2 mRNA as increased in COVID-19 patients in a severity-dependent manner, and the level of sestrin 1 (SESN1) and proprotein convertase subtilisin/kexin type 9 (PCSK9), which are known to regulate the lipid biosynthesis, also showed similar increasing trend as the severity of COVID-19 increases (Supplementary Fig. 2).", [["COVID-19", "CHEMICAL", 302, 310], ["SREBF2", "GENE_OR_GENE_PRODUCT", 22, 28], ["patients", "ORGANISM", 59, 67], ["sestrin 1", "GENE_OR_GENE_PRODUCT", 117, 126], ["SESN1", "GENE_OR_GENE_PRODUCT", 128, 133], ["proprotein convertase subtilisin/kexin type 9", "GENE_OR_GENE_PRODUCT", 139, 184], ["PCSK9", "GENE_OR_GENE_PRODUCT", 186, 191], ["lipid", "SIMPLE_CHEMICAL", 226, 231], ["SREBF2 mRNA", "RNA", 22, 33], ["sestrin 1", "PROTEIN", 117, 126], ["SESN1", "PROTEIN", 128, 133], ["proprotein convertase subtilisin/kexin type 9", "PROTEIN", 139, 184], ["PCSK9", "PROTEIN", 186, 191], ["patients", "SPECIES", 59, 67], ["qRT", "TEST", 13, 16], ["PCR", "TEST", 17, 20], ["SREBF2 mRNA", "TEST", 22, 33], ["COVID", "TEST", 50, 55], ["sestrin", "TEST", 117, 124], ["proprotein convertase subtilisin/kexin type", "TREATMENT", 139, 182], ["the lipid biosynthesis", "TEST", 222, 244], ["COVID", "TEST", 302, 307], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["similar", "OBSERVATION_MODIFIER", 258, 265], ["increasing", "OBSERVATION_MODIFIER", 266, 276], ["trend", "OBSERVATION_MODIFIER", 277, 282]]], ["On the other hand, the mRNA levels of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), an enzyme acting in the upstream of cholesterol synthesis,38 and low-density lipoprotein receptor (LDLR) were not changed irrespective of the severity of COVID-19 (Supplementary Fig. 2).", [["3-hydroxy-3-methylglutaryl-CoA", "CHEMICAL", 38, 68], ["cholesterol", "CHEMICAL", 124, 135], ["3-hydroxy-3-methylglutaryl-CoA", "CHEMICAL", 38, 68], ["cholesterol", "CHEMICAL", 124, 135], ["COVID-19", "CHEMICAL", 242, 250], ["3-hydroxy-3-methylglutaryl-CoA reductase", "GENE_OR_GENE_PRODUCT", 38, 78], ["HMGCR", "GENE_OR_GENE_PRODUCT", 80, 85], ["cholesterol", "SIMPLE_CHEMICAL", 124, 135], ["low-density lipoprotein receptor", "GENE_OR_GENE_PRODUCT", 153, 185], ["LDLR", "GENE_OR_GENE_PRODUCT", 187, 191], ["CoA reductase", "PROTEIN", 65, 78], ["HMGCR", "PROTEIN", 80, 85], ["low-density lipoprotein receptor", "PROTEIN", 153, 185], ["LDLR", "PROTEIN", 187, 191], ["the mRNA levels", "TEST", 19, 34], ["hydroxy", "TEST", 40, 47], ["CoA reductase", "TEST", 65, 78], ["HMGCR", "TEST", 80, 85], ["an enzyme", "TEST", 88, 97], ["cholesterol synthesis", "TEST", 124, 145], ["COVID", "TEST", 242, 247], ["CoA", "ANATOMY", 65, 68]]], ["These results suggest that COVID-19 infection inhibits the direct synthesis pathway of cholesterol by SREBP-2, while increasing its activity as an inflammatory transcription factor.", [["COVID-19", "CHEMICAL", 27, 35], ["infection", "DISEASE", 36, 45], ["cholesterol", "CHEMICAL", 87, 98], ["COVID-19", "CHEMICAL", 27, 35], ["cholesterol", "CHEMICAL", 87, 98], ["COVID-19", "ORGANISM", 27, 35], ["cholesterol", "SIMPLE_CHEMICAL", 87, 98], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 102, 109], ["SREBP-2", "PROTEIN", 102, 109], ["inflammatory transcription factor", "PROTEIN", 147, 180], ["COVID-19 infection", "PROBLEM", 27, 45], ["SREBP", "TEST", 102, 107], ["an inflammatory transcription factor", "PROBLEM", 144, 180], ["inflammatory", "OBSERVATION_MODIFIER", 147, 159]]], ["When the COVID-19 patients\u2019 PBMCs were cultured in vitro, the viability of PBMCs isolated from the blood of COVID-19 ICU and acute respiratory distress syndrome (ARDS) patients was decreased rapidly as time compared to normal case (Fig. 1g).", [["PBMCs", "ANATOMY", 28, 33], ["PBMCs", "ANATOMY", 75, 80], ["blood", "ANATOMY", 99, 104], ["acute respiratory distress syndrome", "DISEASE", 125, 160], ["ARDS", "DISEASE", 162, 166], ["patients", "ORGANISM", 18, 26], ["PBMCs", "CELL", 28, 33], ["PBMCs", "CELL", 75, 80], ["blood", "ORGANISM_SUBSTANCE", 99, 104], ["patients", "ORGANISM", 168, 176], ["PBMCs", "CELL_TYPE", 28, 33], ["PBMCs", "CELL_TYPE", 75, 80], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 168, 176], ["the COVID", "TEST", 5, 14], ["PBMCs", "TREATMENT", 28, 33], ["PBMCs", "TEST", 75, 80], ["COVID", "TEST", 108, 113], ["acute respiratory distress syndrome", "PROBLEM", 125, 160], ["ARDS", "PROBLEM", 162, 166], ["acute", "OBSERVATION_MODIFIER", 125, 130], ["respiratory distress syndrome", "OBSERVATION", 131, 160]]], ["Besides, the activation level of SREBP-2 was increased in cultured PBMCs as time, implying the activation of SREBP-2 is transient (Fig. 1h).The level of SREBP-2 C-term reflect the severity of COVID-19 ::: ResultsPreviously, the role of SREBP-2 N-term was largely demonstrated by many researches.", [["PBMCs", "ANATOMY", 67, 72], ["COVID-19", "CHEMICAL", 192, 200], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 33, 40], ["PBMCs", "CELL", 67, 72], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 109, 116], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 153, 160], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 236, 243], ["SREBP-2", "PROTEIN", 33, 40], ["PBMCs", "CELL_TYPE", 67, 72], ["SREBP-2", "PROTEIN", 109, 116], ["SREBP", "PROTEIN", 153, 158], ["SREBP", "PROTEIN", 236, 241], ["SREBP", "TEST", 33, 38], ["SREBP", "TEST", 109, 114], ["SREBP", "TEST", 153, 158], ["COVID", "TEST", 192, 197], ["SREBP", "TEST", 236, 241], ["many", "OBSERVATION_MODIFIER", 279, 283], ["researches", "OBSERVATION", 284, 294]]], ["Upon the cleavage of SREBP-2 N-term and C-term by S1P and S2P, the N-term was translocated to the nucleus and ultimately regulated the synthesis of cholesterol.14 However, the role of SREBP-2 C-term has not been reported yet.", [["nucleus", "ANATOMY", 98, 105], ["S1P", "CHEMICAL", 50, 53], ["cholesterol", "CHEMICAL", 148, 159], ["S1P", "CHEMICAL", 50, 53], ["cholesterol", "CHEMICAL", 148, 159], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 21, 28], ["S1P", "GENE_OR_GENE_PRODUCT", 50, 53], ["S2P", "GENE_OR_GENE_PRODUCT", 58, 61], ["nucleus", "CELLULAR_COMPONENT", 98, 105], ["cholesterol", "SIMPLE_CHEMICAL", 148, 159], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 184, 191], ["SREBP", "PROTEIN", 21, 26], ["S1P", "PROTEIN", 50, 53], ["S2P", "PROTEIN", 58, 61], ["N-term", "PROTEIN", 67, 73], ["SREBP", "PROTEIN", 184, 189], ["SREBP", "TEST", 21, 26], ["SREBP", "TEST", 184, 189], ["nucleus", "ANATOMY", 98, 105]]], ["Here, we hypothesized that the SREBP-2 C-term should be secreted in the blood of COVID-19 patients in response to the degree to which the SREBP-2 was activated.", [["blood", "ANATOMY", 72, 77], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 31, 38], ["blood", "ORGANISM_SUBSTANCE", 72, 77], ["patients", "ORGANISM", 90, 98], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 138, 145], ["SREBP", "PROTEIN", 31, 36], ["SREBP-2", "PROTEIN", 138, 145], ["patients", "SPECIES", 90, 98], ["the SREBP", "TEST", 27, 36], ["COVID", "TEST", 81, 86], ["the SREBP", "TEST", 134, 143]]], ["Especially, in the severe cases of COVID-19 patients including ICU and deceased cases, the level of SREBP-2 C-term was dramatically increased (Fig. 2a, b).", [["COVID", "DISEASE", 35, 40], ["patients", "ORGANISM", 44, 52], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 100, 107], ["SREBP", "PROTEIN", 100, 105], ["patients", "SPECIES", 44, 52], ["SREBP", "TEST", 100, 105], ["severe", "OBSERVATION_MODIFIER", 19, 25]]], ["The SREBP-2 C-term was also secreted in severe sepsis case (septic shock) (Fig. 2c), implying the availability of SREBP-2 C-term as a general indicator for infectious diseases.", [["sepsis", "DISEASE", 47, 53], ["septic shock", "DISEASE", 60, 72], ["infectious diseases", "DISEASE", 156, 175], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 4, 11], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 114, 121], ["SREBP-2 C-term", "DNA", 4, 18], ["SREBP", "PROTEIN", 114, 119], ["The SREBP", "TEST", 0, 9], ["severe sepsis case", "PROBLEM", 40, 58], ["septic shock", "PROBLEM", 60, 72], ["SREBP", "TEST", 114, 119], ["infectious diseases", "PROBLEM", 156, 175], ["severe", "OBSERVATION_MODIFIER", 40, 46], ["sepsis", "OBSERVATION", 47, 53]]], ["This idea is further supported by the increased level of lactate dehydrogenase (LDH) and C-reactive protein (CRP) in the blood of COVID-19 patients (Fig. 2d, e).", [["blood", "ANATOMY", 121, 126], ["lactate", "CHEMICAL", 57, 64], ["lactate", "CHEMICAL", 57, 64], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 57, 78], ["LDH", "GENE_OR_GENE_PRODUCT", 80, 83], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 89, 107], ["CRP", "GENE_OR_GENE_PRODUCT", 109, 112], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["patients", "ORGANISM", 139, 147], ["lactate dehydrogenase", "PROTEIN", 57, 78], ["LDH", "PROTEIN", 80, 83], ["C-reactive protein", "PROTEIN", 89, 107], ["CRP", "PROTEIN", 109, 112], ["patients", "SPECIES", 139, 147], ["the increased level of lactate dehydrogenase", "PROBLEM", 34, 78], ["LDH", "TEST", 80, 83], ["C-reactive protein", "PROBLEM", 89, 107], ["CRP", "TEST", 109, 112], ["COVID", "TEST", 130, 135], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["reactive protein", "OBSERVATION", 91, 107]]], ["This high level of SREBP-2 C-term is closely related to the hyper-inflammation in lung tissue of COVID-19 patients.", [["lung tissue", "ANATOMY", 82, 93], ["inflammation", "DISEASE", 66, 78], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 19, 26], ["lung tissue", "TISSUE", 82, 93], ["patients", "ORGANISM", 106, 114], ["SREBP", "PROTEIN", 19, 24], ["patients", "SPECIES", 106, 114], ["SREBP", "TEST", 19, 24], ["the hyper-inflammation in lung tissue", "PROBLEM", 56, 93], ["COVID", "TEST", 97, 102], ["hyper", "OBSERVATION", 60, 65], ["inflammation", "OBSERVATION", 66, 78], ["lung", "ANATOMY", 82, 86], ["tissue", "ANATOMY_MODIFIER", 87, 93]]], ["The computed tomography (CT) image of ICU patient with high SREBP-2 C-term (right panel of Fig. 2f) in plasma displayed severe lung inflammation than nonICU patient with low SREBP-2 C-term level (left panel of Fig. 2f).", [["plasma", "ANATOMY", 103, 109], ["lung", "ANATOMY", 127, 131], ["lung inflammation", "DISEASE", 127, 144], ["patient", "ORGANISM", 42, 49], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 60, 67], ["plasma", "ORGANISM_SUBSTANCE", 103, 109], ["lung", "ORGAN", 127, 131], ["patient", "ORGANISM", 157, 164], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 174, 181], ["SREBP", "PROTEIN", 60, 65], ["SREBP", "PROTEIN", 174, 179], ["patient", "SPECIES", 42, 49], ["patient", "SPECIES", 157, 164], ["The computed tomography (CT) image", "TEST", 0, 34], ["high SREBP", "TEST", 55, 65], ["severe lung inflammation", "PROBLEM", 120, 144], ["low SREBP", "TEST", 170, 179], ["right", "ANATOMY_MODIFIER", 76, 81], ["severe", "OBSERVATION_MODIFIER", 120, 126], ["lung", "ANATOMY", 127, 131], ["inflammation", "OBSERVATION", 132, 144], ["left", "ANATOMY_MODIFIER", 196, 200]]], ["To the best of authors\u2019 knowledge, the detection of SREBP-2 C-term and the demonstration of correlation with infectious diseases has not reported yet.The inhibition of NF-\u03baB and SREBP-2 suppresses the SREBP-2 activation and inflammatory cytokine production ::: ResultsWe confirmed the possibility of restoration of SREBP-2 level and subsequent cytokine storm by direct pharmacological inhibition of SREBP-2 with Fatostatin A (a SREBP-2 processing inhibitor) and by regulating upstream NF-\u03baB signaling with SN50 (a NF-\u03baB signaling inhibitor).", [["infectious diseases", "DISEASE", 109, 128], ["Fatostatin A", "CHEMICAL", 412, 424], ["Fatostatin A", "CHEMICAL", 412, 424], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 52, 59], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 168, 173], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 178, 185], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 201, 208], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 315, 322], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 399, 406], ["Fatostatin A", "SIMPLE_CHEMICAL", 412, 424], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 428, 435], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 485, 490], ["SN50", "SIMPLE_CHEMICAL", 506, 510], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 514, 519], ["SREBP", "PROTEIN", 52, 57], ["NF-\u03baB", "PROTEIN", 168, 173], ["SREBP-2", "PROTEIN", 178, 185], ["SREBP-2", "PROTEIN", 201, 208], ["inflammatory cytokine", "PROTEIN", 224, 245], ["SREBP-2", "PROTEIN", 315, 322], ["cytokine", "PROTEIN", 344, 352], ["SREBP-2", "PROTEIN", 399, 406], ["SREBP", "PROTEIN", 428, 433], ["NF-\u03baB", "PROTEIN", 485, 490], ["SN50", "PROTEIN", 506, 510], ["NF-\u03baB", "PROTEIN", 514, 519], ["SREBP", "TEST", 52, 57], ["infectious diseases", "PROBLEM", 109, 128], ["NF", "TEST", 168, 170], ["SREBP", "TEST", 178, 183], ["the SREBP", "TEST", 197, 206], ["SREBP", "TEST", 315, 320], ["subsequent cytokine storm", "TREATMENT", 333, 358], ["SREBP", "TEST", 399, 404], ["Fatostatin A", "TREATMENT", 412, 424], ["a SREBP-2 processing inhibitor", "TREATMENT", 426, 456], ["SN50", "TREATMENT", 506, 510], ["a NF", "TREATMENT", 512, 516], ["B signaling inhibitor", "TREATMENT", 518, 539], ["inflammatory", "OBSERVATION_MODIFIER", 224, 236]]], ["The treatment of SN50 and Fatostatin A suppressed the activation level of SREBP-2 in PBMCs of COVID-19 ICU patients (Fig. 3a).", [["PBMCs", "ANATOMY", 85, 90], ["Fatostatin A", "CHEMICAL", 26, 38], ["Fatostatin A", "CHEMICAL", 26, 38], ["SN50", "SIMPLE_CHEMICAL", 17, 21], ["Fatostatin A", "SIMPLE_CHEMICAL", 26, 38], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 74, 81], ["PBMCs", "CELL", 85, 90], ["patients", "ORGANISM", 107, 115], ["SREBP-2", "PROTEIN", 74, 81], ["PBMCs", "CELL_TYPE", 85, 90], ["patients", "SPECIES", 107, 115], ["The treatment of SN50", "TREATMENT", 0, 21], ["Fatostatin", "TREATMENT", 26, 36], ["SREBP", "TEST", 74, 79], ["COVID", "TEST", 94, 99]]], ["Further, the pharmacological inhibition also suppressed the inflammatory cytokine production such as IL-1\u03b2 and TNF-\u03b1 (Fig. 3b, c). qRT-PCR analysis also confirmed the suppression of relevant mRNAs including SREBF2, IL-1\u03b2, and TNF-\u03b1 (Fig. 3d, f).", [["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 101, 106], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 111, 116], ["c", "GENE_OR_GENE_PRODUCT", 127, 128], ["SREBF2", "GENE_OR_GENE_PRODUCT", 207, 213], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 215, 220], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 226, 231], ["inflammatory cytokine", "PROTEIN", 60, 81], ["IL-1\u03b2", "PROTEIN", 101, 106], ["TNF", "PROTEIN", 111, 114], ["mRNAs", "RNA", 191, 196], ["SREBF2", "PROTEIN", 207, 213], ["IL-1\u03b2", "PROTEIN", 215, 220], ["TNF-\u03b1", "DNA", 226, 231], ["the inflammatory cytokine production", "PROBLEM", 56, 92], ["IL", "TEST", 101, 103], ["TNF", "TEST", 111, 114], ["PCR analysis", "TEST", 135, 147], ["relevant mRNAs", "PROBLEM", 182, 196], ["SREBF2", "TEST", 207, 213], ["IL", "TEST", 215, 217], ["TNF", "TEST", 226, 229], ["inflammatory", "OBSERVATION_MODIFIER", 60, 72]]], ["The mRNA level of SCAP (SREBP cleavage-activating protein) and INSIG1 (insulin-induced gene 1, a negative regulator of SREBP-2) were rescued by the pharmacological inhibition of SREBP-2 and NF-\u03baB (Fig. 3g, h).", [["SCAP", "GENE_OR_GENE_PRODUCT", 18, 22], ["SREBP cleavage-activating protein", "GENE_OR_GENE_PRODUCT", 24, 57], ["INSIG1", "GENE_OR_GENE_PRODUCT", 63, 69], ["insulin-induced gene 1", "GENE_OR_GENE_PRODUCT", 71, 93], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 119, 126], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 178, 185], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 190, 195], ["SCAP", "PROTEIN", 18, 22], ["SREBP cleavage-activating protein", "PROTEIN", 24, 57], ["INSIG1", "PROTEIN", 63, 69], ["insulin-induced gene 1", "DNA", 71, 93], ["SREBP-2", "PROTEIN", 119, 126], ["SREBP-2", "PROTEIN", 178, 185], ["NF-\u03baB", "PROTEIN", 190, 195], ["SCAP (SREBP cleavage", "TEST", 18, 38], ["INSIG1", "TEST", 63, 69], ["insulin", "TEST", 71, 78], ["SREBP", "TEST", 119, 124], ["SREBP", "TEST", 178, 183]]], ["The mRNA expression of SIRT1 as regulator of nucleus SREBP-2 stability was also rescued as a result of pharmacological inhibition.", [["nucleus", "ANATOMY", 45, 52], ["SIRT1", "GENE_OR_GENE_PRODUCT", 23, 28], ["nucleus", "CELLULAR_COMPONENT", 45, 52], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 53, 60], ["SIRT1", "PROTEIN", 23, 28], ["nucleus SREBP-2", "PROTEIN", 45, 60], ["nucleus SREBP", "TEST", 45, 58], ["pharmacological inhibition", "TREATMENT", 103, 129], ["nucleus SREBP", "OBSERVATION", 45, 58]]], ["Although the NF-\u03baB activation could be rescued directly by SN50 treatment, it could not be fully rescued by Fatostatin A, showing that the NF-\u03baB is an upstream regulator of SREBP-2 (Supplementary Fig. 3).SREBP-2 C-term is the indicator of dysregulated vasculature and can be protected by pharmacological inhibition or knockdown of SREBP-2 ::: ResultsTo demonstrate the different translocation target of N-term and C-term of SREBP-2, we performed western blot analysis.", [["vasculature", "ANATOMY", 252, 263], ["SN50", "CHEMICAL", 59, 63], ["Fatostatin A", "CHEMICAL", 108, 120], ["SN50", "CHEMICAL", 59, 63], ["Fatostatin A", "CHEMICAL", 108, 120], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 13, 18], ["SN50", "SIMPLE_CHEMICAL", 59, 63], ["Fatostatin A", "SIMPLE_CHEMICAL", 108, 120], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 139, 144], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 173, 180], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 204, 211], ["vasculature", "MULTI-TISSUE_STRUCTURE", 252, 263], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 331, 338], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 424, 431], ["NF-\u03baB", "PROTEIN", 13, 18], ["NF-\u03baB", "PROTEIN", 139, 144], ["SREBP-2", "PROTEIN", 173, 180], ["SREBP", "PROTEIN", 204, 209], ["SREBP", "PROTEIN", 331, 336], ["SREBP-2", "PROTEIN", 424, 431], ["the NF", "TEST", 9, 15], ["SN50 treatment", "TREATMENT", 59, 73], ["SREBP", "TEST", 173, 178], ["SREBP", "TEST", 204, 209], ["dysregulated vasculature", "PROBLEM", 239, 263], ["SREBP", "TEST", 424, 429], ["blot analysis", "TEST", 454, 467], ["dysregulated", "OBSERVATION", 239, 251], ["vasculature", "ANATOMY", 252, 263]]], ["Upon the exposure to lipopolysaccharide (LPS), the expression of SREBP-2 N-term is transiently increased as time in whole cell lysate (WCL) (Fig. 4a) of HUVEC.", [["whole cell lysate", "ANATOMY", 116, 133], ["WCL", "ANATOMY", 135, 138], ["HUVEC", "ANATOMY", 153, 158], ["lipopolysaccharide", "CHEMICAL", 21, 39], ["LPS", "CHEMICAL", 41, 44], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 21, 39], ["LPS", "SIMPLE_CHEMICAL", 41, 44], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 65, 72], ["cell lysate", "ORGANISM_SUBSTANCE", 122, 133], ["WCL", "CELL", 135, 138], ["HUVEC", "CELL", 153, 158], ["SREBP", "PROTEIN", 65, 70], ["HUVEC", "CELL_TYPE", 153, 158], ["lipopolysaccharide (LPS", "TREATMENT", 21, 44], ["SREBP", "TEST", 65, 70], ["whole cell lysate", "TREATMENT", 116, 133], ["HUVEC", "ANATOMY", 153, 158]]], ["On the other hand, the SREBP-2 C-term was highly expressed in supernatant at the late-stage of LPS stimulation (24 h) (Fig. 4a).", [["supernatant", "ANATOMY", 62, 73], ["LPS", "CHEMICAL", 95, 98], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 23, 30], ["LPS", "SIMPLE_CHEMICAL", 95, 98], ["SREBP-2 C-term", "DNA", 23, 37], ["the SREBP", "TEST", 19, 28], ["LPS stimulation", "TREATMENT", 95, 110]]], ["Similarly, in other cell types such as HEK293 and human umbilical vein endothelial cell (HUVEC), the SREBP-2 N-term was detected in cell lysate, but not observed in culture media (Supplementary Fig. 4).", [["cell", "ANATOMY", 20, 24], ["HEK293", "ANATOMY", 39, 45], ["human umbilical vein endothelial cell", "ANATOMY", 50, 87], ["HUVEC", "ANATOMY", 89, 94], ["cell lysate", "ANATOMY", 132, 143], ["cell", "CELL", 20, 24], ["HEK293", "CELL", 39, 45], ["human umbilical vein endothelial cell", "CELL", 50, 87], ["HUVEC", "CELL", 89, 94], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 101, 108], ["cell lysate", "CELL", 132, 143], ["HEK293", "CELL_LINE", 39, 45], ["human umbilical vein endothelial cell", "CELL_LINE", 50, 87], ["HUVEC", "CELL_LINE", 89, 94], ["SREBP", "PROTEIN", 101, 106], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["HEK293", "TEST", 39, 45], ["HUVEC", "TEST", 89, 94], ["the SREBP", "TEST", 97, 106], ["cell lysate", "TEST", 132, 143], ["culture media", "TEST", 165, 178], ["cell types", "OBSERVATION", 20, 30], ["umbilical vein", "ANATOMY", 56, 70], ["endothelial cell", "OBSERVATION", 71, 87], ["cell lysate", "OBSERVATION", 132, 143]]], ["NF-\u03baB activation by LPS was elevated early, unlike SREBP-2 as late mediator,38 which is interpreted to mediate serious lung injury by crosstalk between NF-\u03baB and SREBP-2 (Fig. 3b).30 The SREBP-2 C-term was detectable in both WCL and supernatant, but the level was higher in supernatant (Fig. 4a).", [["lung", "ANATOMY", 119, 123], ["WCL", "ANATOMY", 225, 228], ["supernatant", "ANATOMY", 233, 244], ["supernatant", "ANATOMY", 274, 285], ["LPS", "CHEMICAL", 20, 23], ["lung injury", "DISEASE", 119, 130], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["LPS", "SIMPLE_CHEMICAL", 20, 23], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 51, 58], ["lung", "ORGAN", 119, 123], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 152, 157], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 162, 169], ["Fig. 3b", "GENE_OR_GENE_PRODUCT", 171, 178], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 187, 194], ["WCL", "CELL", 225, 228], ["NF-\u03baB", "PROTEIN", 0, 5], ["SREBP-2", "PROTEIN", 51, 58], ["NF-\u03baB", "PROTEIN", 152, 157], ["SREBP-2", "PROTEIN", 162, 169], ["SREBP-2 C-term", "DNA", 187, 201], ["WCL", "CELL_TYPE", 225, 228], ["elevated", "PROBLEM", 28, 36], ["SREBP", "TEST", 51, 56], ["serious lung injury", "PROBLEM", 111, 130], ["NF", "TEST", 152, 154], ["SREBP", "TEST", 162, 167], ["The SREBP", "TEST", 183, 192], ["serious", "OBSERVATION_MODIFIER", 111, 118], ["lung", "ANATOMY", 119, 123], ["injury", "OBSERVATION", 124, 130], ["higher", "OBSERVATION_MODIFIER", 264, 270]]], ["The notable difference between N-term and C-term of SREBP-2 was the increasing rate with respect to the simulation time.", [["SREBP-2", "GENE_OR_GENE_PRODUCT", 52, 59], ["SREBP-2", "PROTEIN", 52, 59], ["SREBP", "TEST", 52, 57], ["notable", "OBSERVATION_MODIFIER", 4, 11], ["difference", "OBSERVATION_MODIFIER", 12, 22]]], ["This was consistent with time dependent NF-\u03baB activation upon LPS treatment (Fig. 4b).", [["LPS", "CHEMICAL", 62, 65], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 40, 45], ["LPS", "SIMPLE_CHEMICAL", 62, 65], ["NF-\u03baB", "PROTEIN", 40, 45], ["time dependent NF", "PROBLEM", 25, 42], ["LPS treatment", "TREATMENT", 62, 75], ["consistent with", "UNCERTAINTY", 9, 24]]], ["In contrast to the monotonic increase of SREBP-2 N-term, the SREBP-2 C-term was dramatically increased on 24 h after LPS stimulation (Fig. 4c).SREBP-2 C-term is the indicator of dysregulated vasculature and can be protected by pharmacological inhibition or knockdown of SREBP-2 ::: ResultsThe duration of LPS stimulation induced different consequence in cholesterol metabolism.", [["vasculature", "ANATOMY", 191, 202], ["LPS", "CHEMICAL", 117, 120], ["LPS", "CHEMICAL", 305, 308], ["cholesterol", "CHEMICAL", 354, 365], ["cholesterol", "CHEMICAL", 354, 365], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 41, 48], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 61, 68], ["LPS", "SIMPLE_CHEMICAL", 117, 120], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 143, 150], ["vasculature", "MULTI-TISSUE_STRUCTURE", 191, 202], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 270, 277], ["LPS", "SIMPLE_CHEMICAL", 305, 308], ["cholesterol", "SIMPLE_CHEMICAL", 354, 365], ["SREBP", "PROTEIN", 41, 46], ["SREBP", "PROTEIN", 61, 66], ["SREBP", "PROTEIN", 143, 148], ["SREBP", "PROTEIN", 270, 275], ["SREBP", "TEST", 41, 46], ["the SREBP", "TEST", 57, 66], ["LPS stimulation", "TREATMENT", 117, 132], ["SREBP", "TEST", 143, 148], ["dysregulated vasculature", "PROBLEM", 178, 202], ["LPS stimulation", "TREATMENT", 305, 320], ["different consequence in cholesterol metabolism", "PROBLEM", 329, 376], ["monotonic", "OBSERVATION_MODIFIER", 19, 28], ["increase", "OBSERVATION_MODIFIER", 29, 37], ["dramatically", "OBSERVATION_MODIFIER", 80, 92], ["increased", "OBSERVATION_MODIFIER", 93, 102], ["dysregulated", "OBSERVATION", 178, 190], ["vasculature", "ANATOMY", 191, 202], ["cholesterol metabolism", "OBSERVATION", 354, 376]]], ["Filipin staining which visualizes the intracellular cholesterol showed that cholesterol was accumulated in HUVEC after the 12 h of LPS stimulation (Fig. 4d).", [["intracellular", "ANATOMY", 38, 51], ["HUVEC", "ANATOMY", 107, 112], ["cholesterol", "CHEMICAL", 52, 63], ["cholesterol", "CHEMICAL", 76, 87], ["LPS", "CHEMICAL", 131, 134], ["cholesterol", "CHEMICAL", 52, 63], ["cholesterol", "CHEMICAL", 76, 87], ["Filipin", "SIMPLE_CHEMICAL", 0, 7], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 38, 51], ["cholesterol", "SIMPLE_CHEMICAL", 52, 63], ["cholesterol", "SIMPLE_CHEMICAL", 76, 87], ["HUVEC", "CELL", 107, 112], ["LPS", "SIMPLE_CHEMICAL", 131, 134], ["HUVEC", "CELL_TYPE", 107, 112], ["Filipin staining", "TEST", 0, 16], ["the intracellular cholesterol", "TEST", 34, 63], ["cholesterol", "TEST", 76, 87], ["LPS stimulation", "TREATMENT", 131, 146], ["intracellular cholesterol", "OBSERVATION", 38, 63], ["cholesterol", "OBSERVATION_MODIFIER", 76, 87], ["HUVEC", "ANATOMY", 107, 112]]], ["However, the cholesterol level was decreased 24 h after the LPS stimulation (Fig. 4d).", [["cholesterol", "CHEMICAL", 13, 24], ["LPS", "CHEMICAL", 60, 63], ["cholesterol", "CHEMICAL", 13, 24], ["cholesterol", "SIMPLE_CHEMICAL", 13, 24], ["LPS", "SIMPLE_CHEMICAL", 60, 63], ["the cholesterol level", "TEST", 9, 30], ["the LPS stimulation", "TREATMENT", 56, 75]]], ["The western blot analysis of ATP-binding cassette transporter (ABCA1), also known as the cholesterol efflux regulatory protein (CERP), showed the decreased expression on 24 h than 12 h (Fig. 4e).SREBP-2 C-term is the indicator of dysregulated vasculature and can be protected by pharmacological inhibition or knockdown of SREBP-2 ::: ResultsIn the HUVEC, the LPS stimulation induces upregulated secretion of inflammatory cytokines (upper panel of Fig. 4f).", [["vasculature", "ANATOMY", 243, 254], ["HUVEC", "ANATOMY", 348, 353], ["ATP", "CHEMICAL", 29, 32], ["cholesterol", "CHEMICAL", 89, 100], ["LPS", "CHEMICAL", 359, 362], ["ATP", "CHEMICAL", 29, 32], ["cholesterol", "CHEMICAL", 89, 100], ["ATP-binding cassette transporter", "GENE_OR_GENE_PRODUCT", 29, 61], ["ABCA1", "GENE_OR_GENE_PRODUCT", 63, 68], ["cholesterol efflux regulatory protein", "GENE_OR_GENE_PRODUCT", 89, 126], ["CERP", "GENE_OR_GENE_PRODUCT", 128, 132], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 195, 202], ["vasculature", "MULTI-TISSUE_STRUCTURE", 243, 254], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 322, 329], ["HUVEC", "CELL", 348, 353], ["LPS", "SIMPLE_CHEMICAL", 359, 362], ["ATP-binding cassette transporter", "PROTEIN", 29, 61], ["ABCA1", "PROTEIN", 63, 68], ["cholesterol efflux regulatory protein", "PROTEIN", 89, 126], ["CERP", "PROTEIN", 128, 132], ["SREBP", "PROTEIN", 195, 200], ["SREBP", "PROTEIN", 322, 327], ["HUVEC", "CELL_LINE", 348, 353], ["inflammatory cytokines", "PROTEIN", 408, 430], ["The western blot analysis", "TEST", 0, 25], ["ATP", "TEST", 29, 32], ["the cholesterol efflux", "TEST", 85, 107], ["the decreased expression", "PROBLEM", 142, 166], ["SREBP", "TEST", 195, 200], ["dysregulated vasculature", "PROBLEM", 230, 254], ["SREBP", "TEST", 322, 327], ["the HUVEC", "TREATMENT", 344, 353], ["the LPS stimulation", "TEST", 355, 374], ["inflammatory cytokines", "PROBLEM", 408, 430], ["decreased", "OBSERVATION_MODIFIER", 146, 155], ["expression", "OBSERVATION_MODIFIER", 156, 166], ["dysregulated", "OBSERVATION", 230, 242], ["vasculature", "ANATOMY", 243, 254], ["HUVEC", "ANATOMY", 348, 353], ["inflammatory", "OBSERVATION_MODIFIER", 408, 420]]], ["However, the genetic ablation of SREBP-2 could suppress the cytokine storm even after the LPS stimulation (lower panel of Fig. 4f).", [["LPS", "CHEMICAL", 90, 93], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 33, 40], ["LPS", "SIMPLE_CHEMICAL", 90, 93], ["SREBP-2", "PROTEIN", 33, 40], ["cytokine", "PROTEIN", 60, 68], ["SREBP", "TEST", 33, 38], ["the cytokine storm", "PROBLEM", 56, 74], ["the LPS stimulation", "TREATMENT", 86, 105], ["cytokine storm", "OBSERVATION", 60, 74]]], ["The pharmacological inhibition of NF-\u03baB, SREBP-2, and S1P (PF-429242) and short hairpin RNA (shRNA) of SREBP-2 suppressed the vascular barrier disruption even under LPS stimulation (Fig. 4g).", [["vascular barrier", "ANATOMY", 126, 142], ["S1P", "CHEMICAL", 54, 57], ["PF-429242", "CHEMICAL", 59, 68], ["LPS", "CHEMICAL", 165, 168], ["PF-429242", "CHEMICAL", 59, 68], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 34, 39], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 41, 48], ["S1P", "GENE_OR_GENE_PRODUCT", 54, 57], ["PF-429242", "GENE_OR_GENE_PRODUCT", 59, 68], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 103, 110], ["vascular barrier", "TISSUE", 126, 142], ["LPS", "SIMPLE_CHEMICAL", 165, 168], ["NF-\u03baB", "PROTEIN", 34, 39], ["SREBP-2", "PROTEIN", 41, 48], ["short hairpin RNA", "RNA", 74, 91], ["SREBP-2", "PROTEIN", 103, 110], ["NF", "TEST", 34, 36], ["SREBP", "TEST", 41, 46], ["S1P", "TEST", 54, 57], ["PF", "TEST", 59, 61], ["short hairpin RNA", "PROBLEM", 74, 91], ["SREBP", "TEST", 103, 108], ["the vascular barrier disruption", "PROBLEM", 122, 153], ["LPS stimulation", "TREATMENT", 165, 180], ["vascular", "ANATOMY", 126, 134], ["barrier disruption", "OBSERVATION", 135, 153]]], ["SREBP-2-overexpressed (SREBP-2 O/E) HUVECs were more severely damaged by LPS (Fig. 4g).SREBP-2 inhibitor improves mortality of infectious diseases mouse model ::: ResultsThe pharmacological inhibition of NF-\u03baB signaling and SREBP-2 was valid in the PBMCs of COVID-19 ICU patients as well.", [["HUVECs", "ANATOMY", 36, 42], ["PBMCs", "ANATOMY", 249, 254], ["LPS", "CHEMICAL", 73, 76], ["infectious diseases", "DISEASE", 127, 146], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 0, 7], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 23, 30], ["HUVECs", "CELL", 36, 42], ["LPS", "SIMPLE_CHEMICAL", 73, 76], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 87, 94], ["mouse", "ORGANISM", 147, 152], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 204, 209], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 224, 231], ["PBMCs", "CELL", 249, 254], ["patients", "ORGANISM", 271, 279], ["SREBP-2", "PROTEIN", 0, 7], ["overexpressed (SREBP-2 O/E) HUVECs", "CELL_LINE", 8, 42], ["SREBP", "PROTEIN", 87, 92], ["NF-\u03baB", "PROTEIN", 204, 209], ["SREBP-2", "PROTEIN", 224, 231], ["PBMCs", "CELL_TYPE", 249, 254], ["mouse", "SPECIES", 147, 152], ["patients", "SPECIES", 271, 279], ["mouse", "SPECIES", 147, 152], ["SREBP", "TEST", 0, 5], ["SREBP", "TEST", 23, 28], ["HUVECs", "PROBLEM", 36, 42], ["SREBP", "TEST", 87, 92], ["NF", "TEST", 204, 206], ["SREBP", "TEST", 224, 229]]], ["To validate the effect of SREBP-2 inhibition as a therapeutic target on infectious diseases with septic shock, we utilized the cecal ligation and puncture (CLP) model for recapitulating pathophysiology of sepsis.39 The exogenous incorporation of Fatostatin A and SN50 recovered the mRNA levels of Srebp2, Sens1, and Pcsk9 to lower range (Supplementary Fig. 5a\u2013c).", [["cecal", "ANATOMY", 127, 132], ["infectious diseases", "DISEASE", 72, 91], ["septic shock", "DISEASE", 97, 109], ["sepsis", "DISEASE", 205, 211], ["Fatostatin A", "CHEMICAL", 246, 258], ["Fatostatin A", "CHEMICAL", 246, 258], ["SN50", "CHEMICAL", 263, 267], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 26, 33], ["Fatostatin A", "SIMPLE_CHEMICAL", 246, 258], ["SN50", "SIMPLE_CHEMICAL", 263, 267], ["Srebp2", "GENE_OR_GENE_PRODUCT", 297, 303], ["Sens1", "GENE_OR_GENE_PRODUCT", 305, 310], ["Pcsk9", "GENE_OR_GENE_PRODUCT", 316, 321], ["SREBP-2", "PROTEIN", 26, 33], ["Srebp2", "PROTEIN", 297, 303], ["Sens1", "PROTEIN", 305, 310], ["Pcsk9", "PROTEIN", 316, 321], ["SREBP-2 inhibition", "TREATMENT", 26, 44], ["septic shock", "PROBLEM", 97, 109], ["the cecal ligation", "TREATMENT", 123, 141], ["puncture (CLP) model", "TREATMENT", 146, 166], ["sepsis", "PROBLEM", 205, 211], ["Fatostatin A", "TREATMENT", 246, 258], ["Srebp2", "TEST", 297, 303], ["Sens1", "TREATMENT", 305, 310], ["Pcsk9", "TREATMENT", 316, 321], ["septic shock", "OBSERVATION", 97, 109], ["cecal", "ANATOMY", 127, 132], ["ligation", "OBSERVATION", 133, 141], ["sepsis", "OBSERVATION", 205, 211], ["exogenous incorporation", "OBSERVATION", 219, 242]]], ["Since the mRNA levels of HMGCR and LDLR were not different in response to COVID-19 infection (Supplementary Fig. 2), the pharmacological inhibition did not induce any change in CLP-operated mice (Supplementary Fig. 5d, e).SREBP-2 inhibitor improves mortality of infectious diseases mouse model ::: ResultsFor the SREBP-2 shRNA induced knockdown (KD), SREBP-2 shRNA was delivered via intravenous (i.v.) injection daily the CLP was performed (Supplementary Fig. 6).", [["intravenous", "ANATOMY", 383, 394], ["COVID-19", "CHEMICAL", 74, 82], ["infection", "DISEASE", 83, 92], ["infectious diseases", "DISEASE", 262, 281], ["COVID-19", "CHEMICAL", 74, 82], ["HMGCR", "GENE_OR_GENE_PRODUCT", 25, 30], ["LDLR", "GENE_OR_GENE_PRODUCT", 35, 39], ["mice", "ORGANISM", 190, 194], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 222, 229], ["mouse", "ORGANISM", 282, 287], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 313, 320], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 351, 358], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 383, 394], ["HMGCR", "PROTEIN", 25, 30], ["LDLR", "PROTEIN", 35, 39], ["SREBP", "PROTEIN", 222, 227], ["SREBP", "PROTEIN", 313, 318], ["SREBP-2 shRNA", "DNA", 351, 364], ["mice", "SPECIES", 190, 194], ["mouse", "SPECIES", 282, 287], ["COVID-19", "SPECIES", 74, 82], ["mouse", "SPECIES", 282, 287], ["the mRNA levels", "TEST", 6, 21], ["HMGCR", "TEST", 25, 30], ["LDLR", "TEST", 35, 39], ["COVID", "TEST", 74, 79], ["infection", "PROBLEM", 83, 92], ["any change in CLP", "PROBLEM", 163, 180], ["SREBP", "TEST", 222, 227], ["the SREBP", "TEST", 309, 318], ["SREBP", "TEST", 351, 356], ["the CLP", "TEST", 418, 425], ["LDLR", "ANATOMY", 35, 39], ["infection", "OBSERVATION", 83, 92]]], ["We confirmed that the shSREBP2 reduced the mRNA level of SREBP-2 in mouse plasma (Supplementary Fig. 6).", [["plasma", "ANATOMY", 74, 80], ["shSREBP2", "GENE_OR_GENE_PRODUCT", 22, 30], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 57, 64], ["mouse", "ORGANISM", 68, 73], ["plasma", "ORGANISM_SUBSTANCE", 74, 80], ["shSREBP2", "PROTEIN", 22, 30], ["SREBP-2", "PROTEIN", 57, 64], ["mouse", "SPECIES", 68, 73], ["mouse", "SPECIES", 68, 73], ["the shSREBP2", "TEST", 18, 30], ["SREBP", "TEST", 57, 62]]], ["The inhibition of NF-\u03baB signaling with SN50 (40%) and SREBP-2 with Fatostatin A (40%) and SREBP-2 KD (30%) rescued the survival rate of mouse model, respectively (Fig. 5a).", [["Fatostatin A", "CHEMICAL", 67, 79], ["Fatostatin A", "CHEMICAL", 67, 79], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 18, 23], ["SN50", "GENE_OR_GENE_PRODUCT", 39, 43], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 54, 61], ["Fatostatin A", "SIMPLE_CHEMICAL", 67, 79], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 90, 97], ["mouse", "ORGANISM", 136, 141], ["NF-\u03baB", "PROTEIN", 18, 23], ["SN50", "PROTEIN", 39, 43], ["SREBP-2", "PROTEIN", 54, 61], ["SREBP", "PROTEIN", 90, 95], ["mouse", "SPECIES", 136, 141], ["mouse", "SPECIES", 136, 141], ["NF", "TEST", 18, 20], ["SN50", "TEST", 39, 43], ["SREBP", "TEST", 54, 59], ["Fatostatin A", "TREATMENT", 67, 79], ["SREBP", "TEST", 90, 95]]], ["Histology of mouse lung tissue also confirmed that the inhibition of NF-\u03baB signaling and SREBP-2 prohibited the lung failure (Fig. 5b).", [["lung tissue", "ANATOMY", 19, 30], ["lung", "ANATOMY", 112, 116], ["lung failure", "DISEASE", 112, 124], ["mouse", "ORGANISM", 13, 18], ["lung tissue", "TISSUE", 19, 30], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 69, 74], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 89, 96], ["lung", "ORGAN", 112, 116], ["NF-\u03baB", "PROTEIN", 69, 74], ["SREBP-2", "PROTEIN", 89, 96], ["mouse", "SPECIES", 13, 18], ["mouse", "SPECIES", 13, 18], ["mouse lung tissue", "PROBLEM", 13, 30], ["NF", "TEST", 69, 71], ["SREBP", "TEST", 89, 94], ["the lung failure", "PROBLEM", 108, 124], ["mouse", "ANATOMY_MODIFIER", 13, 18], ["lung", "ANATOMY", 19, 23], ["lung", "ANATOMY", 112, 116], ["failure", "OBSERVATION", 117, 124]]], ["Various tissue damage markers were also decreased in mouse plasma as a result of pharmacological inhibition: liver\u2014alanine aminotransferase (ALT) and aminotransferase (AST), Kidney\u2014blood urea nitrogen (BUN), Inflammation\u2014C-reactive protein (CRP) and lactate dehydrogenase (LDH) (Fig. 5c).", [["tissue", "ANATOMY", 8, 14], ["plasma", "ANATOMY", 59, 65], ["Kidney", "ANATOMY", 174, 180], ["blood", "ANATOMY", 181, 186], ["liver\u2014alanine", "CHEMICAL", 109, 122], ["blood urea nitrogen", "CHEMICAL", 181, 200], ["lactate", "CHEMICAL", 250, 257], ["liver\u2014alanine", "CHEMICAL", 109, 122], ["urea", "CHEMICAL", 187, 191], ["nitrogen", "CHEMICAL", 192, 200], ["lactate", "CHEMICAL", 250, 257], ["tissue", "TISSUE", 8, 14], ["mouse", "ORGANISM", 53, 58], ["plasma", "ORGANISM_SUBSTANCE", 59, 65], ["liver\u2014alanine aminotransferase", "SIMPLE_CHEMICAL", 109, 139], ["ALT", "SIMPLE_CHEMICAL", 141, 144], ["aminotransferase", "SIMPLE_CHEMICAL", 150, 166], ["AST", "SIMPLE_CHEMICAL", 168, 171], ["Kidney", "ORGAN", 174, 180], ["blood", "ORGANISM_SUBSTANCE", 181, 186], ["urea nitrogen", "SIMPLE_CHEMICAL", 187, 200], ["BUN", "SIMPLE_CHEMICAL", 202, 205], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 221, 239], ["CRP", "GENE_OR_GENE_PRODUCT", 241, 244], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 250, 271], ["LDH", "GENE_OR_GENE_PRODUCT", 273, 276], ["liver\u2014alanine aminotransferase", "PROTEIN", 109, 139], ["ALT", "PROTEIN", 141, 144], ["aminotransferase", "PROTEIN", 150, 166], ["AST", "PROTEIN", 168, 171], ["C-reactive protein", "PROTEIN", 221, 239], ["CRP", "PROTEIN", 241, 244], ["lactate dehydrogenase", "PROTEIN", 250, 271], ["LDH", "PROTEIN", 273, 276], ["mouse", "SPECIES", 53, 58], ["mouse", "SPECIES", 53, 58], ["Various tissue damage markers", "PROBLEM", 0, 29], ["pharmacological inhibition", "TEST", 81, 107], ["liver\u2014alanine aminotransferase", "TEST", 109, 139], ["ALT", "TEST", 141, 144], ["aminotransferase", "TEST", 150, 166], ["AST", "TEST", 168, 171], ["Kidney\u2014blood urea nitrogen", "TEST", 174, 200], ["BUN", "TEST", 202, 205], ["Inflammation", "TEST", 208, 220], ["C", "TEST", 221, 222], ["reactive protein", "TEST", 223, 239], ["CRP", "TEST", 241, 244], ["lactate dehydrogenase", "TEST", 250, 271], ["LDH", "TEST", 273, 276], ["tissue", "OBSERVATION_MODIFIER", 8, 14], ["damage", "OBSERVATION", 15, 21], ["decreased", "OBSERVATION_MODIFIER", 40, 49], ["Kidney", "ANATOMY", 174, 180], ["reactive protein", "OBSERVATION", 223, 239]]], ["The inflammatory cytokines including 1L-1\u03b2, IL-6, and TNF-\u03b1, the chemokine monocyte chemoattractant protein 1 (MCP1), and SREBP-2 C-term were also maintained in a low level in mouse plasma (Fig. 5d).", [["plasma", "ANATOMY", 182, 188], ["1L-1\u03b2", "GENE_OR_GENE_PRODUCT", 37, 42], ["IL-6", "GENE_OR_GENE_PRODUCT", 44, 48], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 54, 59], ["monocyte chemoattractant protein 1", "GENE_OR_GENE_PRODUCT", 75, 109], ["MCP1", "GENE_OR_GENE_PRODUCT", 111, 115], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 122, 129], ["mouse", "ORGANISM", 176, 181], ["plasma", "ORGANISM_SUBSTANCE", 182, 188], ["inflammatory cytokines", "PROTEIN", 4, 26], ["1L-1\u03b2, IL-6", "PROTEIN", 37, 48], ["TNF-\u03b1", "PROTEIN", 54, 59], ["chemokine monocyte chemoattractant protein 1", "PROTEIN", 65, 109], ["MCP1", "PROTEIN", 111, 115], ["SREBP", "PROTEIN", 122, 127], ["mouse", "SPECIES", 176, 181], ["mouse", "SPECIES", 176, 181], ["The inflammatory cytokines", "TEST", 0, 26], ["1L", "TEST", 37, 39], ["IL", "TEST", 44, 46], ["TNF", "TEST", 54, 57], ["the chemokine monocyte chemoattractant protein", "TEST", 61, 107], ["MCP1", "TEST", 111, 115], ["SREBP", "TEST", 122, 127], ["inflammatory", "OBSERVATION_MODIFIER", 4, 16], ["TNF", "ANATOMY", 54, 57], ["chemokine monocyte", "ANATOMY", 65, 83]]], ["The mRNA levels of nitrite/nitrate oxide (NOX), which is an indicator of sepsis, NLR family pyrin domain containing 3 (NLRP3) inflammasome, which plays a crucial role in innate immunity and inflammation,40 Il-1\u03b2, vascular cell adhesion molecule 1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and SREBP-2 in mouse lung tissue were also maintained in low level in response to the inhibition of NF-\u03baB signaling and SREBP-2 (Supplementary Fig. 7).", [["lung tissue", "ANATOMY", 322, 333], ["nitrite", "CHEMICAL", 19, 26], ["nitrate oxide", "CHEMICAL", 27, 40], ["sepsis", "DISEASE", 73, 79], ["inflammation", "DISEASE", 190, 202], ["nitrite", "CHEMICAL", 19, 26], ["nitrate oxide", "CHEMICAL", 27, 40], ["nitrite", "SIMPLE_CHEMICAL", 19, 26], ["nitrate oxide", "SIMPLE_CHEMICAL", 27, 40], ["NOX", "GENE_OR_GENE_PRODUCT", 42, 45], ["NLR family pyrin domain containing 3", "GENE_OR_GENE_PRODUCT", 81, 117], ["NLRP3", "GENE_OR_GENE_PRODUCT", 119, 124], ["Il-1\u03b2", "GENE_OR_GENE_PRODUCT", 206, 211], ["vascular cell adhesion molecule 1", "GENE_OR_GENE_PRODUCT", 213, 246], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 248, 254], ["intercellular adhesion molecule-1", "GENE_OR_GENE_PRODUCT", 257, 290], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 292, 298], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 305, 312], ["mouse", "ORGANISM", 316, 321], ["lung tissue", "TISSUE", 322, 333], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 401, 406], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 421, 428], ["NOX", "PROTEIN", 42, 45], ["NLR family pyrin domain containing 3 (NLRP3) inflammasome", "PROTEIN", 81, 138], ["vascular cell adhesion molecule 1", "PROTEIN", 213, 246], ["VCAM", "PROTEIN", 248, 252], ["intercellular adhesion molecule-1", "PROTEIN", 257, 290], ["ICAM", "PROTEIN", 292, 296], ["SREBP-2", "PROTEIN", 305, 312], ["NF-\u03baB", "PROTEIN", 401, 406], ["SREBP-2", "PROTEIN", 421, 428], ["mouse", "SPECIES", 316, 321], ["mouse", "SPECIES", 316, 321], ["The mRNA levels", "TEST", 0, 15], ["nitrite/nitrate oxide", "TREATMENT", 19, 40], ["sepsis", "PROBLEM", 73, 79], ["NLR family pyrin domain containing 3 (NLRP3) inflammasome", "TREATMENT", 81, 138], ["inflammation", "PROBLEM", 190, 202], ["Il", "TEST", 206, 208], ["vascular cell adhesion molecule", "TEST", 213, 244], ["VCAM", "TEST", 248, 252], ["intercellular adhesion molecule", "TEST", 257, 288], ["ICAM", "TEST", 292, 296], ["SREBP", "TEST", 305, 310], ["NF", "TEST", 401, 403], ["SREBP", "TEST", 421, 426], ["sepsis", "OBSERVATION", 73, 79], ["vascular cell", "ANATOMY", 213, 226], ["adhesion molecule", "OBSERVATION", 227, 244], ["lung tissue", "ANATOMY", 322, 333], ["low level", "OBSERVATION_MODIFIER", 358, 367]]], ["The experimental results in both COVID-19 patients\u2019 PBMCs and mouse model collectively suggest that the inhibition of NF-\u03baB signaling and SREBP-2 may play a pivotal role as therapeutics for infectious diseases.DiscussionRecently, the decreased level of total, HDL, and LDL was reported in the COVID-19 patients in Wenzhou, China.41 In our study, the lower level of the total, HDL and LDL were also observed in COVID-19 patients in Daegu, Korea, and the level was further decreased as the symptoms worsens.", [["PBMCs", "ANATOMY", 52, 57], ["infectious diseases", "DISEASE", 190, 209], ["COVID-19", "CELL", 33, 41], ["patients", "ORGANISM", 42, 50], ["PBMCs", "CELL", 52, 57], ["mouse", "ORGANISM", 62, 67], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 118, 123], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 138, 145], ["HDL", "SIMPLE_CHEMICAL", 260, 263], ["LDL", "SIMPLE_CHEMICAL", 269, 272], ["patients", "ORGANISM", 302, 310], ["HDL", "SIMPLE_CHEMICAL", 376, 379], ["LDL", "SIMPLE_CHEMICAL", 384, 387], ["patients", "ORGANISM", 419, 427], ["PBMCs", "CELL_TYPE", 52, 57], ["NF-\u03baB", "PROTEIN", 118, 123], ["SREBP-2", "PROTEIN", 138, 145], ["HDL", "PROTEIN", 260, 263], ["LDL", "PROTEIN", 269, 272], ["HDL", "PROTEIN", 376, 379], ["LDL", "PROTEIN", 384, 387], ["patients", "SPECIES", 42, 50], ["mouse", "SPECIES", 62, 67], ["patients", "SPECIES", 302, 310], ["patients", "SPECIES", 419, 427], ["mouse", "SPECIES", 62, 67], ["COVID", "TEST", 33, 38], ["PBMCs and mouse model", "TREATMENT", 52, 73], ["NF", "TEST", 118, 120], ["SREBP", "TEST", 138, 143], ["infectious diseases", "PROBLEM", 190, 209], ["HDL", "TEST", 260, 263], ["LDL", "TEST", 269, 272], ["the COVID", "TEST", 289, 298], ["our study", "TEST", 335, 344], ["LDL", "TEST", 384, 387], ["COVID", "TEST", 410, 415], ["the symptoms", "PROBLEM", 484, 496], ["decreased", "OBSERVATION_MODIFIER", 234, 243], ["LDL", "ANATOMY", 269, 272], ["decreased", "OBSERVATION_MODIFIER", 471, 480]]], ["Upon the viral infection, as well as in response to the entry of endotoxin, such as LPS, the cholesterol tends to inactivate their biological toxicity through the selective interaction.32,42 It is well known that decreased cholesterol level in serum and cells drives the dissociation of SCAP-SREBP-2 complex from INSIGs and subsequently the SCAP-SREBP-2 complex translocates to Golgi.14 The SREBPs was cleaved into N-term and C-term by enzymes including S1P and S2P, and the SREBP-2 N-term translocates to the nucleus and activates transcription of lipid synthesis.", [["serum", "ANATOMY", 244, 249], ["cells", "ANATOMY", 254, 259], ["nucleus", "ANATOMY", 510, 517], ["viral infection", "DISEASE", 9, 24], ["endotoxin", "CHEMICAL", 65, 74], ["LPS", "CHEMICAL", 84, 87], ["cholesterol", "CHEMICAL", 93, 104], ["toxicity", "DISEASE", 142, 150], ["cholesterol", "CHEMICAL", 223, 234], ["cholesterol", "CHEMICAL", 93, 104], ["cholesterol", "CHEMICAL", 223, 234], ["endotoxin", "GENE_OR_GENE_PRODUCT", 65, 74], ["LPS", "SIMPLE_CHEMICAL", 84, 87], ["cholesterol", "SIMPLE_CHEMICAL", 93, 104], ["cholesterol", "SIMPLE_CHEMICAL", 223, 234], ["serum", "ORGANISM_SUBSTANCE", 244, 249], ["cells", "CELL", 254, 259], ["SCAP", "GENE_OR_GENE_PRODUCT", 287, 291], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 292, 299], ["INSIGs", "GENE_OR_GENE_PRODUCT", 313, 319], ["SCAP", "GENE_OR_GENE_PRODUCT", 341, 345], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 346, 353], ["Golgi.", "GENE_OR_GENE_PRODUCT", 378, 384], ["SREBPs", "GENE_OR_GENE_PRODUCT", 391, 397], ["S1P", "GENE_OR_GENE_PRODUCT", 454, 457], ["S2P", "GENE_OR_GENE_PRODUCT", 462, 465], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 475, 482], ["nucleus", "CELLULAR_COMPONENT", 510, 517], ["lipid", "SIMPLE_CHEMICAL", 549, 554], ["endotoxin", "PROTEIN", 65, 74], ["SCAP", "PROTEIN", 287, 291], ["SREBP-2 complex", "PROTEIN", 292, 307], ["INSIGs", "PROTEIN", 313, 319], ["SCAP", "PROTEIN", 341, 345], ["SREBP-2 complex", "PROTEIN", 346, 361], ["SREBPs", "PROTEIN", 391, 397], ["enzymes", "PROTEIN", 436, 443], ["S1P", "PROTEIN", 454, 457], ["S2P", "PROTEIN", 462, 465], ["SREBP-2 N-term", "PROTEIN", 475, 489], ["the viral infection", "PROBLEM", 5, 24], ["endotoxin", "TREATMENT", 65, 74], ["LPS", "TEST", 84, 87], ["the cholesterol", "TEST", 89, 104], ["their biological toxicity", "PROBLEM", 125, 150], ["decreased cholesterol level in serum and cells", "PROBLEM", 213, 259], ["SCAP", "TEST", 287, 291], ["SREBP", "TEST", 292, 297], ["the SCAP", "TEST", 337, 345], ["SREBP", "TEST", 346, 351], ["The SREBPs", "TEST", 387, 397], ["enzymes", "TEST", 436, 443], ["S1P", "TEST", 454, 457], ["S2P", "TEST", 462, 465], ["the SREBP", "TEST", 471, 480], ["lipid synthesis", "TREATMENT", 549, 564], ["viral", "OBSERVATION_MODIFIER", 9, 14], ["infection", "OBSERVATION", 15, 24], ["decreased", "OBSERVATION_MODIFIER", 213, 222], ["cholesterol", "OBSERVATION", 223, 234], ["SCAP", "OBSERVATION_MODIFIER", 287, 291], ["SCAP", "ANATOMY", 341, 345], ["nucleus", "ANATOMY", 510, 517], ["lipid synthesis", "OBSERVATION", 549, 564]]], ["Similar, it was shown that a cross-talk between TLR4-MyD88-NF-\u03baB and SCAP-SREBP-2 pathways mediate macrophage foam cell formation and thereby inducing inflammatory responses.30 Intracellular cholesterol content was observed and it was shown that LPS increases both gene and protein expression levels of LDLR, HMG-CoAR, SCAP, and SREBP-2, leading to translocation of SREBP to organelles.DiscussionHowever, according to the analysis, the mRNA expression levels of SESN1 and PCSK9, that suppress the lipid biosynthesis, were increased in the PBMCs of COVID-19 patients.", [["macrophage foam cell", "ANATOMY", 99, 119], ["Intracellular", "ANATOMY", 177, 190], ["organelles", "ANATOMY", 375, 385], ["PBMCs", "ANATOMY", 539, 544], ["cholesterol", "CHEMICAL", 191, 202], ["LPS", "CHEMICAL", 246, 249], ["cholesterol", "CHEMICAL", 191, 202], ["TLR4", "GENE_OR_GENE_PRODUCT", 48, 52], ["MyD88", "GENE_OR_GENE_PRODUCT", 53, 58], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 59, 64], ["SCAP", "GENE_OR_GENE_PRODUCT", 69, 73], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 74, 81], ["macrophage foam cell", "CELL", 99, 119], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 177, 190], ["cholesterol", "SIMPLE_CHEMICAL", 191, 202], ["LPS", "SIMPLE_CHEMICAL", 246, 249], ["LDLR", "GENE_OR_GENE_PRODUCT", 303, 307], ["HMG-CoAR", "GENE_OR_GENE_PRODUCT", 309, 317], ["SCAP", "GENE_OR_GENE_PRODUCT", 319, 323], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 329, 336], ["SREBP", "GENE_OR_GENE_PRODUCT", 366, 371], ["organelles", "CELLULAR_COMPONENT", 375, 385], ["SESN1", "GENE_OR_GENE_PRODUCT", 462, 467], ["PCSK9", "GENE_OR_GENE_PRODUCT", 472, 477], ["lipid", "SIMPLE_CHEMICAL", 497, 502], ["PBMCs", "CELL", 539, 544], ["patients", "ORGANISM", 557, 565], ["TLR4", "PROTEIN", 48, 52], ["MyD88", "PROTEIN", 53, 58], ["SCAP", "PROTEIN", 69, 73], ["SREBP-2", "PROTEIN", 74, 81], ["LDLR", "PROTEIN", 303, 307], ["HMG", "PROTEIN", 309, 312], ["CoAR", "PROTEIN", 313, 317], ["SCAP", "PROTEIN", 319, 323], ["SREBP-2", "PROTEIN", 329, 336], ["SREBP", "PROTEIN", 366, 371], ["SESN1", "PROTEIN", 462, 467], ["PCSK9", "PROTEIN", 472, 477], ["PBMCs", "CELL_TYPE", 539, 544], ["patients", "SPECIES", 557, 565], ["a cross", "TEST", 27, 34], ["TLR4", "TEST", 48, 52], ["MyD88", "TEST", 53, 58], ["NF", "TEST", 59, 61], ["SCAP", "TEST", 69, 73], ["SREBP", "TEST", 74, 79], ["macrophage foam cell formation", "TREATMENT", 99, 129], ["Intracellular cholesterol content", "TEST", 177, 210], ["LPS", "PROBLEM", 246, 249], ["protein expression levels", "TEST", 274, 299], ["LDLR", "TEST", 303, 307], ["HMG", "TEST", 309, 312], ["SCAP", "TEST", 319, 323], ["SREBP", "TEST", 329, 334], ["the analysis", "TEST", 418, 430], ["the mRNA expression levels", "TEST", 432, 458], ["SESN1", "TEST", 462, 467], ["PCSK9", "TEST", 472, 477], ["the lipid biosynthesis", "TREATMENT", 493, 515], ["COVID", "TEST", 548, 553], ["SCAP", "ANATOMY", 69, 73], ["macrophage foam cell formation", "OBSERVATION", 99, 129], ["inflammatory", "OBSERVATION_MODIFIER", 151, 163], ["cholesterol content", "OBSERVATION", 191, 210], ["SCAP", "ANATOMY", 319, 323], ["increased", "OBSERVATION_MODIFIER", 522, 531]]], ["Cholesterol biosynthesis is inhibited by the expression of SESN-1 and PCSK9, and is regulated by transcription factor and NRLP3 inflammasome.24,43 A recent study has confirmed that cholesterol biosynthesis is increased by the activity of SREBP-2; but at the same time, SESN-1 and PCSK9 are expressed and inhibitory results were demonstrated.24 In severe COVID-19 patients, the biosynthesis of cholesterol such as intracellular HDL needs to be promoted and then subsequent homeostasis takes place as a result of the increase in SREBP-2 activity.DiscussionAs a result of upregulation of lipid synthesis-suppressing genes, cells do not synthesize cholesterol.", [["intracellular", "ANATOMY", 413, 426], ["cells", "ANATOMY", 620, 625], ["Cholesterol", "CHEMICAL", 0, 11], ["cholesterol", "CHEMICAL", 181, 192], ["COVID", "DISEASE", 354, 359], ["cholesterol", "CHEMICAL", 393, 404], ["cholesterol", "CHEMICAL", 644, 655], ["Cholesterol", "CHEMICAL", 0, 11], ["cholesterol", "CHEMICAL", 181, 192], ["cholesterol", "CHEMICAL", 393, 404], ["cholesterol", "CHEMICAL", 644, 655], ["Cholesterol", "SIMPLE_CHEMICAL", 0, 11], ["SESN-1", "GENE_OR_GENE_PRODUCT", 59, 65], ["PCSK9", "GENE_OR_GENE_PRODUCT", 70, 75], ["NRLP3", "GENE_OR_GENE_PRODUCT", 122, 127], ["cholesterol", "SIMPLE_CHEMICAL", 181, 192], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 238, 245], ["SESN-1", "GENE_OR_GENE_PRODUCT", 269, 275], ["PCSK9", "GENE_OR_GENE_PRODUCT", 280, 285], ["patients", "ORGANISM", 363, 371], ["cholesterol", "SIMPLE_CHEMICAL", 393, 404], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 413, 426], ["HDL", "SIMPLE_CHEMICAL", 427, 430], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 527, 534], ["lipid", "SIMPLE_CHEMICAL", 585, 590], ["cells", "CELL", 620, 625], ["cholesterol", "SIMPLE_CHEMICAL", 644, 655], ["SESN-1", "PROTEIN", 59, 65], ["PCSK9", "PROTEIN", 70, 75], ["transcription factor", "PROTEIN", 97, 117], ["NRLP3 inflammasome", "PROTEIN", 122, 140], ["SREBP-2", "PROTEIN", 238, 245], ["SESN", "PROTEIN", 269, 273], ["PCSK9", "PROTEIN", 280, 285], ["SREBP-2", "PROTEIN", 527, 534], ["patients", "SPECIES", 363, 371], ["Cholesterol biosynthesis", "PROBLEM", 0, 24], ["SESN", "TEST", 59, 63], ["PCSK9", "TEST", 70, 75], ["A recent study", "TEST", 147, 161], ["cholesterol biosynthesis", "PROBLEM", 181, 205], ["SREBP", "TEST", 238, 243], ["SESN", "TEST", 269, 273], ["the biosynthesis of cholesterol", "TREATMENT", 373, 404], ["intracellular HDL", "TREATMENT", 413, 430], ["SREBP", "TEST", 527, 532], ["upregulation of lipid synthesis", "TREATMENT", 569, 600], ["increased", "OBSERVATION_MODIFIER", 209, 218], ["severe", "OBSERVATION_MODIFIER", 347, 353], ["increase", "OBSERVATION_MODIFIER", 515, 523]]], ["Instead, in the COVID-19 infection and sepsis cases, SREBP-2 regulates the production of IL-1\u03b2 and TNF-\u03b1, which is well displayed in Fig. 1e, f.", [["infection", "DISEASE", 25, 34], ["sepsis", "DISEASE", 39, 45], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 53, 60], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 89, 94], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 99, 104], ["SREBP-2", "PROTEIN", 53, 60], ["IL-1\u03b2", "PROTEIN", 89, 94], ["TNF", "PROTEIN", 99, 102], ["\u03b1", "PROTEIN", 103, 104], ["COVID-19", "SPECIES", 16, 24], ["the COVID-19 infection", "PROBLEM", 12, 34], ["sepsis cases", "PROBLEM", 39, 51], ["SREBP", "TEST", 53, 58], ["IL", "TEST", 89, 91], ["TNF", "TEST", 99, 102], ["infection", "OBSERVATION", 25, 34], ["sepsis", "OBSERVATION", 39, 45]]], ["Further, we demonstrated that the SREBP-2 is also upregulated as a consequence of NF-\u03baB.", [["SREBP-2", "GENE_OR_GENE_PRODUCT", 34, 41], ["NF-\u03ba", "GENE_OR_GENE_PRODUCT", 82, 86], ["SREBP-2", "PROTEIN", 34, 41], ["NF-\u03ba", "PROTEIN", 82, 86], ["the SREBP", "TEST", 30, 39], ["NF", "PROBLEM", 82, 84]]], ["This supports a recent report of a biological crosstalk between SREBP2 and NF-\u03baB.30,44,45 When cells are infected, they secrete lipid and cholesterol to inactivate the viruses.32,34,46 Recently, it has been reported that, SREBP2, which regulates cholesterol biosynthesis, act as a signaling hub for inflammation and cholesterol metabolism.33,35 Based on these findings, we can deduce that the activation of cholesterol biosynthesis is as a result of decrease in cellular cholesterol level and subsequent activation of SREBP-2.", [["cells", "ANATOMY", 95, 100], ["cellular", "ANATOMY", 462, 470], ["cholesterol", "CHEMICAL", 138, 149], ["cholesterol", "CHEMICAL", 246, 257], ["inflammation", "DISEASE", 299, 311], ["cholesterol", "CHEMICAL", 316, 327], ["cholesterol", "CHEMICAL", 407, 418], ["cholesterol", "CHEMICAL", 471, 482], ["cholesterol", "CHEMICAL", 138, 149], ["cholesterol", "CHEMICAL", 246, 257], ["cholesterol", "CHEMICAL", 316, 327], ["cholesterol", "CHEMICAL", 407, 418], ["cholesterol", "CHEMICAL", 471, 482], ["SREBP2", "GENE_OR_GENE_PRODUCT", 64, 70], ["NF-\u03ba", "GENE_OR_GENE_PRODUCT", 75, 79], ["cells", "CELL", 95, 100], ["lipid", "SIMPLE_CHEMICAL", 128, 133], ["cholesterol", "SIMPLE_CHEMICAL", 138, 149], ["SREBP2", "GENE_OR_GENE_PRODUCT", 222, 228], ["cholesterol", "SIMPLE_CHEMICAL", 246, 257], ["cholesterol", "SIMPLE_CHEMICAL", 316, 327], ["cholesterol", "SIMPLE_CHEMICAL", 407, 418], ["cellular", "CELL", 462, 470], ["cholesterol", "SIMPLE_CHEMICAL", 471, 482], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 518, 525], ["SREBP2", "PROTEIN", 64, 70], ["NF-\u03baB.30,44,45", "PROTEIN", 75, 89], ["SREBP2", "PROTEIN", 222, 228], ["SREBP-2", "PROTEIN", 518, 525], ["NF", "TEST", 75, 77], ["infected", "PROBLEM", 105, 113], ["the viruses", "PROBLEM", 164, 175], ["SREBP2", "TEST", 222, 228], ["inflammation", "PROBLEM", 299, 311], ["cholesterol metabolism", "PROBLEM", 316, 338], ["cholesterol biosynthesis", "PROBLEM", 407, 431], ["decrease in cellular cholesterol level", "PROBLEM", 450, 488], ["SREBP", "TEST", 518, 523], ["viruses", "OBSERVATION", 168, 175], ["inflammation", "OBSERVATION", 299, 311], ["cholesterol metabolism", "OBSERVATION", 316, 338], ["decrease", "OBSERVATION_MODIFIER", 450, 458], ["cellular cholesterol", "OBSERVATION", 462, 482]]], ["SREBP-2-mediated biosynthesis of cholesterol is involved in the exocytosis process of SARS-CoV2, which explains its role in virus budding and envelop.31,47,48 For the inhibition of this process, Statin-based drugs have been suggested as therapeutic agents.31 These mechanisms collectively suggest that various responses caused by SARS-CoV-2 infection activates SREBP-2, as demonstrated in Fig. 1.DiscussionWe have noticed changes in the circulating levels of HDL and LDL in COVID-19 patients and assume they could serve as markers for prediction of the severity of the disease, given sufficient database is attained and statistical significance is found.", [["cholesterol", "CHEMICAL", 33, 44], ["SARS", "DISEASE", 86, 90], ["Statin", "CHEMICAL", 195, 201], ["SARS", "DISEASE", 330, 334], ["infection", "DISEASE", 341, 350], ["cholesterol", "CHEMICAL", 33, 44], ["Statin", "CHEMICAL", 195, 201], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 0, 7], ["cholesterol", "SIMPLE_CHEMICAL", 33, 44], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 86, 95], ["Statin", "SIMPLE_CHEMICAL", 195, 201], ["SARS-CoV-2", "ORGANISM", 330, 340], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 361, 368], ["HDL", "SIMPLE_CHEMICAL", 459, 462], ["LDL", "SIMPLE_CHEMICAL", 467, 470], ["patients", "ORGANISM", 483, 491], ["SREBP-2", "PROTEIN", 0, 7], ["SREBP-2", "PROTEIN", 361, 368], ["HDL", "PROTEIN", 459, 462], ["LDL", "PROTEIN", 467, 470], ["patients", "SPECIES", 483, 491], ["SARS-CoV", "SPECIES", 330, 338], ["SREBP", "TEST", 0, 5], ["mediated biosynthesis of cholesterol", "TREATMENT", 8, 44], ["SARS", "PROBLEM", 86, 90], ["this process", "PROBLEM", 181, 193], ["Statin-based drugs", "TREATMENT", 195, 213], ["therapeutic agents", "TREATMENT", 237, 255], ["SARS", "PROBLEM", 330, 334], ["CoV-2 infection", "PROBLEM", 335, 350], ["SREBP", "TEST", 361, 366], ["HDL", "TEST", 459, 462], ["LDL", "TEST", 467, 470], ["COVID", "TEST", 474, 479], ["the disease", "PROBLEM", 565, 576], ["SARS", "OBSERVATION", 86, 90], ["virus", "OBSERVATION", 124, 129], ["disease", "OBSERVATION", 569, 576]]], ["A standard need to be established based on the cholesterol level in infected patients with respect to body mass index (BMI).", [["body", "ANATOMY", 102, 106], ["cholesterol", "CHEMICAL", 47, 58], ["cholesterol", "CHEMICAL", 47, 58], ["cholesterol", "SIMPLE_CHEMICAL", 47, 58], ["patients", "ORGANISM", 77, 85], ["body", "ORGANISM_SUBDIVISION", 102, 106], ["patients", "SPECIES", 77, 85], ["the cholesterol level", "TEST", 43, 64], ["body mass index", "TEST", 102, 117], ["infected", "OBSERVATION", 68, 76]]], ["Many researchers have already studied the connection between lipid metabolism and SARS-CoV-2,49 and provided that these results are databased in the future we may be able to suggest HDL and LDL as a severity marker of COVID-19.DiscussionARDS and septic shock are the main symptoms of severe COVID-19 patients, and are the leading causes of death.50,51 In particular, we monitored high levels of activation of the selected treatment targets, SREBP-2 and NF-\u03baB (Fig. 1).", [["septic shock", "DISEASE", 246, 258], ["COVID", "DISEASE", 291, 296], ["death", "DISEASE", 340, 345], ["COVID-19", "CHEMICAL", 218, 226], ["lipid", "SIMPLE_CHEMICAL", 61, 66], ["HDL", "SIMPLE_CHEMICAL", 182, 185], ["LDL", "SIMPLE_CHEMICAL", 190, 193], ["patients", "ORGANISM", 300, 308], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 441, 448], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 453, 458], ["HDL", "PROTEIN", 182, 185], ["LDL", "PROTEIN", 190, 193], ["SREBP-2", "PROTEIN", 441, 448], ["NF-\u03baB", "PROTEIN", 453, 458], ["patients", "SPECIES", 300, 308], ["lipid metabolism", "TEST", 61, 77], ["CoV", "TEST", 87, 90], ["HDL", "TEST", 182, 185], ["LDL", "TEST", 190, 193], ["a severity marker", "TEST", 197, 214], ["COVID", "TEST", 218, 223], ["septic shock", "PROBLEM", 246, 258], ["severe COVID", "PROBLEM", 284, 296], ["death", "PROBLEM", 340, 345], ["the selected treatment targets", "TREATMENT", 409, 439], ["SREBP", "TEST", 441, 446], ["septic shock", "OBSERVATION", 246, 258], ["severe", "OBSERVATION_MODIFIER", 284, 290]]], ["The CLP model that we used in this study is a polymicrobial septic mouse model.", [["septic", "DISEASE", 60, 66], ["mouse", "ORGANISM", 67, 72], ["mouse", "SPECIES", 67, 72], ["mouse", "SPECIES", 67, 72], ["this study", "TEST", 30, 40], ["a polymicrobial septic mouse model", "PROBLEM", 44, 78], ["CLP", "OBSERVATION", 4, 7], ["polymicrobial septic mouse model", "OBSERVATION", 46, 78]]], ["It is widely acknowledged that cecal ligation and puncture (CLP) or lipopolysaccharide (LPS) induces systemic inflammation and overproduction of cytokines in C57BL/6N mice.52 We noticed that the bacterial infection induced not only cytokine storm, but also increased the levels of activated SREBP-2 and NF-\u03baB, and mRNA levels of other related proteins (Fig. 5).", [["cecal", "ANATOMY", 31, 36], ["lipopolysaccharide", "CHEMICAL", 68, 86], ["LPS", "CHEMICAL", 88, 91], ["inflammation", "DISEASE", 110, 122], ["bacterial infection", "DISEASE", 195, 214], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 68, 86], ["LPS", "SIMPLE_CHEMICAL", 88, 91], ["C57BL/6N mice", "ORGANISM", 158, 171], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 291, 298], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 303, 308], ["cytokines", "PROTEIN", 145, 154], ["cytokine", "PROTEIN", 232, 240], ["SREBP", "PROTEIN", 291, 296], ["NF-\u03baB", "PROTEIN", 303, 308], ["mice", "SPECIES", 167, 171], ["mice", "SPECIES", 167, 171], ["cecal ligation", "TREATMENT", 31, 45], ["puncture (CLP", "TREATMENT", 50, 63], ["lipopolysaccharide (LPS)", "TREATMENT", 68, 92], ["systemic inflammation", "PROBLEM", 101, 122], ["cytokines in C57BL/6N mice", "TREATMENT", 145, 171], ["the bacterial infection", "PROBLEM", 191, 214], ["activated SREBP", "TEST", 281, 296], ["NF", "TEST", 303, 305], ["mRNA levels", "TEST", 314, 325], ["cecal", "ANATOMY", 31, 36], ["ligation", "OBSERVATION", 37, 45], ["systemic", "OBSERVATION_MODIFIER", 101, 109], ["inflammation", "OBSERVATION", 110, 122], ["bacterial", "OBSERVATION_MODIFIER", 195, 204], ["infection", "OBSERVATION", 205, 214], ["cytokine storm", "OBSERVATION", 232, 246]]], ["SREBP-2-activated and NF-\u03baB-activated PBMCs of COVID-19 patients, together with CLP mouse model were used in this study to evaluate the therapeutic efficacy of the inhibitors.", [["PBMCs", "ANATOMY", 38, 43], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 0, 7], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 22, 27], ["PBMCs", "CELL", 38, 43], ["COVID-19", "CELL", 47, 55], ["patients", "ORGANISM", 56, 64], ["mouse", "ORGANISM", 84, 89], ["SREBP-2", "PROTEIN", 0, 7], ["NF-\u03baB", "PROTEIN", 22, 27], ["PBMCs", "CELL_TYPE", 38, 43], ["patients", "SPECIES", 56, 64], ["mouse", "SPECIES", 84, 89], ["mouse", "SPECIES", 84, 89], ["SREBP", "TEST", 0, 5], ["COVID", "TEST", 47, 52], ["CLP mouse model", "TREATMENT", 80, 95], ["this study", "TEST", 109, 119], ["the inhibitors", "TREATMENT", 160, 174]]], ["We have used the LPS cellular model because it was previously verified that NF-\u03baB and SREBP-2 are activated by LPS.30,44,45 As for the cellular model, it is important to demonstrate lung damage and long-term damage caused by the viral infection by observing the vascular integrity.", [["cellular", "ANATOMY", 21, 29], ["cellular", "ANATOMY", 135, 143], ["lung", "ANATOMY", 182, 186], ["vascular", "ANATOMY", 262, 270], ["LPS", "CHEMICAL", 111, 114], ["30,44,45", "CHEMICAL", 115, 123], ["lung damage", "DISEASE", 182, 193], ["viral infection", "DISEASE", 229, 244], ["cellular", "CELL", 21, 29], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 76, 81], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 86, 93], ["LPS", "SIMPLE_CHEMICAL", 111, 114], ["cellular", "CELL", 135, 143], ["lung", "ORGAN", 182, 186], ["vascular", "MULTI-TISSUE_STRUCTURE", 262, 270], ["NF-\u03baB", "PROTEIN", 76, 81], ["SREBP-2", "PROTEIN", 86, 93], ["the LPS cellular model", "TREATMENT", 13, 35], ["NF", "TEST", 76, 78], ["SREBP", "TEST", 86, 91], ["the cellular model", "TEST", 131, 149], ["lung damage", "PROBLEM", 182, 193], ["long-term damage", "PROBLEM", 198, 214], ["the viral infection", "PROBLEM", 225, 244], ["cellular model", "OBSERVATION", 135, 149], ["lung", "ANATOMY", 182, 186], ["damage", "OBSERVATION", 187, 193], ["long-term damage", "OBSERVATION_MODIFIER", 198, 214], ["viral", "OBSERVATION_MODIFIER", 229, 234], ["infection", "OBSERVATION", 235, 244], ["vascular", "ANATOMY", 262, 270]]], ["HUVEC was used because the correlation between SARS-CoV-2 and endothelial disruption is important.", [["HUVEC", "ANATOMY", 0, 5], ["endothelial", "ANATOMY", 62, 73], ["HUVEC", "CELL", 0, 5], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 47, 57], ["endothelial", "CELL", 62, 73], ["HUVEC", "CELL_LINE", 0, 5], ["HUVEC", "TEST", 0, 5], ["SARS", "TEST", 47, 51], ["CoV", "TEST", 52, 55], ["endothelial disruption", "PROBLEM", 62, 84], ["endothelial", "ANATOMY", 62, 73], ["disruption", "OBSERVATION", 74, 84]]], ["As for HEK293, it was used in evaluation to assess the activity of SREBP-2 via genetic modification.DiscussionIn addition, since the SREBP-2 is ubiquitously in many cell types, its inhibition can serve as an anticipative therapeutic strategy for infectious diseases.", [["HEK293", "ANATOMY", 7, 13], ["cell", "ANATOMY", 165, 169], ["infectious diseases", "DISEASE", 246, 265], ["HEK293", "CELL", 7, 13], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 67, 74], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 133, 140], ["cell", "CELL", 165, 169], ["HEK293", "CELL_LINE", 7, 13], ["SREBP-2", "PROTEIN", 67, 74], ["SREBP-2", "PROTEIN", 133, 140], ["evaluation", "TEST", 30, 40], ["SREBP", "TEST", 67, 72], ["genetic modification", "TREATMENT", 79, 99], ["the SREBP", "TEST", 129, 138], ["an anticipative therapeutic strategy", "TREATMENT", 205, 241], ["infectious diseases", "PROBLEM", 246, 265]]], ["As shown in our pharmacological inhibition of SREBP-2 and NF-\u03baB using inhibitors and shRNA, the early-stage inhibition of them could indeed suppress the tissue damage, overproduction of inflammatory cytokines, and death.DiscussionIt is noted that we found the SREBP-2 C-term as a diagnostic marker for severity of infectious diseases.", [["tissue", "ANATOMY", 153, 159], ["tissue damage", "DISEASE", 153, 166], ["death", "DISEASE", 214, 219], ["infectious diseases", "DISEASE", 314, 333], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 46, 53], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 58, 63], ["tissue", "TISSUE", 153, 159], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 260, 267], ["SREBP-2", "PROTEIN", 46, 53], ["NF-\u03baB", "PROTEIN", 58, 63], ["inflammatory cytokines", "PROTEIN", 186, 208], ["SREBP", "PROTEIN", 260, 265], ["SREBP", "TEST", 46, 51], ["NF", "TEST", 58, 60], ["inhibitors", "TREATMENT", 70, 80], ["shRNA", "TREATMENT", 85, 90], ["the tissue damage", "PROBLEM", 149, 166], ["inflammatory cytokines", "PROBLEM", 186, 208], ["death", "PROBLEM", 214, 219], ["the SREBP", "TEST", 256, 265], ["infectious diseases", "PROBLEM", 314, 333], ["inflammatory cytokines", "OBSERVATION", 186, 208], ["infectious", "OBSERVATION", 314, 324]]], ["In spite of in-depth studies on SREBP-2 N-term, the roles and trajectories of enzyme-dissociated SREBP-2 C-term has not been reported.", [["SREBP-2", "GENE_OR_GENE_PRODUCT", 32, 39], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 97, 104], ["SREBP", "PROTEIN", 32, 37], ["enzyme", "PROTEIN", 78, 84], ["SREBP", "PROTEIN", 97, 102], ["SREBP", "TEST", 32, 37], ["enzyme-dissociated SREBP", "TEST", 78, 102]]], ["In our study, to the best of our knowledge, we demonstrate the secretion of SREBP-2 C-term for the first time.", [["SREBP-2", "GENE_OR_GENE_PRODUCT", 76, 83], ["SREBP", "PROTEIN", 76, 81], ["our study", "TEST", 3, 12], ["SREBP", "TEST", 76, 81]]], ["According to our study, SREBP-2 C-term is found as a secreted form in the patients\u2019 plasma and culture media, and also detected in PBMCs.", [["plasma", "ANATOMY", 84, 90], ["PBMCs", "ANATOMY", 131, 136], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 24, 31], ["patients", "ORGANISM", 74, 82], ["plasma", "ORGANISM_SUBSTANCE", 84, 90], ["PBMCs", "CELL", 131, 136], ["SREBP", "PROTEIN", 24, 29], ["PBMCs", "CELL_TYPE", 131, 136], ["patients", "SPECIES", 74, 82], ["our study", "TEST", 13, 22], ["SREBP", "TEST", 24, 29], ["culture media", "TEST", 95, 108]]], ["These results showed that SREBP-2 C-term is released out of cells and circulate plasma.", [["cells", "ANATOMY", 60, 65], ["plasma", "ANATOMY", 80, 86], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 26, 33], ["cells", "CELL", 60, 65], ["plasma", "ORGANISM_SUBSTANCE", 80, 86], ["SREBP", "PROTEIN", 26, 31], ["SREBP", "TEST", 26, 31], ["circulate plasma", "TEST", 70, 86]]], ["This extracellular secretion of SREBP-2 C-term can be used for the diagnostic marker.DiscussionHere, inspired by finding of SREBP-2 C-term fragment in blood, we hypothesized that the underlying infection with SREBP-2 mechanism involves (1) signal transduction of cytokine storm and activating vascular inflammatory responses, (2) secretion of cholesterol complex with pathogens, (3) reduction of cytoplasmic cholesterol and SREBP-2 activation by S1P and S2P cleavage, (4) SREBP-2 N-term fragment translocates to nucleus and activation of cholesterol biosynthesis and inflammation, (5) leading to SREBP-2 C-term fragment secretion alone or as a vesicle (granule) along with SCAP in the membrane (Fig. 6).", [["extracellular", "ANATOMY", 5, 18], ["blood", "ANATOMY", 151, 156], ["vascular", "ANATOMY", 293, 301], ["cytoplasmic", "ANATOMY", 396, 407], ["nucleus", "ANATOMY", 512, 519], ["vesicle", "ANATOMY", 644, 651], ["granule", "ANATOMY", 653, 660], ["membrane", "ANATOMY", 685, 693], ["infection", "DISEASE", 194, 203], ["cholesterol", "CHEMICAL", 343, 354], ["cholesterol", "CHEMICAL", 408, 419], ["S1P", "CHEMICAL", 446, 449], ["cholesterol", "CHEMICAL", 538, 549], ["inflammation", "DISEASE", 567, 579], ["cholesterol", "CHEMICAL", 343, 354], ["cholesterol", "CHEMICAL", 408, 419], ["S1P", "CHEMICAL", 446, 449], ["cholesterol", "CHEMICAL", 538, 549], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 5, 18], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 32, 39], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 124, 131], ["blood", "ORGANISM_SUBSTANCE", 151, 156], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 209, 216], ["vascular", "MULTI-TISSUE_STRUCTURE", 293, 301], ["cholesterol", "SIMPLE_CHEMICAL", 343, 354], ["cytoplasmic", "ORGANISM_SUBSTANCE", 396, 407], ["cholesterol", "SIMPLE_CHEMICAL", 408, 419], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 424, 431], ["S1P", "GENE_OR_GENE_PRODUCT", 446, 449], ["S2P", "GENE_OR_GENE_PRODUCT", 454, 457], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 472, 479], ["nucleus", "CELLULAR_COMPONENT", 512, 519], ["cholesterol", "SIMPLE_CHEMICAL", 538, 549], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 596, 603], ["vesicle", "CELLULAR_COMPONENT", 644, 651], ["granule", "CELLULAR_COMPONENT", 653, 660], ["SCAP", "GENE_OR_GENE_PRODUCT", 673, 677], ["membrane", "CELLULAR_COMPONENT", 685, 693], ["SREBP", "PROTEIN", 32, 37], ["SREBP-2 C-term fragment", "DNA", 124, 147], ["SREBP-2", "PROTEIN", 209, 216], ["cytokine", "PROTEIN", 263, 271], ["cholesterol complex", "PROTEIN", 343, 362], ["SREBP-2", "PROTEIN", 424, 431], ["SREBP-2 N-term fragment", "PROTEIN", 472, 495], ["SREBP", "PROTEIN", 596, 601], ["SCAP", "PROTEIN", 673, 677], ["This extracellular secretion of SREBP", "TEST", 0, 37], ["the diagnostic marker", "TEST", 63, 84], ["SREBP", "TEST", 124, 129], ["2 C-term fragment in blood", "PROBLEM", 130, 156], ["the underlying infection", "PROBLEM", 179, 203], ["SREBP", "TEST", 209, 214], ["cytokine storm", "PROBLEM", 263, 277], ["activating vascular inflammatory responses", "PROBLEM", 282, 324], ["secretion of cholesterol complex", "PROBLEM", 330, 362], ["pathogens", "PROBLEM", 368, 377], ["cytoplasmic cholesterol", "TEST", 396, 419], ["SREBP", "TEST", 424, 429], ["S1P and S2P cleavage", "TREATMENT", 446, 466], ["SREBP-2 N-term fragment translocates", "TREATMENT", 472, 508], ["cholesterol biosynthesis", "PROBLEM", 538, 562], ["inflammation", "PROBLEM", 567, 579], ["SREBP", "TEST", 596, 601], ["2 C-term fragment secretion", "PROBLEM", 602, 629], ["a vesicle (granule)", "PROBLEM", 642, 661], ["SCAP in the membrane", "TREATMENT", 673, 693], ["infection", "OBSERVATION", 194, 203], ["cytokine storm", "OBSERVATION", 263, 277], ["vascular", "ANATOMY", 293, 301], ["inflammatory", "OBSERVATION", 302, 314], ["cytoplasmic cholesterol", "OBSERVATION", 396, 419], ["nucleus", "ANATOMY", 512, 519], ["cholesterol biosynthesis", "OBSERVATION", 538, 562], ["inflammation", "OBSERVATION", 567, 579], ["vesicle", "ANATOMY", 644, 651], ["membrane", "ANATOMY_MODIFIER", 685, 693]]], ["Whether generated SREBP-2 C-term fragment undergo lysis, recycle, or exocytosis (secretion), and in what particular form needs to be further elucidated.", [["SREBP-2", "GENE_OR_GENE_PRODUCT", 18, 25], ["SREBP-2 C-term fragment", "DNA", 18, 41], ["SREBP", "TEST", 18, 23], ["lysis", "TREATMENT", 50, 55], ["exocytosis", "PROBLEM", 69, 79], ["SREBP", "OBSERVATION_MODIFIER", 18, 23], ["lysis", "OBSERVATION", 50, 55]]], ["Nonetheless, observation of SREBP-2 C-term fragment in septic patient blood demonstrate that it can be used as a septic biomarker.DiscussionThis discovery of SREBP-2 C-term fragment in patient\u2019s blood considered a suitable biomarker candidate and potentially a can be considered as a theragnostic marker for determining the severity and treatment target for severe COVID-19 patients.", [["blood", "ANATOMY", 70, 75], ["blood", "ANATOMY", 195, 200], ["septic", "DISEASE", 55, 61], ["septic", "DISEASE", 113, 119], ["COVID", "DISEASE", 365, 370], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 28, 35], ["patient", "ORGANISM", 62, 69], ["blood", "ORGANISM_SUBSTANCE", 70, 75], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 158, 165], ["patient", "ORGANISM", 185, 192], ["blood", "ORGANISM_SUBSTANCE", 195, 200], ["patients", "ORGANISM", 374, 382], ["SREBP-2 C-term fragment", "DNA", 28, 51], ["SREBP-2 C-term fragment", "DNA", 158, 181], ["patient", "SPECIES", 62, 69], ["patient", "SPECIES", 185, 192], ["patients", "SPECIES", 374, 382], ["SREBP", "TEST", 28, 33], ["2 C-term fragment", "PROBLEM", 34, 51], ["septic patient blood", "PROBLEM", 55, 75], ["a septic biomarker", "TEST", 111, 129], ["SREBP", "TEST", 158, 163], ["2 C-term fragment", "PROBLEM", 164, 181], ["a theragnostic marker", "TEST", 282, 303], ["severe COVID", "PROBLEM", 358, 370], ["septic", "OBSERVATION", 55, 61], ["septic", "OBSERVATION", 113, 119]]], ["These results collectively suggest that SREBP-2 C-term fragment may be a key therapeutic target for preventing cytokine storm and organ damages in severe COVID-19 patients with sepsis.", [["organ", "ANATOMY", 130, 135], ["organ damages", "DISEASE", 130, 143], ["COVID", "DISEASE", 154, 159], ["sepsis", "DISEASE", 177, 183], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 40, 47], ["organ", "ORGAN", 130, 135], ["patients", "ORGANISM", 163, 171], ["SREBP-2 C-term fragment", "DNA", 40, 63], ["cytokine", "PROTEIN", 111, 119], ["patients", "SPECIES", 163, 171], ["SREBP", "TEST", 40, 45], ["2 C-term fragment", "PROBLEM", 46, 63], ["cytokine storm", "PROBLEM", 111, 125], ["organ damages", "PROBLEM", 130, 143], ["sepsis", "PROBLEM", 177, 183], ["severe", "OBSERVATION_MODIFIER", 147, 153], ["sepsis", "OBSERVATION", 177, 183]]], ["Strategies against SREBP-2 N-term fragment deacetylation and SREBP-2 C-term fragment secretion and their associated cellular cholesterol biosynthesis and inflammatory pathways may have preventive and therapeutic potentials in organ injury.", [["cellular", "ANATOMY", 116, 124], ["organ", "ANATOMY", 226, 231], ["cholesterol", "CHEMICAL", 125, 136], ["organ injury", "DISEASE", 226, 238], ["cholesterol", "CHEMICAL", 125, 136], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 19, 26], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 61, 68], ["cellular", "CELL", 116, 124], ["cholesterol", "SIMPLE_CHEMICAL", 125, 136], ["organ", "ORGAN", 226, 231], ["SREBP", "PROTEIN", 19, 24], ["SREBP", "PROTEIN", 61, 66], ["SREBP", "TEST", 19, 24], ["2 N-term fragment deacetylation", "TREATMENT", 25, 56], ["SREBP", "TEST", 61, 66], ["2 C-term fragment secretion", "PROBLEM", 67, 94], ["their associated cellular cholesterol biosynthesis", "PROBLEM", 99, 149], ["inflammatory pathways", "PROBLEM", 154, 175], ["organ injury", "PROBLEM", 226, 238], ["cellular cholesterol", "OBSERVATION", 116, 136], ["inflammatory", "OBSERVATION_MODIFIER", 154, 166], ["organ", "ANATOMY", 226, 231], ["injury", "OBSERVATION", 232, 238]]], ["The major drawback of current markers of sepsis is that they cannot determine the severity of the disease, whereas higher accuracy and precision is anticipated when comparison is made between the cholesterol and SREBP-2 C-term levels.", [["sepsis", "DISEASE", 41, 47], ["cholesterol", "CHEMICAL", 196, 207], ["cholesterol", "CHEMICAL", 196, 207], ["cholesterol", "SIMPLE_CHEMICAL", 196, 207], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 212, 219], ["SREBP", "PROTEIN", 212, 217], ["sepsis", "PROBLEM", 41, 47], ["the disease", "PROBLEM", 94, 105], ["the cholesterol and SREBP", "TEST", 192, 217], ["sepsis", "OBSERVATION", 41, 47], ["disease", "OBSERVATION", 98, 105]]], ["The advantages of SREBP-2 over the current biomarker of sepsis is that it can determine the severity of the disease as well as higher indication of the positive result can be obtained.", [["sepsis", "DISEASE", 56, 62], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 18, 25], ["SREBP", "PROTEIN", 18, 23], ["SREBP", "TEST", 18, 23], ["sepsis", "PROBLEM", 56, 62], ["the disease", "PROBLEM", 104, 115], ["sepsis", "OBSERVATION", 56, 62], ["disease", "OBSERVATION", 108, 115]]], ["We anticipate new therapeutic possibilities based on targeting and modulating SREBP-2 N-term fragments and/or the changing SREBP-2-dependent epigenetics in cells.Plasma sample ::: Materials and methodsWhole blood was collected from patients admitted at Yeungnam University Medical Center after they were diagnosed with the SARS-CoV-2 infection at a public health center in Daegu, Republic of Korea.", [["cells", "ANATOMY", 156, 161], ["sample", "ANATOMY", 169, 175], ["Whole blood", "ANATOMY", 201, 212], ["SARS-CoV-2 infection", "DISEASE", 323, 343], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 78, 85], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 123, 130], ["cells", "CELL", 156, 161], ["Plasma", "ORGANISM_SUBSTANCE", 162, 168], ["blood", "ORGANISM_SUBSTANCE", 207, 212], ["patients", "ORGANISM", 232, 240], ["CoV-2", "ORGANISM", 328, 333], ["SREBP-2 N-term fragments", "DNA", 78, 102], ["SREBP-2", "PROTEIN", 123, 130], ["patients", "SPECIES", 232, 240], ["SARS-CoV-2", "SPECIES", 323, 333], ["SREBP", "TEST", 78, 83], ["2 N-term fragments", "TREATMENT", 84, 102], ["the changing SREBP", "TEST", 110, 128], ["dependent epigenetics in cells", "PROBLEM", 131, 161], ["Plasma sample", "TEST", 162, 175], ["Whole blood", "TEST", 201, 212], ["the SARS", "PROBLEM", 319, 327], ["CoV-2 infection", "PROBLEM", 328, 343], ["new", "OBSERVATION_MODIFIER", 14, 17], ["therapeutic", "OBSERVATION_MODIFIER", 18, 29], ["infection", "OBSERVATION", 334, 343]]], ["Patients with COVID-19 sepsis were defined using criteria provided by the Sepsis Consensus Conference Committee.53 Pneumonia and septic shock patients were collected from patients admitted at Yeungnam University Medical Center.", [["sepsis", "DISEASE", 23, 29], ["Sepsis", "DISEASE", 74, 80], ["Pneumonia", "DISEASE", 115, 124], ["septic shock", "DISEASE", 129, 141], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 142, 150], ["patients", "ORGANISM", 171, 179], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 142, 150], ["patients", "SPECIES", 171, 179], ["COVID", "TEST", 14, 19], ["sepsis", "PROBLEM", 23, 29], ["Pneumonia", "PROBLEM", 115, 124], ["septic shock", "PROBLEM", 129, 141], ["sepsis", "OBSERVATION", 23, 29], ["Sepsis", "OBSERVATION", 74, 80], ["Pneumonia", "OBSERVATION", 115, 124], ["septic shock", "OBSERVATION", 129, 141]]], ["Healthy volunteers (n = 20) were used as controls.", [["volunteers", "ORGANISM", 8, 18]]], ["In this study, 50 nonICU and 20 ICU patient samples were used.", [["samples", "ANATOMY", 44, 51], ["patient", "ORGANISM", 36, 43], ["patient", "SPECIES", 36, 43], ["this study", "TEST", 3, 13], ["20 ICU patient samples", "TREATMENT", 29, 51]]], ["Clinical data were collected for all the patients (Supplementary Table 1).", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["Clinical data", "TEST", 0, 13]]], ["Plasma samples were prepared by centrifugation at 2000 \u00d7 g for 5 min within 12 h after whole blood collection.", [["Plasma samples", "ANATOMY", 0, 14], ["blood", "ANATOMY", 93, 98], ["Plasma samples", "ORGANISM_SUBSTANCE", 0, 14], ["blood", "ORGANISM_SUBSTANCE", 93, 98], ["Plasma samples", "TEST", 0, 14], ["whole blood collection", "TEST", 87, 109]]], ["The human study protocol was approved by the Institutional Review Board of Yeungnam University Hospital at Daegu in Korea (YUH 2018-05-022, 2020\u201303\u2013057, 2020\u201305\u2013031\u2013001).Total cholesterol, HDL-cholesterol, and LDL-cholesterol in patients blood ::: Materials and methodsThe total cholesterol, HDL-cholesterol, and LDL-cholesterol dataset were analyzed using the modular DPE system (Roche Diagnostics, Basel, Switzerland).54PBMC isolation and culture ::: Materials and methodsSamples from healthy, SARS-CoV-2 pneumonia patients, or discharged patients were obtained from Yeungnam University Medical Center.", [["blood", "ANATOMY", 238, 243], ["PBMC", "ANATOMY", 422, 426], ["cholesterol", "CHEMICAL", 176, 187], ["cholesterol", "CHEMICAL", 193, 204], ["cholesterol", "CHEMICAL", 214, 225], ["cholesterol", "CHEMICAL", 279, 290], ["cholesterol", "CHEMICAL", 296, 307], ["cholesterol", "CHEMICAL", 317, 328], ["SARS", "DISEASE", 496, 500], ["pneumonia", "DISEASE", 507, 516], ["cholesterol", "CHEMICAL", 176, 187], ["cholesterol", "CHEMICAL", 193, 204], ["cholesterol", "CHEMICAL", 214, 225], ["cholesterol", "CHEMICAL", 279, 290], ["cholesterol", "CHEMICAL", 296, 307], ["cholesterol", "CHEMICAL", 317, 328], ["human", "ORGANISM", 4, 9], ["cholesterol", "SIMPLE_CHEMICAL", 176, 187], ["HDL-cholesterol", "SIMPLE_CHEMICAL", 189, 204], ["LDL-cholesterol", "SIMPLE_CHEMICAL", 210, 225], ["patients", "ORGANISM", 229, 237], ["blood", "ORGANISM_SUBSTANCE", 238, 243], ["cholesterol", "SIMPLE_CHEMICAL", 279, 290], ["HDL-cholesterol", "SIMPLE_CHEMICAL", 292, 307], ["LDL", "SIMPLE_CHEMICAL", 313, 316], ["PBMC", "CELL", 422, 426], ["SARS-CoV-2", "ORGANISM", 496, 506], ["patients", "ORGANISM", 517, 525], ["patients", "ORGANISM", 541, 549], ["LDL", "PROTEIN", 210, 213], ["HDL", "PROTEIN", 292, 295], ["LDL", "PROTEIN", 313, 316], ["PBMC", "CELL_TYPE", 422, 426], ["human", "SPECIES", 4, 9], ["patients", "SPECIES", 229, 237], ["patients", "SPECIES", 517, 525], ["patients", "SPECIES", 541, 549], ["human", "SPECIES", 4, 9], ["SARS-CoV", "SPECIES", 496, 504], ["The human study protocol", "TEST", 0, 24], ["Total cholesterol", "TEST", 170, 187], ["HDL", "TEST", 189, 192], ["cholesterol", "TEST", 193, 204], ["LDL", "TEST", 210, 213], ["The total cholesterol", "TEST", 269, 290], ["HDL", "TEST", 292, 295], ["cholesterol", "TEST", 296, 307], ["LDL", "TEST", 313, 316], ["cholesterol dataset", "TEST", 317, 336], ["PBMC isolation", "TEST", 422, 436], ["culture", "TEST", 441, 448], ["methodsSamples", "TEST", 467, 481], ["SARS", "TEST", 496, 500], ["CoV", "TEST", 501, 504], ["pneumonia", "PROBLEM", 507, 516], ["LDL", "ANATOMY", 210, 213], ["pneumonia", "OBSERVATION", 507, 516]]], ["The relevant local Institutional Review Boards and Ethics Committees approved the study.", [["the study", "TEST", 78, 87]]], ["Heparinized blood samples were used fresh within 4 h, and peripheral blood mononuclear cells (PBMCs) were separated from blood using Ficoll\u2013Hypaquek or NycoPrepk according to the manufacturer\u2019s recommendations.", [["blood samples", "ANATOMY", 12, 25], ["peripheral blood mononuclear cells", "ANATOMY", 58, 92], ["PBMCs", "ANATOMY", 94, 99], ["blood", "ANATOMY", 121, 126], ["blood samples", "ORGANISM_SUBSTANCE", 12, 25], ["peripheral blood mononuclear cells", "CELL", 58, 92], ["PBMCs", "CELL", 94, 99], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["Hypaquek", "SIMPLE_CHEMICAL", 140, 148], ["NycoPrepk", "SIMPLE_CHEMICAL", 152, 161], ["peripheral blood mononuclear cells", "CELL_TYPE", 58, 92], ["PBMCs", "CELL_TYPE", 94, 99], ["Heparinized blood samples", "TEST", 0, 25], ["peripheral blood mononuclear cells", "TEST", 58, 92], ["PBMCs", "TEST", 94, 99], ["Ficoll\u2013Hypaquek", "TREATMENT", 133, 148], ["NycoPrepk", "TREATMENT", 152, 161], ["peripheral", "ANATOMY_MODIFIER", 58, 68], ["blood", "ANATOMY", 69, 74], ["mononuclear cells", "OBSERVATION", 75, 92]]], ["Following this, more refined PBMCs were obtained via MACSprep\u2122 PBMC Isolation Kit and cultured in RPMI-1640 with 1 mM Sodium pyruvate, 2 mM l-glutamine, 4.5 mg/l glucose, 10 mM HEPES and 2 mg/l sodium bicarbonate.SREBP-2 transcriptional activity assays ::: Materials and methodsThe transcriptional activities of SREBP-2 were determined by the ELISA method using kits from Abcam (ab133111, Abcam) following manufacturer\u2019s protocol.", [["PBMCs", "ANATOMY", 29, 34], ["RPMI-1640", "CHEMICAL", 98, 107], ["Sodium pyruvate", "CHEMICAL", 118, 133], ["l-glutamine", "CHEMICAL", 140, 151], ["glucose", "CHEMICAL", 162, 169], ["sodium bicarbonate", "CHEMICAL", 194, 212], ["Sodium pyruvate", "CHEMICAL", 118, 133], ["l-glutamine", "CHEMICAL", 140, 151], ["glucose", "CHEMICAL", 162, 169], ["HEPES", "CHEMICAL", 177, 182], ["sodium bicarbonate", "CHEMICAL", 194, 212], ["PBMCs", "CELL", 29, 34], ["RPMI-1640", "CELL", 98, 107], ["Sodium pyruvate", "SIMPLE_CHEMICAL", 118, 133], ["l-glutamine", "SIMPLE_CHEMICAL", 140, 151], ["glucose", "SIMPLE_CHEMICAL", 162, 169], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 194, 212], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 213, 220], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 312, 319], ["Abcam", "GENE_OR_GENE_PRODUCT", 372, 377], ["Abcam", "GENE_OR_GENE_PRODUCT", 389, 394], ["PBMCs", "CELL_TYPE", 29, 34], ["MACSprep\u2122 PBMC", "CELL_LINE", 53, 67], ["SREBP", "PROTEIN", 213, 218], ["SREBP-2", "PROTEIN", 312, 319], ["Abcam (ab133111, Abcam", "PROTEIN", 372, 394], ["PBMCs", "TEST", 29, 34], ["MACSprep\u2122 PBMC Isolation Kit", "TREATMENT", 53, 81], ["RPMI", "TEST", 98, 102], ["Sodium pyruvate", "TEST", 118, 133], ["glutamine", "TREATMENT", 142, 151], ["glucose", "TEST", 162, 169], ["10 mM HEPES", "TREATMENT", 171, 182], ["2 mg/l sodium bicarbonate", "TREATMENT", 187, 212], ["SREBP", "TEST", 213, 218], ["SREBP", "TEST", 312, 317], ["the ELISA method", "TEST", 339, 355], ["Abcam", "TEST", 372, 377], ["manufacturer\u2019s protocol", "TREATMENT", 406, 429]]], ["Briefly, nuclear homogenate equivalent to 30 \u03bcg of the protein content was added to each of the wells of the 96-well plate containing the double-stranded DNA sequence harboring the consensus SREBP-binding sequence (sterol regulatory element, SRE) coated onto the wells.", [["nuclear homogenate", "ANATOMY", 9, 27], ["sterol", "CHEMICAL", 215, 221], ["DNA", "CELLULAR_COMPONENT", 154, 157], ["SREBP", "GENE_OR_GENE_PRODUCT", 191, 196], ["sterol", "SIMPLE_CHEMICAL", 215, 221], ["double-stranded DNA sequence", "DNA", 138, 166], ["consensus SREBP-binding sequence", "DNA", 181, 213], ["sterol regulatory element", "DNA", 215, 240], ["SRE", "DNA", 242, 245], ["the protein content", "TEST", 51, 70], ["the double-stranded DNA sequence", "TREATMENT", 134, 166]]], ["The nuclear extract was allowed to hybridize with the coated double-stranded DNA sequence harboring the consensus SRE in the plate overnight at 4 \u00b0C. The activated SREBP transcription factor complex was detected by addition of a specific primary antibody directed against SREBP-2 and a secondary antibody conjugated to HRP added to provide a sensitive colorimetric readout at 450 nm.NF-\u03baB transcriptional activity assays ::: Materials and methodsPreparation of nuclear extracts and TransAM assays were performed as previously described.55 The activity of individual NF-\u03baB subunits was determined using an ELISA-based NF-\u03baB Family Transcription Factor Assay Kit (43296; Active Motif, Carlsbad, CA, USA).", [["nuclear extract", "ANATOMY", 4, 19], ["nuclear extracts", "ANATOMY", 461, 477], ["nuclear", "CELLULAR_COMPONENT", 4, 11], ["DNA", "CELLULAR_COMPONENT", 77, 80], ["SREBP", "GENE_OR_GENE_PRODUCT", 164, 169], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 272, 279], ["HRP", "SIMPLE_CHEMICAL", 319, 322], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 383, 388], ["nuclear extracts", "ORGANISM_SUBSTANCE", 461, 477], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 566, 571], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 617, 622], ["coated double-stranded DNA sequence", "DNA", 54, 89], ["consensus SRE", "DNA", 104, 117], ["SREBP transcription factor complex", "PROTEIN", 164, 198], ["primary antibody", "PROTEIN", 238, 254], ["SREBP-2", "PROTEIN", 272, 279], ["secondary antibody", "PROTEIN", 286, 304], ["HRP", "PROTEIN", 319, 322], ["NF-\u03baB", "PROTEIN", 383, 388], ["NF-\u03baB subunits", "PROTEIN", 566, 580], ["NF", "PROTEIN", 617, 619], ["the coated double-stranded DNA sequence", "TREATMENT", 50, 89], ["The activated SREBP transcription factor complex", "PROBLEM", 150, 198], ["a specific primary antibody", "TREATMENT", 227, 254], ["SREBP", "TEST", 272, 277], ["a secondary antibody", "TREATMENT", 284, 304], ["nuclear extracts", "TEST", 461, 477], ["TransAM assays", "TEST", 482, 496], ["B subunits", "TREATMENT", 570, 580], ["an ELISA", "TEST", 602, 610]]], ["Briefly, nuclear extracts (2 \u03bcg) were incubated in a 96-well plate, which was coated with NF-\u03baB consensus oligonucleotides.", [["nuclear extracts", "ANATOMY", 9, 25], ["nuclear extracts", "ORGANISM_SUBSTANCE", 9, 25], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 90, 95], ["NF-\u03baB consensus oligonucleotides", "DNA", 90, 122], ["NF", "TEST", 90, 92]]], ["The captured complexes were incubated with specific NF-\u03baB primary Abs and subsequently detected using HRP-conjugated secondary Abs included with the kit.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 52, 57], ["HRP", "SIMPLE_CHEMICAL", 102, 105], ["NF-\u03baB primary Abs", "PROTEIN", 52, 69], ["HRP-conjugated secondary Abs", "PROTEIN", 102, 130], ["specific NF", "TEST", 43, 54], ["HRP", "TEST", 102, 105]]], ["Finally, the optical density (OD) at 450 nm was measured using a Tecan Spark microplate reader (Tecan, Austria GmbH, Austria).SREBP-2 C-term ELISA ::: Materials and methodsWe performed competitive ELISA using antibodies that recognize the SREBP-2 C-term.", [["SREBP-2", "GENE_OR_GENE_PRODUCT", 126, 133], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 239, 246], ["SREBP", "PROTEIN", 126, 131], ["antibodies", "PROTEIN", 209, 219], ["SREBP-2 C-term", "DNA", 239, 253], ["SREBP", "TEST", 126, 131], ["competitive ELISA", "TEST", 185, 202], ["antibodies", "TREATMENT", 209, 219], ["the SREBP", "TEST", 235, 244], ["optical", "OBSERVATION_MODIFIER", 13, 20], ["density", "OBSERVATION", 21, 28]]], ["SREBP-2 C-term (a.a.639\u20131031) proteins were 2 \u03bcg/100 \u03bcl diluted and coated onto Nunc-Immuno\u2122 MicroWell\u2122 96-well plates and incubated overnight at 4 \u00b0C. Prior to use, the plates were washed 3 times with PBST and blocked with 3% BSA in PBS for 30 min at 37 \u00b0C. Primary anti-SREBP2 C-term (a.a.801\u2013900) polyclonal antibody (ab194667, abcam, Cambridge, United Kingdom, 1:2000 dilution, 100 \u03bcl) and plasma sample (20 \u03bcg/100 \u03bcl) was pre-incubated for 1 h at 37 \u00b0C and then the pre-incubated sample were transferred to peptide-coated plate and incubated for 1 h at 37 \u00b0C. The plate was washed five times with PBST.", [["plasma sample", "ANATOMY", 394, 407], ["sample", "ANATOMY", 485, 491], ["a.a.639\u20131031", "CHEMICAL", 16, 28], ["BSA", "CHEMICAL", 227, 230], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 0, 7], ["a.a.639\u20131031", "GENE_OR_GENE_PRODUCT", 16, 28], ["BSA", "SIMPLE_CHEMICAL", 227, 230], ["plasma", "ORGANISM_SUBSTANCE", 394, 400], ["SREBP", "PROTEIN", 0, 5], ["Nunc-Immuno\u2122 MicroWell\u2122 96-well plates", "DNA", 80, 118], ["a.a.801\u2013900) polyclonal antibody", "PROTEIN", 287, 319], ["SREBP", "TEST", 0, 5], ["proteins", "TEST", 30, 38], ["Nunc", "TEST", 80, 84], ["MicroWell\u2122", "TEST", 93, 103], ["the plates", "TREATMENT", 166, 176], ["PBST", "TREATMENT", 202, 206], ["3% BSA in PBS", "TREATMENT", 224, 237], ["polyclonal antibody", "TEST", 300, 319], ["abcam", "TEST", 331, 336], ["plasma sample", "TEST", 394, 407], ["peptide-coated plate", "TREATMENT", 512, 532], ["The plate", "TREATMENT", 565, 574], ["PBST", "TREATMENT", 602, 606], ["plate", "OBSERVATION_MODIFIER", 569, 574]]], ["Secondary antimouse antibody (#7076, Cell Signaling Technology, Beverly, MA, 1:5000 dilution, 100 \u03bcl) was incubated for 30 min at 37 \u00b0C and then the plate was washed five times with PBST.", [["Cell", "ANATOMY", 37, 41], ["Cell", "CELL", 37, 41], ["antimouse antibody", "PROTEIN", 10, 28], ["Secondary antimouse antibody", "TEST", 0, 28], ["the plate", "TREATMENT", 145, 154], ["PBST", "TREATMENT", 182, 186], ["antimouse antibody", "OBSERVATION", 10, 28]]], ["The washed plate was treated with TMB ELISA substrate 100 \u03bcl/well for 10 min 37 \u00b0C and then Stop Solution 100 \u03bcl/well was added.", [["TMB", "CHEMICAL", 34, 37], ["The washed plate", "TREATMENT", 0, 16], ["TMB ELISA substrate", "TREATMENT", 34, 53]]], ["The detection was performed at 450 nm by microplate reader (TECAN M\u00e4nnedorf, Switzerland).Statistical analysis ::: Materials and methodsAll experiments were performed independently at least three times.", [["The detection", "TEST", 0, 13]]], ["Statistically significant differences were determined using unpaired t-test.", [["unpaired t-test", "TEST", 60, 75], ["significant", "OBSERVATION_MODIFIER", 14, 25]]], ["Graphprism 7 was used for statistical analyses.", [["statistical analyses", "TEST", 26, 46]]]], "a5c7949b0e463be922c6e8af63ec3e80bb6ee0b5": [["INTRODUCTIONIn December 2019, a new strain of beta coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that causes coronavirus disease 2019 (COVID-19), emerged in Wuhan, China [1] .", [["beta coronavirus", "DISEASE", 46, 62], ["acute respiratory syndrome coronavirus", "DISEASE", 71, 109], ["coronavirus disease", "DISEASE", 138, 157], ["beta coronavirus", "ORGANISM", 46, 62], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 64, 111], ["SARS-CoV-2", "ORGANISM", 113, 123], ["coronavirus", "SPECIES", 51, 62], ["beta coronavirus", "SPECIES", 46, 62], ["severe acute respiratory syndrome coronavirus", "SPECIES", 64, 109], ["SARS-CoV-2", "SPECIES", 113, 123], ["beta coronavirus", "PROBLEM", 46, 62], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 64, 109], ["SARS-CoV", "TEST", 113, 121], ["coronavirus disease", "PROBLEM", 138, 157], ["COVID", "TEST", 164, 169], ["beta coronavirus", "OBSERVATION", 46, 62], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["respiratory syndrome", "OBSERVATION", 77, 97], ["coronavirus disease", "OBSERVATION", 138, 157]]], ["Subsequently, the virus quickly spread worldwide, and the World Health Organization (WHO) declared COVID-19 a pandemic on 11 March 2020 [2] .", [["the virus", "PROBLEM", 14, 23]]], ["The number of patients is increasing rapidly, stressing health care systems.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["number", "OBSERVATION_MODIFIER", 4, 10], ["increasing", "OBSERVATION_MODIFIER", 26, 36], ["rapidly", "OBSERVATION_MODIFIER", 37, 44]]], ["Hospitals are reporting a shortage of critical equipment for COVID-19 patient care, including personal protective equipment for healthcare workers, owing to the surge in demand [3] .INTRODUCTIONIn response, healthcare authorities recommend staying home for seven days instead of visiting hospitals immediately when COVID-19 symptoms occur [4, 5] .INTRODUCTIONThe Korean Journal of Internal Medicine.", [["patient", "ORGANISM", 70, 77], ["patient", "SPECIES", 70, 77], ["COVID-19 patient care", "TREATMENT", 61, 82], ["symptoms", "PROBLEM", 324, 332], ["Internal Medicine", "TREATMENT", 381, 398]]], ["35, No. 4, July 2020 This recommendation relies on the fact that most COVID-19 patients have mild disease and can recover without medical care.", [["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["mild disease", "PROBLEM", 93, 105], ["medical care", "TREATMENT", 130, 142], ["mild", "OBSERVATION_MODIFIER", 93, 97], ["disease", "OBSERVATION", 98, 105]]], ["In the early report from China, 81% of laboratory-confirmed cases had mild to moderate illness, including non-pneumonia and pneumonia cases [6] .", [["illness", "DISEASE", 87, 94], ["non-pneumonia", "DISEASE", 106, 119], ["pneumonia", "DISEASE", 124, 133], ["mild to moderate illness", "PROBLEM", 70, 94], ["non-pneumonia", "PROBLEM", 106, 119], ["pneumonia cases", "PROBLEM", 124, 139], ["moderate", "OBSERVATION_MODIFIER", 78, 86], ["illness", "OBSERVATION", 87, 94], ["pneumonia", "OBSERVATION", 124, 133]]], ["However, Guan et al. [7] reported that 35.7% of patients classified as non-severe at the point of admission received oxygen therapy during hospitalization, and 2.4% were admitted to an intensive care unit.", [["oxygen", "CHEMICAL", 117, 123], ["oxygen", "CHEMICAL", 117, 123], ["patients", "ORGANISM", 48, 56], ["oxygen", "SIMPLE_CHEMICAL", 117, 123], ["patients", "SPECIES", 48, 56], ["oxygen therapy", "TREATMENT", 117, 131]]], ["Therefore, recommendations for staying home in all suspected COVID-19 patients can be dangerous because some patients presenting with mild symptoms could worsen subsequently, requiring treatment.INTRODUCTIONSince the first imported COVID-19 case from Wuhan, China, was confirmed on 19 January 2020, the Korean Government has maintained a strong quarantine system of admitting all confirmed cases to biocontainment units of hospitals [8] .", [["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 109, 117], ["mild symptoms", "PROBLEM", 134, 147], ["treatment", "TREATMENT", 185, 194]]], ["On 20 February 2020, a massive outbreak occurred among a religious group in the south of Korea, Daegu, and the isolation hospital beds became scarce [9] .", [["a massive outbreak", "PROBLEM", 21, 39], ["massive", "OBSERVATION_MODIFIER", 23, 30], ["outbreak", "OBSERVATION", 31, 39]]], ["To meet the sudden increase in medical and isolation needs, the non-hospital facilities called \"living and treatment centers (LTCs)\" were established in collaboration with the government and tertiary hospitals.", [["medical and isolation needs", "TREATMENT", 31, 58]]], ["LTCs provided a unique opportunity to conduct prospective studies on COVID-19 patients presenting with mild symptoms.", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["prospective studies", "TEST", 46, 65], ["mild symptoms", "PROBLEM", 103, 116], ["mild", "OBSERVATION_MODIFIER", 103, 107], ["symptoms", "OBSERVATION", 108, 116]]], ["Therefore, this study evaluated the safety of non-hospital settings for mild COVID-19 patients describing detailed clinical progression of relatively young patients presenting with mild symptoms.Study setting: living and treatment centerThis study was conducted in one LTC operated by Seoul National University Hospital (SNUH), a tertiary teaching hospital in Korea.", [["patients", "ORGANISM", 86, 94], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 156, 164], ["this study", "TEST", 11, 21], ["mild COVID", "PROBLEM", 72, 82], ["mild symptoms", "PROBLEM", 181, 194], ["This study", "TEST", 237, 247], ["mild", "OBSERVATION_MODIFIER", 181, 185]]], ["The process of converting the accommodation and training facility into an LTC is described previously [10] .", [["an LTC", "TREATMENT", 71, 77]]], ["Patients were isolated in single rooms.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["To minimize contact with infectious patients, a video consultation care system was established, and patients were educated to check body temperature using a thermometer, pulse rate, and oxygen saturation by pulse oximetry, and describe their symptoms.", [["body", "ANATOMY", 132, 136], ["oxygen", "CHEMICAL", 186, 192], ["oxygen", "CHEMICAL", 186, 192], ["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 100, 108], ["body", "ORGANISM_SUBDIVISION", 132, 136], ["oxygen", "SIMPLE_CHEMICAL", 186, 192], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 100, 108], ["body temperature", "TEST", 132, 148], ["pulse rate", "TEST", 170, 180], ["oxygen saturation", "TEST", 186, 203], ["pulse oximetry", "TEST", 207, 221], ["their symptoms", "PROBLEM", 236, 250]]], ["On 9 April 2020, all patients who needed further isolation were transferred to another LTC.Study populationThe Korean Centers for Disease Control and Prevention (KCDC) classified severity of COVID-19 into four categories, namely extremely severe, severe, mild, and asymptomatic.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["further isolation", "TREATMENT", 41, 58], ["Disease Control", "TREATMENT", 130, 145], ["COVID", "TEST", 191, 196], ["extremely severe", "PROBLEM", 229, 245], ["asymptomatic", "PROBLEM", 265, 277], ["severe", "OBSERVATION_MODIFIER", 239, 245], ["severe", "OBSERVATION_MODIFIER", 247, 253], ["mild", "OBSERVATION_MODIFIER", 255, 259], ["asymptomatic", "OBSERVATION_MODIFIER", 265, 277]]], ["Of KCDC's severity classification, only mild or asymptomatic patients with confirmed SARS-CoV-2 infection by real-time reverse transcriptase chain reaction (rRT-PCR) were admitted to the LTC.", [["SARS", "DISEASE", 85, 89], ["infection", "DISEASE", 96, 105], ["patients", "ORGANISM", 61, 69], ["reverse transcriptase", "PROTEIN", 119, 140], ["patients", "SPECIES", 61, 69], ["mild or asymptomatic patients", "PROBLEM", 40, 69], ["SARS", "PROBLEM", 85, 89], ["CoV", "PROBLEM", 90, 93], ["2 infection", "PROBLEM", 94, 105], ["reverse transcriptase chain reaction", "PROBLEM", 119, 155], ["rRT-PCR", "TREATMENT", 157, 164], ["mild", "OBSERVATION_MODIFIER", 40, 44], ["LTC", "ANATOMY", 187, 190]]], ["Detailed admission criteria were as follows: (1) alert, (2) age below 50 years old, (3) no underlying disease or well-controlled underlying disease, (4) body temperature below 38.0\u00b0C, whether taking antipyretics or not, and (5) no dyspnea.", [["body", "ANATOMY", 153, 157], ["dyspnea", "DISEASE", 231, 238], ["body", "ORGANISM_SUBDIVISION", 153, 157], ["underlying disease", "PROBLEM", 91, 109], ["well-controlled underlying disease", "PROBLEM", 113, 147], ["body temperature", "TEST", 153, 169], ["antipyretics", "TREATMENT", 199, 211], ["dyspnea", "PROBLEM", 231, 238], ["disease", "OBSERVATION", 102, 109], ["disease", "OBSERVATION", 140, 147]]], ["In response to the explosive outbreak in the city of Daegu and Gyeosangbuk-do in late February 2020, patients between 50 and 65 years old satisfying the remaining criteria were also admitted to the LTC from the beginning of the center operation.", [["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["the center operation", "TREATMENT", 224, 244]]], ["Patients were released from the LTC when their SARS-CoV-2 rRT-PCR tests results; two tests performed with a 24-hour interval were negative.Data collectionAt admission, detailed interviews were conducted on exposure history, diagnosis date, and symptoms before admission.", [["Patients", "ORGANISM", 0, 8], ["SARS-CoV-2 rRT-PCR tests", "DNA", 47, 71], ["Patients", "SPECIES", 0, 8], ["their SARS", "TEST", 41, 51], ["CoV", "TEST", 52, 55], ["PCR tests", "TEST", 62, 71], ["two tests", "TEST", 81, 90], ["symptoms", "PROBLEM", 244, 252]]], ["During the stay at the LTC, the patients checked their symptoms twice a day and submitted them using the questionnaire in the smartphone application.", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["their symptoms", "PROBLEM", 49, 63]]], ["Doctors and nurses checked the patient's report and monitored patients using a video-consultation system twice a day.", [["patient", "ORGANISM", 31, 38], ["patients", "ORGANISM", 62, 70], ["patient", "SPECIES", 31, 38], ["patients", "SPECIES", 62, 70]]], ["Chest radiography and rRT-PCR of respiratory specimens were performed regularly.Data collectionThe study was approved by the Institutional Review Boards of SNUH (IRB No.", [["respiratory specimens", "ANATOMY", 33, 54], ["Chest radiography", "TEST", 0, 17], ["rRT-PCR of respiratory specimens", "TEST", 22, 54], ["Data collection", "TEST", 80, 95], ["The study", "TEST", 95, 104]]], ["Informed consent was waived by the board.RESULTSFrom 5 March to 9 April 2020, 113 patients were admitted to the LTC operated by SNUH; 52.2% were female, with a median age of 25 years (interquartile range [IQR], 21.5 to 39.5) and 5.3% patients had underlying diseases, of which most common were hypertension (3.5%) and diabetes (0.9%) ( Of 113 patients, 54 (47.8%) were asymptomatic at diagnosis, and 15 (13.3%) had no symptoms until they were released from isolation.", [["hypertension", "DISEASE", 294, 306], ["diabetes", "DISEASE", 318, 326], ["patients", "ORGANISM", 82, 90], ["patients", "ORGANISM", 234, 242], ["patients", "ORGANISM", 343, 351], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 234, 242], ["patients", "SPECIES", 343, 351], ["IQR", "TEST", 205, 208], ["underlying diseases", "PROBLEM", 247, 266], ["hypertension", "PROBLEM", 294, 306], ["diabetes", "PROBLEM", 318, 326], ["symptoms", "PROBLEM", 418, 426], ["diseases", "OBSERVATION", 258, 266], ["hypertension", "OBSERVATION", 294, 306]]], ["The most common symptom during isolation was sputum (57.5%), followed by rhinorrhea (42.5%), cough (40.7%), headache (24.8%), sore throat (16.8%), chest discomfort/dyspnea (15.9%), and a febrile/ chilling sensation (15.0%).", [["sputum", "ANATOMY", 45, 51], ["sore throat", "ANATOMY", 126, 137], ["chest", "ANATOMY", 147, 152], ["rhinorrhea", "DISEASE", 73, 83], ["cough", "DISEASE", 93, 98], ["headache", "DISEASE", 108, 116], ["sore throat", "DISEASE", 126, 137], ["chest discomfort", "DISEASE", 147, 163], ["dyspnea", "DISEASE", 164, 171], ["febrile/ chilling sensation", "DISEASE", 187, 214], ["sputum", "ORGANISM_SUBSTANCE", 45, 51], ["chest", "ORGANISM_SUBDIVISION", 147, 152], ["The most common symptom", "PROBLEM", 0, 23], ["sputum", "TEST", 45, 51], ["rhinorrhea", "PROBLEM", 73, 83], ["cough", "PROBLEM", 93, 98], ["headache", "PROBLEM", 108, 116], ["sore throat", "PROBLEM", 126, 137], ["chest discomfort", "PROBLEM", 147, 163], ["dyspnea", "PROBLEM", 164, 171], ["a febrile/ chilling sensation", "PROBLEM", 185, 214], ["sore throat", "ANATOMY", 126, 137], ["chest", "ANATOMY", 147, 152], ["dyspnea", "OBSERVATION", 164, 171], ["febrile", "OBSERVATION_MODIFIER", 187, 194]]], ["Sputum lasted the longest (median duration 11 days; IQR, 4.5 to 18.5), while febrile sensation and myalgia improved the quickest ( Table 2) .", [["febrile sensation", "DISEASE", 77, 94], ["myalgia", "DISEASE", 99, 106], ["Sputum", "ORGANISM_SUBSTANCE", 0, 6], ["Sputum", "TEST", 0, 6], ["IQR", "TEST", 52, 55], ["febrile sensation", "PROBLEM", 77, 94], ["myalgia", "PROBLEM", 99, 106]]], ["No symptoms were severe enough to limit daily activities.", [["symptoms", "PROBLEM", 3, 11]]], ["Nine (8.0%) of 113 patients demonstrated pulmonary infiltrations on chest radiography upon admission.", [["pulmonary", "ANATOMY", 41, 50], ["chest", "ANATOMY", 68, 73], ["patients", "ORGANISM", 19, 27], ["pulmonary", "ORGAN", 41, 50], ["patients", "SPECIES", 19, 27], ["pulmonary infiltrations", "PROBLEM", 41, 64], ["chest radiography", "TEST", 68, 85], ["pulmonary", "ANATOMY", 41, 50], ["infiltrations", "OBSERVATION", 51, 64], ["chest", "ANATOMY", 68, 73]]], ["Of the remaining 104 patients, four patients developed pulmonary infiltrations during isolation.RESULTSDuring the follow-up period, two (1.8%) patients were transferred to a dedicated COVID-19 hospital.", [["pulmonary", "ANATOMY", 55, 64], ["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 36, 44], ["pulmonary", "ORGAN", 55, 64], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 143, 151], ["pulmonary infiltrations", "PROBLEM", 55, 78], ["pulmonary", "ANATOMY", 55, 64], ["infiltrations", "OBSERVATION", 65, 78]]], ["One pa-tient had shown progression of pulmonary infiltration on serial chest radiography, and the other complained of dyspnea requiring oxygen supply (1 L/min via nasal cannula), which was assumed to be caused by a panic disorder (Fig. 1) .", [["pulmonary", "ANATOMY", 38, 47], ["chest", "ANATOMY", 71, 76], ["nasal", "ANATOMY", 163, 168], ["pulmonary infiltration", "DISEASE", 38, 60], ["dyspnea", "DISEASE", 118, 125], ["oxygen", "CHEMICAL", 136, 142], ["panic disorder", "DISEASE", 215, 229], ["oxygen", "CHEMICAL", 136, 142], ["pulmonary", "ORGAN", 38, 47], ["oxygen", "SIMPLE_CHEMICAL", 136, 142], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 163, 176], ["pulmonary infiltration", "PROBLEM", 38, 60], ["serial chest radiography", "TEST", 64, 88], ["dyspnea", "PROBLEM", 118, 125], ["oxygen supply", "TREATMENT", 136, 149], ["nasal cannula", "TREATMENT", 163, 176], ["a panic disorder", "PROBLEM", 213, 229], ["progression", "OBSERVATION_MODIFIER", 23, 34], ["pulmonary", "ANATOMY", 38, 47], ["infiltration", "OBSERVATION", 48, 60], ["chest", "ANATOMY", 71, 76], ["dyspnea", "OBSERVATION", 118, 125]]], ["Both patients did not progress to severe status during the hospitalization.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["severe status", "PROBLEM", 34, 47]]], ["As of 9 April 2020, 99 patients were released from the LTC after meeting the de-isolation criteria (Fig. 1) .", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31]]], ["Time intervals between diagnosis and release from isolation were not different between patients with or without symptoms (25 days vs. 21 days, p = 0.150).RESULTSWhen comparing patient under 50 years old with patients between 50 and 65 years old, there was no significant difference in clinical course, such as the rate of transfer to hospital (1/95 vs. 1/18, p = 0.318) and isolation periods (23 days vs. 21 days, p = 0.946).DISCUSSIONOur observation cohort consisted of COVID-19 patients under 65 years old, presenting with no symptom or mild symptoms.", [["patients", "ORGANISM", 87, 95], ["patient", "ORGANISM", 176, 183], ["patients", "ORGANISM", 208, 216], ["patients", "ORGANISM", 480, 488], ["patients", "SPECIES", 87, 95], ["patient", "SPECIES", 176, 183], ["patients", "SPECIES", 208, 216], ["patients", "SPECIES", 480, 488], ["isolation", "TREATMENT", 50, 59], ["symptoms", "PROBLEM", 112, 120], ["isolation periods", "TREATMENT", 374, 391], ["symptom", "PROBLEM", 528, 535], ["mild symptoms", "PROBLEM", 539, 552], ["no", "UNCERTAINTY", 256, 258], ["significant", "OBSERVATION_MODIFIER", 259, 270], ["difference", "OBSERVATION_MODIFIER", 271, 281], ["mild", "OBSERVATION_MODIFIER", 539, 543], ["symptoms", "OBSERVATION", 544, 552]]], ["Few cases had concomitant underly-ing diseases that were associated with poor prognosis.", [["concomitant underly-ing diseases", "PROBLEM", 14, 46], ["-ing", "OBSERVATION_MODIFIER", 33, 37], ["diseases", "OBSERVATION", 38, 46]]], ["Through daily close observation, several characteristics of asymptomatic or mildly symptomatic COVID-19 patients were determined.", [["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["asymptomatic or mildly symptomatic COVID", "PROBLEM", 60, 100], ["mildly", "OBSERVATION_MODIFIER", 76, 82], ["symptomatic", "OBSERVATION_MODIFIER", 83, 94]]], ["First, clinical progression rate to severe disease, which requires oxygen therapy, was The WHO-China report, published on 29 February 2020, estimated that actual asymptomatic infections appear to be extremely rare because most of the cases that are asymptomatic on the date of identification go on to develop symptoms [11] .", [["oxygen", "CHEMICAL", 67, 73], ["infections", "DISEASE", 175, 185], ["oxygen", "CHEMICAL", 67, 73], ["oxygen", "SIMPLE_CHEMICAL", 67, 73], ["severe disease", "PROBLEM", 36, 50], ["oxygen therapy", "TREATMENT", 67, 81], ["actual asymptomatic infections", "PROBLEM", 155, 185], ["asymptomatic", "PROBLEM", 249, 261], ["symptoms", "PROBLEM", 309, 317], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["disease", "OBSERVATION", 43, 50], ["oxygen therapy", "OBSERVATION", 67, 81], ["infections", "OBSERVATION", 175, 185]]], ["Several recent studies have documented asymptomatic COVID-19 patients [12] [13] [14] [15] .", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["Several recent studies", "TEST", 0, 22], ["asymptomatic COVID", "TEST", 39, 57]]], ["However, whether reported asymptomatic cases have no symptoms at all remains unclear [16] .", [["symptoms", "PROBLEM", 53, 61]]], ["Upon thorough observation of 113 cases, 15 (13.2%) were completely asymptomatic.", [["thorough observation", "TEST", 5, 25]]], ["The viral shedding period of asymptomatic patients was similar to that of symptomatic patients, which suggests that even asymptomatic patients might spread the SARS-CoV-2 for a considerable period.DISCUSSIONSeveral reports have described the clinical outcome of COVID-19 patients presenting with no symptoms [13, 15] .", [["SARS", "DISEASE", 160, 164], ["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 86, 94], ["patients", "ORGANISM", 134, 142], ["patients", "ORGANISM", 271, 279], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 134, 142], ["patients", "SPECIES", 271, 279], ["symptoms", "PROBLEM", 299, 307], ["viral", "OBSERVATION_MODIFIER", 4, 9]]], ["Wang et al. [13] reported that 70.9% (39/55) of asymptomatic cases developed pneumonia, and 3.6% (2/55) progressed to severe status with hypoxia and were treated with a heated humidified high-flow nasal cannula for 5 days.", [["nasal", "ANATOMY", 197, 202], ["pneumonia", "DISEASE", 77, 86], ["hypoxia", "DISEASE", 137, 144], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 197, 210], ["asymptomatic cases", "PROBLEM", 48, 66], ["pneumonia", "PROBLEM", 77, 86], ["severe status", "PROBLEM", 118, 131], ["hypoxia", "PROBLEM", 137, 144], ["a heated humidified high-flow nasal cannula", "TREATMENT", 167, 210], ["pneumonia", "OBSERVATION", 77, 86], ["severe", "OBSERVATION_MODIFIER", 118, 124], ["hypoxia", "OBSERVATION", 137, 144]]], ["The fact that a patient diagnosed as asymptomatic could progress to severe respiratory distress requiring high-flow nasal cannula may raise concerns that observing patients presenting with mild symptoms in non-hospital settings could be dangerous.", [["respiratory", "ANATOMY", 75, 86], ["nasal", "ANATOMY", 116, 121], ["respiratory distress", "DISEASE", 75, 95], ["patient", "ORGANISM", 16, 23], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 116, 129], ["patients", "ORGANISM", 164, 172], ["patient", "SPECIES", 16, 23], ["patients", "SPECIES", 164, 172], ["asymptomatic", "PROBLEM", 37, 49], ["severe respiratory distress", "PROBLEM", 68, 95], ["high-flow nasal cannula", "TREATMENT", 106, 129], ["mild symptoms", "PROBLEM", 189, 202], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["respiratory distress", "OBSERVATION", 75, 95], ["mild", "OBSERVATION_MODIFIER", 189, 193]]], ["In our cohort, radiological pneumonia occurred in 10.6%, and lowdose oxygen therapy was required in 0.9% of patients, which was due to a panic attack rather than hypoxia.", [["pneumonia", "DISEASE", 28, 37], ["oxygen", "CHEMICAL", 69, 75], ["panic", "DISEASE", 137, 142], ["hypoxia", "DISEASE", 162, 169], ["oxygen", "CHEMICAL", 69, 75], ["lowdose oxygen", "SIMPLE_CHEMICAL", 61, 75], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["radiological pneumonia", "PROBLEM", 15, 37], ["lowdose oxygen therapy", "TREATMENT", 61, 83], ["a panic attack", "PROBLEM", 135, 149], ["hypoxia", "PROBLEM", 162, 169], ["pneumonia", "OBSERVATION", 28, 37], ["oxygen therapy", "OBSERVATION", 69, 83]]], ["The different outcome between the two studies might be due to differences in the demographic characteristics of the populations.", [["the two studies", "TEST", 30, 45], ["different", "OBSERVATION_MODIFIER", 4, 13], ["might be due to", "UNCERTAINTY", 46, 61]]], ["Here, all patients were under 65 years old, and median age was significantly low (25 years old vs. 49 years old).DISCUSSIONAs COVID-19 spreads rapidly, the shortage of medical resources has become a severe problem in many countries [3] .", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["a severe problem", "PROBLEM", 197, 213], ["severe", "OBSERVATION_MODIFIER", 199, 205]]], ["To cope with this scarcity and prevent transmission, several COVID-19 guidelines recommended that mildly ill patients stay home because they can recover without medical care [4, 5] .", [["mildly ill", "DISEASE", 98, 108], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117]]], ["However, the clinical course of COVID-19 presenting with mild symptoms has not been investigated extensively and there have been concern about progression to severe disease while staying home with mild symptoms.", [["COVID", "TEST", 32, 37], ["mild symptoms", "PROBLEM", 57, 70], ["severe disease", "PROBLEM", 158, 172], ["mild symptoms", "PROBLEM", 197, 210], ["severe", "OBSERVATION_MODIFIER", 158, 164], ["disease", "OBSERVATION", 165, 172]]], ["Our data convincingly shows that recommendation of staying home could be a safe alternative to hospitalization for those patients who meet the clinical criteria for mild COVID-19 and were capable to monitor vital signs and symptom changes by themselves.", [["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["Our data", "TEST", 0, 8], ["mild COVID", "PROBLEM", 165, 175], ["vital signs", "TEST", 207, 218], ["symptom changes", "PROBLEM", 223, 238]]], ["Education and precaution should be taken on the patients to prevent household transmission during staying home.", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["precaution", "TREATMENT", 14, 24]]]], "6d4432caa5cf97afa0126e52aa5dbf2e2fddd2be": [["INTRODUCTIONCoccidiosis is an enteric disease of commercial poultry caused by Eimeria, which are coccidian species belonging to the apicomplexan phylum.", [["enteric disease of commercial poultry", "DISEASE", 30, 67], ["Eimeria", "ORGANISM", 78, 85], ["INTRODUCTIONCoccidiosis", "TREATMENT", 0, 23], ["an enteric disease", "PROBLEM", 27, 45], ["Eimeria", "PROBLEM", 78, 85], ["coccidian species", "PROBLEM", 97, 114], ["enteric", "OBSERVATION_MODIFIER", 30, 37], ["disease", "OBSERVATION", 38, 45], ["commercial poultry", "OBSERVATION", 49, 67], ["Eimeria", "OBSERVATION", 78, 85], ["apicomplexan phylum", "OBSERVATION", 132, 151]]], ["Ingestion of sporulated Eimeria oocysts from the environment leads to the development of enteric disease.", [["enteric disease", "DISEASE", 89, 104], ["Eimeria oocysts", "ORGANISM", 24, 39], ["sporulated Eimeria oocysts", "PROBLEM", 13, 39], ["enteric disease", "PROBLEM", 89, 104], ["sporulated Eimeria oocysts", "OBSERVATION", 13, 39], ["enteric", "ANATOMY", 89, 96], ["disease", "OBSERVATION", 97, 104]]], ["Each of the seven species of Eimeria that cause disease in chickens preferentially infects different regions of the intestinal tract and can result in lesions of varying severity, including thickening of the intestinal wall, petechial hemorrhages, and necrosis, to name a few (Conway and McKenzie, 2008a) .", [["intestinal tract", "ANATOMY", 116, 132], ["lesions", "ANATOMY", 151, 158], ["intestinal wall", "ANATOMY", 208, 223], ["petechial", "ANATOMY", 225, 234], ["Eimeria", "DISEASE", 29, 36], ["hemorrhages", "DISEASE", 235, 246], ["necrosis", "DISEASE", 252, 260], ["Eimeria", "ORGANISM", 29, 36], ["chickens", "ORGANISM", 59, 67], ["intestinal tract", "ORGAN", 116, 132], ["lesions", "PATHOLOGICAL_FORMATION", 151, 158], ["intestinal wall", "MULTI-TISSUE_STRUCTURE", 208, 223], ["chickens", "SPECIES", 59, 67], ["chickens", "SPECIES", 59, 67], ["Eimeria", "PROBLEM", 29, 36], ["disease", "PROBLEM", 48, 55], ["lesions of varying severity", "PROBLEM", 151, 178], ["thickening of the intestinal wall", "PROBLEM", 190, 223], ["petechial hemorrhages", "PROBLEM", 225, 246], ["necrosis", "PROBLEM", 252, 260], ["intestinal tract", "ANATOMY", 116, 132], ["lesions", "OBSERVATION", 151, 158], ["varying", "OBSERVATION_MODIFIER", 162, 169], ["severity", "OBSERVATION_MODIFIER", 170, 178], ["thickening", "OBSERVATION", 190, 200], ["intestinal wall", "ANATOMY", 208, 223], ["petechial", "OBSERVATION_MODIFIER", 225, 234], ["hemorrhages", "OBSERVATION", 235, 246], ["necrosis", "OBSERVATION", 252, 260]]], ["Worldwide, the costs arising from coccidia challenge, treatment, and control are estimated to total at least 3 billion US dollars annually (Williams, 1999; Alonso, 2014; Blake and Tomley, 2014) .", [["coccidia", "DISEASE", 34, 42], ["coccidia challenge", "TREATMENT", 34, 52], ["treatment", "TREATMENT", 54, 63], ["coccidia", "OBSERVATION", 34, 42]]], ["Not only is coccidia infection alone an expensive burden for the poultry industry, but infection with Eimeria maxima is known to be a predisposing factor for necrotic enteri-C 2018 Poultry Science Association Inc. Received August 17, 2017.", [["coccidia infection", "DISEASE", 12, 30], ["infection", "DISEASE", 87, 96], ["Eimeria maxima", "DISEASE", 102, 116], ["Eimeria maxima", "SPECIES", 102, 116], ["coccidia infection", "PROBLEM", 12, 30], ["infection", "PROBLEM", 87, 96], ["Eimeria maxima", "PROBLEM", 102, 116], ["coccidia", "OBSERVATION_MODIFIER", 12, 20], ["infection", "OBSERVATION", 21, 30], ["infection", "OBSERVATION", 87, 96], ["necrotic", "OBSERVATION_MODIFIER", 158, 166]]], ["1 Corresponding author: brian89@uga.edu tis (NE) caused by Clostridium perfringens infection (Timbermont et al., 2011) .", [["edu tis", "CHEMICAL", 36, 43], ["NE", "CHEMICAL", 45, 47], ["Clostridium perfringens infection", "DISEASE", 59, 92], ["Clostridium perfringens", "ORGANISM", 59, 82], ["Clostridium perfringens", "SPECIES", 59, 82], ["Clostridium perfringens", "SPECIES", 59, 82], ["Clostridium perfringens infection", "PROBLEM", 59, 92], ["Clostridium perfringens", "OBSERVATION_MODIFIER", 59, 82], ["infection", "OBSERVATION", 83, 92]]], ["Lesions resulting from the subclinical form of NE cause reduced nutrient absorption and feed conversion, and cost producers $6 billion in 2015 (Wade and Keyburn, 2015) .INTRODUCTIONEimeria infection occurs when a susceptible chicken ingests a sporulated oocyst from the environment (Chapman, 2003; Shirley et al., 2005; Conway and McKenzie, 2008a; Chapman et al., 2013; Swayne et al., 2013; Blake and Tomley, 2014) .", [["oocyst", "ANATOMY", 254, 260], ["NE", "CHEMICAL", 47, 49], ["infection", "DISEASE", 189, 198], ["chicken", "ORGANISM", 225, 232], ["chicken", "SPECIES", 225, 232], ["chicken", "SPECIES", 225, 232], ["Lesions", "PROBLEM", 0, 7], ["reduced nutrient absorption", "PROBLEM", 56, 83], ["feed conversion", "TREATMENT", 88, 103], ["infection", "PROBLEM", 189, 198], ["reduced", "OBSERVATION_MODIFIER", 56, 63], ["nutrient absorption", "OBSERVATION", 64, 83], ["infection", "OBSERVATION", 189, 198]]], ["For every oocyst ingested, it is estimated that several hundred thousand may be produced, which are then available for ingestion and infection of other chickens in the poultry house (Sharman et al., 2010) .", [["infection", "DISEASE", 133, 142], ["chickens", "ORGANISM", 152, 160], ["chickens", "SPECIES", 152, 160], ["chickens", "SPECIES", 152, 160], ["infection", "PROBLEM", 133, 142]]], ["Historically, coccidiosis has been treated via the use of anticoccidials, including ionophores and chemicals.", [["coccidiosis", "DISEASE", 14, 25], ["ionophores", "CHEMICAL", 84, 94], ["anticoccidials", "SIMPLE_CHEMICAL", 58, 72], ["ionophores", "SIMPLE_CHEMICAL", 84, 94], ["coccidiosis", "PROBLEM", 14, 25], ["anticoccidials", "TREATMENT", 58, 72], ["ionophores", "TREATMENT", 84, 94], ["chemicals", "TREATMENT", 99, 108], ["coccidiosis", "OBSERVATION", 14, 25]]], ["Although anticoccidial treatments are effective in protecting against disease outbreaks, development of drug resistance, current external pressures on the industry, and regulatory changes have producers turning towards vaccination (Shirley et al., 2007; Newman, 2012; Blake and Tomley, 2014; Chapman, 2014) .", [["anticoccidial treatments", "TREATMENT", 9, 33], ["disease outbreaks", "PROBLEM", 70, 87], ["drug resistance", "PROBLEM", 104, 119], ["current external pressures on the industry", "TREATMENT", 121, 163], ["drug resistance", "OBSERVATION", 104, 119], ["pressures", "OBSERVATION_MODIFIER", 138, 147]]], ["Coccidia vaccines contain live, sporulated oocysts of varying mixtures and concentrations of Eimeria species, and they are given in a low dose to initiate an immunologic response in the bird (Danforth, 1998; Williams, 2002; Tewari and Maharana, 2011) .", [["oocysts", "ANATOMY", 43, 50], ["Coccidia", "CHEMICAL", 0, 8], ["Eimeria", "ORGANISM", 93, 100], ["Coccidia vaccines", "TREATMENT", 0, 17], ["varying mixtures", "TREATMENT", 54, 70], ["Eimeria species", "PROBLEM", 93, 108], ["sporulated", "OBSERVATION_MODIFIER", 32, 42], ["oocysts", "OBSERVATION", 43, 50], ["varying mixtures", "OBSERVATION_MODIFIER", 54, 70], ["Eimeria species", "OBSERVATION", 93, 108]]], ["Unlike other coccidian parasites, infection with Eimeria is self-limiting, as oocysts produced in the intestine are not capable of auto-infection of the host chicken and must be excreted and re-ingested for further infection (Cowper et al., 2012; Wilhelm and Yarovinsky, 2014) .", [["oocysts", "ANATOMY", 78, 85], ["intestine", "ANATOMY", 102, 111], ["infection", "DISEASE", 34, 43], ["Eimeria", "DISEASE", 49, 56], ["infection", "DISEASE", 215, 224], ["coccidian parasites", "ORGANISM", 13, 32], ["Eimeria", "ORGANISM", 49, 56], ["intestine", "ORGAN", 102, 111], ["chicken", "ORGANISM", 158, 165], ["chicken", "SPECIES", 158, 165], ["chicken", "SPECIES", 158, 165], ["other coccidian parasites", "PROBLEM", 7, 32], ["infection", "PROBLEM", 34, 43], ["Eimeria", "PROBLEM", 49, 56], ["oocysts", "PROBLEM", 78, 85], ["further infection", "PROBLEM", 207, 224], ["coccidian parasites", "OBSERVATION", 13, 32], ["infection", "OBSERVATION", 34, 43], ["self-limiting", "OBSERVATION_MODIFIER", 60, 73], ["oocysts", "OBSERVATION", 78, 85], ["intestine", "ANATOMY", 102, 111], ["not capable", "UNCERTAINTY", 116, 127], ["host chicken", "OBSERVATION", 153, 165]]], ["The immune response to Eimeria infection is species specific and requires multiple exposures to oocysts of each Eimeria sp. to achieve sufficient protective immunity (Rose and Hesketh, 1979) .", [["Eimeria infection", "DISEASE", 23, 40], ["Eimeria", "ORGANISM", 23, 30], ["Eimeria sp", "ORGANISM", 112, 122], ["Eimeria infection", "PROBLEM", 23, 40], ["Eimeria infection", "OBSERVATION", 23, 40]]], ["Thus, vaccine companies rely on the concept of \"vaccine oocyst cycling\" in the litter to gain protective immunity in a poultry flock (Joyner and Norton, 1973) .INTRODUCTIONThe traditional method of coccidia vaccine application is in a water-based spray using a hatchery spray cabinet.", [["coccidia", "ORGANISM", 198, 206], ["vaccine", "TREATMENT", 6, 13], ["\"vaccine oocyst cycling", "TREATMENT", 47, 70], ["The traditional method", "TREATMENT", 172, 194], ["coccidia vaccine application", "TREATMENT", 198, 226], ["a water-based spray", "TREATMENT", 233, 252], ["a hatchery spray cabinet", "TREATMENT", 259, 283]]], ["Vaccine coverage is essential, as chicks that do not ingest oocysts at day of hatch will later be exposed to oocysts in the litter, and this higher dose of oocysts can result in clinical infection and gut lesions.", [["gut lesions", "ANATOMY", 201, 212], ["infection", "DISEASE", 187, 196], ["chicks", "ORGANISM", 34, 40], ["gut lesions", "PATHOLOGICAL_FORMATION", 201, 212], ["chicks", "SPECIES", 34, 40], ["Vaccine coverage", "TREATMENT", 0, 16], ["oocysts", "PROBLEM", 156, 163], ["clinical infection", "PROBLEM", 178, 196], ["gut lesions", "PROBLEM", 201, 212], ["oocysts", "OBSERVATION", 109, 116], ["infection", "OBSERVATION", 187, 196], ["gut", "ANATOMY", 201, 204], ["lesions", "OBSERVATION", 205, 212]]], ["Gel vaccination technology for coccidia has been posited as an alternative to spray vaccination.", [["coccidia", "DISEASE", 31, 39], ["coccidia", "ORGANISM", 31, 39], ["Gel vaccination technology", "TREATMENT", 0, 26], ["coccidia", "PROBLEM", 31, 39], ["an alternative to spray vaccination", "TREATMENT", 60, 95]]], ["Gel beads containing Eimeria oocysts have been shown to be protective when delivered in the feed (Danforth et al., 1997; Jenkins et al., 2012; Jenkins et al., 2013) .", [["Eimeria oocysts", "ORGANISM", 21, 36], ["Gel beads", "TREATMENT", 0, 9], ["Eimeria oocysts", "PROBLEM", 21, 36], ["beads", "OBSERVATION_MODIFIER", 4, 9], ["Eimeria oocysts", "OBSERVATION", 21, 36]]], ["Now, coccidia vaccines in gel diluents are being applied to day-old chicks at the hatchery with a gel applicator bar (Ritzi et al., 2016) .", [["chicks", "ORGANISM", 68, 74], ["coccidia vaccines", "TREATMENT", 5, 22], ["gel diluents", "TREATMENT", 26, 38], ["a gel applicator bar", "TREATMENT", 96, 116], ["coccidia vaccines", "OBSERVATION", 5, 22]]], ["There are multiple manufacturers of gel diluents as well as multiple viscosities of individual gel products.", [["gel diluents", "TREATMENT", 36, 48], ["individual gel products", "TREATMENT", 84, 107], ["multiple", "OBSERVATION_MODIFIER", 10, 18], ["manufacturers", "OBSERVATION", 19, 32], ["gel diluents", "OBSERVATION_MODIFIER", 36, 48]]], ["Some gels are only slightly more viscous than water, but create more stable droplets on the chicks when applied.", [["slightly", "OBSERVATION_MODIFIER", 19, 27], ["more viscous", "OBSERVATION_MODIFIER", 28, 40], ["more", "OBSERVATION_MODIFIER", 64, 68], ["stable", "OBSERVATION_MODIFIER", 69, 75], ["droplets", "OBSERVATION", 76, 84]]], ["Other gels are extremely viscous and create very defined and gelatinous drops on chicks.", [["extremely viscous", "PROBLEM", 15, 32], ["gelatinous drops on chicks", "PROBLEM", 61, 87], ["extremely", "OBSERVATION_MODIFIER", 15, 24], ["viscous", "OBSERVATION", 25, 32], ["gelatinous", "OBSERVATION_MODIFIER", 61, 71], ["drops", "OBSERVATION", 72, 77]]], ["The higher viscosity of gel diluents compared to water spray may increase the available vaccine for ingestion.", [["The higher viscosity of gel diluents", "TREATMENT", 0, 36], ["water spray", "TREATMENT", 49, 60], ["the available vaccine", "TREATMENT", 74, 95], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["viscosity", "OBSERVATION_MODIFIER", 11, 20]]], ["Now that alternative methods for coccidia vaccine application are in use, research is needed to confirm that vaccines are still as efficacious with these new application methods as with traditional application.", [["alternative methods", "TREATMENT", 9, 28], ["coccidia vaccine application", "TREATMENT", 33, 61], ["vaccines", "TREATMENT", 109, 117], ["these new application methods", "TREATMENT", 148, 177], ["traditional application", "TREATMENT", 186, 209]]], ["This study aimed to compare the same commercial vaccine applied by the traditional spray method and using a gel application method with both high and low viscosity gels.", [["This study", "TEST", 0, 10], ["the same commercial vaccine", "TREATMENT", 28, 55], ["the traditional spray method", "TREATMENT", 67, 95], ["a gel application method", "TREATMENT", 106, 130], ["both high and low viscosity gels", "TREATMENT", 136, 168], ["low viscosity", "OBSERVATION_MODIFIER", 150, 163]]], ["During the experiment, post-vaccination oocyst shedding was recorded for two cycles along with evaluation of protection from challenge when vaccinating with both methods.Coccidia VaccineThe commercially available coccidia vaccine Coccivac-B52 (Merck Animal Health, Madison, NJ) used in these experiments contains live, sporulated oocysts of E. acervulina, E. mivati, E. tenella, and two strains of E. maxima.", [["oocyst", "ANATOMY", 40, 46], ["Coccivac-B52", "CHEMICAL", 230, 242], ["coccidia", "ORGANISM", 213, 221], ["Coccivac-B52", "ORGANISM", 230, 242], ["oocysts", "ORGANISM", 330, 337], ["E. acervulina", "ORGANISM", 341, 354], ["E. mivati", "ORGANISM", 356, 365], ["E. tenella", "ORGANISM", 367, 377], ["E. maxima", "ORGANISM", 398, 407], ["E. acervulina", "SPECIES", 341, 354], ["E. mivati", "SPECIES", 356, 365], ["E. tenella", "SPECIES", 367, 377], ["Coccivac-B52", "SPECIES", 230, 242], ["E. acervulina", "SPECIES", 341, 354], ["E. mivati", "SPECIES", 356, 365], ["E. tenella", "SPECIES", 367, 377], ["E. maxima", "SPECIES", 398, 407], ["post-vaccination oocyst shedding", "PROBLEM", 23, 55], ["evaluation", "TEST", 95, 105], ["protection", "TREATMENT", 109, 119], ["Coccidia Vaccine", "TREATMENT", 170, 186], ["coccidia vaccine", "TREATMENT", 213, 229], ["Madison, NJ)", "TREATMENT", 265, 277], ["E. acervulina", "TREATMENT", 341, 354], ["E. tenella", "PROBLEM", 367, 377], ["E. maxima", "PROBLEM", 398, 407], ["sporulated oocysts", "OBSERVATION", 319, 337]]], ["Each vaccine bottle contains 10,000 doses of oocysts in an unspecified proportion of Eimeria species.", [["Eimeria", "ORGANISM", 85, 92], ["Each vaccine bottle", "TREATMENT", 0, 19], ["oocysts", "PROBLEM", 45, 52], ["Eimeria species", "PROBLEM", 85, 100], ["Eimeria species", "OBSERVATION", 85, 100]]], ["The vaccine was administered on day of hatch in a volume to deliver one manufacturer's dose per chick.", [["chick", "ORGANISM", 96, 101], ["The vaccine", "TREATMENT", 0, 11]]], ["Vaccine preparation and dilution for each vaccine application method is described below.Coccidia ChallengeEimeria maxima oocysts of the APU1 strain were generously donated by Dr. Mark Jenkins (Jenkins et al., 2017) .", [["Coccidia", "ORGANISM", 88, 96], ["ChallengeEimeria maxima oocysts", "ORGANISM", 97, 128], ["APU1", "GENE_OR_GENE_PRODUCT", 136, 140], ["ChallengeEimeria maxima", "SPECIES", 97, 120], ["Vaccine preparation", "TREATMENT", 0, 19], ["dilution", "TREATMENT", 24, 32], ["each vaccine application method", "TREATMENT", 37, 68], ["Coccidia", "PROBLEM", 88, 96], ["the APU1 strain", "PROBLEM", 132, 147], ["maxima oocysts", "OBSERVATION", 114, 128]]], ["Oocysts were stored at 4C in 2.5% potassium dichromate.", [["Oocysts", "ANATOMY", 0, 7], ["potassium dichromate", "CHEMICAL", 34, 54], ["potassium dichromate", "CHEMICAL", 34, 54], ["Oocysts", "CELL", 0, 7], ["potassium dichromate", "SIMPLE_CHEMICAL", 34, 54], ["Oocysts", "PROBLEM", 0, 7], ["2.5% potassium dichromate", "TREATMENT", 29, 54]]], ["Pathogenic dose was determined by administration of varying doses of sporulated oocysts to 16-day old broiler chickens and scoring of resulting E. maxima-specific gross lesions occurring 7 days postchallenge in the mid-intestine prior to the start of this experiment.", [["oocysts", "ANATOMY", 80, 87], ["lesions", "ANATOMY", 169, 176], ["mid-intestine", "ANATOMY", 215, 228], ["chickens", "ORGANISM", 110, 118], ["gross lesions", "PATHOLOGICAL_FORMATION", 163, 176], ["chickens", "SPECIES", 110, 118], ["chickens", "SPECIES", 110, 118], ["sporulated oocysts", "PROBLEM", 69, 87], ["broiler chickens", "TREATMENT", 102, 118], ["resulting E. maxima-specific gross lesions", "PROBLEM", 134, 176], ["this experiment", "TREATMENT", 251, 266], ["gross", "OBSERVATION_MODIFIER", 163, 168], ["lesions", "OBSERVATION", 169, 176], ["7 days", "OBSERVATION_MODIFIER", 187, 193]]], ["For experimental challenge, oocysts were enumerated to obtain a dose of 5 \u00d7 10 4 oocysts per bird and diluted in deionized water.", [["oocysts", "ANATOMY", 28, 35], ["oocysts", "ORGANISM", 28, 35], ["experimental challenge", "PROBLEM", 4, 26], ["oocysts", "PROBLEM", 28, 35]]], ["Challenge was administered 16 days post-vaccination via the oral gavage route.Experimental AnimalsNon-vaccinated Ross broiler chickens were used to provide a relevant model to commercial poultry operations.", [["oral", "ANATOMY", 60, 64], ["oral", "ORGANISM_SUBDIVISION", 60, 64], ["chickens", "ORGANISM", 126, 134], ["chickens", "SPECIES", 126, 134], ["chickens", "SPECIES", 126, 134], ["the oral gavage route", "TREATMENT", 56, 77], ["Ross broiler chickens", "TREATMENT", 113, 134], ["commercial poultry operations", "TREATMENT", 176, 205]]], ["Day 19 broiler chicken embryos were purchased from a commercial source and hatched at the Poultry Diagnostic and Research Center (Athens, GA).", [["embryos", "ANATOMY", 23, 30], ["chicken", "ORGANISM", 15, 22], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 23, 30], ["chicken", "SPECIES", 15, 22], ["chicken", "SPECIES", 15, 22], ["chicken embryos", "OBSERVATION", 15, 30]]], ["Chicks were randomly assigned to one of the experimental groups.", [["Chicks", "ORGANISM", 0, 6], ["Chicks", "SPECIES", 0, 6]]], ["All chickens were exposed to 20 hours of light daily and offered a non-medicated starter feed and water ad libitum throughout the duration of this experiment.", [["chickens", "ORGANISM", 4, 12], ["chickens", "SPECIES", 4, 12], ["chickens", "SPECIES", 4, 12], ["All chickens", "TREATMENT", 0, 12], ["a non-medicated starter feed", "TREATMENT", 65, 93]]], ["Animal care and use protocols have been approved by the University of Georgia Institutional Animal Care and Use Committee.Experimental DesignThis experiment compared coccidia vaccine infection and oocyst cycling following multiple application methods and protection from Eimeria maxima challenge.", [["oocyst", "ANATOMY", 197, 203], ["infection", "DISEASE", 183, 192], ["coccidia", "ORGANISM", 166, 174], ["Experimental DesignThis experiment", "PROBLEM", 122, 156], ["coccidia vaccine infection", "PROBLEM", 166, 192], ["oocyst cycling", "PROBLEM", 197, 211], ["multiple application methods", "TREATMENT", 222, 250], ["Eimeria maxima challenge", "TREATMENT", 271, 295]]], ["All experimental groups consisted of 100 one-day-old broiler chicks that were vaccinated with the same commercially available coccidia vaccine at the same dosage.", [["chicks", "ORGANISM", 61, 67], ["coccidia", "ORGANISM", 126, 134], ["chicks", "SPECIES", 61, 67], ["old broiler chicks", "TREATMENT", 49, 67], ["coccidia vaccine", "TREATMENT", 126, 142]]], ["Chicks in Group 1 were vaccinated using a traditional spray application with a water based diluent.", [["Chicks", "ORGANISM", 0, 6], ["Chicks", "SPECIES", 0, 6], ["a traditional spray application", "TREATMENT", 40, 71], ["a water based diluent", "TREATMENT", 77, 98]]], ["In Group 2, chicks were vaccinated using the commercially available more viscous (MV) gel vaccine diluent Hydrodrop gel (ClearH 2 O, Westbrook, ME) applied by a gel bar applicator.", [["Hydrodrop gel", "CHEMICAL", 106, 119], ["ClearH 2 O", "CHEMICAL", 121, 131], ["chicks", "ORGANISM", 12, 18], ["Hydrodrop", "SIMPLE_CHEMICAL", 106, 115], ["chicks", "SPECIES", 12, 18], ["MV", "SPECIES", 82, 84], ["more viscous (MV)", "TREATMENT", 68, 85], ["gel vaccine diluent Hydrodrop gel", "TREATMENT", 86, 119], ["a gel bar applicator", "TREATMENT", 159, 179]]], ["In Group 3, chicks were vaccinated using the commercially available less viscous (LV) gel diluent CEVAGEL (Ceva Animal Health, Lenexa, KS) Dry Gel Powder with the same gel applicator bar as was used for the MV gel.", [["chicks", "ORGANISM", 12, 18], ["chicks", "SPECIES", 12, 18], ["MV", "SPECIES", 207, 209], ["less viscous (LV) gel diluent CEVAGEL", "TREATMENT", 68, 105], ["Dry Gel Powder", "TREATMENT", 139, 153], ["the same gel applicator bar", "TREATMENT", 159, 186], ["the MV gel", "TREATMENT", 203, 213]]], ["In Group 4, chicks were vaccinated by oral gavage to serve as a positive vaccination control.", [["oral", "ANATOMY", 38, 42], ["chicks", "ORGANISM", 12, 18], ["oral", "ORGANISM_SUBDIVISION", 38, 42], ["chicks", "SPECIES", 12, 18], ["oral gavage", "TREATMENT", 38, 49], ["a positive vaccination control", "TREATMENT", 62, 92]]], ["One hundred chicks remained unvaccinated to serve as positive and negative challenge controls in Groups 5 and 6.Experimental DesignTo evaluate vaccine oocyst cycling in the litter postvaccination, each group of chicks was placed on fresh litter in separate colony-type houses.", [["chicks", "ORGANISM", 12, 18], ["chicks", "ORGANISM", 211, 217], ["chicks", "SPECIES", 12, 18], ["chicks", "SPECIES", 211, 217], ["Experimental DesignTo evaluate vaccine oocyst cycling", "TREATMENT", 112, 165]]], ["Four days postvaccination, 20 chicks from each vaccinated group were randomly selected and removed for individual chick placement in Horsfall isolators.", [["chicks", "ORGANISM", 30, 36], ["chick", "ORGANISM", 114, 119], ["chicks", "SPECIES", 30, 36], ["each vaccinated group", "TREATMENT", 42, 63], ["individual chick placement in Horsfall isolators", "TREATMENT", 103, 151]]], ["Feces from each chick in each group were collected on days 5 to 8 to evaluate the first cycle of vaccine oocyst shedding.", [["Feces", "ANATOMY", 0, 5], ["oocyst", "ANATOMY", 105, 111], ["chick", "ORGANISM", 16, 21], ["vaccine oocyst", "TREATMENT", 97, 111]]], ["After fecal collection on day 8 post-vaccination, these chicks were removed and euthanized.", [["fecal", "ANATOMY", 6, 11], ["fecal", "ORGANISM_SUBSTANCE", 6, 11], ["chicks", "ORGANISM", 56, 62], ["chicks", "SPECIES", 56, 62], ["fecal collection", "PROBLEM", 6, 22], ["vaccination", "TREATMENT", 37, 48], ["these chicks", "TREATMENT", 50, 62], ["fecal", "ANATOMY", 6, 11], ["collection", "OBSERVATION", 12, 22]]], ["This was repeated 11 days post-vaccination for fecal collection on days 12 to 15 to evaluate the second cycle of vaccine oocyst shedding.", [["fecal", "ANATOMY", 47, 52], ["oocyst", "ANATOMY", 121, 127], ["fecal", "ORGANISM_SUBSTANCE", 47, 52], ["fecal collection", "PROBLEM", 47, 63], ["vaccine oocyst", "TREATMENT", 113, 127]]], ["Oocyst counts were recorded as both E. maximaspecific and total (E. maxima, E. acervulina, E. tenella, and E. mivati) using a McMaster counting chamber.Experimental DesignSixteen days post-vaccination, a pre-challenge body weight was obtained for all 60 remaining chickens in each group, after which time each group was reduced to 20 chickens that were randomly selected for challenge.", [["Oocyst", "ANATOMY", 0, 6], ["body", "ANATOMY", 218, 222], ["E. maxima", "ORGANISM", 65, 74], ["E. acervulina", "ORGANISM", 76, 89], ["E. tenella", "ORGANISM", 91, 101], ["E. mivati", "ORGANISM", 107, 116], ["body", "ORGANISM_SUBDIVISION", 218, 222], ["chickens", "ORGANISM", 264, 272], ["chickens", "ORGANISM", 334, 342], ["E. maxima", "SPECIES", 65, 74], ["E. acervulina", "SPECIES", 76, 89], ["E. tenella", "SPECIES", 91, 101], ["E. mivati", "SPECIES", 107, 116], ["chickens", "SPECIES", 264, 272], ["chickens", "SPECIES", 334, 342], ["E. maxima", "SPECIES", 65, 74], ["E. acervulina", "SPECIES", 76, 89], ["E. tenella", "SPECIES", 91, 101], ["E. mivati", "SPECIES", 107, 116], ["chickens", "SPECIES", 264, 272], ["chickens", "SPECIES", 334, 342], ["Oocyst counts", "TEST", 0, 13], ["total (E. maxima", "TREATMENT", 58, 74], ["E. acervulina", "TREATMENT", 76, 89], ["E. tenella", "TREATMENT", 91, 101], ["a pre-challenge body weight", "TEST", 202, 229]]], ["All chickens in all groups excluding the negative challenge control, Group 6, were challenged with 5 \u00d7 10 4 pathogenic E. maxima oocysts via oral gavage.", [["oocysts", "ANATOMY", 129, 136], ["oral", "ANATOMY", 141, 145], ["chickens", "ORGANISM", 4, 12], ["oral", "ORGANISM_SUBDIVISION", 141, 145], ["chickens", "SPECIES", 4, 12], ["E. maxima", "SPECIES", 119, 128], ["chickens", "SPECIES", 4, 12], ["E. maxima", "SPECIES", 119, 128], ["All chickens", "TREATMENT", 0, 12], ["oral gavage", "TREATMENT", 141, 152], ["chickens", "OBSERVATION", 4, 12], ["negative", "OBSERVATION", 41, 49]]], ["Seven days post-challenge, birds were weighed, humanely euthanized, and evaluated for gross lesions.", [["gross lesions", "ANATOMY", 86, 99], ["birds", "ORGANISM", 27, 32], ["gross lesions", "PATHOLOGICAL_FORMATION", 86, 99], ["gross lesions", "PROBLEM", 86, 99], ["lesions", "OBSERVATION", 92, 99]]], ["In addition, slide smears were taken from the mid-intestines for oocyst count scoring and segments of the mid-intestine were collected and placed in formalin for histological microscopic lesion scoring as described below.Vaccination ProcedureIndividual vials from the same lot of Coccivac-B52 vaccine were prepared for use in different application methods.", [["mid-intestines", "ANATOMY", 46, 60], ["oocyst", "ANATOMY", 65, 71], ["mid-intestine", "ANATOMY", 106, 119], ["Coccivac-B52", "CHEMICAL", 280, 292], ["formalin", "CHEMICAL", 149, 157], ["mid-intestine", "CANCER", 106, 119], ["formalin", "SIMPLE_CHEMICAL", 149, 157], ["slide smears", "TEST", 13, 25], ["oocyst count scoring", "TEST", 65, 85], ["formalin", "TREATMENT", 149, 157], ["histological microscopic lesion scoring", "PROBLEM", 162, 201], ["Vaccination ProcedureIndividual vials", "TREATMENT", 221, 258], ["Coccivac-B52 vaccine", "TREATMENT", 280, 300], ["mid-intestine", "ANATOMY", 106, 119], ["microscopic", "OBSERVATION_MODIFIER", 175, 186], ["lesion", "OBSERVATION", 187, 193]]], ["For the oral gavage method, the vaccine was diluted in sterile deionized water to reach a concentration of 1 dose per 0.5 mL.", [["oral", "ANATOMY", 8, 12], ["oral", "ORGANISM_SUBDIVISION", 8, 12], ["the oral gavage method", "TREATMENT", 4, 26], ["the vaccine", "TREATMENT", 28, 39], ["sterile deionized water", "TREATMENT", 55, 78]]], ["The spray, MV gel, and LV gel were all prepared to apply 100 doses of vaccine per chick basket.", [["chick", "ORGANISM", 82, 87], ["MV", "SPECIES", 11, 13], ["The spray", "TREATMENT", 0, 9], ["MV gel", "TREATMENT", 11, 17], ["LV gel", "TREATMENT", 23, 29], ["vaccine", "TREATMENT", 70, 77], ["LV", "ANATOMY", 23, 25]]], ["The spray method required dilution of vaccine in sterile deionized water.", [["The spray method", "TREATMENT", 0, 16], ["dilution of vaccine", "TREATMENT", 26, 45], ["sterile deionized water", "TREATMENT", 49, 72]]], ["The MV gel diluent was mixed with vaccine using a paddle mixer.", [["MV", "SPECIES", 4, 6], ["The MV gel diluent", "TREATMENT", 0, 18], ["vaccine", "TREATMENT", 34, 41], ["a paddle mixer", "TREATMENT", 48, 62]]], ["Seventy grams of the LV gel diluent dry gel powder was added to 2.5 L sterile deionized water and mixed with a blender until combined, at which time the manufacturer's dye and the vaccine were added.", [["LV", "ANATOMY", 21, 23], ["the LV gel diluent dry gel powder", "TREATMENT", 17, 50], ["2.5 L sterile deionized water", "TREATMENT", 64, 93], ["a blender", "TREATMENT", 109, 118], ["the manufacturer's dye", "TREATMENT", 149, 171], ["the vaccine", "TREATMENT", 176, 187], ["LV", "ANATOMY", 21, 23]]], ["For direct comparison of the two gel diluents, both the MV and LV gels were applied using the same gel applicator bar (Merck Animal Health, Madison, NJ).", [["LV", "ANATOMY", 63, 65], ["MV", "SPECIES", 56, 58], ["the two gel diluents", "TREATMENT", 25, 45], ["the MV", "TREATMENT", 52, 58], ["LV gels", "TREATMENT", 63, 70], ["the same gel applicator bar", "TREATMENT", 90, 117], ["LV", "ANATOMY", 63, 65]]], ["The spray application dispensed 24 mL of vaccine suspension per 100 chicks.", [["The spray application", "TREATMENT", 0, 21], ["vaccine suspension", "TREATMENT", 41, 59]]], ["The MV gel was dropped from the gel applicator bar to apply 25 mL of gel diluent onto a basket of 100 chicks.", [["MV", "SPECIES", 4, 6], ["The MV gel", "TREATMENT", 0, 10], ["the gel applicator bar", "TREATMENT", 28, 50], ["gel diluent", "TREATMENT", 69, 80]]], ["The LV gel also dispensed 25 mL per chick basket.Coccidia Vaccine Dose Determination for each Application MethodTo confirm that each vaccination method was applying the same dose of oocysts, a sample of one vaccine application volume was taken from the MV gel, LV gel, and spray application devices using a 50 mL tube placed under the vaccine applicator.", [["LV", "ANATOMY", 4, 6], ["LV", "ANATOMY", 261, 263], ["LV", "MULTI-TISSUE_STRUCTURE", 4, 6], ["chick", "ORGANISM", 36, 41], ["tube", "TISSUE", 313, 317], ["MV", "SPECIES", 253, 255], ["The LV gel", "TREATMENT", 0, 10], ["Coccidia Vaccine", "TREATMENT", 49, 65], ["each vaccination method", "TREATMENT", 128, 151], ["one vaccine application volume", "TREATMENT", 203, 233], ["the MV gel", "TREATMENT", 249, 259], ["LV gel", "TREATMENT", 261, 267], ["spray application devices", "TREATMENT", 273, 298], ["a 50 mL tube", "TREATMENT", 305, 317], ["the vaccine applicator", "TREATMENT", 331, 353], ["LV", "ANATOMY", 4, 6], ["LV", "ANATOMY", 261, 263]]], ["A 1 mL aliquot was removed from each sample from the MV, LV, and spray applications, and 1 mL was also taken from the gavage solution.", [["sample", "ANATOMY", 37, 43], ["LV", "ANATOMY", 57, 59], ["LV", "MULTI-TISSUE_STRUCTURE", 57, 59], ["MV", "SPECIES", 53, 55], ["A 1 mL aliquot", "TREATMENT", 0, 14], ["LV", "TREATMENT", 57, 59], ["spray applications", "TREATMENT", 65, 83], ["the gavage solution", "TREATMENT", 114, 133], ["LV", "ANATOMY", 57, 59]]], ["Sporulated oocysts from each 1 mL aliquot were counted using a McMaster chamber (Conway and McKenzie, 2008b) .", [["oocysts", "ANATOMY", 11, 18], ["Sporulated oocysts", "PROBLEM", 0, 18], ["a McMaster chamber", "TREATMENT", 61, 79], ["oocysts", "OBSERVATION", 11, 18]]], ["E. maxima and total oocysts/mL were enumerated using the formula: (# oocysts)\u00d7(dilution factor)\u00d7(6.67).", [["E. maxima", "ORGANISM", 0, 9], ["total oocysts/mL", "TREATMENT", 14, 30], ["maxima", "OBSERVATION_MODIFIER", 3, 9]]], ["The calculated oocysts/mL and the volumes of the doses for the gavage (0.5 mL per bird), spray (0.24 mL per bird), MV gel (0.25 mL per bird), and LV gel (0.25 mL per bird) that were administered during application were used to obtain the oocysts/dose for each method.Oocyst Enumeration from Fecal Samples using the McMaster Counting MethodOocysts were enumerated daily for each of the 20 birds per group housed in isolation units for the first and second cycles of oocyst shedding using a McMaster counting chamber in a method based on one described by Conway and McKenzie (Conway and McKenzie, 2008b) .", [["LV", "ANATOMY", 146, 148], ["oocyst", "ANATOMY", 465, 471], ["MV", "SPECIES", 115, 117], ["The calculated oocysts/mL", "TREATMENT", 0, 25], ["the gavage", "TREATMENT", 59, 69], ["spray", "TREATMENT", 89, 94], ["MV gel", "TREATMENT", 115, 121], ["LV gel", "TREATMENT", 146, 152], ["the oocysts/dose", "TREATMENT", 234, 250], ["each method", "TREATMENT", 255, 266], ["Oocyst Enumeration", "TEST", 267, 285], ["Fecal Samples", "TEST", 291, 304], ["the McMaster Counting MethodOocysts", "TREATMENT", 311, 346], ["oocyst shedding", "PROBLEM", 465, 480], ["a McMaster counting chamber", "TREATMENT", 487, 514], ["oocysts", "OBSERVATION", 15, 22], ["LV", "ANATOMY", 146, 148], ["Fecal", "ANATOMY", 291, 296]]], ["After collection, feces of each bird were weighed and resuspended in deionized water at a volume of 10\u00d7 the fecal weight and allowed to soak overnight at 4 \u2022 C in 500 mL bottles.", [["feces", "ANATOMY", 18, 23], ["fecal", "ANATOMY", 108, 113], ["feces", "ORGANISM_SUBSTANCE", 18, 23], ["bird", "ORGANISM", 32, 36], ["fecal", "ORGANISM_SUBDIVISION", 108, 113], ["collection", "PROBLEM", 6, 16], ["feces of each bird", "TREATMENT", 18, 36], ["feces", "OBSERVATION_MODIFIER", 18, 23]]], ["The next day, the bottles were shaken vigorously, and the fecal suspensions were filtered through a double layer of cheesecloth.", [["fecal suspensions", "ANATOMY", 58, 75], ["the fecal suspensions", "TREATMENT", 54, 75], ["a double layer of cheesecloth", "TREATMENT", 98, 127], ["fecal", "ANATOMY", 58, 63]]], ["For each sample, filtrate was collected into a 15 mL centrifuge tube and centrifuged for 5 minutes at 486 \u2022 g to pellet the solids.", [["sample", "ANATOMY", 9, 15], ["filtrate", "TREATMENT", 17, 25], ["a 15 mL centrifuge tube", "TREATMENT", 45, 68]]], ["The supernatant was discarded and the pellet was resuspended in a saturated salt solution to a volume of 15 mL.", [["supernatant", "ANATOMY", 4, 15], ["The supernatant", "TREATMENT", 0, 15], ["the pellet", "TREATMENT", 34, 44], ["a saturated salt solution", "TREATMENT", 64, 89]]], ["After inversion of the tube, a sample was removed with a transfer pipet and a Mc-Master counting chamber was filled.", [["tube", "ANATOMY", 23, 27], ["sample", "ANATOMY", 31, 37], ["tube", "TISSUE", 23, 27], ["the tube", "TREATMENT", 19, 27], ["a transfer pipet", "TREATMENT", 55, 71], ["a Mc-Master counting chamber", "TREATMENT", 76, 104], ["tube", "OBSERVATION", 23, 27]]], ["Oocysts within the chamber were counted as Eimeria maxima and total.", [["Oocysts", "ANATOMY", 0, 7]]], ["The oocysts/g of fecal material was calculated as (# oocysts/0.15)\u00d710, where each oocyst counted is equivalent to 67 oocysts per gram of sample.", [["oocysts", "ANATOMY", 4, 11], ["fecal material", "ANATOMY", 17, 31], ["oocyst", "ANATOMY", 82, 88], ["sample", "ANATOMY", 137, 143], ["fecal material", "MULTI-TISSUE_STRUCTURE", 17, 31], ["fecal material", "PROBLEM", 17, 31], ["oocysts", "PROBLEM", 53, 60], ["oocysts", "OBSERVATION", 4, 11], ["fecal", "ANATOMY", 17, 22]]], ["In cases where the oocysts were too numerous to count, tenfold dilutions of the oocyst suspension were made in saturated salt water until the oocysts reached a countable concentration in the McMaster chamber.", [["oocysts", "ANATOMY", 19, 26], ["oocysts", "ANATOMY", 142, 149], ["oocysts", "CELL", 19, 26], ["the oocysts", "PROBLEM", 15, 26], ["tenfold dilutions", "TREATMENT", 55, 72], ["the oocyst suspension", "TREATMENT", 76, 97], ["saturated salt water", "TREATMENT", 111, 131], ["the oocysts", "PROBLEM", 138, 149], ["oocysts", "OBSERVATION", 19, 26], ["oocyst suspension", "OBSERVATION", 80, 97]]], ["When dilutions were made, the dilution factor was applied to the # oocysts before calculating the oocysts/g of fecal material.Gross Lesion ScoringEimeria maxima gross lesions in the midgut were scored for all experimental groups 7 days post-challenge according to a method first described by Johnson and Reid (Johnson and Reid, 1970) .", [["gross lesions", "ANATOMY", 161, 174], ["midgut", "ANATOMY", 182, 188], ["fecal material", "MULTI-TISSUE_STRUCTURE", 111, 125], ["gross lesions", "PATHOLOGICAL_FORMATION", 161, 174], ["midgut", "ORGAN", 182, 188], ["the dilution factor", "TREATMENT", 26, 45], ["oocysts", "PROBLEM", 67, 74], ["fecal material", "PROBLEM", 111, 125], ["Gross Lesion ScoringEimeria maxima gross lesions in the midgut", "PROBLEM", 126, 188], ["fecal", "ANATOMY", 111, 116], ["Lesion", "OBSERVATION", 132, 138], ["maxima", "OBSERVATION_MODIFIER", 154, 160], ["gross", "OBSERVATION_MODIFIER", 161, 166], ["lesions", "OBSERVATION", 167, 174], ["midgut", "ANATOMY", 182, 188]]], ["The midgut was identified by the presence of the Meckel's diverticulum, and scores were assigned on a scale of 0 to 4, with 0 being no lesions present, 1 showing small numbers of petechiae on the serosal surface of the intestine, 2 showing moreOocyst Count ScoringEimeria maxima oocyst counts were scored for all experimental groups 7 days post-challenge.", [["midgut", "ANATOMY", 4, 10], ["Meckel's diverticulum", "ANATOMY", 49, 70], ["lesions", "ANATOMY", 135, 142], ["petechiae", "ANATOMY", 179, 188], ["serosal surface", "ANATOMY", 196, 211], ["intestine", "ANATOMY", 219, 228], ["Meckel's diverticulum", "DISEASE", 49, 70], ["petechiae", "DISEASE", 179, 188], ["midgut", "ORGAN", 4, 10], ["Meckel's diverticulum", "PATHOLOGICAL_FORMATION", 49, 70], ["lesions", "PATHOLOGICAL_FORMATION", 135, 142], ["petechiae", "PATHOLOGICAL_FORMATION", 179, 188], ["serosal surface", "MULTI-TISSUE_STRUCTURE", 196, 211], ["intestine", "ORGAN", 219, 228], ["the Meckel's diverticulum", "PROBLEM", 45, 70], ["scores", "TEST", 76, 82], ["a scale", "TEST", 100, 107], ["lesions", "PROBLEM", 135, 142], ["small numbers of petechiae", "PROBLEM", 162, 188], ["moreOocyst Count", "TEST", 240, 256], ["maxima oocyst counts", "TEST", 272, 292], ["midgut", "ANATOMY", 4, 10], ["Meckel", "ANATOMY", 49, 55], ["diverticulum", "OBSERVATION", 58, 70], ["no", "UNCERTAINTY", 132, 134], ["lesions", "OBSERVATION", 135, 142], ["small", "OBSERVATION_MODIFIER", 162, 167], ["numbers", "OBSERVATION_MODIFIER", 168, 175], ["petechiae", "OBSERVATION", 179, 188], ["serosal", "ANATOMY_MODIFIER", 196, 203], ["surface", "ANATOMY_MODIFIER", 204, 211], ["intestine", "ANATOMY", 219, 228], ["maxima", "OBSERVATION_MODIFIER", 272, 278], ["oocyst counts", "OBSERVATION", 279, 292]]], ["Following gross lesion scoring, a smear of the midgut of each bird was applied to a microscope slide and one field was viewed under a 10\u00d7 objective lens.", [["gross lesion", "ANATOMY", 10, 22], ["midgut", "ANATOMY", 47, 53], ["midgut", "ORGAN", 47, 53], ["gross lesion scoring", "PROBLEM", 10, 30], ["a smear", "TEST", 32, 39], ["a microscope slide", "TEST", 82, 100], ["gross", "OBSERVATION_MODIFIER", 10, 15], ["lesion", "OBSERVATION", 16, 22], ["midgut", "ANATOMY", 47, 53]]], ["The score system of Goodwin et al. was used, in which 0 = no oocysts seen, 1 = 1 to 20 oocysts per field, 2 = 21 to 50 oocysts per field, 3 = 51 to 100 oocysts per field, and 4 = Too Numerous to Count (TNTC) (Goodwin et al., 1998) .Microscopic Lesion ScoringMicroscopic lesion scoring followed the method described by Goodwin et al (Goodwin, Brown and Bounous, 1998) .", [["oocysts", "PROBLEM", 61, 68], ["Microscopic Lesion ScoringMicroscopic lesion scoring", "PROBLEM", 232, 284], ["oocysts", "OBSERVATION", 61, 68], ["Lesion", "OBSERVATION", 244, 250], ["ScoringMicroscopic", "OBSERVATION_MODIFIER", 251, 269], ["lesion", "OBSERVATION", 270, 276]]], ["A 2.5 cm portion of the jejunum proximal to the Meckel's diverticulum was collected from 5 birds in each experimental group and immersed in 10% buffered formalin.", [["jejunum", "ANATOMY", 24, 31], ["Meckel's diverticulum", "ANATOMY", 48, 69], ["formalin", "CHEMICAL", 153, 161], ["formalin", "CHEMICAL", 153, 161], ["jejunum", "ORGAN", 24, 31], ["Meckel's diverticulum", "CANCER", 48, 69], ["formalin", "SIMPLE_CHEMICAL", 153, 161], ["the Meckel's diverticulum", "PROBLEM", 44, 69], ["2.5 cm", "OBSERVATION_MODIFIER", 2, 8], ["jejunum", "ANATOMY", 24, 31], ["Meckel", "ANATOMY", 48, 54], ["diverticulum", "OBSERVATION", 57, 69]]], ["Portions of each intestinal segment were cut parallel to the longitudinal axis and placed into coded cassettes for processing through graded ethanols and xylene and embedding in paraffin.", [["intestinal", "ANATOMY", 17, 27], ["ethanols", "CHEMICAL", 141, 149], ["xylene", "CHEMICAL", 154, 160], ["ethanols", "CHEMICAL", 141, 149], ["xylene", "CHEMICAL", 154, 160], ["paraffin", "CHEMICAL", 178, 186], ["intestinal segment", "MULTI-TISSUE_STRUCTURE", 17, 35], ["ethanols", "SIMPLE_CHEMICAL", 141, 149], ["xylene", "SIMPLE_CHEMICAL", 154, 160], ["processing through graded ethanols", "TREATMENT", 115, 149], ["xylene", "TREATMENT", 154, 160], ["embedding in paraffin", "TREATMENT", 165, 186], ["each", "ANATOMY_MODIFIER", 12, 16], ["intestinal segment", "ANATOMY", 17, 35], ["longitudinal axis", "ANATOMY", 61, 78]]], ["Three \u03bcm sections of deparaffinized formalin-fixed mid-intestine were placed onto glass slides and stained with hematoxylin and eosin for scoring by a pathologist.", [["\u03bcm sections", "ANATOMY", 6, 17], ["mid-intestine", "ANATOMY", 51, 64], ["formalin", "CHEMICAL", 36, 44], ["formalin", "CHEMICAL", 36, 44], ["hematoxylin", "CHEMICAL", 112, 123], ["eosin", "CHEMICAL", 128, 133], ["mid-intestine", "CANCER", 51, 64], ["hematoxylin", "SIMPLE_CHEMICAL", 112, 123], ["eosin", "SIMPLE_CHEMICAL", 128, 133], ["deparaffinized formalin", "TREATMENT", 21, 44], ["fixed mid-intestine", "TREATMENT", 45, 64], ["hematoxylin", "TREATMENT", 112, 123]]], ["Eimeria maxima was scored based on the presence of developmental stages in the intestinal material.", [["intestinal material", "ANATOMY", 79, 98], ["intestinal material", "MULTI-TISSUE_STRUCTURE", 79, 98], ["Eimeria maxima", "PROBLEM", 0, 14], ["developmental stages in the intestinal material", "PROBLEM", 51, 98], ["intestinal", "ANATOMY", 79, 89]]], ["The microscopic lesion score is the sum of A+B.", [["lesion", "ANATOMY", 16, 22], ["The microscopic lesion score", "PROBLEM", 0, 28], ["microscopic", "OBSERVATION_MODIFIER", 4, 15], ["lesion", "OBSERVATION", 16, 22]]], ["\"A\" represents the distribution of developmental stages of E. maxima along the intestinal segment.", [["intestinal segment", "ANATOMY", 79, 97], ["intestinal segment", "MULTI-TISSUE_STRUCTURE", 79, 97], ["E. maxima", "PROBLEM", 59, 68], ["intestinal", "ANATOMY", 79, 89], ["segment", "ANATOMY_MODIFIER", 90, 97]]], ["Four fields were viewed at a 10\u00d7 objective, and the scoring system for distribution is as follows: 0 = no parasites, 1 = parasites in one field, 2 = parasites in two fields, 3 = parasites in three fields, and 4 = parasites in all four fields.", [["parasites", "PROBLEM", 106, 115], ["parasites in two fields", "TEST", 149, 172], ["parasites in three fields", "TEST", 178, 203], ["no", "UNCERTAINTY", 103, 105], ["parasites", "OBSERVATION", 106, 115], ["parasites", "OBSERVATION", 149, 158], ["two", "ANATOMY_MODIFIER", 162, 165], ["fields", "ANATOMY_MODIFIER", 166, 172], ["parasites", "OBSERVATION_MODIFIER", 178, 187], ["three", "ANATOMY_MODIFIER", 191, 196], ["fields", "ANATOMY_MODIFIER", 197, 203], ["parasites", "OBSERVATION", 213, 222], ["all four", "ANATOMY_MODIFIER", 226, 234], ["fields", "ANATOMY_MODIFIER", 235, 241]]], ["\"B\" represents the severity of Eimeria maxima infection within the four examined fields, where 0 = parasites in 0% of the villi, 1 = parasites in <25% of the villi, 2 = parasites in 25 to 50% of the villi, 3 = parasites in 51 to 75% of the villi, and 4 = parasites in >75% of the villi.", [["villi", "ANATOMY", 122, 127], ["villi", "ANATOMY", 158, 163], ["villi", "ANATOMY", 199, 204], ["villi", "ANATOMY", 240, 245], ["villi", "ANATOMY", 280, 285], ["Eimeria maxima infection", "DISEASE", 31, 55], ["B", "GENE_OR_GENE_PRODUCT", 1, 2], ["Eimeria maxima", "ORGANISM", 31, 45], ["villi", "MULTI-TISSUE_STRUCTURE", 122, 127], ["villi", "TISSUE", 158, 163], ["villi", "TISSUE", 199, 204], ["villi", "MULTI-TISSUE_STRUCTURE", 240, 245], ["villi", "MULTI-TISSUE_STRUCTURE", 280, 285], ["Eimeria maxima", "SPECIES", 31, 45], ["Eimeria maxima", "SPECIES", 31, 45], ["Eimeria maxima infection", "PROBLEM", 31, 55], ["parasites", "TEST", 99, 108], ["parasites", "TEST", 133, 142], ["parasites", "TEST", 169, 178], ["parasites", "TEST", 210, 219], ["parasites", "TEST", 255, 264], ["Eimeria", "OBSERVATION", 31, 38], ["maxima infection", "OBSERVATION", 39, 55], ["villi", "ANATOMY", 122, 127], ["villi", "ANATOMY", 158, 163], ["villi", "ANATOMY", 199, 204], ["villi", "ANATOMY", 240, 245], ["villi", "ANATOMY", 280, 285]]], ["The initial microscopic lesion scores could range from 0 to 8, but to compare to gross lesion scores and oocyst count scores the microscopic lesion score was divided by 2 to give a final score range of 0 to 4.Statistical AnalysisStatistical analysis was performed using GraphPad Prism software (La Jolla, CA) using an alpha of 0.05.", [["lesion", "ANATOMY", 24, 30], ["gross lesion", "ANATOMY", 81, 93], ["oocyst", "ANATOMY", 105, 111], ["lesion", "ANATOMY", 141, 147], ["The initial microscopic lesion scores", "PROBLEM", 0, 37], ["gross lesion scores", "PROBLEM", 81, 100], ["oocyst count", "TEST", 105, 117], ["Statistical AnalysisStatistical analysis", "TEST", 209, 249], ["Prism software", "TEST", 279, 293], ["an alpha", "TEST", 315, 323], ["microscopic", "OBSERVATION_MODIFIER", 12, 23], ["lesion", "OBSERVATION", 24, 30], ["lesion", "OBSERVATION", 87, 93], ["oocyst", "OBSERVATION_MODIFIER", 105, 111], ["lesion", "OBSERVATION", 141, 147]]], ["Oocyst per gram shedding statistical comparisons were analyzed by two-way ANOVA with Holm-Sidak multiple comparisons testing.", [["multiple comparisons testing", "TEST", 96, 124]]], ["Prism software was also used to calculate the per cent coefficient of variation for total and E. maxima shedding of each group and each time point.", [["total and E. maxima shedding of each group", "TREATMENT", 84, 126]]], ["Pre-challenge mean body weight, post-challenge body weight gain, and post-challenge lesion scores were all analyzed by comparison of the means with SEM.Vaccine DosesVaccine doses for each vaccine application method are shown in Table 1 from samples taken directly from the applicator mechanism.", [["body", "ANATOMY", 19, 23], ["body", "ANATOMY", 47, 51], ["lesion", "ANATOMY", 84, 90], ["weight gain", "DISEASE", 52, 63], ["DosesVaccine", "CHEMICAL", 160, 172], ["body", "ORGANISM_SUBDIVISION", 19, 23], ["body", "ORGANISM_SUBDIVISION", 47, 51], ["DosesVaccine", "SIMPLE_CHEMICAL", 160, 172], ["Pre-challenge mean body weight", "TEST", 0, 30], ["post-challenge lesion scores", "TEST", 69, 97], ["Vaccine DosesVaccine doses", "TREATMENT", 152, 178], ["each vaccine application method", "TREATMENT", 183, 214]]], ["The dose was highest in the MV gel group with 1,751 oocysts/dose, followed by the gavage, LV gel, and finally the spray with 1,089 oocysts/dose.", [["LV", "ANATOMY", 90, 92], ["MV", "SPECIES", 28, 30], ["LV gel", "TREATMENT", 90, 96]]], ["When calculating only sporulated E. maxima oocysts per dose, the order was the same as that of the total with MV gel providing the highest dose of 567 oocysts/dose, then gavage and LV gel with 501 and 500 oocysts/dose, and lastly spray with 448 oocysts/dose.Cycle 1 Oocyst SheddingDuring the first cycle, the birds vaccinated by gavage were shedding the highest numbers of total oocysts at all time points, although the gavage group oocysts per gram shed was not significantly different from the LV gel oocyst shedding at day 6, and not significantly different from the MV gel oocyst shedding at day 8 ( Figure 1A ).", [["LV", "ANATOMY", 181, 183], ["E. maxima oocysts", "ORGANISM", 33, 50], ["birds", "ORGANISM", 309, 314], ["E. maxima", "SPECIES", 33, 42], ["MV", "SPECIES", 110, 112], ["MV", "SPECIES", 570, 572], ["MV gel", "TREATMENT", 110, 116], ["LV gel", "TREATMENT", 181, 187], ["the birds vaccinated", "TREATMENT", 305, 325], ["total oocysts", "PROBLEM", 373, 386], ["the gavage group oocysts", "TREATMENT", 416, 440], ["total", "OBSERVATION_MODIFIER", 373, 378], ["oocysts", "OBSERVATION", 379, 386], ["LV", "ANATOMY", 496, 498], ["oocyst", "OBSERVATION", 503, 509], ["oocyst", "OBSERVATION", 577, 583]]], ["The percentage of chickens vaccinated by gavage that were shedding oocysts in cycle 1 was higher than that of all other groups, peaking at 100% on days 6 to 8.", [["chickens", "ORGANISM", 18, 26], ["chickens", "SPECIES", 18, 26], ["chickens", "SPECIES", 18, 26], ["chickens vaccinated", "TREATMENT", 18, 37], ["shedding oocysts", "PROBLEM", 58, 74], ["percentage", "OBSERVATION_MODIFIER", 4, 14]]], ["Of the other vaccine application methods, only the less viscous gel group reached 100% of chickens shedding oocysts at day 6.", [["chickens", "ORGANISM", 90, 98], ["chickens", "SPECIES", 90, 98], ["chickens", "SPECIES", 90, 98], ["the other vaccine application methods", "TREATMENT", 3, 40], ["the less viscous gel group", "TREATMENT", 47, 73], ["chickens shedding oocysts", "PROBLEM", 90, 115]]], ["Ninety-five per cent of the chickens vaccinated by the MV gel were shedding oocysts on days 6 and 7.", [["chickens", "ORGANISM", 28, 36], ["chickens", "SPECIES", 28, 36], ["chickens", "SPECIES", 28, 36], ["MV", "SPECIES", 55, 57], ["the chickens vaccinated", "TREATMENT", 24, 47], ["the MV gel", "TREATMENT", 51, 61], ["shedding oocysts", "PROBLEM", 67, 83], ["oocysts", "OBSERVATION", 76, 83]]], ["The spray vaccinated chickens peaked at day 7 with 95% of chickens shedding oocysts ( Figure 1B) .", [["chickens", "ORGANISM", 21, 29], ["chickens", "ORGANISM", 58, 66], ["chickens", "SPECIES", 21, 29], ["chickens", "SPECIES", 58, 66], ["chickens", "SPECIES", 21, 29], ["chickens", "SPECIES", 58, 66], ["The spray vaccinated chickens", "TREATMENT", 0, 29], ["chickens shedding oocysts", "PROBLEM", 58, 83]]], ["The percent coefficient of variation (%CV) for total oocyst shedding throughout the first cycle shows that the variation of oocyst numbers shed by the spray group was highest, and variation was lowest in the gavage vaccinated group.", [["oocyst", "ANATOMY", 53, 59], ["oocyst", "ANATOMY", 124, 130], ["variation (%CV)", "TREATMENT", 27, 42], ["total oocyst shedding", "PROBLEM", 47, 68], ["oocyst numbers", "PROBLEM", 124, 138], ["percent", "OBSERVATION_MODIFIER", 4, 11], ["coefficient", "OBSERVATION_MODIFIER", 12, 23], ["oocyst", "OBSERVATION", 124, 130]]], ["The lowest %CV seen in the gavage group was on day 7 with a value of 115.2.", [["The lowest %CV", "TREATMENT", 0, 14], ["a value", "TEST", 58, 65], ["lowest", "OBSERVATION_MODIFIER", 4, 10]]], ["Within the spray group, the lowest %CV was seen on day 6, with a value of 156.2.", [["the lowest %CV", "TEST", 24, 38], ["a value", "TEST", 63, 70]]], ["The MV gel group showed the least variation on day 7 with a value of 100.5, and the LV gel group showed the least variation for total oocyst shedding on Day 6, with a value of 101.5 (Table 2) .", [["LV", "ANATOMY", 84, 86], ["oocyst", "ANATOMY", 134, 140], ["MV", "SPECIES", 4, 6], ["The MV gel group", "TEST", 0, 16], ["a value", "TEST", 58, 65], ["the LV gel group", "TEST", 80, 96], ["total oocyst shedding", "PROBLEM", 128, 149], ["a value", "TEST", 165, 172], ["oocyst", "OBSERVATION", 134, 140]]], ["Eimeria maxima oocyst shedding data for the first cycle of fecal collection followed a similar trend to the total oocyst shedding, with the chickens vaccinated by gavage shedding significantly higher E. maxima oocysts per gram than any of the other experimental groups ( Figure 1C ).", [["oocyst", "ANATOMY", 15, 21], ["fecal", "ANATOMY", 59, 64], ["oocyst", "ANATOMY", 114, 120], ["fecal", "ORGANISM_SUBSTANCE", 59, 64], ["chickens", "ORGANISM", 140, 148], ["chickens", "SPECIES", 140, 148], ["E. maxima", "SPECIES", 200, 209], ["chickens", "SPECIES", 140, 148], ["E. maxima", "SPECIES", 200, 209], ["Eimeria maxima oocyst shedding data", "TEST", 0, 35], ["fecal collection", "PROBLEM", 59, 75], ["the chickens vaccinated", "TREATMENT", 136, 159], ["fecal", "ANATOMY", 59, 64], ["collection", "OBSERVATION", 65, 75]]], ["The percentages of chickens shedding E. maxima in each group were lower than those for the to-tal oocyst shedding, peaking at 7 days post-vaccination with 85% of the chickens vaccinated by gavage shedding E. maxima.", [["oocyst", "ANATOMY", 98, 104], ["chickens", "ORGANISM", 19, 27], ["E. maxima", "ORGANISM", 37, 46], ["chickens", "ORGANISM", 166, 174], ["chickens", "SPECIES", 19, 27], ["E. maxima", "SPECIES", 37, 46], ["chickens", "SPECIES", 166, 174], ["chickens", "SPECIES", 19, 27], ["chickens", "SPECIES", 166, 174], ["E. maxima", "SPECIES", 205, 214], ["chickens shedding E. maxima", "PROBLEM", 19, 46], ["the chickens vaccinated", "TREATMENT", 162, 185], ["percentages", "OBSERVATION_MODIFIER", 4, 15], ["maxima", "OBSERVATION_MODIFIER", 40, 46], ["oocyst", "OBSERVATION", 98, 104]]], ["In the other groups, the MV gel group had the highest percentage of chickens shedding E. maxima oocysts with 65% shedding on days 7 and 8 ( Figure 1D ).", [["chickens", "ORGANISM", 68, 76], ["E. maxima oocysts", "ORGANISM", 86, 103], ["chickens", "SPECIES", 68, 76], ["E. maxima", "SPECIES", 86, 95], ["MV", "SPECIES", 25, 27], ["chickens", "SPECIES", 68, 76], ["E. maxima", "SPECIES", 86, 95], ["the MV gel group", "TEST", 21, 37], ["chickens shedding E. maxima oocysts", "PROBLEM", 68, 103], ["maxima oocysts", "OBSERVATION", 89, 103]]], ["The variation in numbers of E. maxima oocysts shed by the gavage gel group was the lowest throughout the first cycle, and %CV in the first cycle increased with the MV gel, followed by the LV gel and spray groups.", [["LV", "ANATOMY", 188, 190], ["E. maxima oocysts", "ORGANISM", 28, 45], ["E. maxima", "SPECIES", 28, 37], ["E. maxima", "SPECIES", 28, 37], ["MV", "SPECIES", 164, 166], ["E. maxima oocysts", "TREATMENT", 28, 45], ["the gavage gel group", "TREATMENT", 54, 74], ["the MV gel", "TREATMENT", 160, 170], ["the LV gel and spray groups", "TREATMENT", 184, 211], ["variation", "OBSERVATION_MODIFIER", 4, 13], ["numbers", "OBSERVATION_MODIFIER", 17, 24], ["maxima oocysts", "OBSERVATION", 31, 45], ["LV", "ANATOMY", 188, 190]]], ["The gavage, spray, and MV gel groups showed their lowest %CV for E. maxima shedding in the first cycle on day 7, with values of 131.3, 280.5, and 123.4, respectively.", [["MV", "SPECIES", 23, 25], ["E. maxima", "SPECIES", 65, 74], ["The gavage, spray", "TREATMENT", 0, 17], ["MV gel groups", "TREATMENT", 23, 36], ["E. maxima shedding", "PROBLEM", 65, 83], ["values", "TEST", 118, 124]]], ["The lowest %CV seen in the LV gel group was 251.3 on day 8 (Table 3) .Cycle 2 Oocyst SheddingIn the second cycle, the gavage group total oocyst shedding became more consistent with that of the other groups.", [["LV", "ANATOMY", 27, 29], ["oocyst", "ANATOMY", 137, 143], ["The lowest %CV", "TEST", 0, 14], ["the gavage group total oocyst", "TREATMENT", 114, 143], ["LV", "ANATOMY", 27, 29], ["Oocyst", "OBSERVATION", 78, 84]]], ["On day 12, the gavage, spray, and LV gel groups were all shedding significantly higher total oocysts per gram than the MV gel group, which was decreased tenfold compared to the other groups.", [["LV", "ANATOMY", 34, 36], ["MV", "SPECIES", 119, 121], ["the gavage, spray", "TREATMENT", 11, 28], ["LV gel groups", "TREATMENT", 34, 47], ["decreased tenfold", "PROBLEM", 143, 160], ["decreased", "OBSERVATION_MODIFIER", 143, 152], ["tenfold", "OBSERVATION_MODIFIER", 153, 160]]], ["By day 13, the spray group had the highest mean total oocysts per gram shed (650,033), and throughout days 14 and 15 there was no significant difference in oocyst shedding between any of the groups (Figure 2A) .", [["oocyst", "ANATOMY", 156, 162], ["significant difference in oocyst shedding", "PROBLEM", 130, 171], ["no", "UNCERTAINTY", 127, 129], ["significant", "OBSERVATION_MODIFIER", 130, 141], ["difference", "OBSERVATION", 142, 152], ["oocyst", "OBSERVATION", 156, 162]]], ["Although the numbers of oocysts per gram differed between the groups significantly on days 12 and 13 and numerically throughout the second cycle, there was 100% shedding of total oocysts for the birds in each group on all days in cycle 2 except for day 12 ( Figure 2B ).", [["oocysts", "CELL", 24, 31], ["total oocysts", "PROBLEM", 173, 186], ["numbers", "OBSERVATION_MODIFIER", 13, 20], ["oocysts", "OBSERVATION", 24, 31], ["gram differed", "OBSERVATION_MODIFIER", 36, 49], ["oocysts", "OBSERVATION", 179, 186]]], ["The %CV for total oocyst shedding in cycle 2 was decreased in all groups compared to the first cycle, and variation was lowest in the spray vaccinated group (53.6 on day 15) and highest in the MV gel group, which only reached a low value of 120.3 on day 15 (Table 2) .Cycle 2 Oocyst SheddingEimeria maxima shedding during the second cycle was quite low and did not show the same increase in shedding from cycle 1 that was seen with the total oocyst shedding, although the spray group shedding had increased significantly compared to all other groups by day 15 ( Figure 2C ).", [["oocyst", "ANATOMY", 18, 24], ["oocyst", "ANATOMY", 442, 448], ["MV", "SPECIES", 193, 195], ["The %CV", "TREATMENT", 0, 7], ["total oocyst", "PROBLEM", 12, 24], ["Eimeria maxima shedding", "PROBLEM", 291, 314], ["the total oocyst shedding", "PROBLEM", 432, 457], ["the spray group shedding", "TREATMENT", 468, 492], ["oocyst", "OBSERVATION", 18, 24], ["decreased", "OBSERVATION_MODIFIER", 49, 58], ["Oocyst", "OBSERVATION", 276, 282], ["increase", "OBSERVATION_MODIFIER", 379, 387]]], ["In addition to the low E. maxima oocyst numbers being shed during the second cycle, the percentage of chickens positive for shedding E. maxima in each group was low during days 12 to 14, with an increase in the percent positive at day 15 ( Figure 2D ).", [["chickens", "ORGANISM", 102, 110], ["chickens", "SPECIES", 102, 110], ["chickens", "SPECIES", 102, 110], ["the low E. maxima oocyst numbers", "PROBLEM", 15, 47], ["chickens positive", "PROBLEM", 102, 119], ["shedding E. maxima", "PROBLEM", 124, 142], ["increase", "OBSERVATION_MODIFIER", 195, 203]]], ["The %CV for the second cycle of E. maxima oocyst shedding was increased in all groups except for the spray vaccinated group compared to the first cycle.", [["oocyst", "ANATOMY", 42, 48], ["E. maxima oocyst", "ORGANISM", 32, 48], ["E. maxima", "SPECIES", 32, 41], ["The %CV", "TREATMENT", 0, 7], ["E. maxima oocyst shedding", "PROBLEM", 32, 57], ["the spray vaccinated group", "TREATMENT", 97, 123], ["maxima oocyst", "OBSERVATION", 35, 48], ["increased", "OBSERVATION_MODIFIER", 62, 71]]], ["The %CV throughout the second cycle was highest in the MV gel vaccinated group and lowest in the spray group.", [["MV", "SPECIES", 55, 57], ["the MV gel vaccinated group", "TREATMENT", 51, 78]]], ["The lowest %CV value seen in the second cycle was in the spray group with a value of 119.9 on day 15.", [["The lowest %CV value", "TEST", 0, 20], ["a value", "TEST", 74, 81]]], ["The highest value reached was 447.2, which was seen in the gavage group on day 12, and in the MV gel and LV gel groups on day 13 (Table 3) .Pre-and Post-Challenge Body WeightThere was no significant difference in the mean body weight recorded 16 days post-vaccination between any of the vaccinated groups or the non-vaccinated control group ( Figure 3A ).", [["LV", "ANATOMY", 105, 107], ["Body", "ANATOMY", 163, 167], ["body", "ANATOMY", 222, 226], ["body", "ORGANISM_SUBDIVISION", 222, 226], ["MV", "SPECIES", 94, 96], ["The highest value", "TEST", 0, 17], ["the MV gel", "TREATMENT", 90, 100], ["Body Weight", "TEST", 163, 174], ["significant difference", "PROBLEM", 187, 209], ["the mean body weight", "TEST", 213, 233], ["the vaccinated groups", "TREATMENT", 283, 304], ["LV", "ANATOMY", 105, 107], ["no", "UNCERTAINTY", 184, 186], ["significant", "OBSERVATION_MODIFIER", 187, 198], ["difference", "OBSERVATION_MODIFIER", 199, 209]]], ["The body weight gain recorded 7 days post-challenge did not show a significant difference between any of the vaccinated groups and the nonvaccinated/non-challenged group.", [["body", "ANATOMY", 4, 8], ["weight gain", "DISEASE", 9, 20], ["body", "ORGANISM_SUBDIVISION", 4, 8], ["The body weight gain", "PROBLEM", 0, 20], ["a significant difference", "PROBLEM", 65, 89]]], ["However, the MV gel vaccinated group body weight gain was also not significantly higher than the non-vaccinated/challenged group ( Figure 3B ).Gross LesionsNone of the vaccinated groups differed significantly when evaluating gross lesion scores, with all vaccinated groups having gross lesion scores below 1.", [["body", "ANATOMY", 37, 41], ["gross lesion", "ANATOMY", 225, 237], ["lesion", "ANATOMY", 286, 292], ["weight gain", "DISEASE", 42, 53], ["body", "ORGANISM_SUBDIVISION", 37, 41], ["MV", "SPECIES", 13, 15], ["the MV gel vaccinated group body weight gain", "TEST", 9, 53], ["gross lesion scores", "PROBLEM", 225, 244], ["gross lesion scores", "PROBLEM", 280, 299], ["LesionsNone", "OBSERVATION", 149, 160], ["lesion", "OBSERVATION", 231, 237], ["gross", "OBSERVATION_MODIFIER", 280, 285], ["lesion", "OBSERVATION", 286, 292]]], ["The gavage, more viscous gel, and less viscous gel groups also all did not differ significantly from the non-vaccinated/non-challenged group.", [["The gavage", "TREATMENT", 0, 10], ["more viscous gel", "TREATMENT", 12, 28], ["less viscous gel groups", "TREATMENT", 34, 57]]], ["The non-vaccinated/challenged group showed significantly higher gross lesion scores than all other groups, with a mean score greater than 2 ( Figure 4A ).Oocyst Count ScoresE. maxima oocyst enumeration from mid-intestine scrapings showed that the vaccinated groups did not differ significantly in oocyst count scores from each other or from the non-vaccinated/challenged group, and all scores were below 2.", [["gross lesion", "ANATOMY", 64, 76], ["mid-intestine scrapings", "ANATOMY", 207, 230], ["oocyst", "ANATOMY", 297, 303], ["significantly higher gross lesion scores", "PROBLEM", 43, 83], ["a mean score", "TEST", 112, 124], ["Oocyst Count", "TEST", 154, 166], ["ScoresE", "TEST", 167, 174], ["maxima oocyst enumeration", "TEST", 176, 201], ["mid-intestine scrapings", "TEST", 207, 230], ["the vaccinated groups", "PROBLEM", 243, 264], ["oocyst count scores", "TEST", 297, 316], ["significantly", "OBSERVATION_MODIFIER", 43, 56], ["higher", "OBSERVATION_MODIFIER", 57, 63], ["gross", "OBSERVATION_MODIFIER", 64, 69], ["lesion", "OBSERVATION", 70, 76], ["maxima", "OBSERVATION_MODIFIER", 176, 182], ["oocyst enumeration", "OBSERVATION", 183, 201]]], ["The non-vaccinated/nonchallenged group had a score of 0, which was significantly lower than all other groups ( Figure 4B ).Microscopic LesionsMicroscopic lesion scores ranged from 2.5 to 3 for all challenged groups, with none of the E. maxima challenged groups differing significantly.", [["lesion", "ANATOMY", 154, 160], ["Microscopic LesionsMicroscopic lesion scores", "PROBLEM", 123, 167], ["lesion", "OBSERVATION", 154, 160]]], ["The nonvaccinated/non-challenged group had a score of 0 which was significantly lower than all other groups ( Figure 4C ).DISCUSSIONThe influence of each application method is shown in the cycle 1 total oocyst shedding.", [["oocyst", "ANATOMY", 203, 209], ["each application method", "TREATMENT", 149, 172]]], ["The birds vaccinated by gavage were shedding higher numbers of total and E. maxima oocysts than any of the experimentally vaccinated groups in the first cycle.", [["birds", "ORGANISM", 4, 9], ["E. maxima oocysts", "ORGANISM", 73, 90], ["E. maxima", "SPECIES", 73, 82], ["E. maxima", "SPECIES", 73, 82], ["The birds vaccinated", "TREATMENT", 0, 20], ["total and E. maxima oocysts", "TREATMENT", 63, 90], ["the experimentally vaccinated groups", "TREATMENT", 103, 139]]], ["When vaccinating by oral gavage, the oocyst suspension is deposited directly into the crop, resulting in more efficient delivery of the oocysts to the intestinal tract.", [["oral", "ANATOMY", 20, 24], ["oocysts", "ANATOMY", 136, 143], ["intestinal tract", "ANATOMY", 151, 167], ["oral", "ORGANISM_SUBDIVISION", 20, 24], ["intestinal tract", "ORGAN", 151, 167], ["oral gavage", "TREATMENT", 20, 31], ["the oocyst suspension", "TREATMENT", 33, 54], ["more", "OBSERVATION_MODIFIER", 105, 109], ["efficient", "OBSERVATION_MODIFIER", 110, 119], ["oocysts", "OBSERVATION", 136, 143], ["intestinal tract", "ANATOMY", 151, 167]]], ["This controlled vaccination method also produced the least variation of total oocyst shedding numbers in the first cycle, as all chickens vaccinated were ensured to receive a proper vaccine dose.", [["oocyst", "ANATOMY", 78, 84], ["chickens", "ORGANISM", 129, 137], ["chickens", "SPECIES", 129, 137], ["chickens", "SPECIES", 129, 137], ["This controlled vaccination method", "TREATMENT", 0, 34], ["all chickens vaccinated", "TREATMENT", 125, 148], ["a proper vaccine dose", "TREATMENT", 173, 194]]], ["The spray, MV gel, and LV gel methods require chicks to actively ingest oocysts both from preening and from pecking in the hatchery basket, resulting in a potential loss of vaccine.", [["MV", "SPECIES", 11, 13], ["The spray", "TREATMENT", 0, 9], ["MV gel", "TREATMENT", 11, 17], ["LV gel methods", "TREATMENT", 23, 37], ["a potential loss of vaccine", "TREATMENT", 153, 180], ["LV", "ANATOMY", 23, 25]]], ["Both gel vaccines produced less variation in oocyst shedding during the first cycle compared to the variation seen in the spray vaccinated group, perhaps indicating that the gel beads provide a more stable vehicle for vaccine delivery than a liquid spray.", [["oocyst", "ANATOMY", 45, 51], ["Both gel vaccines", "TREATMENT", 0, 17], ["oocyst shedding", "PROBLEM", 45, 60], ["the spray vaccinated group", "TREATMENT", 118, 144], ["the gel beads", "TREATMENT", 170, 183], ["vaccine delivery", "TREATMENT", 218, 234], ["a liquid spray", "TREATMENT", 240, 254], ["less", "OBSERVATION_MODIFIER", 27, 31], ["variation", "OBSERVATION_MODIFIER", 32, 41], ["oocyst", "OBSERVATION", 45, 51]]], ["Furthermore, the MV gel vaccinated chickens shed numerically higher total and E. maxima oocysts in the feces than the spray and LV gel groups in the first cycle, which is consistent with the higher doses of oocysts for that application method.DISCUSSIONDuring the second cycle of fecal oocyst shedding, the total oocysts shed increased tenfold for the gavage, spray, and less viscous gel groups.", [["feces", "ANATOMY", 103, 108], ["fecal oocyst", "ANATOMY", 280, 292], ["oocysts", "ANATOMY", 313, 320], ["chickens", "ORGANISM", 35, 43], ["feces", "ORGANISM_SUBSTANCE", 103, 108], ["fecal", "ORGANISM_SUBSTANCE", 280, 285], ["oocyst", "ORGANISM_SUBSTANCE", 286, 292], ["chickens", "SPECIES", 35, 43], ["E. maxima", "SPECIES", 78, 87], ["MV", "SPECIES", 17, 19], ["chickens", "SPECIES", 35, 43], ["E. maxima", "SPECIES", 78, 87], ["the MV gel", "TREATMENT", 13, 23], ["E. maxima oocysts in the feces", "PROBLEM", 78, 108], ["oocysts", "PROBLEM", 207, 214], ["that application method", "TREATMENT", 219, 242], ["fecal oocyst shedding", "PROBLEM", 280, 301], ["the total oocysts", "TREATMENT", 303, 320], ["the gavage, spray", "TREATMENT", 348, 365], ["less viscous gel groups", "TREATMENT", 371, 394], ["maxima oocysts", "OBSERVATION", 81, 95], ["LV", "ANATOMY", 128, 130], ["consistent with", "UNCERTAINTY", 171, 186], ["oocysts", "OBSERVATION", 207, 214], ["fecal", "ANATOMY", 280, 285], ["oocyst", "OBSERVATION", 286, 292], ["increased", "OBSERVATION_MODIFIER", 326, 335], ["tenfold", "OBSERVATION_MODIFIER", 336, 343]]], ["This was expected as the birds ingested the higher doses of oocysts present in the litter following the first cycle of shedding.", [["birds", "ORGANISM", 25, 30], ["oocysts", "PROBLEM", 60, 67], ["higher doses", "OBSERVATION_MODIFIER", 44, 56], ["oocysts", "OBSERVATION", 60, 67]]], ["In addition, the spray, gavage, and less viscous gel groups all had lower variation within the groups for oocyst shedding in the second cycle, and all coefficient of variation values for those groups were very similar.", [["oocyst", "ANATOMY", 106, 112], ["the spray", "TREATMENT", 13, 22], ["gavage", "TREATMENT", 24, 30], ["less viscous gel groups", "TREATMENT", 36, 59], ["oocyst shedding", "PROBLEM", 106, 121]]], ["This decrease in variation compared to the first cycle of oocyst shedding may be attributed to the exposure of chickens that did not receive vaccine to the sporulated oocysts in the litter from the first cycle of shedding, leading to more consistent infection and shedding of all birds within the groups.", [["oocyst", "ANATOMY", 58, 64], ["oocysts", "ANATOMY", 167, 174], ["infection", "DISEASE", 250, 259], ["chickens", "ORGANISM", 111, 119], ["chickens", "SPECIES", 111, 119], ["chickens", "SPECIES", 111, 119], ["This decrease in variation", "PROBLEM", 0, 26], ["oocyst shedding", "PROBLEM", 58, 73], ["vaccine", "TREATMENT", 141, 148], ["the sporulated oocysts", "PROBLEM", 152, 174], ["consistent infection", "PROBLEM", 239, 259], ["decrease", "OBSERVATION_MODIFIER", 5, 13], ["variation", "OBSERVATION_MODIFIER", 17, 26], ["may be attributed to", "UNCERTAINTY", 74, 94], ["oocysts", "OBSERVATION", 167, 174], ["infection", "OBSERVATION", 250, 259]]], ["However, the birds vaccinated by the more viscous gel method were shedding significantly lower numbers of total oocysts than the other vaccinated groups, although 100% of the birds in that group were shedding oocysts at all time points except for day 12.", [["birds", "ORGANISM", 13, 18], ["birds", "ORGANISM", 175, 180], ["the more viscous gel method", "TREATMENT", 33, 60], ["total oocysts", "PROBLEM", 106, 119], ["shedding oocysts", "PROBLEM", 200, 216]]], ["Although the temperature of each colony room that each group was held in remained consistent, it is possible that there was reduced humidity in the more viscous gel room, leading to lower sporulation rates of the oocysts shed in the first cycle and therefore lower doses of oocysts ingested by those birds, however this is only speculation.DISCUSSIONLike the data for the first cycle of E. maxima oocyst shedding, the numbers of oocysts shed during the second cycle were quite low in all groups except for day 15, when the spray group was shedding significantly higher oocysts per gram than the other groups.", [["oocyst", "ANATOMY", 397, 403], ["oocysts", "ANATOMY", 429, 436], ["E. maxima", "SPECIES", 387, 396], ["reduced humidity", "PROBLEM", 124, 140], ["lower sporulation rates", "PROBLEM", 182, 205], ["the oocysts", "PROBLEM", 209, 220], ["oocysts", "PROBLEM", 274, 281], ["E. maxima oocyst", "PROBLEM", 387, 403], ["oocysts", "PROBLEM", 429, 436], ["the spray group", "TREATMENT", 519, 534], ["reduced", "OBSERVATION_MODIFIER", 124, 131], ["humidity", "OBSERVATION_MODIFIER", 132, 140], ["oocysts", "OBSERVATION", 213, 220], ["lower doses", "OBSERVATION_MODIFIER", 259, 270], ["oocysts", "OBSERVATION", 274, 281], ["maxima oocyst", "OBSERVATION", 390, 403], ["oocysts", "OBSERVATION", 429, 436]]], ["In addition, the percentage of birds in each group positive for E. maxima shedding was low until day 15.", [["birds", "ORGANISM", 31, 36], ["E. maxima", "ORGANISM", 64, 73], ["E. maxima", "SPECIES", 64, 73], ["E. maxima shedding", "PROBLEM", 64, 82]]], ["This is also seen in the increased variation seen within the gavage, more viscous gel, and less viscous gel groups compared to the first cycle of E. maxima shedding, as there were very few birds within those groups shedding E. maxima oocysts during the second cycle.", [["E. maxima", "ORGANISM", 146, 155], ["E. maxima oocysts", "ORGANISM", 224, 241], ["E. maxima", "SPECIES", 224, 233], ["E. maxima", "SPECIES", 146, 155], ["E. maxima", "SPECIES", 224, 233], ["the increased variation", "PROBLEM", 21, 44], ["viscous gel", "TREATMENT", 74, 85], ["less viscous gel groups", "TREATMENT", 91, 114], ["E. maxima shedding", "PROBLEM", 146, 164], ["increased", "OBSERVATION_MODIFIER", 25, 34], ["variation", "OBSERVATION_MODIFIER", 35, 44], ["very", "OBSERVATION_MODIFIER", 180, 184], ["few", "OBSERVATION_MODIFIER", 185, 188], ["maxima oocysts", "OBSERVATION", 227, 241]]], ["It is possible that the start of shedding for the second cycle was delayed, and higher numbers would have been seen had fecal collection continued beyond 15 days.", [["fecal", "ANATOMY", 120, 125], ["fecal", "ORGANISM_SUBSTANCE", 120, 125], ["fecal collection", "PROBLEM", 120, 136], ["fecal", "ANATOMY", 120, 125], ["collection", "OBSERVATION", 126, 136]]], ["This trend can be seen in Figure 2D , where the percentage of chicks shedding E. maxima increased every day.DISCUSSIONE. maxima was deemed to be the most appropriate species of Eimeria to use as a challenge, as it is a component in the development of necrotic enteritis, and is therefore of extreme relevance to the poultry industry (Williams et al., 2003) .", [["necrotic enteritis", "DISEASE", 251, 269], ["Eimeria", "ORGANISM", 177, 184], ["necrotic enteritis", "PROBLEM", 251, 269], ["necrotic", "OBSERVATION_MODIFIER", 251, 259], ["enteritis", "OBSERVATION", 260, 269]]], ["There was no difference in pre-challenge body weight between any of the groups, which runs counter to the common industry concern of reduced performance when using live coccidia vaccines.", [["body", "ANATOMY", 41, 45], ["body", "ORGANISM_SUBDIVISION", 41, 45], ["difference in pre-challenge body weight", "PROBLEM", 13, 52], ["reduced performance", "PROBLEM", 133, 152], ["live coccidia vaccines", "TREATMENT", 164, 186], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23]]], ["In future experiments, further performance analysis could be performed to better understand the effect of coccidia vaccination on body weight gain.", [["body", "ANATOMY", 130, 134], ["coccidia", "DISEASE", 106, 114], ["weight gain", "DISEASE", 135, 146], ["coccidia", "ORGANISM", 106, 114], ["body", "ORGANISM_SUBDIVISION", 130, 134], ["further performance analysis", "TEST", 23, 51], ["coccidia vaccination", "TREATMENT", 106, 126], ["body weight gain", "PROBLEM", 130, 146]]], ["Following challenge, the mean body weight gains of the vaccinated groups were not significantly different from the non-challenge controls, indicating protection.", [["body", "ANATOMY", 30, 34], ["body", "ORGANISM_SUBDIVISION", 30, 34], ["the mean body weight", "TEST", 21, 41], ["the non-challenge controls", "TREATMENT", 111, 137], ["significantly different", "OBSERVATION_MODIFIER", 82, 105]]], ["The mean body weight of the negative control group was significantly increased compared to the non-vaccinated challenged control group, showing that the challenge had an influence on body weight for non-vaccinated birds.", [["body", "ANATOMY", 9, 13], ["body", "ANATOMY", 183, 187], ["body", "ORGANISM_SUBDIVISION", 9, 13], ["body", "ORGANISM_SUBDIVISION", 183, 187], ["The mean body weight", "TEST", 0, 20], ["body weight", "TEST", 183, 194], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["increased", "OBSERVATION_MODIFIER", 69, 78]]], ["Interestingly, the MV gel group, which showed significantly reduced oocyst shedding in the second cycle compared to the other groups, did not significantly differ in average body weight gain from the non-vaccinated, challenged control group.", [["oocyst", "ANATOMY", 68, 74], ["body", "ANATOMY", 174, 178], ["weight gain", "DISEASE", 179, 190], ["body", "ORGANISM_SUBDIVISION", 174, 178], ["MV", "SPECIES", 19, 21], ["the MV gel group", "TEST", 15, 31], ["significantly reduced oocyst shedding", "PROBLEM", 46, 83], ["significantly", "OBSERVATION_MODIFIER", 46, 59], ["reduced", "OBSERVATION_MODIFIER", 60, 67], ["oocyst", "OBSERVATION", 68, 74]]], ["This illustrates the importance of re-exposure to oocysts in the litter in order to achieve complete protection.DISCUSSIONWhen evaluating gross lesions, scores for the vaccinated groups were low, and the gavage, more viscous gel, and less viscous gel group scores all were statistically the same as the negative control group, indicating protection from challenge.", [["gross lesions", "ANATOMY", 138, 151], ["gross lesions", "PATHOLOGICAL_FORMATION", 138, 151], ["oocysts", "PROBLEM", 50, 57], ["gross lesions", "PROBLEM", 138, 151], ["the vaccinated groups", "TREATMENT", 164, 185], ["the gavage", "TREATMENT", 200, 210], ["more viscous gel", "TREATMENT", 212, 228], ["less viscous gel group scores", "TREATMENT", 234, 263], ["oocysts", "OBSERVATION", 50, 57], ["lesions", "OBSERVATION", 144, 151]]], ["The spray group did not have significantly different scores from the other vaccinated groups, but did have a significantly higher mean gross lesion score than the negative control group.", [["gross lesion", "ANATOMY", 135, 147], ["significantly different scores", "PROBLEM", 29, 59], ["a significantly higher mean gross lesion score", "PROBLEM", 107, 153], ["gross", "OBSERVATION_MODIFIER", 135, 140], ["lesion", "OBSERVATION", 141, 147]]], ["The oocyst count scores and the microscopic lesion scores of the vaccinated groups were all statistically the same as the mean score of the positive challenge control group.", [["oocyst", "ANATOMY", 4, 10], ["lesion", "ANATOMY", 44, 50], ["The oocyst count scores", "TEST", 0, 23], ["the microscopic lesion scores of the vaccinated groups", "PROBLEM", 28, 82], ["the positive challenge control group", "TREATMENT", 136, 172], ["microscopic", "OBSERVATION_MODIFIER", 32, 43], ["lesion", "OBSERVATION", 44, 50]]], ["However, interpretation of these scores is difficult, considering that the birds were all kept on litter during the 7 days postchallenge, and could have continued to cycle vaccine oocysts during this time, rendering it nearly impossible to distinguish between vaccine and challenge oocysts present in the mid-intestine.", [["mid-intestine", "ANATOMY", 305, 318], ["birds", "ORGANISM", 75, 80], ["mid-intestine", "CANCER", 305, 318], ["these scores", "TEST", 27, 39], ["vaccine", "TREATMENT", 260, 267], ["challenge oocysts", "PROBLEM", 272, 289], ["oocysts", "OBSERVATION", 282, 289]]], ["Although the positive challenge control group did not differ significantly in oocyst count and microscopic lesion scores from the vaccinated/challenged groups, it is possible that the E. maxima scored for the positive control assays was present from challenge, whereas the E. maxima seen in the vaccinated/challenge groups may have been from vaccine.", [["oocyst", "ANATOMY", 78, 84], ["lesion", "ANATOMY", 107, 113], ["E. maxima", "ORGANISM", 184, 193], ["E. maxima", "ORGANISM", 273, 282], ["E. maxima", "SPECIES", 184, 193], ["E. maxima", "SPECIES", 273, 282], ["oocyst count", "TEST", 78, 90], ["microscopic lesion scores", "PROBLEM", 95, 120], ["the vaccinated/challenged groups", "TREATMENT", 126, 158], ["the E. maxima", "PROBLEM", 180, 193], ["the positive control assays", "PROBLEM", 205, 232], ["the E. maxima", "PROBLEM", 269, 282], ["the vaccinated/challenge groups", "TREATMENT", 291, 322], ["vaccine", "TREATMENT", 342, 349], ["lesion", "OBSERVATION", 107, 113]]], ["This makes the body weight and the gross lesion scores the more reliable methods for evaluating protection.DISCUSSIONThis experiment demonstrates that vaccine application method can influence the dosage of oocysts per chicken.", [["body", "ANATOMY", 15, 19], ["gross lesion", "ANATOMY", 35, 47], ["body", "ORGANISM_SUBDIVISION", 15, 19], ["chicken", "ORGANISM", 218, 225], ["chicken", "SPECIES", 218, 225], ["chicken", "SPECIES", 218, 225], ["the body weight", "TEST", 11, 26], ["the gross lesion scores", "PROBLEM", 31, 54], ["vaccine application method", "TREATMENT", 151, 177], ["gross", "OBSERVATION_MODIFIER", 35, 40], ["lesion", "OBSERVATION", 41, 47]]], ["Even though all vaccines were mixed so that each chick basket would receive the same dosage of oocysts, there was a difference in the number of oocysts collected from each application method.", [["chick", "ORGANISM", 49, 54], ["all vaccines", "TREATMENT", 12, 24], ["each chick basket", "TREATMENT", 44, 61], ["oocysts", "PROBLEM", 95, 102], ["oocysts", "PROBLEM", 144, 151], ["oocysts", "OBSERVATION", 95, 102], ["oocysts", "OBSERVATION", 144, 151]]], ["The gel application methods had oocyst numbers in each dose consistent with the gavage preparation (where vaccine is not mass applied).", [["The gel application methods", "TREATMENT", 0, 27], ["the gavage preparation", "TREATMENT", 76, 98], ["vaccine", "TREATMENT", 106, 113], ["mass", "PROBLEM", 121, 125]]], ["Contrastingly, there was a loss of oocysts during vaccination for the spray method, which is consistent with other reports showing that infectious bronchitis virus vaccine is lost when applied by spray (Roh et al., 2015) .", [["infectious bronchitis virus", "DISEASE", 136, 163], ["infectious bronchitis virus", "ORGANISM", 136, 163], ["infectious bronchitis virus", "SPECIES", 136, 163], ["a loss of oocysts", "PROBLEM", 25, 42], ["vaccination", "TREATMENT", 50, 61], ["the spray method", "TREATMENT", 66, 82], ["infectious bronchitis virus vaccine", "TREATMENT", 136, 171], ["loss", "OBSERVATION_MODIFIER", 27, 31], ["oocysts", "OBSERVATION", 35, 42], ["consistent with", "UNCERTAINTY", 93, 108], ["infectious", "OBSERVATION_MODIFIER", 136, 146]]], ["While these differences in total oocysts delivered to chicks varied between application methods, there was no difference in body weight gain or protection from challenge between birds vaccinated using water spray, more viscous gel bar, less viscous gel bar, or gavage.", [["body", "ANATOMY", 124, 128], ["weight gain", "DISEASE", 129, 140], ["body", "ORGANISM_SUBDIVISION", 124, 128], ["birds", "ORGANISM", 178, 183], ["total oocysts", "PROBLEM", 27, 40], ["application methods", "TREATMENT", 76, 95], ["body weight gain", "PROBLEM", 124, 140], ["water spray", "TREATMENT", 201, 212], ["more viscous gel bar", "TREATMENT", 214, 234], ["less viscous gel bar", "TREATMENT", 236, 256], ["total", "OBSERVATION_MODIFIER", 27, 32], ["oocysts", "OBSERVATION", 33, 40], ["no", "UNCERTAINTY", 107, 109]]], ["This demonstrates that when these methods are used properly and chickens are exposed to an appropriate dosage of coccidia vaccine, protection will be achieved, regardless of the vaccine application.", [["chickens", "ORGANISM", 64, 72], ["chickens", "SPECIES", 64, 72], ["chickens", "SPECIES", 64, 72], ["coccidia vaccine", "TREATMENT", 113, 129], ["protection", "TREATMENT", 131, 141], ["the vaccine application", "TREATMENT", 174, 197]]]], "PMC7180330": [["To the Editor\u2014As of April 1, the total number of SARS-Cov-2\u2013positive cases in Vietnam reached 218, and 37 of these were infected within a public hospital in Hanoi, the capital of Vietnam.1 Thus far, this hospital is the largest COVID-19 hotspot in the country.", [["SARS", "DISEASE", 49, 53], ["COVID-19 hotspot", "DNA", 228, 244], ["infected", "OBSERVATION", 120, 128]]]], "PMC7126760": [["IntroductionMullis et al. developed the polymerase chain reaction (PCR) in 1986 to clone specified deoxyribonucleic acid (DNA) fragments in vitro by using temperature cycling [1].", [["deoxyribonucleic acid", "CHEMICAL", 99, 120], ["deoxyribonucleic acid", "SIMPLE_CHEMICAL", 99, 120], ["DNA", "CELLULAR_COMPONENT", 122, 125], ["deoxyribonucleic acid (DNA) fragments", "DNA", 99, 136], ["the polymerase chain reaction", "PROBLEM", 36, 65], ["PCR", "TEST", 67, 70], ["deoxyribonucleic acid (DNA) fragments", "TREATMENT", 99, 136], ["temperature cycling", "TEST", 155, 174]]], ["A real-time PCR (RT-PCR) machine was introduced in 1997 by integrating a fluorometer with a temperature cycler [2], [3].", [["A real-time PCR (RT-PCR) machine", "TREATMENT", 0, 32], ["a temperature cycler", "TREATMENT", 90, 110]]], ["This RT-PCR system identifies DNA amplification by detecting the fluorescence-labeling dye in the PCR mix during the early phase of reaction.", [["DNA", "CELLULAR_COMPONENT", 30, 33], ["This RT-PCR system", "TEST", 0, 18], ["DNA amplification", "TEST", 30, 47], ["the fluorescence", "TEST", 61, 77], ["the PCR mix", "TREATMENT", 94, 105], ["reaction", "PROBLEM", 132, 140]]], ["In addition, the recorded time history of fluorescence intensity can be used to determine the concentration of target DNA fragments in the PCR mix before thermal cycling.", [["DNA", "CELLULAR_COMPONENT", 118, 121], ["target DNA fragments", "DNA", 111, 131], ["fluorescence intensity", "PROBLEM", 42, 64], ["target DNA fragments", "PROBLEM", 111, 131], ["the PCR mix", "TREATMENT", 135, 146]]], ["However, an RT-PCR machine requires using a complex thermal controller for repetitively heating and cooling samples, usually for 35\u201350 cycles.", [["samples", "ANATOMY", 108, 115], ["an RT-PCR machine", "TREATMENT", 9, 26], ["a complex thermal controller", "TREATMENT", 42, 70], ["repetitively heating and cooling samples", "TREATMENT", 75, 115]]], ["Restricted by the large size, costliness, and long amplification time, using traditional PCR thermocyclers have been limited to principal hospitals and laboratories.", [["traditional PCR thermocyclers", "TREATMENT", 77, 106], ["large", "OBSERVATION_MODIFIER", 18, 23], ["size", "OBSERVATION_MODIFIER", 24, 28]]], ["Recently, new platforms have been advanced by simplifying the equipment structure and reducing the amplification times.IntroductionA promising solution is to induce natural convection with temperature gradients, thereby enhancing the amplification of DNA [4].", [["DNA", "CELLULAR_COMPONENT", 251, 254], ["IntroductionA promising solution", "TREATMENT", 119, 151], ["temperature gradients", "PROBLEM", 189, 210]]], ["When the reagents in a sample circulate repeatedly among temperature zones because of the natural convection effect, the sample is anticipated to undergo three steps of a PCR cycle (i.e., nucleic acid denaturation, annealing, and extension) in a single circulation.", [["sample", "ANATOMY", 23, 29], ["nucleic acid", "CHEMICAL", 188, 200], ["a PCR cycle", "TEST", 169, 180], ["nucleic acid denaturation", "PROBLEM", 188, 213], ["natural convection", "OBSERVATION", 90, 108]]], ["Therefore, convective PCR can substantially shorten the amplification time from multiple hours to 30\u201340 min [5], [6].", [["convective PCR", "TEST", 11, 25]]], ["By using this mechanism, a dedicated thermocycler, the most expensive module of the conventional PCR, is not required.", [["the conventional PCR", "TEST", 80, 100]]], ["The real-time convective PCR (RT-cPCR) apparatus could also be devised by combining fluorescence detectors.", [["convective PCR", "TEST", 14, 28]]], ["However, the current RT-cPCR systems adopt two or even more individual temperature controllers and elaborate designs necessitating a specific shape of tubing or additional chambers to circulate the sample fluids thoroughly [7], [8], [9], [10], [11].", [["[8]", "SIMPLE_CHEMICAL", 228, 231], ["[9]", "SIMPLE_CHEMICAL", 233, 236], ["[10]", "SIMPLE_CHEMICAL", 238, 242], ["a specific shape of tubing", "TREATMENT", 131, 157], ["additional chambers", "TREATMENT", 161, 180], ["the sample fluids", "TEST", 194, 211]]], ["Current RT-cPCR systems also require skillful manipulation for certain operations such as loading and unloading reagents from thin tubing as well as sealing both tube ends without trapping air bubbles in the tube, thus causing detection errors.IntroductionChou et al. designed and fabricated a novel capillary convective PCR (ccPCR) platform with a capillary tube mounted on a heater at a constant temperature of 95 \u00b0C [12], [13], [14].", [["tube", "ANATOMY", 162, 166], ["tube", "ANATOMY", 208, 212], ["capillary", "ANATOMY", 300, 309], ["capillary tube", "ANATOMY", 349, 363], ["tube", "TISSUE", 162, 166], ["tube", "TISSUE", 208, 212], ["capillary", "TISSUE", 300, 309], ["capillary tube", "TISSUE", 349, 363], ["Current RT-cPCR systems", "TREATMENT", 0, 23], ["skillful manipulation", "TREATMENT", 37, 58], ["certain operations", "TREATMENT", 63, 81], ["loading and unloading reagents", "TREATMENT", 90, 120], ["thin tubing", "TREATMENT", 126, 137], ["sealing both tube ends", "TREATMENT", 149, 171], ["trapping air bubbles in the tube", "PROBLEM", 180, 212], ["a novel capillary convective PCR", "TREATMENT", 292, 324], ["a capillary tube", "TREATMENT", 347, 363], ["a heater", "TREATMENT", 375, 383], ["a constant temperature", "TEST", 387, 409], ["tube", "OBSERVATION", 162, 166], ["air bubbles", "OBSERVATION", 189, 200], ["tube", "OBSERVATION", 208, 212], ["capillary tube", "OBSERVATION", 349, 363]]], ["When using this platform, no complex microfluidic chip design, special tubing, or vessels are required.", [["vessels", "ANATOMY", 82, 89], ["vessels", "MULTI-TISSUE_STRUCTURE", 82, 89], ["complex microfluidic chip design", "PROBLEM", 29, 61], ["special tubing", "TREATMENT", 63, 77], ["microfluidic chip", "OBSERVATION", 37, 54], ["vessels", "ANATOMY", 82, 89]]], ["The constantly heated capillary base drives the lowest part of the sample fluids and raises them by convection while denaturing the template simultaneously.", [["capillary", "ANATOMY", 22, 31], ["sample fluids", "ANATOMY", 67, 80], ["capillary", "TISSUE", 22, 31], ["capillary", "ANATOMY_MODIFIER", 22, 31], ["base", "ANATOMY_MODIFIER", 32, 36]]], ["During the ascending of the sample, its temperature falls because of cooling from the surrounding air.", [["sample", "ANATOMY", 28, 34], ["its temperature falls", "PROBLEM", 36, 57], ["ascending", "OBSERVATION_MODIFIER", 11, 20], ["air", "OBSERVATION", 98, 101]]], ["As the sample reaches the cool temperature zone near the top of the tube, it undergoes annealing and extension, after which the DNA template descends and is heated again.", [["sample", "ANATOMY", 7, 13], ["tube", "TISSUE", 68, 72], ["DNA", "CELLULAR_COMPONENT", 128, 131], ["the cool temperature zone", "PROBLEM", 22, 47], ["the DNA template descends", "TREATMENT", 124, 149], ["cool", "OBSERVATION_MODIFIER", 26, 30], ["temperature", "OBSERVATION_MODIFIER", 31, 42], ["zone", "OBSERVATION_MODIFIER", 43, 47], ["top", "OBSERVATION_MODIFIER", 57, 60], ["tube", "OBSERVATION", 68, 72], ["annealing", "OBSERVATION_MODIFIER", 87, 96], ["descends", "OBSERVATION_MODIFIER", 141, 149]]], ["Thus, PCR cycles are achieved by natural convection.", [["PCR cycles", "TREATMENT", 6, 16], ["natural convection", "OBSERVATION", 33, 51]]], ["This study adopted a concept similar to that of Chou et al. to form a real-time convective PCR machine in a capillary tube instrumented with a CCD-based fluorometer.", [["capillary tube", "ANATOMY", 108, 122], ["capillary tube", "TISSUE", 108, 122], ["This study", "TEST", 0, 10], ["a real-time convective PCR machine", "TREATMENT", 68, 102], ["a capillary tube instrumented", "TREATMENT", 106, 135], ["a CCD-based fluorometer", "TREATMENT", 141, 164], ["capillary tube", "OBSERVATION", 108, 122]]], ["In such a simple platform without costly and delicate thermocyclers and additional complex hardware, this study demonstrates that correct primer and amplicon design are essential to perform DNA amplification successfully.", [["DNA", "CELLULAR_COMPONENT", 190, 193], ["costly and delicate thermocyclers", "PROBLEM", 34, 67], ["additional complex hardware", "TREATMENT", 72, 99], ["this study", "TEST", 101, 111], ["DNA amplification", "TREATMENT", 190, 207], ["complex", "OBSERVATION_MODIFIER", 83, 90], ["hardware", "OBSERVATION", 91, 99]]], ["Moreover, the computer-aided analysis was implemented using the computational fluid dynamics (CFD) simulations to resolve the flow pattern in the capillary of an RT-cPCR machine and to determine the time required for completing an RT-cPCR cycle.", [["capillary", "ANATOMY", 146, 155], ["capillary", "TISSUE", 146, 155], ["the computational fluid dynamics", "TEST", 60, 92], ["the flow pattern", "TEST", 122, 138], ["an RT-cPCR cycle", "TREATMENT", 228, 244], ["flow pattern", "OBSERVATION", 126, 138], ["capillary", "ANATOMY_MODIFIER", 146, 155]]], ["To assess the performance of the prototype, a single DNA template, HBV 122 base pairs, with known concentrations and a single labeling dye, SYBR Green I, was used in the PCR mixes undergoing the same thermal cycling in both the prototype and commercial RT-PCR machines for comparing their measured and predicted fluorescence intensities emitted from the glass capillaries.", [["capillaries", "ANATOMY", 360, 371], ["DNA", "CELLULAR_COMPONENT", 53, 56], ["SYBR Green I", "GENE_OR_GENE_PRODUCT", 140, 152], ["capillaries", "TISSUE", 360, 371], ["DNA template", "DNA", 53, 65], ["HBV 122 base pairs", "DNA", 67, 85], ["SYBR Green I", "PROTEIN", 140, 152], ["a single DNA template", "TREATMENT", 44, 65], ["HBV 122 base pairs", "PROBLEM", 67, 85], ["known concentrations", "PROBLEM", 92, 112], ["a single labeling dye", "PROBLEM", 117, 138], ["commercial RT-PCR machines", "TREATMENT", 242, 268], ["fluorescence intensities", "TEST", 312, 336], ["glass capillaries", "OBSERVATION", 354, 371]]], ["We claim that the current RT-cPCR machine can offer a new DNA amplification method with ease of operation and low cost that is well suited for point-of-care applications in less-developed countries.Experimental apparatus", [["DNA", "CELLULAR_COMPONENT", 58, 61], ["the current RT-cPCR machine", "TREATMENT", 14, 41], ["a new DNA amplification method", "TREATMENT", 52, 82], ["operation and low cost", "TREATMENT", 96, 118], ["Experimental apparatus", "PROBLEM", 198, 220]]]], "PMC7121321": [["IntroductionCPPs are a class of diverse peptides, typically 5\u201330 amino acids in length, and unlike most peptides, they can cross the cellular plasma membrane.", [["cellular plasma membrane", "ANATOMY", 133, 157], ["amino acids", "CHEMICAL", 65, 76], ["amino acids", "CHEMICAL", 65, 76], ["amino acids", "AMINO_ACID", 65, 76], ["cellular", "CELLULAR_COMPONENT", 133, 141], ["plasma membrane", "CELLULAR_COMPONENT", 142, 157], ["amino acids", "TEST", 65, 76], ["cellular plasma membrane", "OBSERVATION", 133, 157]]], ["CPPs are a family of peptides that are structurally diverse but share the ability to translocate a wide range of different bioactive molecules into living cells [1].", [["cells", "ANATOMY", 155, 160], ["cells", "CELL", 155, 160], ["living cells", "CELL_TYPE", 148, 160], ["CPPs", "PROBLEM", 0, 4], ["a wide range of different bioactive molecules", "TREATMENT", 97, 142]]], ["The list of available CPPs has grown rapidly and CPPs have been employed for a variety of applications.", [["available CPPs", "TEST", 12, 26], ["CPPs", "TEST", 49, 53]]], ["CPPs serving as vectors can successfully facilitate the intracellular transport of cargoes, such as small-molecule therapeutic agents [2], proteins, quantum dots [3], and MRI contrast agents [4], both in vitro and in vivo [5].", [["intracellular", "ANATOMY", 56, 69], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 56, 69], ["CPPs", "PROBLEM", 0, 4], ["the intracellular transport of cargoes", "TREATMENT", 52, 90], ["small-molecule therapeutic agents", "TREATMENT", 100, 133], ["proteins, quantum dots", "TREATMENT", 139, 161], ["MRI contrast agents", "TREATMENT", 171, 190]]], ["In addition, this efficient transport system has lower cytotoxicity in a variety of cell lines compared with other delivery methods [6].IntroductionThe mechanism of the internalization of CPPs and their cargo is not well understood and has recently been the subject of controversy.", [["cell lines", "ANATOMY", 84, 94], ["cell lines", "CELL", 84, 94], ["CPPs", "GENE_OR_GENE_PRODUCT", 188, 192], ["cell lines", "CELL_LINE", 84, 94], ["lower cytotoxicity", "PROBLEM", 49, 67], ["cell lines", "TREATMENT", 84, 94], ["other delivery methods", "TREATMENT", 109, 131], ["the internalization of CPPs", "TREATMENT", 165, 192], ["lower", "OBSERVATION_MODIFIER", 49, 54], ["cytotoxicity", "OBSERVATION", 55, 67], ["cell lines", "OBSERVATION", 84, 94]]], ["CPPs can interact with multiple cell surface molecules, including membrane lipids and membrane-associated proteoglycans [7].", [["cell surface", "ANATOMY", 32, 44], ["membrane lipids", "ANATOMY", 66, 81], ["membrane", "ANATOMY", 86, 94], ["CPPs", "GENE_OR_GENE_PRODUCT", 0, 4], ["cell surface molecules", "CELLULAR_COMPONENT", 32, 54], ["membrane lipids", "CELLULAR_COMPONENT", 66, 81], ["membrane", "CELLULAR_COMPONENT", 86, 94], ["multiple cell surface molecules", "PROTEIN", 23, 54], ["CPPs", "PROBLEM", 0, 4], ["multiple cell surface molecules", "TREATMENT", 23, 54], ["membrane lipids", "TEST", 66, 81]]], ["CPPs can be taken up by cells via multiple pathways, such as direct translocation through the membrane bilayer or endocytosis-mediated uptake.", [["cells", "ANATOMY", 24, 29], ["membrane bilayer", "ANATOMY", 94, 110], ["CPPs", "SIMPLE_CHEMICAL", 0, 4], ["cells", "CELL", 24, 29], ["membrane bilayer", "CELLULAR_COMPONENT", 94, 110], ["CPPs", "PROBLEM", 0, 4], ["direct translocation through the membrane bilayer", "TEST", 61, 110], ["mediated uptake", "PROBLEM", 126, 141]]], ["Although molecules entering cells prefer the direct membrane translocation pathway, endocytosis, composed of two steps, endocytotic entry and endosomal escape, is the major cellular uptake pathway for most CPPs as most reports have pointed out [8].", [["cells", "ANATOMY", 28, 33], ["membrane", "ANATOMY", 52, 60], ["endosomal", "ANATOMY", 142, 151], ["cellular", "ANATOMY", 173, 181], ["cells", "CELL", 28, 33], ["membrane", "CELLULAR_COMPONENT", 52, 60], ["endocytotic", "CELLULAR_COMPONENT", 120, 131], ["endosomal", "CELLULAR_COMPONENT", 142, 151], ["cellular", "CELL", 173, 181], ["molecules entering cells", "PROBLEM", 9, 33], ["the direct membrane translocation pathway", "TEST", 41, 82], ["endocytosis", "PROBLEM", 84, 95], ["endosomal escape", "OBSERVATION", 142, 158]]], ["Endocytosis occurs by various formats, which can be classified into caveolae and/or lipid raft-mediated endocytosis [9], micropinocytosis [10], through clathrin-mediated endocytosis [11] or via a cholesterol-dependent clathrin-mediated endocytosis [12].", [["caveolae", "ANATOMY", 68, 76], ["lipid raft", "ANATOMY", 84, 94], ["cholesterol", "CHEMICAL", 196, 207], ["cholesterol", "CHEMICAL", 196, 207], ["caveolae", "CELLULAR_COMPONENT", 68, 76], ["lipid raft", "CELLULAR_COMPONENT", 84, 94], ["clathrin", "GENE_OR_GENE_PRODUCT", 152, 160], ["cholesterol", "SIMPLE_CHEMICAL", 196, 207], ["clathrin", "GENE_OR_GENE_PRODUCT", 218, 226], ["clathrin", "PROTEIN", 152, 160], ["clathrin", "PROTEIN", 218, 226], ["Endocytosis", "PROBLEM", 0, 11], ["lipid raft", "TEST", 84, 94], ["mediated endocytosis", "PROBLEM", 95, 115], ["micropinocytosis", "TEST", 121, 137], ["mediated endocytosis", "PROBLEM", 161, 181], ["a cholesterol", "TEST", 194, 207], ["dependent clathrin", "PROBLEM", 208, 226], ["mediated endocytosis", "PROBLEM", 227, 247]]], ["The endocytosis pathway is proposed based on the fact that CPP uptake in cells was found to adopt an energy-dependent mechanism [13].", [["cells", "ANATOMY", 73, 78], ["CPP", "CHEMICAL", 59, 62], ["CPP", "SIMPLE_CHEMICAL", 59, 62], ["cells", "CELL", 73, 78], ["The endocytosis pathway", "PROBLEM", 0, 23], ["CPP uptake in cells", "PROBLEM", 59, 78]]], ["However, cellular uptake is not completely prohibited at low temperatures or in the presence of endocytosis inhibitors [13], suggesting a non-energy consuming route.", [["cellular", "ANATOMY", 9, 17], ["cellular", "CELL", 9, 17], ["cellular uptake", "PROBLEM", 9, 24], ["low temperatures", "PROBLEM", 57, 73], ["endocytosis inhibitors", "PROBLEM", 96, 118], ["cellular uptake", "OBSERVATION", 9, 24], ["not completely prohibited", "OBSERVATION_MODIFIER", 28, 53], ["low temperatures", "OBSERVATION_MODIFIER", 57, 73]]], ["Recently, the finding of strong peptide\u2013lipid interactions supports direct translocation of the peptides across the membrane [14].", [["membrane", "ANATOMY", 116, 124], ["peptide\u2013lipid", "SIMPLE_CHEMICAL", 32, 45], ["membrane", "CELLULAR_COMPONENT", 116, 124], ["strong peptide\u2013lipid interactions", "PROBLEM", 25, 58]]], ["In addition, many studies also propose cellular uptake can follow multiple routes depending on experimental conditions, specific CPP sequence, and the cargo structure [15].IntroductionBesides CPPs, another important category of cationic membrane peptides are antimicrobial peptides (AMPs).", [["cellular", "ANATOMY", 39, 47], ["membrane", "ANATOMY", 237, 245], ["cellular", "CELL", 39, 47], ["CPP sequence", "PROTEIN", 129, 141], ["many studies", "TEST", 13, 25], ["cellular uptake", "PROBLEM", 39, 54], ["experimental conditions", "TEST", 95, 118], ["specific CPP sequence", "TEST", 120, 141], ["cationic membrane peptides", "TREATMENT", 228, 254], ["antimicrobial peptides", "TREATMENT", 259, 281]]], ["Antimicrobial peptides, a major class of antibacterial agents, share amphiphilicity and cationic structural properties with cell-penetrating peptides.", [["cell", "ANATOMY", 124, 128], ["cell", "CELL", 124, 128], ["Antimicrobial peptides", "TREATMENT", 0, 22], ["antibacterial agents", "TREATMENT", 41, 61], ["amphiphilicity and cationic structural properties", "TREATMENT", 69, 118], ["cell-penetrating peptides", "TREATMENT", 124, 149], ["antibacterial agents", "OBSERVATION", 41, 61], ["penetrating peptides", "OBSERVATION", 129, 149]]], ["However, the concept that AMPs need to be cationic was changed later with the discovery of negatively charged AMPs in 1997 [16].", [["AMPs", "TREATMENT", 26, 30]]], ["For example, maximin-H5 [17] discovered from frog skin and dermicidin [18] secreted from human sweat gland tissues are both anionic peptides.", [["skin", "ANATOMY", 50, 54], ["sweat gland tissues", "ANATOMY", 95, 114], ["maximin-H5", "CHEMICAL", 13, 23], ["dermicidin", "CHEMICAL", 59, 69], ["maximin-H5", "GENE_OR_GENE_PRODUCT", 13, 23], ["frog", "ORGANISM", 45, 49], ["skin", "ORGAN", 50, 54], ["dermicidin [18]", "GENE_OR_GENE_PRODUCT", 59, 74], ["human", "ORGANISM", 89, 94], ["sweat gland tissues", "TISSUE", 95, 114], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94], ["example", "TEST", 4, 11], ["maximin", "TEST", 13, 20], ["dermicidin", "TREATMENT", 59, 69], ["skin", "ANATOMY", 50, 54], ["sweat gland", "ANATOMY", 95, 106], ["anionic peptides", "OBSERVATION", 124, 140]]], ["They also have a positive net charge, normally in the range of +4 to +6, which is due to the frequent presence of lysines and arginines in the amino acid sequence [19].", [["amino acid", "CHEMICAL", 143, 153], ["lysines", "CHEMICAL", 114, 121], ["arginines", "CHEMICAL", 126, 135], ["amino acid", "CHEMICAL", 143, 153], ["arginines", "AMINO_ACID", 126, 135], ["amino acid", "AMINO_ACID", 143, 153], ["amino acid sequence", "PROTEIN", 143, 162], ["a positive net charge", "PROBLEM", 15, 36], ["lysines", "PROBLEM", 114, 121], ["the amino acid sequence", "TEST", 139, 162], ["positive", "OBSERVATION_MODIFIER", 17, 25], ["net charge", "OBSERVATION", 26, 36], ["lysines", "OBSERVATION", 114, 121]]], ["Additionally, nearly 50 % of their structure often consists of hydrophobic residues.", [["hydrophobic residues", "PROBLEM", 63, 83], ["hydrophobic residues", "OBSERVATION", 63, 83]]], ["They kill a broad spectrum of microbes including bacteria and fungi by destroying their cell membranes and are important components of the innate immune system of many animals and plants [20].CPPs and AMPs: How Different Are They?CPPs and AMPs share common characteristics.", [["cell membranes", "ANATOMY", 88, 102], ["immune system", "ANATOMY", 146, 159], ["cell membranes", "CELLULAR_COMPONENT", 88, 102], ["AMPs", "GENE_OR_GENE_PRODUCT", 239, 243], ["microbes", "PROBLEM", 30, 38], ["bacteria", "PROBLEM", 49, 57], ["fungi", "PROBLEM", 62, 67], ["CPPs", "TEST", 230, 234], ["AMPs", "TREATMENT", 239, 243], ["cell membranes", "OBSERVATION", 88, 102]]], ["CPPs and AMPs are similar in the structural motif of amino acid composition, but differ in biological activities within the lipid membrane.", [["lipid membrane", "ANATOMY", 124, 138], ["amino acid", "CHEMICAL", 53, 63], ["amino acid", "CHEMICAL", 53, 63], ["AMPs", "GENE_OR_GENE_PRODUCT", 9, 13], ["amino acid", "AMINO_ACID", 53, 63], ["lipid membrane", "CELLULAR_COMPONENT", 124, 138], ["CPPs", "TEST", 0, 4], ["AMPs", "TREATMENT", 9, 13], ["amino acid composition", "TEST", 53, 75], ["amino acid", "OBSERVATION", 53, 63], ["lipid membrane", "OBSERVATION", 124, 138]]], ["Common to both groups are interactions of cell membrane components with the charged amino acid residues of the peptides.", [["cell membrane", "ANATOMY", 42, 55], ["amino acid", "CHEMICAL", 84, 94], ["amino acid", "CHEMICAL", 84, 94], ["cell membrane components", "CELLULAR_COMPONENT", 42, 66], ["amino acid", "AMINO_ACID", 84, 94], ["cell membrane components", "TREATMENT", 42, 66], ["the charged amino acid residues", "TREATMENT", 72, 103], ["both", "ANATOMY_MODIFIER", 10, 14], ["cell membrane", "OBSERVATION", 42, 55]]], ["This is probably the first step in cell association that leads to cellular uptake.", [["cell", "ANATOMY", 35, 39], ["cellular", "ANATOMY", 66, 74], ["cell", "CELL", 35, 39], ["cellular", "CELL", 66, 74], ["cellular uptake", "OBSERVATION", 66, 81]]], ["Anionic phospholipids or phosphate groups of lipopolysaccharides (for gram-negative bacteria) or acidic polysaccharides, teichoic acids, and lipoteichoic acids (for gram-positive bacteria) are the membrane components at the cell surface responsible for generating an overall negative net charge, making the binding of positively charged or amphipathic peptides possible [21].", [["membrane components", "ANATOMY", 197, 216], ["cell surface", "ANATOMY", 224, 236], ["phosphate", "CHEMICAL", 25, 34], ["lipopolysaccharides", "CHEMICAL", 45, 64], ["teichoic acids", "CHEMICAL", 121, 135], ["lipoteichoic acids", "CHEMICAL", 141, 159], ["phosphate", "CHEMICAL", 25, 34], ["teichoic acids", "CHEMICAL", 121, 135], ["lipoteichoic acids", "CHEMICAL", 141, 159], ["Anionic phospholipids", "SIMPLE_CHEMICAL", 0, 21], ["phosphate", "SIMPLE_CHEMICAL", 25, 34], ["lipopolysaccharides", "SIMPLE_CHEMICAL", 45, 64], ["acidic polysaccharides", "SIMPLE_CHEMICAL", 97, 119], ["teichoic acids", "SIMPLE_CHEMICAL", 121, 135], ["lipoteichoic acids", "SIMPLE_CHEMICAL", 141, 159], ["gram-positive bacteria", "GENE_OR_GENE_PRODUCT", 165, 187], ["membrane components", "CELLULAR_COMPONENT", 197, 216], ["cell surface", "CELLULAR_COMPONENT", 224, 236], ["Anionic phospholipids", "TEST", 0, 21], ["phosphate groups of lipopolysaccharides", "PROBLEM", 25, 64], ["gram-negative bacteria", "PROBLEM", 70, 92], ["acidic polysaccharides", "TEST", 97, 119], ["teichoic acids", "TEST", 121, 135], ["lipoteichoic acids", "TEST", 141, 159], ["gram-positive bacteria", "PROBLEM", 165, 187], ["the membrane components", "PROBLEM", 193, 216], ["amphipathic peptides", "PROBLEM", 340, 360], ["net charge", "OBSERVATION", 284, 294]]], ["Furthermore, the lipid bilayer of bacterial membrane contains mainly lipids with negatively charged phospholipid headgroups, while fungi, in contrast, exhibit a zwitterionic lipid bilayer composition, upon which the uptake is driven by hydrophobic N- or C-terminus or particular amino acids of the peptide sequence, resulting in the accumulation of the peptide, which finally induces strong hydrophobic interaction to the membrane.CPPs and AMPs: How Different Are They?Charge interactions between cationic residues and lipids are essential to the biological function of many membrane peptides and proteins, for example, cellular translocation of CPPs, and membrane disruption of AMPs.", [["lipid bilayer", "ANATOMY", 17, 30], ["membrane", "ANATOMY", 44, 52], ["membrane", "ANATOMY", 422, 430], ["membrane", "ANATOMY", 575, 583], ["cellular", "ANATOMY", 620, 628], ["membrane", "ANATOMY", 656, 664], ["amino acids", "CHEMICAL", 279, 290], ["N", "CHEMICAL", 248, 249], ["C", "CHEMICAL", 254, 255], ["amino acids", "CHEMICAL", 279, 290], ["lipid bilayer", "CELLULAR_COMPONENT", 17, 30], ["bacterial membrane", "CELLULAR_COMPONENT", 34, 52], ["lipids", "SIMPLE_CHEMICAL", 69, 75], ["phospholipid headgroups", "SIMPLE_CHEMICAL", 100, 123], ["amino acids", "AMINO_ACID", 279, 290], ["membrane", "CELLULAR_COMPONENT", 422, 430], ["lipids", "SIMPLE_CHEMICAL", 519, 525], ["membrane", "CELLULAR_COMPONENT", 575, 583], ["cellular", "CELL", 620, 628], ["CPPs", "GENE_OR_GENE_PRODUCT", 646, 650], ["membrane", "CELLULAR_COMPONENT", 656, 664], ["AMPs", "GENE_OR_GENE_PRODUCT", 679, 683], ["hydrophobic N- or C-terminus", "PROTEIN", 236, 264], ["AMPs", "PROTEIN", 679, 683], ["bacterial membrane", "PROBLEM", 34, 52], ["a zwitterionic lipid bilayer composition", "PROBLEM", 159, 199], ["hydrophobic N", "TEST", 236, 249], ["the accumulation of the peptide", "PROBLEM", 329, 360], ["cationic residues", "TREATMENT", 497, 514], ["lipids", "TREATMENT", 519, 525], ["cellular translocation of CPPs", "PROBLEM", 620, 650], ["membrane disruption of AMPs", "PROBLEM", 656, 683], ["bacterial membrane", "OBSERVATION", 34, 52], ["strong", "OBSERVATION_MODIFIER", 384, 390], ["hydrophobic interaction", "OBSERVATION", 391, 414], ["membrane disruption", "OBSERVATION", 656, 675]]], ["The ratio between the cationic lysine (Lys) and arginine (Arg) residues influences membrane selectivity since the guanidino functionalities of arginines promote a more efficient interaction with eukaryotic membranes as compared to lysine.", [["membrane", "ANATOMY", 83, 91], ["membranes", "ANATOMY", 206, 215], ["lysine", "CHEMICAL", 31, 37], ["Lys", "CHEMICAL", 39, 42], ["arginine", "CHEMICAL", 48, 56], ["Arg", "CHEMICAL", 58, 61], ["guanidino", "CHEMICAL", 114, 123], ["lysine", "CHEMICAL", 231, 237], ["lysine", "CHEMICAL", 31, 37], ["Lys", "CHEMICAL", 39, 42], ["arginine", "CHEMICAL", 48, 56], ["Arg", "CHEMICAL", 58, 61], ["guanidino", "CHEMICAL", 114, 123], ["arginines", "CHEMICAL", 143, 152], ["lysine", "CHEMICAL", 231, 237], ["Lys", "AMINO_ACID", 39, 42], ["arginine", "AMINO_ACID", 48, 56], ["Arg", "AMINO_ACID", 58, 61], ["membrane", "CELLULAR_COMPONENT", 83, 91], ["arginines", "AMINO_ACID", 143, 152], ["membranes", "CELLULAR_COMPONENT", 206, 215], ["lysine", "AMINO_ACID", 231, 237], ["The ratio", "TEST", 0, 9], ["the cationic lysine (Lys)", "TREATMENT", 18, 43], ["arginine (Arg) residues influences membrane selectivity", "TREATMENT", 48, 103], ["the guanidino functionalities of arginines", "TREATMENT", 110, 152], ["eukaryotic membranes", "TREATMENT", 195, 215], ["eukaryotic membranes", "OBSERVATION", 195, 215]]], ["This is, however, most often at the expense of increased cytotoxicity.", [["increased cytotoxicity", "PROBLEM", 47, 69], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["cytotoxicity", "OBSERVATION", 57, 69]]], ["A high Lys content has been correlated with selectivity toward bacterial cells over eukaryotic cells [22].", [["cells", "ANATOMY", 73, 78], ["cells", "ANATOMY", 95, 100], ["Lys", "CHEMICAL", 7, 10], ["Lys", "CHEMICAL", 7, 10], ["Lys", "AMINO_ACID", 7, 10], ["bacterial cells", "CELL", 63, 78], ["eukaryotic cells", "CELL", 84, 100], ["bacterial cells", "CELL_TYPE", 63, 78], ["eukaryotic cells", "CELL_TYPE", 84, 100], ["A high Lys content", "PROBLEM", 0, 18], ["high Lys", "OBSERVATION", 2, 10]]], ["Furthermore, the ability of CPPs to permeate cell membranes appears to be directly linked to their propensity to fold into a well-defined secondary structure (\u03b1-helix or \u03b2-sheet) while interacting with biological membranes [23].", [["cell membranes", "ANATOMY", 45, 59], ["membranes", "ANATOMY", 213, 222], ["cell membranes", "CELLULAR_COMPONENT", 45, 59], ["\u03b1-helix", "PROTEIN", 159, 166], ["\u03b2-sheet", "PROTEIN", 170, 177], ["cell membranes", "OBSERVATION", 45, 59], ["secondary structure", "OBSERVATION", 138, 157]]], ["Likewise, the antimicrobial activity of \u03b1-helical AMPs depends on their propensity to form an \u03b1-helix [24].", [["\u03b1-helical AMPs", "GENE_OR_GENE_PRODUCT", 40, 54], ["\u03b1-helical AMPs", "PROTEIN", 40, 54], ["\u03b1-helical AMPs", "TREATMENT", 40, 54]]], ["The highly basic Arg guanidinium and Lys ammonium groups remain protonated under physiological pH conditions and thus can function as hydrogen bond (H-bond) donors in various protein\u2013protein and protein\u2013lipid interactions.", [["Arg guanidinium", "CHEMICAL", 17, 32], ["Lys ammonium", "CHEMICAL", 37, 49], ["Arg guanidinium and Lys ammonium", "CHEMICAL", 17, 49], ["hydrogen", "CHEMICAL", 134, 142], ["H", "CHEMICAL", 149, 150], ["Arg guanidinium", "SIMPLE_CHEMICAL", 17, 32], ["Lys ammonium groups", "SIMPLE_CHEMICAL", 37, 56], ["protein\u2013lipid", "SIMPLE_CHEMICAL", 195, 208], ["basic Arg guanidinium", "TREATMENT", 11, 32], ["Lys ammonium groups", "TREATMENT", 37, 56], ["various protein\u2013protein and protein\u2013lipid interactions", "TREATMENT", 167, 221], ["Arg guanidinium", "OBSERVATION", 17, 32]]], ["In lipid membranes, the guanidinium group in protein side chain can form a branched moiety by interacting with water and lipid molecules.", [["lipid membranes", "ANATOMY", 3, 18], ["guanidinium", "CHEMICAL", 24, 35], ["guanidinium", "CHEMICAL", 24, 35], ["lipid membranes", "CELLULAR_COMPONENT", 3, 18], ["water", "SIMPLE_CHEMICAL", 111, 116], ["lipid molecules", "SIMPLE_CHEMICAL", 121, 136], ["protein side chain", "PROTEIN", 45, 63], ["the guanidinium group in protein side chain", "TREATMENT", 20, 63], ["a branched moiety", "TREATMENT", 73, 90], ["water and lipid molecules", "TREATMENT", 111, 136], ["lipid membranes", "OBSERVATION", 3, 18]]], ["In the past few years, many CPPs and AMPs have been extensively investigated to elucidate the structural basis of how these cationic macromolecules interact with membrane lipids and water [25].CPPs and AMPs: How Different Are They?Two examples of AMPs in the recent studies include protegrin-1 (PG-1) [26] and human neutrophil peptide-1 (HNP-1) [27].", [["membrane lipids", "ANATOMY", 162, 177], ["PG-1", "CHEMICAL", 295, 299], ["AMPs", "GENE_OR_GENE_PRODUCT", 37, 41], ["membrane lipids", "CELLULAR_COMPONENT", 162, 177], ["protegrin-1", "GENE_OR_GENE_PRODUCT", 282, 293], ["PG-1", "GENE_OR_GENE_PRODUCT", 295, 299], ["human", "ORGANISM", 310, 315], ["neutrophil peptide-1", "GENE_OR_GENE_PRODUCT", 316, 336], ["HNP-1", "GENE_OR_GENE_PRODUCT", 338, 343], ["human", "SPECIES", 310, 315], ["human", "SPECIES", 310, 315], ["many CPPs", "PROBLEM", 23, 32], ["AMPs", "TREATMENT", 37, 41], ["membrane lipids", "TREATMENT", 162, 177], ["AMPs", "TEST", 247, 251], ["the recent studies", "TEST", 255, 273], ["protegrin-", "TEST", 282, 292], ["PG", "TEST", 295, 297], ["human neutrophil peptide", "TEST", 310, 334], ["HNP", "TEST", 338, 341]]], ["PG-1 is representative of many \u03b2-sheet AMPs in its disulfide-linked structure and has an Arg-rich sequence.", [["PG", "CHEMICAL", 0, 2], ["disulfide", "CHEMICAL", 51, 60], ["PG-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["disulfide-linked structure", "PROTEIN", 51, 77], ["Arg-rich sequence", "DNA", 89, 106], ["many \u03b2-sheet AMPs", "TREATMENT", 26, 43], ["an Arg-rich sequence", "TEST", 86, 106]]], ["HNP-1 belongs to the \u03b1-defensin family of antimicrobial peptides and is the mediator of the host innate immune response.", [["HNP-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["\u03b1-defensin", "GENE_OR_GENE_PRODUCT", 21, 31], ["HNP-1", "PROTEIN", 0, 5], ["\u03b1-defensin family", "PROTEIN", 21, 38], ["antimicrobial peptides", "TREATMENT", 42, 64]]], ["Most AMPs adopt rigid amphipathic secondary structures, either \u03b1-helical or \u03b2-sheet [28].", [["\u03b1-helical", "SIMPLE_CHEMICAL", 63, 72], ["\u03b2", "PROTEIN", 76, 77], ["rigid amphipathic secondary structures", "PROBLEM", 16, 54]]], ["The two CPPs, TAT and penetratin, are the first two discovered and also most frequently applied CPPs [25].", [["penetratin", "CHEMICAL", 22, 32], ["penetratin", "CHEMICAL", 22, 32], ["TAT", "GENE_OR_GENE_PRODUCT", 14, 17], ["penetratin", "SIMPLE_CHEMICAL", 22, 32], ["TAT", "PROTEIN", 14, 17], ["TAT and penetratin", "TREATMENT", 14, 32], ["CPPs", "TEST", 96, 100]]], ["They display a turn-rich conformation and random coil structure in lipid bilayers, respectively, suggesting that the absence of intra- or intermolecular H-bonded conformation and high molecular mobility may be the hallmarks of CPPs which differentiates them from AMPs.", [["lipid bilayers", "ANATOMY", 67, 81], ["H", "CHEMICAL", 153, 154], ["H", "CHEMICAL", 153, 154], ["lipid bilayers", "SIMPLE_CHEMICAL", 67, 81], ["CPPs", "SIMPLE_CHEMICAL", 227, 231], ["AMPs", "GENE_OR_GENE_PRODUCT", 263, 267], ["a turn-rich conformation", "PROBLEM", 13, 37], ["random coil structure in lipid bilayers", "PROBLEM", 42, 81], ["intra- or intermolecular H-bonded conformation", "PROBLEM", 128, 174], ["high molecular mobility", "PROBLEM", 179, 202], ["CPPs", "PROBLEM", 227, 231], ["AMPs", "PROBLEM", 263, 267]]], ["Due to the similar Arg-rich structural motif, CPPs and AMPs have strong Arg-lipid and Arg-water interactions, which stabilize these hydrophobic peptides by membrane neutralization and water solvation and thus facilitate the insertion.", [["membrane", "ANATOMY", 156, 164], ["Arg-lipid", "CHEMICAL", 72, 81], ["Arg", "CHEMICAL", 86, 89], ["Arg-lipid", "CHEMICAL", 72, 81], ["Arg", "CHEMICAL", 86, 89], ["CPPs", "SIMPLE_CHEMICAL", 46, 50], ["Arg-lipid", "SIMPLE_CHEMICAL", 72, 81], ["membrane", "CELLULAR_COMPONENT", 156, 164], ["water", "SIMPLE_CHEMICAL", 184, 189], ["Arg-rich structural motif", "PROTEIN", 19, 44], ["CPPs", "TEST", 46, 50], ["AMPs", "TEST", 55, 59], ["Arg-water interactions", "TREATMENT", 86, 108], ["these hydrophobic peptides", "TREATMENT", 126, 152], ["membrane neutralization and water solvation", "TREATMENT", 156, 199], ["the insertion", "TREATMENT", 220, 233]]], ["However, CPPs interact with the cellular membrane in a non-invasive manner, while AMPs function by disrupting the lipid membrane.", [["cellular membrane", "ANATOMY", 32, 49], ["lipid membrane", "ANATOMY", 114, 128], ["CPPs", "GENE_OR_GENE_PRODUCT", 9, 13], ["cellular membrane", "CELLULAR_COMPONENT", 32, 49], ["AMPs", "GENE_OR_GENE_PRODUCT", 82, 86], ["lipid membrane", "CELLULAR_COMPONENT", 114, 128], ["CPPs", "PROBLEM", 9, 13], ["AMPs function", "TEST", 82, 95], ["cellular membrane", "OBSERVATION", 32, 49], ["lipid membrane", "OBSERVATION", 114, 128]]], ["In addition, CPPs also experience charge\u2013charge interaction from the distal phosphate layer and the guanidinium\u2013phosphate interactions stabilize the CPP peptides in lipids and facilitate the insertion, while the plastic conformation and high mobility further promote the translocation.CPPs and AMPs: How Different Are They?For AMPs that preferentially attack internal cellular targets, similar translocation mechanisms have been reported: for buforin 2, which translocates efficiently, but with little membrane activity [29], the structure and orientation in the bilayer have been observed to be very similar to those of magainin 2 [30].", [["cellular", "ANATOMY", 368, 376], ["membrane", "ANATOMY", 502, 510], ["phosphate", "CHEMICAL", 76, 85], ["guanidinium\u2013phosphate", "CHEMICAL", 100, 121], ["phosphate", "CHEMICAL", 76, 85], ["guanidinium\u2013phosphate", "CHEMICAL", 100, 121], ["buforin 2", "CHEMICAL", 443, 452], ["magainin 2", "CHEMICAL", 621, 631], ["guanidinium\u2013phosphate", "SIMPLE_CHEMICAL", 100, 121], ["lipids", "SIMPLE_CHEMICAL", 165, 171], ["AMPs", "GENE_OR_GENE_PRODUCT", 327, 331], ["cellular", "CELL", 368, 376], ["buforin 2", "GENE_OR_GENE_PRODUCT", 443, 452], ["membrane", "CELLULAR_COMPONENT", 502, 510], ["bilayer", "CELLULAR_COMPONENT", 563, 570], ["magainin 2", "GENE_OR_GENE_PRODUCT", 621, 631], ["buforin 2", "PROTEIN", 443, 452], ["CPPs", "PROBLEM", 13, 17], ["charge\u2013charge interaction", "PROBLEM", 34, 59], ["the distal phosphate layer", "TREATMENT", 65, 91], ["the guanidinium\u2013phosphate interactions", "TREATMENT", 96, 134], ["the CPP peptides", "TREATMENT", 145, 161], ["the insertion", "TREATMENT", 187, 200], ["the plastic conformation", "TREATMENT", 208, 232], ["AMPs", "TREATMENT", 327, 331], ["buforin", "TREATMENT", 443, 450], ["distal", "ANATOMY_MODIFIER", 69, 75], ["phosphate layer", "OBSERVATION", 76, 91], ["cellular targets", "OBSERVATION", 368, 384]]], ["From these results a model was proposed whereby buforin 2 molecules would form a toroidal pore, just as magainin 2 does, but less stable; this would result in shorter pore lifetimes\u2014with a concomitant decrease in permeabilization\u2014at the same time that the translocation rate would increase because pore disintegration, which is the actual translocation step, would become more frequent [29, 30].", [["pore", "ANATOMY", 90, 94], ["pore", "ANATOMY", 167, 171], ["pore", "ANATOMY", 298, 302], ["buforin 2", "CHEMICAL", 48, 57], ["buforin 2", "GENE_OR_GENE_PRODUCT", 48, 57], ["magainin 2", "GENE_OR_GENE_PRODUCT", 104, 114], ["pore", "CELLULAR_COMPONENT", 298, 302], ["buforin 2 molecules", "PROTEIN", 48, 67], ["a toroidal pore", "TREATMENT", 79, 94], ["a concomitant decrease", "PROBLEM", 187, 209], ["the translocation rate", "PROBLEM", 252, 274], ["pore disintegration", "PROBLEM", 298, 317], ["toroidal pore", "OBSERVATION_MODIFIER", 81, 94], ["stable", "OBSERVATION_MODIFIER", 130, 136]]], ["This model is supported by results that show that the presence of bilayer components that prevent the formation of toroidal pores (such as dioleyl phosphatidylethanolamine [31]) inhibit buforin 2 translocation, whereas anionic phospholipids, which decrease the charge repulsions between the cationic peptide molecules, stabilize the pore to a point that significant leakage and flip-flop is observed [30].", [["pore", "ANATOMY", 333, 337], ["dioleyl phosphatidylethanolamine", "CHEMICAL", 139, 171], ["dioleyl phosphatidylethanolamine", "CHEMICAL", 139, 171], ["buforin 2", "CHEMICAL", 186, 195], ["dioleyl phosphatidylethanolamine [31]", "SIMPLE_CHEMICAL", 139, 176], ["buforin 2", "GENE_OR_GENE_PRODUCT", 186, 195], ["anionic phospholipids", "SIMPLE_CHEMICAL", 219, 240], ["buforin 2", "PROTEIN", 186, 195], ["bilayer components", "PROBLEM", 66, 84], ["toroidal pores (such as dioleyl phosphatidylethanolamine", "TREATMENT", 115, 171], ["buforin 2 translocation", "TREATMENT", 186, 209], ["anionic phospholipids", "TREATMENT", 219, 240], ["the charge repulsions", "TREATMENT", 257, 278], ["the cationic peptide molecules", "TREATMENT", 287, 317], ["significant leakage and flip-flop", "PROBLEM", 354, 387], ["toroidal pores", "OBSERVATION", 115, 129], ["significant", "OBSERVATION_MODIFIER", 354, 365], ["leakage", "OBSERVATION", 366, 373]]], ["Buforin 2 translocation has also been shown to withstand cargo addition, as demonstrated by the attachment of green fluorescent protein [32], which makes this peptide a promising candidate for its development into a CPP.", [["Buforin 2", "GENE_OR_GENE_PRODUCT", 0, 9], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 110, 135], ["Buforin 2", "PROTEIN", 0, 9], ["green fluorescent protein", "PROTEIN", 110, 135], ["Buforin", "TREATMENT", 0, 7], ["green fluorescent protein", "TEST", 110, 135], ["a CPP", "TEST", 214, 219]]], ["A \u201cmembrane-thinning\u201d effect was proposed for the AMP magainin 2 [33], in which the peptide aggregates on the surface of the membrane and the decreased local surface tension allows the peptide to intercalate the membrane.Origin of AMPs ::: Origins and Classification of AMPs ::: Antimicrobial PeptidesAMPs can be commonly classified into four groups according to their origins.", [["membrane", "ANATOMY", 3, 11], ["surface", "ANATOMY", 110, 117], ["membrane", "ANATOMY", 125, 133], ["surface", "ANATOMY", 158, 165], ["membrane", "ANATOMY", 212, 220], ["AMP", "CHEMICAL", 50, 53], ["AMP", "CHEMICAL", 50, 53], ["membrane", "CELLULAR_COMPONENT", 3, 11], ["AMP", "SIMPLE_CHEMICAL", 50, 53], ["surface", "CELLULAR_COMPONENT", 110, 117], ["membrane", "CELLULAR_COMPONENT", 125, 133], ["membrane", "CELLULAR_COMPONENT", 212, 220], ["PeptidesAMPs", "SIMPLE_CHEMICAL", 293, 305], ["AMPs", "PROTEIN", 231, 235], ["the AMP magainin", "TREATMENT", 46, 62], ["the decreased local surface tension", "TREATMENT", 138, 173], ["AMPs", "TEST", 270, 274], ["Antimicrobial PeptidesAMPs", "TREATMENT", 279, 305], ["membrane", "ANATOMY_MODIFIER", 125, 133], ["decreased", "OBSERVATION_MODIFIER", 142, 151], ["local", "OBSERVATION_MODIFIER", 152, 157], ["surface tension", "OBSERVATION", 158, 173], ["membrane", "ANATOMY_MODIFIER", 212, 220], ["AMPs", "OBSERVATION", 231, 235]]], ["They can originate from insects, other animals, synthesis, and genetically engineered microorganisms.", [["synthesis, and genetically engineered microorganisms", "PROBLEM", 48, 100]]], ["These artificial sources of AMPs are useful for the modification of existing AMPs and for designing new synthetic AMPs.", [["AMPs", "GENE_OR_GENE_PRODUCT", 28, 32], ["AMPs", "TREATMENT", 28, 32], ["existing AMPs", "TREATMENT", 68, 81], ["new synthetic AMPs", "TREATMENT", 100, 118]]], ["Such modifications have potential to change the targets of AMPs and improve the stability of AMPs against proteases [45].", [["AMPs", "GENE_OR_GENE_PRODUCT", 59, 63], ["proteases", "PROTEIN", 106, 115], ["AMPs", "TREATMENT", 59, 63], ["AMPs against proteases", "TREATMENT", 93, 115]]], ["Despite these advantageous features of AMPs, there are still some challenges to their applications, such as potential toxicity to humans [46], sensitivity to harsh environmental conditions (susceptibility to proteases and extreme pH) [47], lack of selectivity against specific strains [48], high production costs [49], folding issues of some large AMPs [50], reduced activity when used for surface coating, and bacterial resistance to some AMPs [51].Origin of AMPs ::: Origins and Classification of AMPs ::: Antimicrobial PeptidesHistorically, AMPs have also been referred to as cationic host defense peptides [52], anionic antimicrobial peptides/proteins [53], cationic amphipathic peptides [54], cationic AMPs [55], host defense peptides [56], and \u03b1-helical antimicrobial peptides [57].", [["surface", "ANATOMY", 390, 397], ["toxicity", "DISEASE", 118, 126], ["humans", "ORGANISM", 130, 136], ["anionic antimicrobial peptides", "SIMPLE_CHEMICAL", 616, 646], ["cationic amphipathic peptides", "SIMPLE_CHEMICAL", 662, 691], ["cationic AMPs [55]", "SIMPLE_CHEMICAL", 698, 716], ["proteases", "PROTEIN", 208, 217], ["AMPs", "PROTEIN", 460, 464], ["humans", "SPECIES", 130, 136], ["humans", "SPECIES", 130, 136], ["AMPs", "TREATMENT", 39, 43], ["their applications", "TREATMENT", 80, 98], ["harsh environmental conditions", "PROBLEM", 158, 188], ["proteases", "TEST", 208, 217], ["extreme pH", "TEST", 222, 232], ["specific strains", "PROBLEM", 268, 284], ["high production costs", "PROBLEM", 291, 312], ["folding issues", "PROBLEM", 319, 333], ["some large AMPs", "PROBLEM", 337, 352], ["surface coating", "TREATMENT", 390, 405], ["bacterial resistance", "PROBLEM", 411, 431], ["some AMPs", "TEST", 435, 444], ["Antimicrobial PeptidesHistorically", "TREATMENT", 508, 542], ["AMPs", "TREATMENT", 544, 548], ["anionic antimicrobial peptides", "TEST", 616, 646], ["proteins", "TEST", 647, 655], ["cationic amphipathic peptides", "TEST", 662, 691], ["cationic AMPs", "TEST", 698, 711], ["host defense peptides", "TREATMENT", 718, 739], ["\u03b1-helical antimicrobial peptides", "TREATMENT", 750, 782], ["bacterial resistance", "OBSERVATION", 411, 431], ["AMPs", "OBSERVATION", 460, 464]]], ["The discovery of AMPs dates back to 1939, when Dubos extracted an antimicrobial agent from a soil Bacillus strain.", [["Bacillus strain", "ORGANISM", 98, 113], ["an antimicrobial agent", "TREATMENT", 63, 85], ["a soil Bacillus strain", "PROBLEM", 91, 113]]], ["This extract was demonstrated to protect mice from pneumococci infection.", [["extract", "ANATOMY", 5, 12], ["pneumococci infection", "DISEASE", 51, 72], ["mice", "ORGANISM", 41, 45], ["pneumococci", "CANCER", 51, 62], ["mice", "SPECIES", 41, 45], ["mice", "SPECIES", 41, 45], ["This extract", "TREATMENT", 0, 12], ["pneumococci infection", "PROBLEM", 51, 72], ["pneumococci", "OBSERVATION_MODIFIER", 51, 62], ["infection", "OBSERVATION", 63, 72]]], ["In the following year, Hotchkiss and Dubos fractionated this extract and identified an AMP which was named gramicidin [58].", [["extract", "ANATOMY", 61, 68], ["AMP", "CHEMICAL", 87, 90], ["gramicidin", "CHEMICAL", 107, 117], ["AMP", "CHEMICAL", 87, 90], ["AMP", "SIMPLE_CHEMICAL", 87, 90], ["gramicidin", "SIMPLE_CHEMICAL", 107, 117], ["an AMP", "TEST", 84, 90]]], ["In 1941, another AMP, tyrocidine, was discovered and found to be effective against both gram-negative and gram-positive bacteria.", [["AMP", "CHEMICAL", 17, 20], ["tyrocidine", "CHEMICAL", 22, 32], ["AMP", "CHEMICAL", 17, 20], ["tyrocidine", "CHEMICAL", 22, 32], ["AMP", "SIMPLE_CHEMICAL", 17, 20], ["tyrocidine", "SIMPLE_CHEMICAL", 22, 32], ["another AMP", "TREATMENT", 9, 20], ["tyrocidine", "TREATMENT", 22, 32], ["gram", "TEST", 88, 92], ["gram", "TEST", 106, 110], ["positive bacteria", "PROBLEM", 111, 128], ["positive bacteria", "OBSERVATION", 111, 128]]], ["However, tyrocidine exhibited toxicity to human blood cells.", [["blood cells", "ANATOMY", 48, 59], ["tyrocidine", "CHEMICAL", 9, 19], ["toxicity", "DISEASE", 30, 38], ["tyrocidine", "CHEMICAL", 9, 19], ["tyrocidine", "SIMPLE_CHEMICAL", 9, 19], ["human", "ORGANISM", 42, 47], ["blood cells", "CELL", 48, 59], ["human blood cells", "CELL_TYPE", 42, 59], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["tyrocidine", "TREATMENT", 9, 19], ["human blood cells", "TEST", 42, 59]]], ["In the same year, another AMP was isolated from a plant Triticumaestivum, which was later named purothionin and found effective against fungi and some pathogenic bacteria [58].", [["AMP", "CHEMICAL", 26, 29], ["Triticumaestivum", "CHEMICAL", 56, 72], ["purothionin", "CHEMICAL", 96, 107], ["AMP", "CHEMICAL", 26, 29], ["purothionin", "CHEMICAL", 96, 107], ["AMP", "SIMPLE_CHEMICAL", 26, 29], ["Triticumaestivum", "ORGANISM", 56, 72], ["purothionin", "SIMPLE_CHEMICAL", 96, 107], ["another AMP", "TREATMENT", 18, 29], ["a plant Triticumaestivum", "TREATMENT", 48, 72], ["fungi", "PROBLEM", 136, 141], ["some pathogenic bacteria", "PROBLEM", 146, 170]]], ["The first reported animal-originated AMP is defensin, which was isolated from rabbit leukocytes in 1956.", [["leukocytes", "ANATOMY", 85, 95], ["AMP", "CHEMICAL", 37, 40], ["AMP", "CHEMICAL", 37, 40], ["AMP", "SIMPLE_CHEMICAL", 37, 40], ["defensin", "GENE_OR_GENE_PRODUCT", 44, 52], ["rabbit", "ORGANISM", 78, 84], ["leukocytes", "CELL", 85, 95], ["defensin", "PROTEIN", 44, 52], ["rabbit leukocytes", "CELL_TYPE", 78, 95], ["rabbit", "SPECIES", 78, 84], ["rabbit", "SPECIES", 78, 84], ["defensin", "PROBLEM", 44, 52], ["rabbit leukocytes", "TEST", 78, 95], ["defensin", "OBSERVATION", 44, 52], ["rabbit leukocytes", "OBSERVATION", 78, 95]]], ["In the following years, bombinin from epithelia and lactoferrin from cow milk were both described.", [["epithelia", "ANATOMY", 38, 47], ["milk", "ANATOMY", 73, 77], ["bombinin", "CHEMICAL", 24, 32], ["bombinin", "CHEMICAL", 24, 32], ["bombinin", "SIMPLE_CHEMICAL", 24, 32], ["epithelia", "TISSUE", 38, 47], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 52, 63], ["cow", "ORGANISM", 69, 72], ["milk", "ORGANISM_SUBSTANCE", 73, 77], ["lactoferrin", "PROTEIN", 52, 63], ["cow", "SPECIES", 69, 72], ["cow", "SPECIES", 69, 72], ["bombinin from epithelia", "PROBLEM", 24, 47], ["lactoferrin from cow milk", "TREATMENT", 52, 77]]], ["During the same time, it was also proven that human leukocytes contain AMPs in their lysosomes [58].How Do AMPs Get Inside Cells? ::: Origins and Classification of AMPs ::: Antimicrobial PeptidesThere is no common molecular entry route for AMPs\u2014it depends on the nature of the peptide, the membrane lipid composition and the peptide/lipid ratio.", [["leukocytes", "ANATOMY", 52, 62], ["lysosomes", "ANATOMY", 85, 94], ["Cells", "ANATOMY", 123, 128], ["membrane", "ANATOMY", 290, 298], ["human", "ORGANISM", 46, 51], ["leukocytes", "CELL", 52, 62], ["AMPs", "GENE_OR_GENE_PRODUCT", 71, 75], ["lysosomes", "CELLULAR_COMPONENT", 85, 94], ["AMPs\u2014it", "SIMPLE_CHEMICAL", 240, 247], ["membrane", "CELLULAR_COMPONENT", 290, 298], ["lipid", "SIMPLE_CHEMICAL", 333, 338], ["human leukocytes", "CELL_TYPE", 46, 62], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 46, 51], ["human leukocytes", "TEST", 46, 62], ["AMPs", "TEST", 164, 168], ["Antimicrobial Peptides", "TREATMENT", 173, 195], ["the membrane lipid composition", "TEST", 286, 316], ["the peptide/lipid ratio", "TEST", 321, 344], ["no", "UNCERTAINTY", 204, 206], ["common", "OBSERVATION_MODIFIER", 207, 213]]], ["The mechanism comprises several stages which are not yet fully understood, despite extensive studies.", [["extensive studies", "TEST", 83, 100], ["several stages", "OBSERVATION_MODIFIER", 24, 38]]], ["The necessary step is peptide\u2019s association with membrane lipids which results in long-range defects.", [["membrane lipids", "ANATOMY", 49, 64], ["membrane lipids", "CELLULAR_COMPONENT", 49, 64], ["membrane lipids", "TREATMENT", 49, 64], ["long-range defects", "PROBLEM", 82, 100], ["range defects", "OBSERVATION", 87, 100]]], ["The different molecular mechanisms postulated (such as barrel-stave or toroidal/wormhole pore formation, aggregate channel formation or surfactant-like interactions [59]) assume that aggregation/oligomerization of AMP in the cytoplasmic membrane is the necessary step leading to the membrane lysis.Classification ::: Origins and Classification of AMPs ::: Antimicrobial PeptidesMost AMPs reported to date can be classified based on one of the following four types based on their secondary structural features: such as cathelicidins (with a linear \u03b1-helical structure), defensins (with a \u03b2-strand structure), and bactenecins (with a loop structure) [60], and extended helices with a predominance of one or more amino acids.", [["wormhole pore", "ANATOMY", 80, 93], ["cytoplasmic membrane", "ANATOMY", 225, 245], ["membrane", "ANATOMY", 283, 291], ["AMP", "CHEMICAL", 214, 217], ["amino acids", "CHEMICAL", 710, 721], ["AMP", "CHEMICAL", 214, 217], ["bactenecins", "CHEMICAL", 612, 623], ["amino acids", "CHEMICAL", 710, 721], ["AMP", "SIMPLE_CHEMICAL", 214, 217], ["cytoplasmic membrane", "CELLULAR_COMPONENT", 225, 245], ["membrane", "CELLULAR_COMPONENT", 283, 291], ["cathelicidins", "GENE_OR_GENE_PRODUCT", 518, 531], ["bactenecins", "SIMPLE_CHEMICAL", 612, 623], ["amino acids", "AMINO_ACID", 710, 721], ["cathelicidins", "PROTEIN", 518, 531], ["linear \u03b1-helical structure", "PROTEIN", 540, 566], ["defensins", "PROTEIN", 569, 578], ["\u03b2-strand structure", "PROTEIN", 587, 605], ["bactenecins", "PROTEIN", 612, 623], ["loop structure", "PROTEIN", 632, 646], ["barrel-stave", "TREATMENT", 55, 67], ["toroidal/wormhole pore formation", "TREATMENT", 71, 103], ["aggregation", "PROBLEM", 183, 194], ["AMP in the cytoplasmic membrane", "TREATMENT", 214, 245], ["the membrane lysis", "TREATMENT", 279, 297], ["AMPs", "TEST", 347, 351], ["Antimicrobial Peptides", "TREATMENT", 356, 378], ["cathelicidins", "PROBLEM", 518, 531], ["a linear \u03b1-helical structure)", "PROBLEM", 538, 567], ["defensins", "PROBLEM", 569, 578], ["a \u03b2-strand structure)", "PROBLEM", 585, 606], ["bactenecins", "TREATMENT", 612, 623], ["more amino acids", "TREATMENT", 705, 721], ["different", "OBSERVATION_MODIFIER", 4, 13], ["molecular mechanisms", "OBSERVATION", 14, 34], ["cytoplasmic membrane", "OBSERVATION", 225, 245], ["membrane lysis", "OBSERVATION", 283, 297]]], ["Among these structural groups, \u03b1-helix and \u03b2-sheet structures are more common [61] and \u03b1-helical peptides are the most studied AMPs to date.", [["\u03b1-helix", "CHEMICAL", 31, 38], ["\u03b1-helix", "SIMPLE_CHEMICAL", 31, 38], ["[61]", "SIMPLE_CHEMICAL", 78, 82], ["\u03b1-helical peptides", "SIMPLE_CHEMICAL", 87, 105]]], ["The best known examples of such AMPs are protegrin, magainin, cyclic indolicin, and coiled indolicin [57] and \u03b1-helical peptides without the presence of cysteines in the sequence, such as melittin [62]. \u03b2-Sheet peptides are composed of at least two \u03b2-strands with disulfide bonds between these strands [63], such as the protegrins [64].", [["protegrin", "CHEMICAL", 41, 50], ["magainin", "CHEMICAL", 52, 60], ["cyclic indolicin", "CHEMICAL", 62, 78], ["indolicin", "CHEMICAL", 91, 100], ["melittin", "CHEMICAL", 188, 196], ["protegrin", "CHEMICAL", 41, 50], ["magainin", "CHEMICAL", 52, 60], ["cyclic indolicin", "CHEMICAL", 62, 78], ["indolicin", "CHEMICAL", 91, 100], ["cysteines", "CHEMICAL", 153, 162], ["melittin", "CHEMICAL", 188, 196], ["disulfide", "CHEMICAL", 264, 273], ["AMPs", "GENE_OR_GENE_PRODUCT", 32, 36], ["protegrin", "SIMPLE_CHEMICAL", 41, 50], ["magainin", "SIMPLE_CHEMICAL", 52, 60], ["cyclic indolicin", "SIMPLE_CHEMICAL", 62, 78], ["coiled indolicin [57]", "SIMPLE_CHEMICAL", 84, 105], ["\u03b1-helical peptides", "SIMPLE_CHEMICAL", 110, 128], ["melittin [62]", "SIMPLE_CHEMICAL", 188, 201], ["such AMPs", "TREATMENT", 27, 36], ["protegrin", "TREATMENT", 41, 50], ["magainin", "TREATMENT", 52, 60], ["cyclic indolicin", "TREATMENT", 62, 78], ["coiled indolicin", "TREATMENT", 84, 100], ["\u03b1-helical peptides", "TREATMENT", 110, 128], ["cysteines in the sequence", "PROBLEM", 153, 178], ["Sheet peptides", "TREATMENT", 205, 219]]], ["And the AMPs with intermolecular disulfide bonds exhibiting loop/hairpin-like structures, such as bactenecin [65], belong to the third group.", [["bactenecin", "CHEMICAL", 98, 108], ["disulfide", "CHEMICAL", 33, 42], ["bactenecin", "CHEMICAL", 98, 108], ["AMPs", "GENE_OR_GENE_PRODUCT", 8, 12], ["the AMPs", "TREATMENT", 4, 12], ["intermolecular disulfide bonds", "TREATMENT", 18, 48], ["loop/hairpin-like structures", "PROBLEM", 60, 88], ["bactenecin", "TEST", 98, 108], ["loop", "OBSERVATION_MODIFIER", 60, 64], ["hairpin", "OBSERVATION", 65, 72]]], ["The final groups are peptides with predominance of one or more distinct amino acids, such as the proline/arginine-rich peptide Bac7 [66].AMP Design ::: Origins and Classification of AMPs ::: Antimicrobial PeptidesThe design of novel AMPs requires consideration of several factors, including secondary structure, amphipathicity, and the presence of positively charged residues.", [["amino acids", "CHEMICAL", 72, 83], ["proline", "CHEMICAL", 97, 104], ["arginine", "CHEMICAL", 105, 113], ["AMP", "CHEMICAL", 137, 140], ["amino acids", "CHEMICAL", 72, 83], ["proline", "CHEMICAL", 97, 104], ["arginine", "CHEMICAL", 105, 113], ["AMP", "CHEMICAL", 137, 140], ["amino acids", "AMINO_ACID", 72, 83], ["proline", "AMINO_ACID", 97, 104], ["arginine", "AMINO_ACID", 105, 113], ["AMP", "SIMPLE_CHEMICAL", 137, 140], ["distinct amino acids", "TREATMENT", 63, 83], ["the proline/arginine", "TREATMENT", 93, 113], ["AMPs", "TEST", 182, 186], ["Antimicrobial Peptides", "TREATMENT", 191, 213], ["novel AMPs", "TREATMENT", 227, 237], ["secondary structure, amphipathicity", "PROBLEM", 291, 326], ["positively charged residues", "PROBLEM", 348, 375], ["amino acids", "OBSERVATION", 72, 83], ["charged residues", "OBSERVATION", 359, 375]]], ["It is believed that an amphipathic secondary structure is required in order for AMPs to function, although the exact mechanism of action is still unclear.", [["AMPs", "GENE_OR_GENE_PRODUCT", 80, 84], ["amphipathic secondary structure", "PROTEIN", 23, 54], ["AMPs", "PROTEIN", 80, 84], ["an amphipathic secondary structure", "PROBLEM", 20, 54], ["AMPs", "TREATMENT", 80, 84], ["amphipathic", "OBSERVATION_MODIFIER", 23, 34], ["secondary structure", "OBSERVATION", 35, 54]]], ["As pointed out by Tossi et al. [67], the design of AMPs is generally based on: (a) amino acid residue analogues of natural peptides (e.g. congeners) that differ at one or more residue positions, are shortened or contain deletions, as well as hybrid AMPs composed of fragments of two different natural peptides; (b) amino acid residues that maximize the amphipathic nature of AMPs; (c) amino acid sequences from combinatorial libraries; and (d) amino acid sequences that are patterned from known, naturally occurring, \u03b1-helical peptide domains.AMP Design ::: Origins and Classification of AMPs ::: Antimicrobial PeptidesImportant factors to consider when designing AMPs are the length of the peptide [68], net charge [69, 57], amphipathicity [70], and possible modifications such as phosphorylation [71], addition of d-amino acids [72], methylation [19], amidation [73], glycosylation [74], formation of disulfide linkage [75], and proteolytic cleavage [76].Mechanisms of Action of AMPs ::: Antimicrobial PeptidesIt is generally accepted that positively charged peptides interact directly with the negatively charged cellular membranes of bacterial cells, resulting in the increase of membrane permeability, which leads to a rapid cell death [77].", [["cellular membranes", "ANATOMY", 1116, 1134], ["cells", "ANATOMY", 1148, 1153], ["membrane", "ANATOMY", 1184, 1192], ["cell", "ANATOMY", 1230, 1234], ["amino acid", "CHEMICAL", 83, 93], ["amino acid", "CHEMICAL", 315, 325], ["amino acid", "CHEMICAL", 385, 395], ["amino acid", "CHEMICAL", 444, 454], ["AMP", "CHEMICAL", 543, 546], ["d-amino acids", "CHEMICAL", 816, 829], ["death", "DISEASE", 1235, 1240], ["amino acid", "CHEMICAL", 83, 93], ["amino acid", "CHEMICAL", 315, 325], ["amino acid", "CHEMICAL", 385, 395], ["amino acid", "CHEMICAL", 444, 454], ["AMP", "CHEMICAL", 543, 546], ["d-amino acids", "CHEMICAL", 816, 829], ["disulfide", "CHEMICAL", 903, 912], ["amino acid", "AMINO_ACID", 83, 93], ["amino acid", "AMINO_ACID", 315, 325], ["amino acid", "AMINO_ACID", 385, 395], ["amino acid", "AMINO_ACID", 444, 454], ["AMP", "SIMPLE_CHEMICAL", 543, 546], ["d-amino acids", "SIMPLE_CHEMICAL", 816, 829], ["[19]", "SIMPLE_CHEMICAL", 848, 852], ["disulfide linkage [75]", "SIMPLE_CHEMICAL", 903, 925], ["cellular membranes", "CELLULAR_COMPONENT", 1116, 1134], ["bacterial cells", "CELL", 1138, 1153], ["membrane", "CELLULAR_COMPONENT", 1184, 1192], ["cell", "CELL", 1230, 1234], ["AMPs", "PROTEIN", 375, 379], ["\u03b1-helical peptide domains", "PROTEIN", 517, 542], ["Antimicrobial PeptidesImportant factors", "PROTEIN", 597, 636], ["bacterial cells", "CELL_TYPE", 1138, 1153], ["AMPs", "TREATMENT", 51, 55], ["a) amino acid residue analogues", "TREATMENT", 80, 111], ["natural peptides", "PROBLEM", 115, 131], ["hybrid AMPs", "TREATMENT", 242, 253], ["fragments of two different natural peptides", "PROBLEM", 266, 309], ["b) amino acid residues", "TREATMENT", 312, 334], ["amino acid sequences", "TEST", 385, 405], ["combinatorial libraries", "TEST", 411, 434], ["d) amino acid sequences", "TEST", 441, 464], ["Antimicrobial PeptidesImportant factors", "TREATMENT", 597, 636], ["amphipathicity", "TEST", 726, 740], ["d-amino acids", "TREATMENT", 816, 829], ["amidation", "TREATMENT", 854, 863], ["glycosylation", "TREATMENT", 870, 883], ["formation of disulfide linkage", "TREATMENT", 890, 920], ["proteolytic cleavage", "TREATMENT", 931, 951], ["AMPs", "TREATMENT", 981, 985], ["Antimicrobial Peptides", "TREATMENT", 990, 1012], ["bacterial cells", "PROBLEM", 1138, 1153], ["membrane permeability", "PROBLEM", 1184, 1205], ["a rapid cell death", "PROBLEM", 1222, 1240], ["cellular membranes", "OBSERVATION", 1116, 1134], ["bacterial cells", "OBSERVATION", 1138, 1153], ["increase", "OBSERVATION_MODIFIER", 1172, 1180], ["membrane permeability", "OBSERVATION", 1184, 1205], ["rapid", "OBSERVATION_MODIFIER", 1224, 1229], ["cell death", "OBSERVATION", 1230, 1240]]], ["The groups of AMPs can be divided as: (a) antibacterials; (b) antivirals; (c) antifungals; (d) antiparasitics; and (e) anticancer peptides.", [["anticancer", "ANATOMY", 119, 129], ["anticancer", "CANCER", 119, 129], ["AMPs", "TREATMENT", 14, 18], ["a) antibacterials", "TREATMENT", 39, 56], ["b) antivirals", "TREATMENT", 59, 72], ["antifungals", "TREATMENT", 78, 89], ["anticancer peptides", "TREATMENT", 119, 138]]], ["AMPs kill bacteria by inhibiting some important pathways inside the cell such as DNA replication and protein synthesis [78].", [["cell", "ANATOMY", 68, 72], ["AMPs", "GENE_OR_GENE_PRODUCT", 0, 4], ["cell", "CELL", 68, 72], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["AMPs kill bacteria", "PROBLEM", 0, 18], ["DNA replication", "TEST", 81, 96], ["protein synthesis", "TEST", 101, 118]]], ["Antiviral AMPs neutralize viruses by integrating in either the viral envelope or the host cell membrane.", [["cell membrane", "ANATOMY", 90, 103], ["AMPs", "GENE_OR_GENE_PRODUCT", 10, 14], ["cell membrane", "CELLULAR_COMPONENT", 90, 103], ["Antiviral AMPs neutralize viruses", "TREATMENT", 0, 33], ["viral envelope", "OBSERVATION", 63, 77], ["host cell membrane", "OBSERVATION", 85, 103]]], ["AMPs can integrate into viral envelopes and cause membrane instability, rendering the viruses unable to infect host cells [79].", [["membrane", "ANATOMY", 50, 58], ["cells", "ANATOMY", 116, 121], ["AMPs", "GENE_OR_GENE_PRODUCT", 0, 4], ["membrane", "CELLULAR_COMPONENT", 50, 58], ["host cells", "CELL", 111, 121], ["host cells", "CELL_TYPE", 111, 121], ["AMPs", "TREATMENT", 0, 4], ["viral envelopes", "PROBLEM", 24, 39], ["membrane instability", "PROBLEM", 50, 70], ["the viruses", "PROBLEM", 82, 93], ["membrane instability", "OBSERVATION", 50, 70]]], ["AMPs can also reduce the binding of viruses to host cells [80].", [["cells", "ANATOMY", 52, 57], ["AMPs", "GENE_OR_GENE_PRODUCT", 0, 4], ["host cells", "CELL", 47, 57], ["host cells", "CELL_TYPE", 47, 57], ["AMPs", "TREATMENT", 0, 4], ["the binding of viruses", "PROBLEM", 21, 43]]], ["Some of antifungal peptides are capable of binding to chitin.", [["chitin", "GENE_OR_GENE_PRODUCT", 54, 60], ["chitin", "PROTEIN", 54, 60], ["antifungal peptides", "TREATMENT", 8, 27], ["antifungal peptides", "OBSERVATION", 8, 27]]], ["Such binding ability helps AMPs to target fungal cells efficiently.", [["cells", "ANATOMY", 49, 54], ["AMPs", "GENE_OR_GENE_PRODUCT", 27, 31], ["fungal cells", "CELL", 42, 54], ["fungal cells", "CELL_TYPE", 42, 54], ["Such binding ability", "PROBLEM", 0, 20], ["AMPs", "TREATMENT", 27, 31], ["target fungal cells", "PROBLEM", 35, 54], ["fungal cells", "OBSERVATION", 42, 54]]], ["Cell wall-targeting antifungal AMPs kill the target cells by disrupting the integrity of fungal membranes by increasing permeabilization of the plasma membrane [81], or by forming pores directly [82].", [["Cell wall", "ANATOMY", 0, 9], ["cells", "ANATOMY", 52, 57], ["membranes", "ANATOMY", 96, 105], ["plasma membrane", "ANATOMY", 144, 159], ["Cell", "CELL", 0, 4], ["cells", "CELL", 52, 57], ["fungal membranes", "CELLULAR_COMPONENT", 89, 105], ["plasma membrane", "CELLULAR_COMPONENT", 144, 159], ["target cells", "CELL_TYPE", 45, 57], ["Cell wall", "TREATMENT", 0, 9], ["antifungal AMPs", "TREATMENT", 20, 35], ["fungal membranes", "PROBLEM", 89, 105], ["the plasma membrane", "TEST", 140, 159], ["wall", "ANATOMY_MODIFIER", 5, 9], ["antifungal AMPs", "OBSERVATION", 20, 35], ["fungal membranes", "OBSERVATION", 89, 105], ["increasing", "OBSERVATION_MODIFIER", 109, 119], ["permeabilization", "OBSERVATION", 120, 136]]], ["An example of antiparasitic peptide is cathelicidin, which is able to kill Caernohabditis elegans by forming pores in the cell membrane [83].", [["pores", "ANATOMY", 109, 114], ["cell membrane", "ANATOMY", 122, 135], ["cathelicidin", "GENE_OR_GENE_PRODUCT", 39, 51], ["Caernohabditis elegans", "ORGANISM", 75, 97], ["cell membrane", "CELLULAR_COMPONENT", 122, 135], ["Caernohabditis elegans", "SPECIES", 75, 97], ["Caernohabditis elegans", "SPECIES", 75, 97], ["antiparasitic peptide", "TREATMENT", 14, 35], ["cathelicidin", "TREATMENT", 39, 51], ["cell membrane", "OBSERVATION", 122, 135]]], ["Even though some parasitic microorganisms are multicellular, the mode of action of antiparasitic peptides is the same as other AMPs.", [["AMPs", "GENE_OR_GENE_PRODUCT", 127, 131], ["some parasitic microorganisms", "PROBLEM", 12, 41], ["antiparasitic peptides", "TREATMENT", 83, 105], ["parasitic", "OBSERVATION_MODIFIER", 17, 26], ["microorganisms", "OBSERVATION", 27, 41], ["multicellular", "OBSERVATION_MODIFIER", 46, 59]]], ["They kill cells by directly interacting with cell membrane [83].", [["cells", "ANATOMY", 10, 15], ["cell membrane", "ANATOMY", 45, 58], ["cells", "CELL", 10, 15], ["cell membrane", "CELLULAR_COMPONENT", 45, 58]]], ["Anticancer peptides are also known as host defense peptides.", [["Anticancer peptides", "TREATMENT", 0, 19]]], ["They unction by targeting the cell membrane, as to date, more than 100 host defense peptides are known.AMP-Based Drug Development ::: Applications of AMPs ::: Antimicrobial PeptidesIn addition to the previously mentioned applications of AMPs, there are much broader uses for the peptides.", [["cell membrane", "ANATOMY", 30, 43], ["AMP", "CHEMICAL", 103, 106], ["AMP", "CHEMICAL", 103, 106], ["cell membrane", "CELLULAR_COMPONENT", 30, 43], ["AMP", "SIMPLE_CHEMICAL", 103, 106], ["AMP", "TEST", 103, 106], ["AMPs", "TREATMENT", 150, 154], ["Antimicrobial Peptides", "TREATMENT", 159, 181], ["AMPs", "TREATMENT", 237, 241], ["the peptides", "TREATMENT", 275, 287], ["cell membrane", "OBSERVATION", 30, 43]]], ["This is a subject that has been previously thoroughly reviewed by several authors [84\u201386], therefore only the select few approaches that the authors regarded to be of interest will be discussed in the section at hand.AMP-Based Drug Development ::: Applications of AMPs ::: Antimicrobial PeptidesOne noteworthy example entails the CPP-PMO conjugate developed in cooperation with AVI Biopharma.", [["hand", "ANATOMY", 212, 216], ["AMP", "CHEMICAL", 217, 220], ["CPP", "CHEMICAL", 330, 333], ["AMP", "CHEMICAL", 217, 220], ["hand", "ORGANISM_SUBDIVISION", 212, 216], ["AMP", "SIMPLE_CHEMICAL", 217, 220], ["CPP", "SIMPLE_CHEMICAL", 330, 333], ["AMP", "TEST", 217, 220], ["AMPs", "TREATMENT", 264, 268], ["Antimicrobial Peptides", "TREATMENT", 273, 295], ["the CPP", "TEST", 326, 333]]], ["The AVI-6002 and AVI-6003 molecules developed by them show promising results against the mRNA translation process of Ebola virus and Marburg virus, which becomes increasingly important in the light of the recent Ebola outbreak.", [["AVI-6002", "CHEMICAL", 4, 12], ["AVI-6003", "CHEMICAL", 17, 25], ["Ebola virus", "DISEASE", 117, 128], ["Ebola", "DISEASE", 212, 217], ["AVI-6002", "CHEMICAL", 4, 12], ["AVI-6003", "CHEMICAL", 17, 25], ["AVI-6002", "SIMPLE_CHEMICAL", 4, 12], ["AVI-6003", "CELL", 17, 25], ["Ebola virus", "ORGANISM", 117, 128], ["Marburg virus", "ORGANISM", 133, 146], ["Ebola", "ORGANISM", 212, 217], ["AVI-6002 and AVI-6003 molecules", "DNA", 4, 35], ["Ebola virus", "SPECIES", 117, 128], ["Ebola virus", "SPECIES", 117, 128], ["Marburg virus", "SPECIES", 133, 146], ["The AVI", "TEST", 0, 7], ["AVI", "PROBLEM", 17, 20], ["the mRNA translation process", "PROBLEM", 85, 113], ["Ebola virus", "PROBLEM", 117, 128], ["Marburg virus", "PROBLEM", 133, 146], ["the recent Ebola outbreak", "PROBLEM", 201, 226], ["Ebola virus", "OBSERVATION", 117, 128], ["Ebola", "OBSERVATION", 212, 217]]], ["Various in vivo studies have been conducted with these drug candidates, including mice, guinea pigs and primates [87, 88].", [["mice", "ORGANISM", 82, 86], ["guinea pigs", "ORGANISM", 88, 99], ["primates", "ORGANISM", 104, 112], ["mice", "SPECIES", 82, 86], ["guinea pigs", "SPECIES", 88, 99], ["mice", "SPECIES", 82, 86], ["pigs", "SPECIES", 95, 99], ["vivo studies", "TEST", 11, 23]]], ["Recently, they have been conducting preliminary clinical trials as well and have obtained positive results from phase 1 trials [88].AMP-Based Drug Development ::: Applications of AMPs ::: Antimicrobial PeptidesAnother molecule of interest is a cationic peptide-based drug targeting fungal infections on toenails, is showing promise and has recently entered clinical studies.", [["toenails", "ANATOMY", 303, 311], ["AMP", "CHEMICAL", 132, 135], ["fungal infections", "DISEASE", 282, 299], ["AMP", "CHEMICAL", 132, 135], ["AMP", "SIMPLE_CHEMICAL", 132, 135], ["AMP", "TEST", 132, 135], ["AMPs", "TREATMENT", 179, 183], ["Antimicrobial Peptides", "TREATMENT", 188, 210], ["a cationic peptide", "PROBLEM", 242, 260], ["fungal infections on toenails", "PROBLEM", 282, 311], ["clinical studies", "TEST", 357, 373], ["fungal", "OBSERVATION_MODIFIER", 282, 288], ["infections", "OBSERVATION", 289, 299]]], ["Novabiotics has created a cyclic hepta-arginine antimicrobial peptide that shows potency in inhibiting fungal growth by disrupting cellular membranes, leading to the loss of viability in affected fungal cells.", [["cellular membranes", "ANATOMY", 131, 149], ["cells", "ANATOMY", 203, 208], ["Novabiotics", "DISEASE", 0, 11], ["cyclic hepta-arginine", "CHEMICAL", 26, 47], ["cellular membranes", "CELLULAR_COMPONENT", 131, 149], ["fungal cells", "CELL", 196, 208], ["fungal cells", "CELL_TYPE", 196, 208], ["Novabiotics", "TREATMENT", 0, 11], ["a cyclic hepta-arginine antimicrobial peptide", "TREATMENT", 24, 69], ["potency in inhibiting fungal growth", "PROBLEM", 81, 116], ["disrupting cellular membranes", "PROBLEM", 120, 149], ["the loss of viability in affected fungal cells", "PROBLEM", 162, 208], ["fungal growth", "OBSERVATION", 103, 116], ["cellular membranes", "OBSERVATION", 131, 149], ["loss", "OBSERVATION_MODIFIER", 166, 170], ["viability", "OBSERVATION_MODIFIER", 174, 183], ["affected", "OBSERVATION_MODIFIER", 187, 195], ["fungal cells", "OBSERVATION", 196, 208]]], ["The cyclic form that was introduced to the molecule is claimed to enhance the antifungal capabilities of the peptide and to increase its stability [89].CPPs with AMP Properties ::: Applications of AMPs ::: Antimicrobial PeptidesIn recent years it has been discovered that the Tat peptide shows potent antibacterial activity (MIC 2\u20138 \u03bcM) against a broad spectrum of pathogens including gram-positive and gram-negative bacteria such as S. aureus and also fungi such as Saccharomyces cerevisiae and Candida albicans [90, 91].", [["AMP", "CHEMICAL", 162, 165], ["AMP", "CHEMICAL", 162, 165], ["AMP", "SIMPLE_CHEMICAL", 162, 165], ["S. aureus", "ORGANISM", 434, 443], ["Saccharomyces cerevisiae", "ORGANISM", 467, 491], ["Candida albicans", "ORGANISM", 496, 512], ["S. aureus", "SPECIES", 434, 443], ["Saccharomyces cerevisiae", "SPECIES", 467, 491], ["Candida albicans", "SPECIES", 496, 512], ["S. aureus", "SPECIES", 434, 443], ["Saccharomyces cerevisiae", "SPECIES", 467, 491], ["Candida albicans", "SPECIES", 496, 512], ["the peptide", "TREATMENT", 105, 116], ["AMPs", "TREATMENT", 197, 201], ["Antimicrobial Peptides", "TREATMENT", 206, 228], ["the Tat peptide", "TEST", 272, 287], ["potent antibacterial activity", "PROBLEM", 294, 323], ["pathogens", "PROBLEM", 365, 374], ["gram", "TEST", 385, 389], ["gram-negative bacteria", "PROBLEM", 403, 425], ["S. aureus", "PROBLEM", 434, 443], ["fungi", "PROBLEM", 453, 458], ["Saccharomyces cerevisiae", "TEST", 467, 491], ["Candida albicans", "TEST", 496, 512], ["stability", "OBSERVATION_MODIFIER", 137, 146], ["negative bacteria", "OBSERVATION_MODIFIER", 408, 425], ["aureus", "OBSERVATION", 437, 443]]], ["The peptide internalizes without any damage to the cell membrane, thus being cytotoxic inside the cells, leading for example to a fast accumulation in the nucleus in fungi, where it causes cell cycle arrest in G1 phase.", [["cell membrane", "ANATOMY", 51, 64], ["cells", "ANATOMY", 98, 103], ["nucleus", "ANATOMY", 155, 162], ["fungi", "ANATOMY", 166, 171], ["cell", "ANATOMY", 189, 193], ["cell membrane", "CELLULAR_COMPONENT", 51, 64], ["cells", "CELL", 98, 103], ["nucleus", "CELLULAR_COMPONENT", 155, 162], ["cell", "CELL", 189, 193], ["The peptide", "TEST", 0, 11], ["any damage to the cell membrane", "PROBLEM", 33, 64], ["a fast accumulation in the nucleus in fungi", "PROBLEM", 128, 171], ["cell cycle arrest", "PROBLEM", 189, 206], ["without", "UNCERTAINTY", 25, 32], ["damage", "OBSERVATION", 37, 43], ["cell membrane", "OBSERVATION", 51, 64], ["cytotoxic", "OBSERVATION_MODIFIER", 77, 86], ["fast", "OBSERVATION_MODIFIER", 130, 134], ["accumulation", "OBSERVATION", 135, 147], ["nucleus", "ANATOMY", 155, 162], ["fungi", "OBSERVATION", 166, 171], ["cell cycle arrest", "OBSERVATION", 189, 206]]], ["The uptake of the Tat peptide seems to be sequence-dependent and not induced by its secondary structure [92].", [["Tat", "GENE_OR_GENE_PRODUCT", 18, 21], ["Tat", "PROTEIN", 18, 21], ["the Tat peptide", "PROBLEM", 14, 29], ["uptake", "OBSERVATION_MODIFIER", 4, 10]]], ["Nearly 20 years after its discovery, it was observed that the CPP penetratin is a potent antimicrobic against gram-negative and gram-positive bacteria such as Bacillus megaterium.", [["penetratin", "CHEMICAL", 66, 76], ["penetratin", "CHEMICAL", 66, 76], ["CPP penetratin", "SIMPLE_CHEMICAL", 62, 76], ["Bacillus megaterium", "ORGANISM", 159, 178], ["Bacillus megaterium", "SPECIES", 159, 178], ["Bacillus megaterium", "SPECIES", 159, 178], ["the CPP penetratin", "TEST", 58, 76], ["gram", "TEST", 110, 114], ["gram-positive bacteria", "PROBLEM", 128, 150], ["Bacillus megaterium", "PROBLEM", 159, 178], ["positive bacteria", "OBSERVATION_MODIFIER", 133, 150], ["Bacillus megaterium", "OBSERVATION", 159, 178]]], ["An MIC of 0.5\u20134 \u03bcM was measured, and the peptide showed no cytotoxicity against mammalian cells.CPPs with AMP Properties ::: Applications of AMPs ::: Antimicrobial PeptidesIn the 18-amino-acid peptide pVEC, uptake takes place by a non-endocytotic mechanism of translocation without alteration of plasma membrane permeability or cell morphology.", [["cells", "ANATOMY", 90, 95], ["plasma membrane", "ANATOMY", 296, 311], ["cell", "ANATOMY", 328, 332], ["AMP", "CHEMICAL", 106, 109], ["18-amino-acid", "CHEMICAL", 179, 192], ["pVEC", "CHEMICAL", 201, 205], ["AMP", "CHEMICAL", 106, 109], ["18-amino-acid", "CHEMICAL", 179, 192], ["mammalian cells", "CELL", 80, 95], ["AMP", "SIMPLE_CHEMICAL", 106, 109], ["18-amino-acid", "SIMPLE_CHEMICAL", 179, 192], ["pVEC", "SIMPLE_CHEMICAL", 201, 205], ["plasma membrane", "CELLULAR_COMPONENT", 296, 311], ["cell", "CELL", 328, 332], ["mammalian cells", "CELL_TYPE", 80, 95], ["An MIC", "TEST", 0, 6], ["the peptide", "TEST", 37, 48], ["cytotoxicity", "PROBLEM", 59, 71], ["mammalian cells", "PROBLEM", 80, 95], ["AMPs", "TREATMENT", 141, 145], ["Antimicrobial PeptidesIn", "TEST", 150, 174], ["amino-acid peptide pVEC", "TREATMENT", 182, 205], ["plasma membrane permeability", "TEST", 296, 324], ["no", "UNCERTAINTY", 56, 58], ["cytotoxicity", "OBSERVATION", 59, 71], ["mammalian cells", "OBSERVATION", 80, 95], ["plasma membrane permeability", "OBSERVATION", 296, 324], ["cell morphology", "OBSERVATION", 328, 343]]], ["After the internalization process, it is mainly localized in nuclear structures and was used as a carrier for peptide nucleic acids (PNAs) and proteins [93].", [["nuclear structures", "ANATOMY", 61, 79], ["nucleic acids", "CHEMICAL", 118, 131], ["nuclear structures", "CELLULAR_COMPONENT", 61, 79], ["peptide nucleic acids", "SIMPLE_CHEMICAL", 110, 131], ["the internalization process", "TREATMENT", 6, 33], ["peptide nucleic acids", "TEST", 110, 131], ["proteins", "TEST", 143, 151]]], ["It can enter mammalian and microbial cells and preferentially permeates and kills microbes; for example, it was described to killMycobacterium smegmatis at low micromolar doses at which normal human cells were not damaged [94].CPPs with AMP Properties ::: Applications of AMPs ::: Antimicrobial PeptidesPep-1 has a hydrophobic tryptophan-rich domain, a spacer domain, and a hydrophilic lysine-rich domain and is characterized by an amphipathic \u03b1-helical structure [95].", [["cells", "ANATOMY", 37, 42], ["cells", "ANATOMY", 199, 204], ["AMP", "CHEMICAL", 237, 240], ["PeptidesPep-1", "CHEMICAL", 295, 308], ["tryptophan", "CHEMICAL", 327, 337], ["AMP", "CHEMICAL", 237, 240], ["tryptophan", "CHEMICAL", 327, 337], ["lysine", "CHEMICAL", 386, 392], ["mammalian", "CELL", 13, 22], ["microbial cells", "CELL", 27, 42], ["Mycobacterium smegmatis", "ORGANISM", 129, 152], ["human", "ORGANISM", 193, 198], ["cells", "CELL", 199, 204], ["AMP", "SIMPLE_CHEMICAL", 237, 240], ["PeptidesPep-1", "GENE_OR_GENE_PRODUCT", 295, 308], ["mammalian and microbial cells", "CELL_TYPE", 13, 42], ["normal human cells", "CELL_TYPE", 186, 204], ["Antimicrobial PeptidesPep-1", "PROTEIN", 281, 308], ["hydrophobic tryptophan-rich domain", "PROTEIN", 315, 349], ["spacer domain", "PROTEIN", 353, 366], ["hydrophilic lysine-rich domain", "PROTEIN", 374, 404], ["amphipathic \u03b1-helical structure", "PROTEIN", 432, 463], ["Mycobacterium smegmatis", "SPECIES", 129, 152], ["human", "SPECIES", 193, 198], ["Mycobacterium smegmatis", "SPECIES", 129, 152], ["human", "SPECIES", 193, 198], ["Mycobacterium smegmatis", "PROBLEM", 129, 152], ["low micromolar doses", "TREATMENT", 156, 176], ["Antimicrobial PeptidesPep", "TEST", 281, 306], ["a hydrophobic tryptophan", "TREATMENT", 313, 337], ["a spacer domain", "TREATMENT", 351, 366], ["a hydrophilic lysine", "TREATMENT", 372, 392], ["an amphipathic \u03b1-helical structure", "PROBLEM", 429, 463], ["microbial cells", "OBSERVATION", 27, 42], ["human cells", "OBSERVATION", 193, 204], ["hydrophilic lysine", "OBSERVATION", 374, 392], ["amphipathic", "OBSERVATION_MODIFIER", 432, 443]]], ["Pep-1 has a broad antimicrobial spectrum against gram-negative and gram-positive bacterial strains but weak antibacterial activity [96].", [["strains", "ANATOMY", 91, 98], ["Pep-1", "CHEMICAL", 0, 5], ["Pep-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["Pep", "TEST", 0, 3], ["gram", "TEST", 49, 53], ["gram", "TEST", 67, 71], ["positive bacterial strains", "PROBLEM", 72, 98], ["weak antibacterial activity", "PROBLEM", 103, 130], ["positive bacterial", "OBSERVATION_MODIFIER", 72, 90]]], ["A bacteria-selective variant could be designed by replacing several glutamic acids with lysines.", [["glutamic acids", "CHEMICAL", 68, 82], ["glutamic acids", "CHEMICAL", 68, 82], ["lysines", "CHEMICAL", 88, 95], ["glutamic acids", "AMINO_ACID", 68, 82], ["A bacteria-selective variant", "PROBLEM", 0, 28], ["several glutamic acids with lysines", "TREATMENT", 60, 95], ["bacteria", "OBSERVATION", 2, 10], ["selective variant", "OBSERVATION", 11, 28]]], ["The modified peptide showed high activity (MIC 1\u20132 \u03bcM) against strains of gram-positive and gram-negative bacteria as well as against clinical isolates of multidrug-resistant Pseudomonas aeruginosa (MDRPA) and methicillin-resistant S. aureus (MIC 1\u20138 \u03bcM) [96].", [["MDRPA", "CHEMICAL", 199, 204], ["methicillin", "CHEMICAL", 210, 221], ["MIC", "CHEMICAL", 243, 246], ["methicillin", "CHEMICAL", 210, 221], ["multidrug-resistant", "ORGANISM", 155, 174], ["Pseudomonas aeruginosa", "ORGANISM", 175, 197], ["MDRPA", "SIMPLE_CHEMICAL", 199, 204], ["methicillin-resistant", "SIMPLE_CHEMICAL", 210, 231], ["S. aureus", "ORGANISM", 232, 241], ["Pseudomonas aeruginosa", "SPECIES", 175, 197], ["S. aureus", "SPECIES", 232, 241], ["Pseudomonas aeruginosa", "SPECIES", 175, 197], ["S. aureus", "SPECIES", 232, 241], ["The modified peptide", "TEST", 0, 20], ["high activity", "PROBLEM", 28, 41], ["gram", "TEST", 74, 78], ["gram-negative bacteria", "PROBLEM", 92, 114], ["multidrug-resistant Pseudomonas aeruginosa", "PROBLEM", 155, 197], ["methicillin-resistant S. aureus", "PROBLEM", 210, 241], ["high activity", "OBSERVATION", 28, 41], ["negative bacteria", "OBSERVATION", 97, 114], ["aureus", "OBSERVATION", 235, 241]]], ["Certain chimeric peptides, such as Pep-1, may even be considered a \u201cblend\u201d between AMPs and CPPs.", [["Pep-1", "GENE_OR_GENE_PRODUCT", 35, 40], ["AMPs", "GENE_OR_GENE_PRODUCT", 83, 87], ["Pep", "PROTEIN", 35, 38], ["Certain chimeric peptides", "PROBLEM", 0, 25], ["Pep", "TEST", 35, 38], ["AMPs and CPPs", "TREATMENT", 83, 96]]], ["Although reported as a CPP, Pep-1 is a strongly amphipathic cationic peptide, rich in basic amino acids and tryptophan, having a proline residue in its sequence.", [["amino acids", "CHEMICAL", 92, 103], ["tryptophan", "CHEMICAL", 108, 118], ["proline", "CHEMICAL", 129, 136], ["amino acids", "CHEMICAL", 92, 103], ["tryptophan", "CHEMICAL", 108, 118], ["proline", "CHEMICAL", 129, 136], ["Pep-1", "GENE_OR_GENE_PRODUCT", 28, 33], ["amino acids", "AMINO_ACID", 92, 103], ["tryptophan", "AMINO_ACID", 108, 118], ["Pep-1", "PROTEIN", 28, 33], ["a CPP", "TEST", 21, 26], ["Pep", "TEST", 28, 31], ["a strongly amphipathic cationic peptide", "PROBLEM", 37, 76], ["basic amino acids", "TEST", 86, 103], ["a proline residue in its sequence", "PROBLEM", 127, 160], ["amino acids", "OBSERVATION", 92, 103]]], ["These are the classical characteristics attributed to AMPs.", [["AMPs", "GENE_OR_GENE_PRODUCT", 54, 58], ["AMPs", "PROBLEM", 54, 58]]], ["The ability to cysteine-bridge monomers, which greatly improves translocation efficiency, further increases the similarities to AMPs.", [["cysteine", "CHEMICAL", 15, 23], ["cysteine", "AMINO_ACID", 15, 23], ["cysteine-bridge monomers", "TREATMENT", 15, 39], ["translocation efficiency", "PROBLEM", 64, 88], ["AMPs", "TEST", 128, 132], ["translocation efficiency", "OBSERVATION", 64, 88]]], ["Not surprisingly, Pep-1 uses mainly physical routes to translocate membranes.", [["membranes", "ANATOMY", 67, 76], ["Pep-1", "GENE_OR_GENE_PRODUCT", 18, 23], ["membranes", "CELLULAR_COMPONENT", 67, 76], ["Pep-1", "PROTEIN", 18, 23], ["Pep", "TEST", 18, 21]]], ["However, this route is not always operative [95] and endocytic pathways are alternatives.CPPs with AMP Properties ::: Applications of AMPs ::: Antimicrobial PeptidesTransportan (TP) is a 27 amino acid chimeric peptide composed of the neuropeptide galanin and mastoparan-X linked by a lysine.", [["AMP", "CHEMICAL", 99, 102], ["Transportan", "CHEMICAL", 165, 176], ["amino acid", "CHEMICAL", 190, 200], ["galanin", "CHEMICAL", 247, 254], ["mastoparan", "CHEMICAL", 259, 269], ["lysine", "CHEMICAL", 284, 290], ["AMP", "CHEMICAL", 99, 102], ["amino acid", "CHEMICAL", 190, 200], ["lysine", "CHEMICAL", 284, 290], ["AMP", "SIMPLE_CHEMICAL", 99, 102], ["Transportan", "GENE_OR_GENE_PRODUCT", 165, 176], ["TP", "GENE_OR_GENE_PRODUCT", 178, 180], ["galanin", "GENE_OR_GENE_PRODUCT", 247, 254], ["mastoparan-X", "GENE_OR_GENE_PRODUCT", 259, 271], ["Antimicrobial Peptides", "TREATMENT", 143, 165], ["a 27 amino acid chimeric peptide", "TREATMENT", 185, 217], ["the neuropeptide galanin", "TREATMENT", 230, 254], ["mastoparan", "TREATMENT", 259, 269], ["a lysine", "TREATMENT", 282, 290]]], ["It exhibits rapid and non-endocytotic uptake and was used for delivery of peptides, PNA oligomers or even intact proteins [97].", [["PNA oligomers", "SIMPLE_CHEMICAL", 84, 97], ["rapid and non-endocytotic uptake", "PROBLEM", 12, 44], ["delivery of peptides", "TREATMENT", 62, 82], ["PNA oligomers", "PROBLEM", 84, 97], ["rapid", "OBSERVATION_MODIFIER", 12, 17], ["non-endocytotic uptake", "OBSERVATION", 22, 44], ["PNA", "OBSERVATION", 84, 87]]], ["TP 10 is a 21-amino-acid deletion analog of the chimeric CPP transportan that contains the mastoparan sequence but lacks the toxicity of its parent compound.", [["TP", "CHEMICAL", 0, 2], ["21-amino-acid", "CHEMICAL", 11, 24], ["mastoparan", "CHEMICAL", 91, 101], ["toxicity", "DISEASE", 125, 133], ["21-amino-acid", "CHEMICAL", 11, 24], ["TP 10", "GENE_OR_GENE_PRODUCT", 0, 5], ["21-amino-acid", "SIMPLE_CHEMICAL", 11, 24], ["chimeric CPP transportan", "PROTEIN", 48, 72], ["TP", "TEST", 0, 2], ["a 21-amino-acid deletion analog", "PROBLEM", 9, 40], ["the chimeric CPP transportan", "TREATMENT", 44, 72], ["the mastoparan sequence", "TEST", 87, 110]]], ["It can enter mammalian and microbial cells and preferably permeate and kill microbes such as S. aureus at low micromolar doses but does not damage human cells [98].CPPs with AMP Properties ::: Applications of AMPs ::: Antimicrobial PeptidesThe cationic and amphipathic model peptide (MAP) is another CPP with antimicrobial properties.", [["cells", "ANATOMY", 37, 42], ["cells", "ANATOMY", 153, 158], ["AMP", "CHEMICAL", 174, 177], ["AMP", "CHEMICAL", 174, 177], ["mammalian", "CELL", 13, 22], ["microbial cells", "CELL", 27, 42], ["S. aureus", "ORGANISM", 93, 102], ["human", "ORGANISM", 147, 152], ["cells", "CELL", 153, 158], ["AMP", "SIMPLE_CHEMICAL", 174, 177], ["MAP", "SIMPLE_CHEMICAL", 284, 287], ["CPP", "SIMPLE_CHEMICAL", 300, 303], ["mammalian and microbial cells", "CELL_TYPE", 13, 42], ["human cells", "CELL_TYPE", 147, 158], ["S. aureus", "SPECIES", 93, 102], ["human", "SPECIES", 147, 152], ["S. aureus", "SPECIES", 93, 102], ["human", "SPECIES", 147, 152], ["S. aureus", "PROBLEM", 93, 102], ["low micromolar doses", "TREATMENT", 106, 126], ["damage human cells", "PROBLEM", 140, 158], ["Antimicrobial Peptides", "TREATMENT", 218, 240], ["The cationic and amphipathic model peptide (MAP", "TREATMENT", 240, 287], ["antimicrobial properties", "TREATMENT", 309, 333], ["microbial cells", "OBSERVATION", 27, 42], ["aureus", "OBSERVATION", 96, 102], ["antimicrobial properties", "OBSERVATION", 309, 333]]], ["The uptake of the peptide again seems to be a combination of energy-dependent and energy-independent mechanisms, whereas the amphipathicity of the peptide is crucial for uptake [99].", [["uptake", "OBSERVATION", 4, 10], ["dependent", "OBSERVATION_MODIFIER", 68, 77]]], ["It exhibits an antimicrobial effect against gram-positive bacteria such as B. megaterium and gram-negative bacteria such as E. coli in a low micromolar range.", [["B. megaterium", "ORGANISM", 75, 88], ["E. coli", "ORGANISM", 124, 131], ["B. megaterium", "SPECIES", 75, 88], ["E. coli", "SPECIES", 124, 131], ["B. megaterium", "SPECIES", 75, 88], ["E. coli", "SPECIES", 124, 131], ["gram-positive bacteria", "PROBLEM", 44, 66], ["B. megaterium", "TEST", 75, 88], ["gram-negative bacteria", "PROBLEM", 93, 115], ["E. coli", "PROBLEM", 124, 131], ["antimicrobial effect", "OBSERVATION", 15, 35], ["positive bacteria", "OBSERVATION_MODIFIER", 49, 66], ["negative bacteria", "OBSERVATION_MODIFIER", 98, 115], ["E. coli", "OBSERVATION", 124, 131], ["low micromolar range", "OBSERVATION_MODIFIER", 137, 157]]], ["However, no antifungal activity against yeast S. cerevisiae has been observed [94].", [["yeast S. cerevisiae", "ORGANISM", 40, 59], ["yeast", "SPECIES", 40, 45], ["S. cerevisiae", "SPECIES", 46, 59], ["yeast", "SPECIES", 40, 45], ["S. cerevisiae", "SPECIES", 46, 59], ["antifungal activity", "PROBLEM", 12, 31], ["yeast S. cerevisiae", "PROBLEM", 40, 59], ["no", "UNCERTAINTY", 9, 11], ["antifungal activity", "OBSERVATION", 12, 31]]], ["A pore-formation mechanism was proposed for MPG (a 27-residue amphipathic peptide) and Pep-1 [100], which is also a common mechanism used by antimicrobial peptides (Table 1).", [["MPG", "CHEMICAL", 44, 47], ["MPG", "CHEMICAL", 44, 47], ["MPG", "SIMPLE_CHEMICAL", 44, 47], ["Pep-1", "GENE_OR_GENE_PRODUCT", 87, 92], ["MPG (a 27-residue amphipathic peptide", "TREATMENT", 44, 81], ["Pep", "TEST", 87, 90], ["antimicrobial peptides", "TREATMENT", 141, 163]]]]}